IDEAS home Printed from
MyIDEAS: Login to follow this JEL code

Research classified by Journal of Economic Literature (JEL) codes

/ D: Microeconomics
/ / D0: General
/ / D1: Household Behavior
/ / D2: Production and Organizations
/ / D3: Distribution
/ / D4: Market Structure, Pricing, and Design
/ / D5: General Equilibrium and Disequilibrium
/ / D6: Welfare Economics
/ / D7: Analysis of Collective Decision-Making
/ / D8: Information, Knowledge, and Uncertainty
/ / D9: Intertemporal Choice

This topic is covered by the following reading lists:
  1. SOEP based publications

Most recent items first, undated at the end.
  • 2015 Asset index, child nutritional status and pro-poor growth analysis in Malawi
    by Anderson Sawira Gondwe

  • 2015 Underlying Energy Efficiency in the US
    by Massimo Filippini & Lester C Hunt

  • 2015 Transient and Persistent Energy Efficiency in the US Residential Sector: Evidence from Household-level Data
    by Massimo Anna Alberini & Massimo Filippini

  • 2015 Measurement of Energy Efficiency Based on Economic Foundations
    by Massimo Filippini & Lester Hunt

  • 2015 Dynamic Model of Markets of Homogenous Non-Durables
    by Kaldasch, Joachim

  • 2015 The Prospect of remittances in Albania
    by Albana GJONI (KARAMETA) & Holta KORA (BAKO)

  • 2015 Uzroci i posljedice reprodukovanja institucionalnog vakuuma u državama Jugoistocne Evrope
    by Nikša Grgurevic

  • 2015 Childhood roots of financial literacy
    by Grohmann, Antonia & Kouwenberg, Roy & Menkhoff, Lukas

  • 2015 Examining the relationship between creativity and innovation: A meta-analysis of organizational, cultural, and environmental factors
    by Sarooghi, Hessamoddin & Libaers, Dirk & Burkemper, Andrew

  • 2015 Strategic investment in merchant transmission: The impact of capacity utilization rules
    by Boffa, Federico & Pingali, Viswanath & Sala, Francesca

  • 2015 Measurement of energy efficiency based on economic foundations
    by Filippini, Massimo & Hunt, Lester C.

  • 2015 Dynamic demand for residential electricity in Taiwan under seasonality and increasing-block pricing
    by Hung, Ming-Feng & Huang, Tai-Hsin

  • 2015 Prices and investment with collateral and default
    by Magill, Michael & Quinzii, Martine

  • 2014 Exports, agglomeration and workforce diversity: An empirical assessment of German establishments
    by Stephan Brunow & Luise Grünwald

  • 2014 Literature review and model development
    by Tim Jackson & Ben Drake & Peter Victor & Kurt Kratena & Mark Sommer

  • 2014 Going beyond tradition: Estimating residential electricity demand using an appliance index and energy services
    by Nina Boogen & Souvik Datta & Massimo Filippini

  • 2014 The Wealth of Households: An Analysis of the 2013 Survey of Consumer Finances
    by David Rosnick & Dean Baker

  • 2014 The State of REDD+ Finance - Working Paper 378
    by Marigold Norman and Smita Nakhooda

  • 2014 Metody jakosciowe w badaniu przedsiebiorczosci (Qualitative Methods in the Research on Entrepreneurship)
    by Bartlomiej J. Gabrys

  • 2014 Psychologiczne podejscie do rozumienia postaw konsumenckich (Psychological approach to consumers’ attitudes)
    by Dominika Maison & Katarzyna Stasiuk

  • 2014 Saving in Foreign Currency
    by Niþu Oana & Niþu Claudiu Valentin & Tileagã Cosmin

  • 2014 The Analysis of the Organizational Learning Processes in Local Organizations
    by Lazãr Cristina & Nancu Dorinela

  • 2014 Bidding Price Foundation And Update
    by Vãduva Cecilia Elena

  • 2014 The irresistible charm of the micro-foundations dogma or the overwhelming force of the discipline's hard core?
    by Thanos Skouras & Yiannis Kitromilides

  • 2014 Aggregate sentiment dynamics: A canonical modelling approach and its pleasant nonlinearities
    by Franke, Reiner

  • 2014 Zur empirischen Prüfbarkeit des homo oeconomicus anhand der Messung der Motive ehrenamtlichen Engagements in Sportvereinen
    by Jens Flatau & Eike Emrich & Christian Pierdzioch

  • 2014 Quality Dimensions, Value, Service Cost and Recommendation Behaviour: Evidence from the Nigerian Cellular Industry
    by Abolaji Joachim Abiodun & Kenneth Sola Adeyemi & Adewale Omotayo Osibanjo

  • 2013 R and D Spillovers Across the Supply Chain: Evidence from the Indian Automobile Industry
    by Madhuri Saripalle

  • 2013 (De)Regulation and Market Thickness
    by Jean Guillaume Forand & Vikram Maheshri

  • 2013 Strategic manipulability of self-selective social choice rules
    by Mostapha Diss

  • 2013 Measurement of the “Underlying energy efficiency” in Chinese provinces
    by Massimo Filippini & Lin Zhang

  • 2013 'Underlying Energy Efficiency' in the US
    by Massimo Filippini & Lester C. Hunt

  • 2013 Why Does the Minimum Wage Have No Discernible Effect on Employment?
    by John Schmitt

  • 2013 Wykorzystanie uslug doradczych jako czynnik rozwoju zarzadzania organizacjami. (Consulting as a factor in the development of organizational management .)
    by Kinga Korniejenko & Katarzyna Lichwa

  • 2013 Invisible Hand Processes and the Theory of Money
    by Hillel Steiner

  • 2013 Implementing Cloud Computing Based Information Systems
    by Robu Maximilian Iosif

  • 2013 Relevant Performance Indicators in the Analysis of Corporate Governance
    by Georgescu Cristina Elena

  • 2013 Aspects Regarding the Influence of the Governance Structure on the Company’s Performace
    by Georgescu Cristina Elena

  • 2013 Analysis of the Impacts of Foreign Currency SavingsAbstract:Studying the ways of training, of the influence factors and of the ways to place people's savings by making such research, offers the possibility of scientific development and reasoning of the appropriate model of population on saving in the difficult conditions in which it is now Romania. Household savings trends are reflected in the standards of living and welfare. Savings, as an influencing factor of the standard of living and welfare depends on the level of inflation, the interest rate liabilities and the income, which suggests that, before drawing any conclusion about saving, changes of the size of people savings should be considered. In Romania, in the current period, occures a series of studies and analyzes, in which, statistically, they are assessed and defined multiple concepts of living. These studies were signed by researchers from the National Institute of Statistics, the National Bank and the Deposit Guarantee Fund in the Banking System
    by Nicodim Liliana & Tileagã Cosmin

  • 2013 A Microeconomic Approach of a Company’s in a Competitive Environment
    by Alexandru Trifu

  • 2013 Relative consumption, working time, and trade unions
    by Goerke, Laszlo & Hillesheim, Inga

  • 2013 Motivation and affective processing biases in risky decision making: A counter-regulation account
    by Schwager, Susanne & Rothermund, Klaus

  • 2013 Generalizing the core design principles for the efficacy of groups
    by Wilson, David Sloan & Ostrom, Elinor & Cox, Michael E.

  • 2013 Regional impact of changes in disposable income on Spanish electricity demand: A spatial econometric analysis
    by Blázquez Gomez, Leticia M. & Filippini, Massimo & Heimsch, Fabian

  • 2013 Power TAC: A competitive economic simulation of the smart grid
    by Ketter, Wolfgang & Collins, John & Reddy, Prashant

  • 2013 Residential electricity demand in Spain: New empirical evidence using aggregate data
    by Blázquez, Leticia & Boogen, Nina & Filippini, Massimo

  • 2013 Profit sharing and relative consumption
    by Goerke, Laszlo

  • 2013 KSU (national service system) services as basis of regional entrepreneurship
    by Elzbieta Skapska

  • 2013 Communication Abilities Of Dambovita’S Managers

  • 2012 Stable Matching with Incomplete Information, Second Version
    by Qingmin Liu & George J. Mailath & Andrew Postlewaite & Larry Samuelson

  • 2012 Matching with Incomplete Information
    by Qingmin Liu & George J. Mailath & Andrew Postlewaite & Larry Samuelson

  • 2012 Modeling Artisanal Fisheries and Hydroelectricity in Relation to the Itezhi-tezhi Dam on the Kafue River, Zambia
    by Richard Jensen

  • 2012 Economic Policy for Invasive Species
    by Richard Jensen

  • 2012 Un’analisi critica dei lavori recenti del mainstream sugli effetti economici delle spese militari
    by Eleonora Gentilucci & Rémy Herrera

  • 2012 Window-Dressing and Lobbying in Performance-Budgeting: a Model for the Public Sector
    by Ivo Bischoff & Frédéric Blaeschke

  • 2012 Barro-Becker with Credit Frictions
    by Cordoba, Juan Carlos & Ripoll, Marla

  • 2012 Barro-Becker with Credit Frictions
    by Cordoba, Juan Carlos & Ripoll, Marla

  • 2012 Life, Death and World Inequality
    by Cordoba, Juan Carlos & Ripoll, Marla

  • 2012 Small-Dollar Lending: Is There A Responsible Path Forward?
    by Jim Campen

  • 2012 Missing the Story: The OECD's Analysis of Inequality
    by David Rosnick & Dean Baker

  • 2012 The Impact on Inequality of Raising the Social Security Retirement Age
    by Dean Baker & David Rosnick

  • 2012 Analysing the Impact of ENERGY STAR Rebate Policies in the US
    by Souvik Datta & Massimo Filippini

  • 2012 Residential electricity demand for Spain: new empirical evidence using aggregated data
    by Blazquez Leticia & Nina Boogen & Massimo Filippini

  • 2012 A Pilot Study to Identify Areas for Further Improvements in Patient and Public Involvement in Health Technology Assessments for Medicines
    by Josie Messina & David. L. Grainger

  • 2012 Estimating Preference-Based EQ-5D Health State Utilities or Item Responses from Neuropathic Pain Scores
    by Ning Yan. Gu & Chris Bell & Marc F. Botteman & Xiang Ji & John A. Carter & Ben van Hout

  • 2012 Patients' Perceptions of the Interpersonal Sensitivity of Their Healthcare Providers: The Potential Role of Patient-Provider Racial/Ethnic Concordance
    by Karon L. Phillips & David A. Chiriboga & Yuri Jang

  • 2012 Psychometric Evaluation of an Inpatient Consumer Survey Measuring Satisfaction with Psychiatric Care
    by Glorimar Ortiz & Lucille Schacht

  • 2012 Comparison of Expected Outcomes between Patients and Neurologists Using Kano's Methodology in Symptomatic Migraine Treatment
    by J. Matas-Guiu & M.T. Caloto & G. Nocea

  • 2012 Practicing Patient-Centered Care: The Questions Clinically Excellent Physicians Use to Get to Know their Patients as Individuals
    by Laura A. Hanyok & David B. Hellmann & Cynthia Rand & Roy C. Ziegelstein

  • 2012 Cognitive Testing and Readability of an Item Bank for Measuring the Impact of Headache on Health-Related Quality of Life
    by Diane M. Turner-Bowker & Renee N. Saris-Baglama & Michael A. DeRosa & Christine A. Paulsen

  • 2012 Patient and Public Involvement in Patient-Reported Outcome Measures: Evolution Not Revolution
    by Sophie Staniszewska & Kirstie L. Haywood & Jo Brett & Liz Tutton

  • 2012 Patient and Public Involvement in Developing Patient-Reported Outcome Measures: Indispensable, Desirable, Challenging
    by Oliver Groene

  • 2012 Seeking What Matters: Patients as Research Partners
    by Musa Mayer

  • 2012 Assessing Stakeholder Opinion on Relations between Cancer Patient Groups and Pharmaceutical Companies in Europe
    by Susanna Leto di Priolo & Andras Fehervary & Phil Riggins & Kathy Redmond

  • 2012 Content Validity of Visual Analog Scales to Assess Symptom Severity of Acute Angioedema Attacks in Adults with Hereditary Angioedema: An Interview Study
    by Carolyn Vivienne. McMillan & Jane Speight & Anurag Relan & Luca Bellizzi & Gerald Haase & Marco Cicardi

  • 2012 Designing Family-Centered Male Circumcision Services: A Conjoint Analysis Approach
    by John F.P. Bridges & Sarah C. Searle & Frederic W. Selck & Neil A. Martinson

  • 2012 Burden of a Multiple Sclerosis Relapse: The Patient's Perspective
    by MerriKay Oleen-Burkey & Jane Castelli-Haley & Maureen J. Lage & Kenneth P. Johnson

  • 2012 A Comparison of Analytic Hierarchy Process and Conjoint Analysis Methods in Assessing Treatment Alternatives for Stroke Rehabilitation
    by Maarten J. IJzerman & Janine A. van Til & John F.P. Bridges

  • 2012 Patient Preferences for First-Line Oral Treatment for Mild-to-Moderate Ulcerative Colitis: A Discrete-Choice Experiment
    by Paul Hodgkins & Paul Swinburn & Dory Solomon & Linnette Yen & Sarah Dewilde & Andrew Lloyd

  • 2012 Re-Engineering the Post-Discharge Appointment Process for General Medicine Patients
    by Robert Chang & David Spahlinger & Christopher S. Kim

  • 2012 Test-Retest Reliability of an Interactive Voice Response Version of the EQ-5D in a Sample of Cancer Survivors
    by J. Jason. Lundy & Stephen Joel. Coons

  • 2012 Patients' Perceptions of Sharing in Decisions: A Systematic Review of Interventions to Enhance Shared Decision Making in Routine Clinical Practice
    by France Lgar & Stphane Turcotte & Dawn Stacey & Stphane Ratt & Jennifer Kryworuchko & Ian D. Graham

  • 2012 The Authors' Reply
    by Hareth Al-Janabi & Terry N. Flynn & Joanna Coast

  • 2012 Caregivers' Quality of Life and Economic Evaluations
    by Afschin Gandjour

  • 2012 Dabigatran Etexilate: A Pharmacoeconomic Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
    by Kate McKeage

  • 2012 A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary Disease
    by Petra Menn & Reiner Leidl & Rolf Holle

  • 2012 Costs Associated with Febrile Neutropenia in the US
    by Shannon L. Michels & Rich L. Barron & Matthew W. Reynolds & Karen Smoyer Tomic & Jingbo Yu & Gary H. Lyman

  • 2012 Lost Productivity in Four European Countries among Patients with Rheumatic Disorders: Are Absenteeism and Presenteeism Transferable?
    by Saskia Knies & Math J.J.M. Candel & Annelies Boonen & Silvia M.A.A. Evers & Andre J.H.A. Ament & Johan L. Severens

  • 2012 Reimbursement Decisions of the All Wales Medicines Strategy Group: Influence of Policy and Clinical and Economic Factors
    by Warren G. Linley & Dyfrig A. Hughes

  • 2012 Cost of Illness of Cystic Fibrosis in Germany: Results from a Large Cystic Fibrosis Centre
    by Mareike Heimeshoff & Helge Hollmeyer & Jonas Schreygg & Oliver Tiemann & Doris Staab

  • 2012 Assessing the Quality of Pharmacoeconomic Studies in India: A Systematic Review
    by Pooja R. Desai & Hitesh S. Chandwani & Karen L. Rascati

  • 2012 Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
    by Vanja Sikirica & M. Haim Erder & Jipan Xie & Dendy Macaulay & Melissa Diener & Paul Hodgkins & Eric Q. Wu

  • 2012 Valuation of the Child Health Utility 9D Index
    by Katherine Stevens

  • 2012 Developing Adolescent-Specific Health State Values for Economic Evaluation: An Application of Profile Case Best-Worst Scaling to the Child Health Utility 9D
    by Julie Ratcliffe & Terry Flynn & Frances Terlich & Katherine Stevens & John Brazier & Michael Sawyer

  • 2012 A Parent-Child Dyad Approach to the Assessment of Health Status and Health-Related Quality of Life in Children with Asthma
    by Wendy J. Ungar & Katherine Boydell & Sharon Dell & Brian M. Feldman & Deborah Marshall & Andrew Willan & James G. Wright

  • 2012 The Impact of Rotavirus Vaccination on Discounted Net Tax Revenue in Egypt: A Government Perspective Analysis
    by Mark P. Connolly & Oleksandr Topachevskyi & Baudouin Standaert & Omayra Ortega & Maarten Postma

  • 2012 Preference-Based Health-Related Quality-of-Life Outcomes in Children with Autism Spectrum Disorders: A Comparison of Generic Instruments
    by J. Mick. Tilford & Nalin Payakachat & Erica Kovacs & Jeffrey M. Pyne & Werner Brouwer & Todd G. Nick & Jayne Bellando & Karen A. Kuhlthau

  • 2012 Economic Evaluations of Childhood Influenza Vaccination: A Critical Review
    by Anthony T. Newall & Mark Jit & Philippe Beutels

  • 2012 Comparative Effectiveness and Child Health
    by Lisa A. Prosser

  • 2012 Valuing Children's Health: Whose Quality of Life Matters?
    by Eve Wittenberg

  • 2012 Quetiapine: A Pharmacoeconomic Review of its Use in Bipolar Disorder
    by Greg L. Plosker

  • 2012 Duloxetine Use in Chronic Low Back Pain: Treatment Patterns and Costs
    by Jasmina I. Ivanova & Howard G. Birnbaum & Evan Kantor & Matt Schiller & Ralph W. Swindle

  • 2012 Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis: An Application of Bayesian Methods for Evidence Synthesis in a Markov Model
    by Christine M. Nguyen & Mark Bounthavong & Margaret A.S. Mendes & Melissa L.D. Christopher & Josephine N. Tran & Rashid Kazerooni & Anthony P. Morreale

  • 2012 Hospital Reimbursement Price Cap for Cancer Drugs: The French Experience in Controlling Hospital Drug Expenditures
    by A. Degrassat-Thas & M. Bensadon & C. Rieu & M. Angalakuditi & C. Le Pen & P. Paubel

  • 2012 Economic Evaluation of Smoking-Cessation Therapies: A Critical and Systematic Review of Simulation Models
    by Kristian Bolin

  • 2012 Cost Effectiveness of Rituximab for Non-Hodgkin's Lymphoma: A Systematic Review
    by Philipp W.P. Auweiler & Dirk Mller & Stephanie Stock & Andreas Gerber

  • 2012 Corrigendum
    by Adis International Limited

  • 2012 The Authors' Reply
    by A. George. Awad & Lakshmi N.P. Voruganti

  • 2012 The Lack of Impact of Quality-of-Life Measures in Schizophrenia: A Shared Responsibility?
    by Laurent Boyer & Pascal Auquier

  • 2012 Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode
    by Mattias Ekman & Peter Lindgren & Carolin Miltenburger & Genevieve Meier & Julie C. Locklear & Mary Lou. Chatterton

  • 2012 Pharmacoeconomics of the Myeloid Growth Factors: A Critical and Systematic Review
    by Bradford R. Hirsch & Gary H. Lyman

  • 2012 Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal
    by Dwayne Boyers & Xueli Jia & David Jenkinson & Graham Mowatt

  • 2012 A Critical Review of Model-Based Economic Studies of Depression: Modelling Techniques, Model Structure and Data Sources
    by Hossein Haji Ali Afzali & Jonathan Karnon & Jodi Gray

  • 2012 Value of Information and Pricing New Healthcare Interventions
    by Andrew R. Willan & Simon Eckermann

  • 2012 The Authors' Reply
    by Livio Garattini & Katelijne van de Vooren & Alessandro Curto

  • 2012 Human Papillomavirus Vaccination Is Not Exclusively a Matter of Price
    by Alessandro Capone & Giampiero Favato

  • 2012 The Impact of Co-Morbidity Burden on Preference-Based Health-Related Quality of Life in the United States
    by Patrick W. Sullivan & Vahram H. Ghushchyan & Elizabeth A. Bayliss

  • 2012 Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals: Pharmacokinetic/Pharmacodynamic/Pharmacoeconomic Analysis of Rituximab for Follicular Lymphoma
    by Joshua Pink & Steven Lane & Dyfrig A. Hughes

  • 2012 Anti-Inflammatory Medication Adherence, Healthcare Utilization and Expenditures among Medicaid and Children's Health Insurance Program Enrollees with Asthma
    by Jill Boylston. Herndon & Soeren Mattke & Alison Evans Cuellar & Seo Yeon. Hong & Elizabeth A. Shenkman

  • 2012 Changes in Antipsychotic Medication Use after Implementation of a Medicaid Mental Health Carve-Out in the US
    by John Robst

  • 2012 Pharmacoeconomics of Bisphosphonates for Skeletal-Related Event Prevention in Metastatic Non-Breast Solid Tumours
    by John A. Carter & Avani D. Joshi & Satyin Kaura & Marc F. Botteman

  • 2012 Issues in the Economic Evaluation of Influenza Vaccination by Injection of Healthy Working Adults in the US: A Review and Decision Analysis of Ten Published Studies
    by Thomas J. Hogan

  • 2012 Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program
    by Nadia Demarteau & Thomas Breuer & Baudouin Standaert

  • 2012 Changes in Utilization and Costs for Patients with Rheumatoid Arthritis, 1997 to 2006
    by Howard G. Birnbaum & Crystal Pike & Ritesh Banerjee & Tracy Waldman & Mary Cifaldi

  • 2012 Cost Effectiveness of Anticoagulation in Acute Coronary Syndromes
    by Jaime Latour-Prez & Eva de-Miguel-Balsa

  • 2012 Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease: A Review of the Evidence and Methodological Issues
    by Maureen P.M.H. Rutten-van Mlken & Lucas M.A. Goossens

  • 2012 Golimumab for the Treatment of Psoriatic Arthritis: A NICE Single Technology Appraisal
    by Huiqin Yang & Dawn Craig & David Epstein & Laura Bojke & Kate Light & Ian N. Bruce & Mark Sculpher & Nerys Woolacott

  • 2012 Rufinamide: A Pharmacoeconomic Profile of its Use as Adjunctive Therapy in Lennox-Gastaut Syndrome
    by Paul L. McCormack

  • 2012 Common Drug Review Recommendations: An Evidence Base for Expectations?
    by Angela Rocchi & Elizabeth Miller & Robert B. Hopkins & Ron Goeree

  • 2012 Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands
    by Ties Hoomans & Johan L. Severens & Nicole van der Roer & Gepke O. Delwel

  • 2012 Pricing Human Papillomavirus Vaccines: Lessons from Italy
    by Livio Garattini & Katelijne van de Vooren & Alessandro Curto

  • 2012 Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001-7
    by Frank R. Lichtenberg

  • 2012 Measuring Quality of Life in Patients with Schizophrenia: An Update
    by A. George. Awad & Lakshmi N.P. Voruganti

  • 2012 Population- versus Cohort-Based Modelling Approaches
    by Olivier Ethgen & Baudouin Standaert

  • 2012 Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer's Perspective
    by Aurea Duran & Nishan Sengupta & Alexander Diamantopoulos & Fiona Forster & Louis Kwong & Michael Lees

  • 2012 Health Utility Elicitation: Is There Still a Role for Direct Methods?
    by Lisa A. Prosser & Scott D. Grosse & Eve Wittenberg

  • 2012 Osteoporotic Fractures: A Systematic Review of US Healthcare Costs and Resource Utilization
    by Sangeeta Budhia & Yeshi Mikyas & Michael Tang & Enkhe Badamgarav

  • 2012 Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery: A NICE Single Technology Appraisal
    by Michael Holmes & Christopher Carroll & Diana Papaioannou

  • 2012 Real Economics Needs to Reflect Real Decisions: A Response to Johnson
    by Mark Sculpher & Karl Claxton

  • 2012 Why Not Real Economics?
    by F. Reed. Johnson

  • 2012 Incorporating Calibrated Model Parameters into Sensitivity Analyses: Deterministic and Probabilistic Approaches
    by Douglas C.A. Taylor & Vivek Pawar & Denise T. Kruzikas & Kristen E. Gilmore & Myrlene Sanon & Milton C. Weinstein

  • 2012 Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer
    by Robert I. Griffiths & Richard L. Barron & Michelle L. Gleeson & Mark D. Danese & Anthony OHagan & Victoria M. Chia & Jason C. Legg & Gary H. Lyman

  • 2012 Erratum
    by Adis International Limited

  • 2012 A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis
    by Christopher Fitzpatrick & Katherine Floyd

  • 2012 Does the EQ-5D Reflect Lost Earnings?
    by Carl Tilling & Marieke Krol & Aki Tsuchiya & John Brazier & Job van Exel & Werner Brouwer

  • 2012 Dronedarone for the Treatment of Atrial Fibrillation: A NICE Single Technology Appraisal
    by Claire McKenna & Emma Maund & Muhammad Sarowar & David Fox & Matt Stevenson & Chris Pepper & Nerys Woolacott & Stephen Palmer

  • 2012 Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
    by Mathilda L. Bongers & Veerle M.H. Coup & Elise P. Jansma & Egbert F. Smit & Carin A. Uyl-de Groot

  • 2012 Economic and Humanistic Burden of External Genital Warts
    by Adam J.N. Raymakers & Mohsen Sadatsafavi & Fawziah Marra & Carlo A. Marra

  • 2012 Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets
    by Liv Ariane Augestad & Kim Rand-Hendriksen & Ivar Snb Kristiansen & Knut Stavem

  • 2012 What's Good and Bad About Contraceptive Products?: A Best-Worst Attribute Experiment Comparing the Values of Women Consumers and GPs
    by Stephanie A. Knox & Rosalie C. Viney & Deborah J. Street & Marion R. Haas & Denzil G. Fiebig & Edith Weisberg & Deborah Bateson

  • 2012 Chemotherapy Administration: Modelling the Costs of Alternative Protocols
    by Philip Haywood & Johan de Raad & Kees van Gool & Marion Haas & Gisselle Gallego & Sallie-Anne Pearson & Margaret Faedo & Robyn Ward

  • 2012 Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex) for Spasticity in Multiple Sclerosis
    by Lanting Lu & Hilary Pearce & Chris Roome & James Shearer & Iain A. Lang & Ken Stein

  • 2012 Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis: A Critical and Systematic Review
    by Ccile Gaujoux-Viala & Bruno Fautrel

  • 2012 A Systematic Review and Critical Assessment of Health State Utilities: Weight Change and Type 2 Diabetes Mellitus
    by Scott Doyle & Andrew Lloyd & Lee Moore & Joshua Ray & Alastair Gray

  • 2012 Bevacizumab for Metastatic Colorectal Cancer: A NICE Single Technology Appraisal
    by Sophie Whyte & Abdullah Pandor & Matt Stevenson

  • 2012 Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis
    by Marta O. Soares & Lusa Canto e Castro

  • 2012 Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6-11 Years: A NICE Single Technology Appraisal
    by Jane Burch & Susan Griffin & Claire McKenna & Simon Walker & James Paton & Kath Wright & Nerys Woolacott

  • 2012 Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis: A Case for Excluding Dialysis Costs
    by Daniel T. Grima & Lisa M. Bernard & Elizabeth S. Dunn & Philip A. McFarlane & David C. Mendelssohn

  • 2012 Erratum
    by Adis International Limited

  • 2012 The General Public's Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimer's Disease Medication
    by Mark Oremus & Jean-Eric Tarride & Parminder Raina & Lehana Thabane & Gary Foster & Charlie H. Goldsmith & Natasha Clayton

  • 2012 The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes: A New Zealand Evaluation
    by Laura Panattoni & Paul M. Brown & Braden Te Ao & Mark Webster & Patrick Gladding

  • 2012 A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand
    by Rajan Ragupathy & Katri Aaltonen & June Tordoff & Pauline Norris & David Reith

  • 2012 Losing Sight of the Wood for the Trees: Some Issues in Describing and Valuing Health, and Another Possible Approach
    by Paul Dolan & Henry Lee & Tessa Peasgood

  • 2012 Cost Effectiveness of Hepatitis C-Related Interventions Targeting Substance Users and Other High-Risk Groups: A Systematic Review
    by Ava John-Baptiste & Man Wah Yeung & Victoria Leung & Gabrielle van der Velde & Murray Krahn

  • 2012 The Burden of Moderate to Severe Psoriasis: An Overview
    by Giovanna Raho & Daniela Mihajlova Koleva & Livio Garattini & Luigi Naldi

  • 2012 The Authors' Reply
    by Ties Hoomans & Johan L. Severens & Nicole van der Roer & Gepke O. Delwel

  • 2012 Is There a Role for Pharmacoeconomics in Decision Making?
    by Johan C.F. van Luijn

  • 2012 Validity of Cost and Utility Results?
    by Alex Diamantopoulos & Laura Sawyer & Sarika Ogale & Fred Dejonckheere

  • 2012 The Authors' Reply
    by Mark Bounthavong & Christine M. Nguyen & Margaret A.S. Mendes & Melissa L.D. Christopher & Josephine N. Tran & Rashid Kazerooni & Anthony P. Morreale

  • 2012 Patient Preferences for Community Pharmacy Asthma Services: A Discrete Choice Experiment
    by Pradnya Naik-Panvelkar & Carol Armour & John M. Rose & Bandana Saini

  • 2012 Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting
    by Laura McCullagh & Cathal Walsh & Michael Barry

  • 2012 The State of Health Economic Research in South Africa: A Systematic Review
    by Paul Gavaza & Karen L. Rascati & Abiola O. Oladapo & Star Khoza

  • 2012 The Cost Effectiveness of Newer Epilepsy Treatments: A Review of the Literature on Partial-Onset Seizures
    by Kristian Bolin & Lars Forsgren

  • 2012 Counting the Cost of Not Costing HIV Health Facilities Accurately: Pay Now, or Pay More Later
    by Eduard J. Beck & Carlos Avila & Sofia Gerbase & Guy Harling & Paul De Lay

  • 2012 New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses
    by Douglas W. Mapel & Melissa H. Roberts

  • 2012 Private Manufacturers' Thresholds to Invest in Comparative Effectiveness Trials
    by Anirban Basu & David Meltzer

  • 2012 Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?
    by Jaume Puig-Junoy

  • 2012 Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain: The ECOBIM Study
    by Tatiana Dilla & Amparo Valladares & Claudia Nicolay & Javier Salvador & Jess Reviriego & Mara Costi

  • 2012 What Explains Willingness to Pay for Smoking-Cessation Treatments - Addiction Level, Quit-Rate Effectiveness or the Opening Bid?
    by Jan Abel. Olsen & Ole J. Rgeberg & Knut Stavem

  • 2012 Insensitivity to Scope in Contingent Valuation Studies: Reason for Dismissal of Valuations?
    by Rikke Sgaard & Jes Lindholt & Dorte Gyrd-Hansen

  • 2012 Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison
    by M. Haim Erder & Jipan Xie & James E. Signorovitch & Kristina S. Chen & Paul Hodgkins & Mei Lu & Eric Q. Wu & Vanja Sikirica

  • 2012 Inclusion of Compliance and Persistence in Economic Models: Past, Present and Future
    by Ananth Kadambi & Robert J. Leipold & Anuraag R. Kansal & Sonja Sorensen & Denis Getsios

  • 2012 Insensitivity to Scope in Contingent Valuation Studies: New Direction for an Old Problem
    by Jennifer A. Whitty

  • 2012 Acknowledgement
    by Adis International Limited

  • 2012 Five-Year Evolution of Drug Prescribing in a University Adult Intensive Care Unit
    by Christine Carron & Pierre Voirol & Philippe Eggimann & Andr Pannatier & Ren Chiolro & Jean-Blaise Wasserfallen

  • 2012 Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis: Results from a 1-Year, Multicentre, Open-Label, Single-Arm Study in a Clinical Setting
    by Ronald Vender & Charles Lynde & Vincent Ho & Dina Chau & Melanie Poulin-Costello

  • 2012 Clopidogrel versus Aspirin in Patients with Atherothrombosis: A CAPRIE-Based Cost-Effectiveness Model for Greece
    by Georgia Kourlaba & Vassilis Fragoulakis & Nikos Maniadakis

  • 2012 Estimating Incremental Costs with Skew: A Cautionary Note
    by Linnea A. Polgreen & John M. Brooks

  • 2012 Lifetime Productivity Losses Associated with Obesity Status in Early Adulthood: A Population-Based Study of Swedish Men
    by Kristian Neovius & Clas Rehnberg & Finn Rasmussen & Martin Neovius

  • 2012 PleurX Peritoneal Catheter Drainage System for Vacuum-Assisted Drainage of Treatment-Resistant, Recurrent Malignant Ascites: A NICE Medical Technology Guidance
    by Judith White & Grace Carolan-Rees

  • 2012 NICE Medical Technologies Guidance: A Novel and Rigorous Methodology to Address a New Health Technology Assessment Challenge
    by Bruce Campbell & Mark Campbell

  • 2012 Is More Expensive Medical Technology Better?: The Use of Analytics in the Evaluation of Clinical Outcomes for Different Material Compositions of Total Knee Implants
    by Jeffrey Voigt & Michael Mosier

  • 2012 Alcohol Reform in Viet Nam: Confronting Rising Consumption, Injury and Harm
    by Nguyen Minh. Tam & Christopher M. Doran & Peter S. Hill & Michael P. Dunne

  • 2012 Cost-Effectiveness Analysis of Treatments for Vertebral Compression Fractures
    by Avram A. Edidin & Kevin L. Ong & Edmund Lau & Jordana K. Schmier & Jason E. Kemner & Steven M. Kurtz

  • 2012 Economic Evaluation of Clopidogrel in Acute Coronary Syndrome Patients without ST-Segment Elevation in Greece: A Cost-Utility Analysis
    by Georgia Kourlaba & Vassilis Fragoulakis & Nikos Maniadakis

  • 2012 Resource Utilization and Outcomes in Patients with Atrial Fibrillation: A Case Control Study
    by Rachael Boggon & Gregory Y.H. Lip & Arlene M. Gallagher & Tjeerd P. van Staa

  • 2012 Cost Effectiveness of Drug-Eluting Stents in Acute Myocardial Infarction Patients in Germany: Results from Administrative Data Using a Propensity Score-Matching Approach
    by Michael Bumler & Tom Stargardt & Jonas Schreygg & Reinhard Busse

  • 2012 Economic Consequences of the Demography of MRSA Patients and the Impact of Broad-Spectrum Antimicrobials
    by K. Kaier & S. Moog

  • 2012 A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
    by Ulf Persson & Johanna Svensson & Billie Pettersson

  • 2012 Cost-Effectiveness Analysis of Early versus Non-Early Intervention in Acute Migraine Based on Evidence from the 'Act when Mild' Study
    by John Slof

  • 2012 National Health Insurance Reform in South Africa: Estimating the Implications for Demand for Private Health Insurance
    by Okore Apia Okorafor

  • 2012 Cost Effectiveness of Prostacyclins in Pulmonary Arterial Hypertension
    by Antonio Roman & Joan A. Barber & Pilar Escribano & Maria L. Sala & Laia Febrer & Itziar Oyagez & Eliazar Sabater & Miguel . Casado

  • 2012 Direct Healthcare Costs of Osteoporosis-Related Fractures in Managed Care Patients Receiving Pharmacological Osteoporosis Therapy
    by Hema N. Viswanathan & Jeffrey R. Curtis & Jingbo Yu & Jeffrey White & Bradley S. Stolshek & Claire Merinar & Akhila Balasubramanian & Joel D. Kallich & John L. Adams & Sally W. Wade

  • 2012 Economic Evaluations of Adult Weight Management Interventions: A Systematic Literature Review Focusing on Methods Used for Determining Health Impacts
    by Ulla K. Griffiths & Benedict Anigbogu & Kiran Nanchahal

  • 2012 Understanding Consumer Preferences in the Context of Managed Competition: Evidence from a Choice Experiment in Colombia
    by Antonio J. Trujillo & Fernando Ruiz & John F.P. Bridges & Jeannette L. Amaya & Christine Buttorff & Anglica M. Quiroga

  • 2012 Evaluating the Epidemiology and Morbidity Burden Associated with Human Papillomavirus in Israel: Accounting for CIN1 and Genital Warts in Addition to CIN2/3 and Cervical Cancer
    by Oren Shavit & Raanan Raz & Michal Stein & Gabriel Chodick & Eduardo Schejter & Yehuda Ben-David & Raanan Cohen & Daphna Arbel & Varda Shalev

  • 2012 Using the Economics of Certification to Improve the Safety and Quality of Male Circumcision in Developing Countries: Three Models of Implementation
    by Michael R. Richards

  • 2012 The Need for Measurement of Efficiency in Greek Primary Healthcare: The Case for Rural Southern and Western Greece
    by Nikolaos Oikonomou & Yannis Tountas & John Kyriopoulos

  • 2012 Budget Impact Analysis of Switching to Darunavir/Ritonavir Monotherapy for HIV-Infected People in Spain
    by Juan Pasquau & Joana Gostkorzewicz & Francisco Ledesma & Anne Anceau & Andrew Hill & Christiane Moecklinghoff

  • 2012 A Cost-Utility Analysis of Cinacalcet in Secondary Hyperparathyroidism in Five European Countries
    by Sergio Iannazzo & Michela Carsi & Silvia Chiroli

  • 2012 Insights from Triangulation of Two Purchase Choice Elicitation Methods to Predict Social Decision Making in Healthcare
    by Jennifer A. Whitty & Sharyn R. Rundle-Thiele & Paul A. Scuffham

  • 2012 Alcohol Policy and Taxation in South Africa: An Examination of the Economic Burden of Alcohol Tax
    by John Ele-Ojo. Ataguba

  • 2012 Tackling Alcohol Misuse: Purchasing Patterns Affected by Minimum Pricing for Alcohol
    by Anne Ludbrook & Dennis Petrie & Lynda McKenzie & Shelley Farrar

  • 2012 The Efficiency of a Volumetric Alcohol Tax in Australia
    by Joshua Byrnes & Dennis J. Petrie & Christopher M. Doran & Anthony Shakeshaft

  • 2012 The Role of Health Economics in Alcohol Policy
    by Christopher M. Doran & Joshua Byrnes

  • 2012 Intra-Operative vs Pre-Operative Endoscopic Sphincterotomy in Patients with Gallbladder and Common Bile Duct Stones: Cost-Utility and Value-of-Information Analysis
    by Kurinchi Gurusamy & Edward Wilson & Andrew K. Burroughs & Brian R. Davidson

  • 2012 Triangulating Health Expenditure Estimates from Different Data Sources in Developing Countries: The Case of Pakistan's Private Health Expenditure
    by Christian Lorenz

  • 2012 Economic Implications of Rasburicase Treatment in Adult Patients with Tumour Lysis Syndrome
    by Michael Eaddy & Brian Seal & Krishna Tangirala & Elizabeth Hackney. Davies & Ken ODay

  • 2012 Saving In Foreign Currency And Its Effects: An Empirical Analysis
    by Oana NITU & Claudiu Valentin NITU & Cosmin TILEAGA

  • 2012 Recession of Economy and the New Aspects of Consumer Behaviour: the Case of Romania
    by Anghelina Andrei,

  • 2012 Consideration Regarding the Approach of Sme’s Development Modalities, in Context of Knowledge-Based Economy, from the Perspective of Firm Theories
    by Popescu Manoela & Crenicean Cecilia Luminita

  • 2012 The Influence of Conflicts of Interest on Firm Value
    by Georgescu Cristina Elena

  • 2012 The Modalities to Resolve Conflicts of Interest between Stakeholders
    by Georgescu Cristina Elena

  • 2012 Information and Communication Technologies- Vector of Development of the Knowledge Based Economy
    by Cuºu Dorinela & Chiriac Marius & Teliceanu Viorel

  • 2012 A New Social Class-The Knowledge Workers
    by Cuºu Dorinela & Brailoiu Liviu & Bujduveanu Aurica

  • 2012 Imkb’de Islem Goren Cimento Sektorundeki Sirketlerin Finansal Performanslarinin VIKOR Yontemi Ile Siralanmasi
    by Unal H. Ozden & Ozlem Deniz Basar & Seda Bagdatli Kalkan

  • 2012 Old is not sexy. How media do (not) report about older people, and how older Swiss journalists started their own newspapers online
    by Stephan RUSS-MOHL & Karen TORBEN-NIELSEN

  • 2012 Out of control? How online papers are both shaping and being shaped by user generated content
    by Michael KARLSSON & Mart OTS

  • 2012 Médias et marché alternatif : une nouvelle lecture de l’espace public pendant la Roumanie de Ceausescu
    by Alexandra BARDAN

  • 2012 Determinants of a throwaway society – A sustainable consumption issue
    by McCollough, John

  • 2012 The effect of question wording on consumers’ reported inflation expectations
    by Bruine de Bruin, Wändi & van der Klaauw, Wilbert & Topa, Giorgio & Downs, Julie S. & Fischhoff, Baruch & Armantier, Olivier

  • 2012 Investment risk – The perspective of individual investors
    by Sachse, Katharina & Jungermann, Helmut & Belting, Julia M.

  • 2012 Housing submarkets and the impacts of foreclosures on property prices
    by Biswas, Arnab

  • 2012 Does the public sector over-provide club goods? A general result
    by al-Nowaihi, Ali & Fraser, Clive D.

  • 2012 The co-evolution of reciprocity-based wage offers and effort choices
    by Schliffke, Philipp

  • 2011 How to Move Product Market Regulation in New Zealand Back Towards the Frontier
    by Paul Conway

  • 2011 A Stochastic Life Cycle Model of Academic Research and Patent Licensing
    by Richard Jensen

  • 2011 L’accès à des services énergétiques réduit-il la malnutrition des enfants au Sénégal ? Evaluation du programme des plateformes multifonctionnelles
    by Marie-Charlotte BUISSON

  • 2011 The Normative Bias In Entrepreneurial Theory

  • 2011 How Should A Public Good Be Provided? A Transaction Cost Approach

  • 2011 Can Destructive Network Activities Push An Economy To A Lower Level Of Specialization? A Theoretical Illustration

  • 2011 Can Patients Diagnosed with Schizophrenia Complete Choice-Based Conjoint Analysis Tasks?
    by John F.P. Bridges & Elizabeth T. Kinter & Annette Schmeding & Ina Rudolph & Axel Mhlbacher

  • 2011 Comparison of Scores Derived from the Box Score-11 Scale and the Pain Attribute of the Health Utilities Index-3
    by Michael Iskedjian & Barbara Jaszewski & Olivier Desjardins

  • 2011 Estimation of Utilities in Attention-Deficit Hyperactivity Disorder for Economic Evaluations
    by Andrew Lloyd & Paul Hodgkins & Rahul Sasane & Ron Akehurst & Edmund J.S. Sonuga-Barke & Patrick Fitzgerald & Annabel Nixon & Haim Erder & John Brazier

  • 2011 Offering Results to Participants in a Diabetes Survey: Effects on Survey Response Rates
    by Jeanette Y. Ziegenfuss & Nilay D. Shah & James R. Deming & Holly K. Van Houten & Steven A. Smith & Timothy J. Beebe

  • 2011 Treatment Satisfaction Instruments for Different Purposes during a Product's Lifecycle: Keeping the End in Mind
    by Diana Rofail & Fiona Taylor & Antoine Regnault & Anna Filonenko

  • 2011 Societal Values in the Allocation of Healthcare Resources: Is it All About the Health Gain?
    by Tania Stafinski & Devidas Menon & Deborah Marshall & Timothy Caulfield

  • 2011 Acknowledgment
    by Adis International Limited

  • 2011 Medication Non-Compliance in Zagreb, Croatia
    by Marcel Leppe & Josip Culig & Jelena Boskovic

  • 2011 Impact of Walking Impairment in Multiple Sclerosis: Perspectives of Patients and Care Partners
    by Nicholas G. LaRocca

  • 2011 Establishing the Content Validity of the King's Health Questionnaire in Men and Women with Overactive Bladder in the US
    by Mary Kay. Margolis & Vasudha Vats & Karin S. Coyne & Con Kelleher

  • 2011 Elicitation of Ostomy Pouch Preferences: A Discrete-Choice Experiment
    by Ole Bonnichsen

  • 2011 Integrating Evidence and Individual Preferences Using a Web-Based Multi-Criteria Decision Analytic Tool: An Application to Prostate Cancer Screening
    by Michelle Cunich & Glenn Salkeld & Jack Dowie & Joan Henderson & Clare Bayram & Helena Britt & Kirsten Howard

  • 2011 Exploring Qualitative Research Synthesis: The Role of Patients' Perspectives in Health Policy Design and Decision Making
    by Helle Ploug. Hansen & Eva Draborg & Finn Brlum. Kristensen

  • 2011 Great Expectations: What Do Patients Using Complementary and Alternative Medicine Hope For?
    by E. Ernst & S.K. Hung

  • 2011 Analysis of Health-Related Quality-of-Life Instruments Measuring the Impact of Bariatric Surgery: Systematic Review of the Instruments Used and their Content Validity
    by Raed Tayyem & Abdulmajid Ali & John Atkinson & Colin R. Martin

  • 2011 Patient Advocacy in Research: Merely an Afterthought?
    by Musa Mayer

  • 2011 Persistence with Prostaglandin Agonist Use with and without Adjunctive Therapy for Glaucoma Patients: A Canadian Population-Based Analysis
    by Michael Iskedjian & David W. Covert & John H. Walker

  • 2011 Eliciting Preferences for Reimbursed Drugs Selection Criteria in C�te d'Ivoire
    by Vakaramoko Diaby & Henri Di Kakou & Jean Lachaine

  • 2011 An Instrument to Assess the Needs of Patients with Type 2 Diabetes Mellitus for Health-Promotion Activities
    by Anneke N. van Dijk-de Vries & Inge G.P. Duimel-Peeters & Hubertus J.M. Vrijhoef

  • 2011 Impact of Gastrointestinal Problems on Adherence to Low-Dose Acetylsalicylic Acid: A Quantitative Study in Patients with Cardiovascular Risk
    by Christina Moberg & Jrgen Naesdal & Lars-Erik Svedberg & Delphine Duchateau & Nicola Harte

  • 2011 A Qualitative Study on Feasibility of a Web-Based Women's Health Portal and Information System
    by Min Yang & Mark Kosinski & Rosemarie Boulanger

  • 2011 Family Burden after Severe Brain Injury: The Italian Experience with Families and Volunteer Associations
    by Paola Mosconi & Mariangela Taricco & Mirna Bergamini & Luisella Bosisio Fazzi & Cinzia Colombo & Valentina Patrucco & Marinella Corti & Dario Giobbe & Massimo Guerreschi & Maria Rita. Magnarella & Giovanni Sallemi

  • 2011 Patient Preferences for Treatment of Achilles Tendon Pain: Results from a Discrete-Choice Experiment
    by Kent R. Sweeting & Jennifer A. Whitty & Paul A. Scuffham & Michael J. Yelland

  • 2011 Development of an Electronic Daily Uterine Fibroid Symptom Diary
    by Linda S. Deal & Valerie S.L. Williams & Sheri E. Fehnel

  • 2011 Understanding and Assessing the Impact of End-Stage Renal Disease on Quality of Life: A Systematic Review of the Content Validity of Self-Administered Instruments Used to Assess Health-Related Quality of Life in End-Stage Renal Disease
    by Cheryl Glover & Pauline Banks & Amanda Carson & Colin R. Martin & Tim Duffy

  • 2011 Patient-Reported Outcomes, Patient-Reported Information: From Randomized Controlled Trials to the Social Web and Beyond
    by Mike Baldwin & Andrew Spong & Lynda Doward & Ari Gnanasakthy

  • 2011 Public and Patient Involvement at the UK National Institute for Health and Clinical Excellence
    by Leela Barham

  • 2011 Cinacalcet: A Pharmacoeconomic Review of its Use in Secondary Hyperparathyroidism in End-Stage Renal Disease
    by Greg L. Plosker

  • 2011 Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand
    by Naiyana Praditsitthikorn & Yot Teerawattananon & Sripen Tantivess & Supon Limwattananon & Arthorn Riewpaiboon & Saibua Chichareon & Nantakan Ieumwananonthachai & Viroj Tangcharoensathien

  • 2011 To Fund or Not to Fund: Development of a Decision-Making Framework for the Coverage of New Health Technologies
    by Tania Stafinski & Devidas Menon & Christopher McCabe & Donald J. Philippon

  • 2011 Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure: A Systematic Review
    by Alexander Goehler & Benjamin P. Geisler & Jennifer M. Manne & Beate Jahn & Annette Conrads-Frank & Petra Schnell-Inderst & G. Scott. Gazelle & Uwe Siebert

  • 2011 Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies: Reviewing the Available Evidence
    by Petros Pechlivanoglou & Robin De. Vries & Simon M.G.J. Daenen & Maarten J. Postma

  • 2011 Value-Based Pricing: Incentive for Innovation or Zero Net Benefit?
    by Dyfrig A. Hughes

  • 2011 Estimating the Relationship between Preference-Based Generic Utility Instruments and Disease-Specific Quality-of-Life Measures in Severe Chronic Constipation: Challenges in Practice
    by Mark Parker & Alan Haycox & Jane Graves

  • 2011 Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis: Focus on Critically Ill Patients
    by Annette C. Reboli & Coleman Rotstein & Daniel H. Kett & Michael Maschio & Shannon Cartier & Richard Chambers & Miriam Tarallo

  • 2011 Cost Estimation of Cardiovascular Disease Events in the US
    by Amy K. OSullivan & Jaime Rubin & Joshua Nyambose & Andreas Kuznik & David J. Cohen & David Thompson

  • 2011 US FDA Modernization Act, Section 114: Uses, Opportunities and Implications for Comparative Effectiveness Research
    by Peter J. Neumann & Pei-Jung Lin & Tom E. Hughes

  • 2011 Using QALYs in Cancer: A Review of the Methodological Limitations
    by Martina Garau & Koonal K. Shah & Anne R. Mason & Qing Wang & Adrian Towse & Michael F. Drummond

  • 2011 Cost-of-Illness Studies: A Guide to Critical Evaluation
    by Allison Larg & John R. Moss

  • 2011 Challenges in Health State Valuation in Paediatric Economic Evaluation: Are QALYs Contraindicated?
    by Wendy J. Ungar

  • 2011 The Case for Less, Not More, US FDA Regulation
    by John A. Vernon & Joseph H. Golec

  • 2011 Medication Costs to Private Insurers of Diversion of Medications for Attention-Deficit Hyperactivity Disorder
    by Arnie P. Aldridge & Larry A. Kroutil & Alexander J. Cowell & Daniel B. Reeves & David L. Van Brunt

  • 2011 Do Productivity Costs Matter?: The Impact of Including Productivity Costs on the Incremental Costs of Interventions Targeted at Depressive Disorders
    by Marieke Krol & Joc Papenburg & Marc Koopmanschap & Werner Brouwer

  • 2011 Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV: A Systematic Review for Low- and Middle-Income Countries
    by Omar Galrraga & Veronika J. Wirtz & Alejandro Figueroa-Lara & Yared Santa-Ana-Tellez & Ibrahima Coulibaly & Kirsi Viisainen & Antonieta Medina-Lara & Eline L. Korenromp

  • 2011 Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies
    by Simon Eckermann & Andrew R. Willan

  • 2011 Prioritizing Comparative Effectiveness Research: Are Drug and Implementation Trials Equally Worth Funding?
    by Afschin Gandjour

  • 2011 Reflections on the Changing Face of German Pharmaceutical Policy: How Far is Germany from Value-Based Pricing?
    by Andreas Gerber & Stephanie Stock & Charalabos-Markos Dintsios

  • 2011 PAID 1.0 in Practice: A Brief Clarification Regarding its Possibilities and Limitations
    by Pieter van Baal & Werner Brouwer

  • 2011 Intravenous Esomeprazole: A Pharmacoeconomic Profile of its Use in the Prevention of Recurrent Peptic Ulcer Bleeding
    by Gillian M. Keating

  • 2011 A Value Set for the EQ-5D Based on Experienced Health States: Development and Testing for the German Population
    by Reiner Leidl & Peter Reitmeir

  • 2011 The Direct Medical Costs Associated with Suspected Heparin-Induced Thrombocytopenia
    by Natasha Nanwa & Nicole Mittmann & Sandra Knowles & Claudia Bucci & Rita Selby & Neil Shear & Scott E. Walker & William Geerts

  • 2011 A Discrete-Event Simulation of Smoking-Cessation Strategies Based on Varenicline Pivotal Trial Data
    by James G. Xenakis & Elizabeth T. Kinter & K. Jack. Ishak & Alexandra J. Ward & Jen P. Marton & Richard J. Willke & Simon Davies & J. Jaime. Caro

  • 2011 Health Technology Funding Decision-Making Processes Around the World: The Same, Yet Different
    by Tania Stafinski & Devidas Menon & Donald J. Philippon & Christopher McCabe

  • 2011 Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the US: A Literature Review
    by Bin Zhang & Prina Z. Donga & Mitra Corral & Medha Sasane & Jeffrey D. Miller & Chris L. Pashos

  • 2011 The Appropriate Elicitation of Expert Opinion in Economic Models: Making Expert Data Fit for Purpose
    by William Sullivan & Katherine Payne

  • 2011 Rotavirus Vaccine RIX4414 (Rotarix™): A Pharmacoeconomic Review of its Use in the Prevention of Rotavirus Gastroenteritis in Developed Countries
    by Greg L. Plosker

  • 2011 The Authors' Reply
    by Zaheer-Ud-Din Babar & Shane L. Scahill

  • 2011 Is There a Role for Pharmacoeconomics in Developing Countries?
    by Jonathan R. Harper

  • 2011 Is There a Role for Pharmacoeconomics in Developing Countries?
    by Romn Prez Velasco & Yot Teerawattananon

  • 2011 Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer: A UK Perspective Considering Duration of Benefit, Long-Term Toxicity and Pattern of Recurrence
    by Peter S. Hall & Claire Hulme & Christopher McCabe & Yemi Oluboyede & Jeff Round & David A. Cameron

  • 2011 Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease: Australian, Canadian and Swedish Healthcare Perspectives
    by Nicole Mittmann & Paul Hernandez & Carl Mellstrm & Lance Brannman & Tobias Welte

  • 2011 Cost Effectiveness of Treatments for Inflammatory Bowel Disease
    by Keith Bodger

  • 2011 Modelling the Epidemiology of Infectious Diseases for Decision Analysis: A Primer
    by Mark Jit & Marc Brisson

  • 2011 Health Economic and Infectious Disease Modelling: A Guide to Merging Streams
    by Andrea Anonychuk & Murray Krahn

  • 2011 Adjuvant Trastuzumab for Breast Cancer: Uncertainties in Clinical and Economic Evidence Following Early Stopping of the HERA Trial
    by Tallal Younis & Chris Skedgel

  • 2011 Bivalirudin: A Pharmacoeconomic Profile of its Use in Patients with Acute Coronary Syndromes
    by Katherine A. Lyseng-Williamson

  • 2011 Economic Burden of Renal Cell Carcinoma in the US: Part II - An Updated Analysis
    by Ya-Chen T. Shih & Chun-Ru Chien & Ying Xu & I-Wen Pan & Grace L. Smith & Thomas A. Buchholz

  • 2011 Economic Burden of Renal Cell Carcinoma: Part I - An Updated Review
    by Ya-Chen T. Shih & Chun-Ru Chien & Ying Xu & I-Wen Pan & Grace L. Smith & Thomas A. Buchholz

  • 2011 Sensitivity Analysis in Cost-Effectiveness Studies: From Guidelines to Practice
    by Rahul Jain & Michael Grabner & Eberechukwu Onukwugha

  • 2011 Sample Size and Power for Cost-Effectiveness Analysis (Part 2): The Effect of Maximum Willingness to Pay
    by Henry A. Glick

  • 2011 The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma: An Overview of Clinical and Economic Information
    by Andrea Messori & Dario Maratea & Chiara Nozzoli & Alberto Bosi

  • 2011 Posaconazole: A Pharmacoeconomic Review of its Use in the Prophylaxis of Invasive Fungal Disease in Immunocompromised Hosts
    by Katherine A. Lyseng-Williamson

  • 2011 Comparing Methods of Data Synthesis: Re-Estimating Parameters of an Existing Probabilistic Cost-Effectiveness Model
    by Mark Oppe & Maiwenn Al & Maureen Rutten-van Mlken

  • 2011 Value of Information in the Osteoarthritis Setting: Cost Effectiveness of COX-2 Selective Inhibitors, Traditional NSAIDs and Proton Pump Inhibitors
    by Nicholas Latimer & Joanne Lord & Robert L. Grant & Rachel OMahony & John Dickson & Philip G. Conaghan

  • 2011 Advances in Cancer Therapeutics and Patient Access to New Drugs
    by George Dranitsaris & Ilse Truter & Martie S. Lubbe & Eitan Amir & William Evans

  • 2011 Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children: A Review
    by Chantal W.B. Boonacker & Pieter H. Broos & Elisabeth A.M. Sanders & Anne G.M. Schilder & Maroeska M. Rovers

  • 2011 Sample Size and Power for Cost-Effectiveness Analysis (Part 1)
    by Henry A. Glick

  • 2011 Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations
    by Pieter H.M. van Baal & Albert Wong & Laurentius C.J. Slobbe & Johan J. Polder & Werner B.F. Brouwer & G. Ardine. de Wit

  • 2011 Including Indirect Medical Care Costs from Survivor Years of Life in Economic Evaluations
    by John A. Nyman & Hawre J. Jalal

  • 2011 A Model to Transfer Trial-Based Pharmacoeconomic Analyses to Clinical Practice
    by Afschin Gandjour

  • 2011 Consistently Estimating Absolute Risk Difference when Translating Evidence to Jurisdictions of Interest
    by Simon Eckermann & Michael Coory & Andrew R. Willan

  • 2011 Impact of Treatment Success on Health Service Use and Cost in Depression: Longitudinal Database Analysis
    by Sarah Byford & Barbara Barrett & Nicolas Despigel & Alan Wade

  • 2011 A Systematic Review to Assess the Policy-Making Relevance of Dementia Cost-of-Illness Studies in the US and Canada
    by Mark Oremus & S. Carolina. Aguilar

  • 2011 Febuxostat for the Management of Hyperuricaemia in Patients with Gout: A NICE Single Technology Appraisal
    by Matt Stevenson & Abdullah Pandor

  • 2011 Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration
    by Paul Mitchell & Lieven Annemans & Richard White & Meghan Gallagher & Simu Thomas

  • 2011 The Authors' Reply
    by Zaheer-Ud-Din Babar & Shane Scahill

  • 2011 Is There a Role for Pharmacoeconomics in Developing Countries?
    by Asrul Akmal. Shafie & Mohamed Azmi. Hassali

  • 2011 Availability of and Access to Orphan Drugs: An International Comparison of Pharmaceutical Treatments for Pulmonary Arterial Hypertension, Fabry Disease, Hereditary Angioedema and Chronic Myeloid Leukaemia
    by Carl Rudolf. Blankart & Tom Stargardt & Jonas Schreygg

  • 2011 Calibrating Models in Economic Evaluation: A Comparison of Alternative Measures of Goodness of Fit, Parameter Search Strategies and Convergence Criteria
    by Jonathan Karnon & Tazio Vanni

  • 2011 Calibrating Models in Economic Evaluation: A Seven-Step Approach
    by Tazio Vanni & Jonathan Karnon & Jason Madan & Richard G. White & W. John. Edmunds & Anna M. Foss & Rosa Legood

  • 2011 Effects of Reference Pricing in Pharmaceutical Markets: A Review
    by Matteo Maria. Galizzi & Simone Ghislandi & Marisa Miraldo

  • 2011 Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis
    by Martin Hoyle

  • 2011 Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective
    by Helen Dakin & Morris Sherman & Scott Fung & Carrie Fidler & Anthony Bentley

  • 2011 Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection
    by Hui-Fang Hung & Hsiu-Hsi Chen

  • 2011 Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy: A NICE Single Technology Appraisal
    by Rumona Dickson & Adrian Bagust & Angela Boland & Michaela Blundell & Helen Davis & Yenal Dundar & Juliet Hockenhull & Carlos Martin Saborido & James Oyee & Vidhya Sagar. Ramani

  • 2011 Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: A Methodological Review
    by Judith Dams & Bernhard Bornschein & Jens Peter Reese & Annette Conrads-Frank & Wolfgang H. Oertel & Uwe Siebert & Richard Dodel

  • 2011 QALYs and Carers
    by Hareth Al-Janabi & Terry N. Flynn & Joanna Coast

  • 2011 Erratum
    by Adis International Limited

  • 2011 Acknowledgement
    by Adis International Limited

  • 2011 Rotavirus Vaccine RIX4414 (Rotarix™): A Pharmacoeconomic Review of its Use in the Prevention of Rotavirus Gastroenteritis in Developing Countries
    by Greg L. Plosker

  • 2011 Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma
    by Ateesha F. Mohamed & A. Brett. Hauber & Maureen P. Neary

  • 2011 Willingness to Pay for Adverse Drug Event Regulatory Actions
    by Jacoline Bouvy & Just Weemers & Huub Schellekens & Marc Koopmanschap

  • 2011 Denosumab for the Prevention of Osteoporotic Fractures in Post-Menopausal Women: A NICE Single Technology Appraisal
    by Graham Scotland & Norman Waugh & Pamela Royle & Paul McNamee & Rob Henderson & Rosemary Hollick

  • 2011 Sample Size Determination for Cost-Effectiveness Trials
    by Andrew R. Willan

  • 2011 Utility Estimation in Chronic Obstructive Pulmonary Disease: A Preference for Change?
    by Jennifer Petrillo & Floortje van Nooten & Paul Jones & Maureen Rutten-van Mlken

  • 2011 The Importance of the Comparator in Economic Evaluations: Working on the Efficiency Frontier
    by Mattias Neyt & Hans Van Brabandt

  • 2011 Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium
    by Mickal Hiligsmann & Jean-Yves Reginster

  • 2011 Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs
    by Alain Denis & Lut Mergaert & Christel Fostier & Irina Cleemput & Frank Hulstaert & Steven Simoens

  • 2011 Does the Market Share of Generic Medicines Influence the Price Level?: A European Analysis
    by Pieter Dylst & Steven Simoens

  • 2011 Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer: A Systematic Review of the Literature
    by Gery P. Guy & Donatus U. Ekwueme

  • 2011 A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease: Implications for Policy
    by Joseph Menzin & Lisa M. Lines & Daniel E. Weiner & Peter J. Neumann & Christine Nichols & Lauren Rodriguez & Irene Agodoa & Tracy Mayne

  • 2011 Cautions Regarding the Fitting and Interpretation of Survival Curves: Examples from NICE Single Technology Appraisals of Drugs for Cancer
    by Martin Connock & Chris Hyde & David Moore

  • 2011 Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions: The Case for Reference Models
    by Hossein Haji Ali Afzali & Jonathan Karnon

  • 2011 A Review of the Cost Effectiveness of Bisphosphonates in the Treatment of Post-Menopausal Osteoporosis in Switzerland
    by Kurt Lippuner & Richard F. Pollock & Jayne Smith-Palmer & Thomas Meury & William J. Valentine

  • 2011 An Application of a Proposed Framework for Formulary Listing in Low-Income Countries: The Case of C�te d'Ivoire
    by Vakaramoko Diaby & Jean Lachaine

  • 2011 Excess Costs Associated with Patients with Chronic Thromboembolic Pulmonary Hypertension in a US Privately Insured Population
    by Noam Y. Kirson & Howard G. Birnbaum & Jasmina I. Ivanova & Tracy Waldman & Vijay Joish & Todd Williamson

  • 2011 Early Retirement and Income Loss in Patients with Early and Advanced Parkinson's Disease
    by Scott Johnson & Matthew Davis & Anna Kaltenboeck & Howard Birnbaum & ElizaBeth Grubb & Marcy Tarrants & Andrew Siderowf

  • 2011 Cost Effectiveness of Self-Monitoring of Blood Glucose (SMBG) for Patients with Type 2 Diabetes and Not on Insulin: Impact of Modelling Assumptions on Recent Canadian Findings
    by Sandra L. Tunis

  • 2011 Early Assessment of Medical Technologies to Inform Product Development and Market Access: A Review of Methods and Applications
    by Maarten J. IJzerman & Lotte M.G. Steuten

  • 2011 Assessing Quality of Life among British Older People Using the ICEPOP CAPability (ICECAP-O) Measure
    by Terry N. Flynn & Phil Chan & Joanna Coast & Tim J. Peters

  • 2011 Cost Effectiveness of Chemoprevention for Prostate Cancer with Dutasteride in a High-Risk Population Based on Results from the REDUCE Clinical Trial
    by Michael W. Kattan & Stephanie R. Earnshaw & Cheryl L. McDade & Libby K. Black & Gerald L. Andriole

  • 2011 Excess Costs Associated with Patients with Pulmonary Arterial Hypertension in a US Privately Insured Population
    by Noam Y. Kirson & Howard G. Birnbaum & Jasmina I. Ivanova & Tracy Waldman & Vijay Joish & Todd Williamson

  • 2011 Nutrition Therapy Cost Analysis in the US: Pre-Mixed Multi-Chamber Bag vs Compounded Parenteral Nutrition
    by Robin S. Turpin & Todd Canada & Frank Xiaoqing. Liu & Catherine J. Mercaldi & Alessandro Pontes-Arruda & Paul Wischmeyer

  • 2011 Drugs for Rare Diseases: Influence of Orphan Designation Status on Price
    by Eline Picavet & Marc Dooms & David Cassiman & Steven Simoens

  • 2011 Cost Effectiveness of Secondary vs Tertiary Prevention for Post-Menopausal Osteoporosis
    by Dirk Mueller & Afschin Gandjour

  • 2011 The Use of Decision-Analytic Models in Parkinson's Disease: A Systematic Review and Critical Appraisal
    by James Shearer & Colin Green & Carl E. Counsell & John P. Zajicek

  • 2011 Ordering Errors, Objections and Invariance in Utility Survey Responses: A Framework for Understanding Who, Why and What to Do
    by Eve Wittenberg & Lisa A. Prosser

  • 2011 Cost-Efficacy Analysis of the MONET Trial Using UK Antiretroviral Drug Prices
    by Brian Gazzard & Andrew Hill & Anne Anceau

  • 2011 Design of Patient Access Schemes in the UK: Influence of Health Technology Assessment by the National Institute for Health and Clinical Excellence
    by Szymon Jarosawski & Mondher Toumi

  • 2011 Hospital Costs, Length of Stay and Mortality Associated with Childhood, Adolescent and Young Adult Meningococcal Disease in the US
    by Keith L. Davis & Timothy J. Bell & Jacqueline M. Miller & Derek A. Misurski & Bela Bapat

  • 2011 Cost Effectiveness of Tobacco Control Policies in Vietnam: The Case of Population-Level Interventions
    by Hideki Higashi & Khoa D. Truong & Jan J. Barendregt & Phuong K. Nguyen & Mai L. Vuong & Thuy T. Nguyen & Phuong T. Hoang & Angela L. Wallace & Tien V. Tran & Cuong Q. Le & Christopher M. Doran

  • 2011 Patent Extension Policy for Paediatric Indications: An Evaluation of the Impact within Three Drug Classes in a State Medicaid Programme
    by Richard E. Nelson & Carrie McAdam-Marx & Megan L. Evans & Robert Ward & Benjamin Campbell & Diana Brixner & Joanne Lafleur

  • 2011 Assessing the Performance of a New Generic Measure of Health-Related Quality of Life for Children and Refining it for Use in Health State Valuation
    by Katherine Stevens

  • 2011 Valuing Health at Different Ages: Evidence from a Nationally Representative Survey in the US
    by Daniel Eisenberg & Gary L. Freed & Matthew M. Davis & Dianne Singer & Lisa A. Prosser

  • 2011 The Impact of Inclusion Criteria in Health Economic Assessments
    by Anke Richter & Patricia Thieda & Kylie Thaler & Gerald Gartlehner

  • 2011 The Economics of the NHS Cancer Drugs Fund
    by Alan Maynard & Karen Bloor

  • 2011 Influenza Vaccination in Healthy Working Adults in Russia: Observational Study of Effectiveness and Return on Investment for the Employer
    by O. Yu. Atkov & A.V. Azarov & D.A. Zhukov & N. Nicoloyannis & L. Durand

  • 2011 Citizens' Preferences for Brand Name Drugs for Treating Acute and Chronic Conditions: A Pilot Study
    by Arina Denoth & Christophe Pinget & Jean-Blaise Wasserfallen

  • 2011 Public and Decision Maker Stated Preferences for Pharmaceutical Subsidy Decisions: A Pilot Study
    by Jennifer A. Whitty & Paul A. Scuffham & Sharyn R. Rundle-Thiele

  • 2011 Germany's Decision Rule for Setting Ceiling Prices of Drugs: A Comparative Analysis with Other Decision Rules
    by Afschin Gandjour

  • 2011 Impact of Fibromyalgia Severity on Health Economic Costs: Results from a European Cross-Sectional Study
    by Andreas Winkelmann & Serge Perrot & Caroline Schaefer & Kellie Ryan & Arthi Chandran & Alesia Sadosky & Gergana Zlateva

  • 2011 Current and Future Economic Burden of Osteoporosis in New Zealand
    by Paul Brown & Rob McNeill & William Leung & Eman Radwan & Jane Willingale

  • 2011 Influence of Patient Co-Payments on Atypical Antipsychotic Choice in Poland: Implications Once Generic Atypicals are Available
    by Magda Wladysiuk & Aleksander Araszkiewicz & Brian Godman & Katarzyna Szabert; Prescribing Research Group, University of Liverpool Management School, Liverpool, UK; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden & Corrado Barbui & Alan Haycox

  • 2011 The Impact of CT Colonography for Colorectal Cancer Screening on the UK NHS: Costs, Healthcare Resources and Health Outcomes
    by Alison Sweet & David Lee & Kerry Gairy & Denver Phiri & Timothy Reason & Kevin Lock

  • 2011 Determinants of Out-of-Pocket Health Expenditure in China: Analysis Using China Health and Nutrition Survey Data
    by Xuedan You & Yasuki Kobayashi

  • 2011 Costs to Hospitals of Acquiring and Processing Blood in the US: A Survey of Hospital-Based Blood Banks and Transfusion Services
    by Richard W. Toner & Laura Pizzi & Brian Leas & Samir K. Ballas & Alyson Quigley & Neil I. Goldfarb

  • 2011 Valuing Child Health Utility 9D Health States with a Young Adolescent Sample: A Feasibility Study to Compare Best-Worst Scaling Discrete-Choice Experiment, Standard Gamble and Time Trade-Off Methods
    by Julie Ratcliffe & Leah Couzner & Terry Flynn & Michael Sawyer & Katherine Stevens & John Brazier & Leonie Burgess

  • 2011 The Chinese Healthcare System: Structure, Problems and Challenges
    by Jens Leth. Hougaard & Lars Peter. sterdal & Yi Yu

  • 2011 Knowledge Based Company– a Theoretical Approach
    by Cuºu Dorinela

  • 2011 The Knowledge Based Society and Economy. Literature Review
    by Cuºu Dorinela

  • 2010 Fleet Restructuring, Rent Generation and the Design of Individual Transferable Fishing Quota Programs: Empirical Evidence from the Pacific Coast Groundfish Fishery
    by "Lian, Carl"

  • 2010 US Residential Energy Demand and Energy Efficiency: A Stochastic Demand Frontier Approach
    by Massimo Filippini & Lester C Hunt

  • 2010 Energy demand and energy efficiency in the OECD countries: a stochastic demand frontier approach
    by Massimo Filippini & Lester C Hunt

  • 2010 Monitoring to Reduce Agency Costs: Examining the Behavior of Independent and Non-Independent Boards
    by Frank Milne & Lynnette Purda & Anita Anand

  • 2010 Agent-Based Modeling: The Right Mathematics for the Social Sciences?
    by Borrill, Paul L. & Tesfatsion, Leigh

  • 2010 Utilità intertemporale ed equità fra generazioni
    by Vinicio Guidi

  • 2010 Inflation Expectations and Stability in an Overlapping Generations Experiment with Money Creation
    by Peter Heemeijer & Cars Hommes & Joep Sonnemans & Jan Tuinstra

  • 2010 Residential Consumption of Gas and Electricity in the U.S.: The Role of Prices and Income
    by Anna Alberini & Gans Will & Daniel Lopez-Velez

  • 2010 Short and long-run time-of-use price elasticities in Swiss residential electricity demand
    by Massimo Filippini

  • 2010 Response of Residential Electricity Demand to Price: The Effect of Measurement Error
    by Massimo Filippini & Anna Alberini

  • 2010 Analysis of Patients' Preferences: Direct Assessment and Discrete-Choice Experiment in Therapy of Adults with Attention-Deficit Hyperactivity Disorder
    by Axel C. Mhlbacher & Matthias Nbling

  • 2010 Using Best-Worst Scaling Choice Experiments to Measure Public Perceptions and Preferences for Healthcare Reform in Australia
    by Jordan J. Louviere & Terry N. Flynn

  • 2010 Adaptive Choice-Based Conjoint Analysis: A New Patient-Centered Approach to the Assessment of Health Service Preferences
    by Charles E. Cunningham & Ken Deal & Yvonne Chen

  • 2010 Conjoint Analysis Applications in Health - How are Studies being Designed and Reported?: An Update on Current Practice in the Published Literature between 2005 and 2008
    by Deborah Marshall & John F.P. Bridges & Brett Hauber & Ruthanne Cameron & Lauren Donnalley & Ken Fyie & F. Reed. Johnson

  • 2010 Multi-Criteria Clinical Decision Support: A Primer on the Use of Multiple-Criteria Decision-Making Methods to Promote Evidence-Based, Patient-Centered Healthcare
    by James G. Dolan

  • 2010 Patient Preferences and Linear Scoring Rules for Patient-Reported Outcomes
    by Ateesha F. Mohamed & A. Brett. Hauber & F. Reed. Johnson & Cheryl D. Coon

  • 2010 Feasibility of Using Modified Adaptive Conjoint Analysis Importance Questions
    by Liana Fraenkel

  • 2010 Deborah Marshall, PhD: An Advocate for Patient-Centered Research
    by Rebecca L. Hancock-Howard

  • 2010 Quality of Life in Restless Legs Syndrome: A Systematic Review of Clinical Trials and a Critical Review of Instruments
    by Jane Speight & Ana Howarth

  • 2010 Electronic Patient Diaries and Questionnaires - ePRO Now Delivering on the Promise?
    by Brian Tiplady

  • 2010 Technology, Reform, and Personal Medical Care
    by Norman Makous

  • 2010 Patient Views on Determinants of Compliance with Tuberculosis Treatment in the Eastern Cape, South Africa: An Application of Q-Methodology
    by Jane Murray. Cramm & Job van Exel & Valerie Mller & Harry Finkenflgel

  • 2010 Towards Patient-Centered Care for Depression: Conjoint Methods to Tailor Treatment Based on Preferences
    by Marsha N. Wittink & Mark Cary & Thomas TenHave & Jonathan Baron & Joseph J. Gallo

  • 2010 Patient-Reported Outcomes in Rheumatoid Arthritis: Assessing the Equivalence of Electronic and Paper Data Collection
    by Brian Tiplady & Kirsteen Goodman & Geraldine Cummings & Dawn Lyle & Robert Carrington & Clare Battersby & Stuart H. Ralston

  • 2010 Qualitative Development of the Rhinitis Control Assessment Test (RCAT), an Instrument for Evaluating Rhinitis Symptom Control
    by Robert A. Nathan & Anand A. Dalal & Richard H. Stanford & Eli O. Meltzer & Michael Schatz & Jennifer Derebery & Matthew Mintz & Michelle A. Thompson & Dana B. DiBenedetti

  • 2010 Measuring Preferences for Colorectal Cancer Screening: What are the Implications for Moving Forward?
    by Deborah Marshall & S. Elizabeth McGregor & Gillian Currie

  • 2010 'New' Evidence for Clinical Practice Guidelines: Should we Search for 'Preference Evidence'?
    by Murray Krahn

  • 2010 Explorative Evaluation of the Impact of Premenstrual Disorder on Daily Functioning and Quality of Life
    by Lothar A.J. Heinemann & Thai Do Minh & Anna Filonenko & Kerstin Uhl-Hochgrber

  • 2010 Assessing Drug Treatment Preferences of Patients with Crohn's Disease: A Conjoint Analysis
    by Gary R. Lichtenstein & Heidi C. Waters & Jenna Kelly & Susan S. McDonald & Elaine L. Zanutto & David Hendricks & Mirza I. Rahman

  • 2010 Contemporary Adult Diabetes Mellitus Management Perceptions
    by William Corser & Catherine Lein & Margaret Holmes-Rovner & Ved Gossain

  • 2010 Effects of HIV Medication Complexity and Depression on Adherence to HIV Medication
    by Virender Kumar & William Encinosa

  • 2010 Development and Testing of the Insulin Treatment Experience Questionnaire (ITEQ)
    by Jrn Moock & Franz Hessel & Diana Ziegeler & Thomas Kubiak & Thomas Kohlmann

  • 2010 Pharmacological Rhythm and Rate Control Treatment for Atrial Fibrillation: Patient and Physician Satisfaction
    by Nils Edvardsson & Anders Westlund & Margareta Thimell & Karin Rise & Alexander Todoran & Tanja berg Kurn & John Kindblom & Olle Almgren

  • 2010 Is it Possible to Measure What Truly Matters? The Paradox of Clinical Audit in Developing Continence Service Standards for Older People
    by Patrick Brown & Jenny Billings & Adrian Wagg & Jonathan Potter

  • 2010 Assessing Preferences Regarding Healthcare Interventions that Involve Non-Health Outcomes: An Overview of Clinical Studies
    by Brent C. Opmeer & Corianne A.J.M. de Borgie & Ben W.J. Mol & Patrick M.M. Bossuyt

  • 2010 Cost Effectiveness of Darunavir/Ritonavir in Highly Treatment-Experienced, HIV-1-Infected Adults in the USA
    by Josephine Mauskopf & Anita Brogan & Silas Martin & Erik Smets

  • 2010 Costs to Achieve Undetectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy in Highly Pretreated Patients: The POWER Experience
    by Andrew M. Hill & Bonaventura Clotet & Margaret Johnson & Matthias Stoll & Nicholas Bellos & Erik Smets

  • 2010 The Cost of Managing HIV Infection in Highly Treatment-Experienced, HIV-Infected Adults in France
    by Xavier Colin & Antoine Lafuma & Dominique Costagliola & Jean-Marie Lang & Pascal Guillon

  • 2010 Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden
    by Ola Ghatnekar & Catharina Hjortsberg & Magnus Gissln & Stefan Lindbck & Mickael Lthgren

  • 2010 The Impact of Disease Stage on Direct Medical Costs of HIV Management: A Review of the International Literature
    by Adrian Levy & Karissa Johnston & Lieven Annemans & Andrea Tramarin & Julio Montaner

  • 2010 Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France
    by Xavier Colin & Antoine Lafuma & Dominique Costagliola & Erik Smets & Josephine Mauskopf & Pascal Guillon

  • 2010 Clinical Management of Treatment-Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era
    by Mark A. Boyd & Andrew M. Hill

  • 2010 Predicting Direct Costs of HIV Care During the First Year of Darunavir-Based Highly Active Antiretroviral Therapy Using CD4 Cell Counts: Evidence from POWER
    by Andrew M. Hill & Kelly Gebo & Lindsay Hemmett & Mickael Lthgren & Gabriele Allegri & Erik Smets

  • 2010 Cost Effectiveness of Darunavir/Ritonavir 600/100 mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK
    by Karen Moeremans & Lindsay Hemmett & Jonas Hjelmgren & Gabriele Allegri & Erik Smets

  • 2010 US Cost Effectiveness of Darunavir/Ritonavir 600/100 mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial
    by Anita Brogan & Josephine Mauskopf & Sandra E. Talbird & Erik Smets

  • 2010 Cost Effectiveness of Darunavir/Ritonavir 600/100 mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK
    by Karen Moeremans & Lieven Annemans & Mickael Lthgren & Gabriele Allegri & Veronique Wyffels & Lindsay Hemmet & Karin Caekelbergh & Erik Smets

  • 2010 A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection
    by Josephine Mauskopf & Lieven Annemans & Andrew M. Hill & Erik Smets

  • 2010 The Authors' Reply
    by Laura McCullagh & Lesley Tilson & Cathal Walsh & Michael Barry

  • 2010 The Authors' Reply
    by Alok Kapoor & Nila Radhakrishnan & Kenneth J. Smith

  • 2010 Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement:: A Systematic Review
    by Jonathan M. Plumb & Andreas Clemens & Brigitta U. Monz

  • 2010 An Economic Evaluation of Colesevelam when Added to Metformin-, Insulin- or Sulfonylurea-Based Therapies in Patients with Uncontrolled Type 2 Diabetes Mellitus
    by W. Robert. Simons & Michael A. Hagan

  • 2010 Cost Effectiveness of Adjunctive Quetiapine Fumarate Extended-Release Tablets with Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder
    by Tatia Chay. Woodward & Eskinder Tafesse & Peter Quon & Arthur Lazarus

  • 2010 A New Method for Examining the Cost Savings of Reducing COPD Exacerbations
    by Douglas W. Mapel & Michael Schum & Eva Lydick & Jeno P. Marton

  • 2010 Frequency of Treatment-Effect Modification Affecting Indirect Comparisons: A Systematic Review
    by Michael Coory & Susan Jordan

  • 2010 Using Conjoint Analysis and Choice Experiments to Estimate QALY Values: Issues to Consider
    by Terry N. Flynn

  • 2010 The Value of Value of Information: Best Informing Research Design and Prioritization Using Current Methods
    by Simon Eckermann & Jon Karnon & Andrew R. Willan

  • 2010 Fondaparinux: A Pharmacoeconomic Review of its Use in the Management of Non-ST-Segment Elevation Acute Coronary Syndrome
    by Kate McKeage & Katherine A. Lyseng-Williamson

  • 2010 Economic Burden of Epilepsy among the Privately Insured in the US
    by Jasmina I. Ivanova & Howard G. Birnbaum & Yohanne Kidolezi & Ying Qiu & David Mallett & Sue Caleo

  • 2010 Assessing the Relationship between Computational Speed and Precision: A Case Study Comparing an Interpreted versus Compiled Programming Language using a Stochastic Simulation Model in Diabetes Care
    by Phil McEwan & Klas Bergenheim & Yong Yuan & Anthony P. Tetlow & Jason P. Gordon

  • 2010 Impact of European Pharmaceutical Price Regulation on Generic Price Competition: A Review
    by Jaume Puig-Junoy

  • 2010 Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer: A Critical and Systematic Review
    by Patricia R. Blank & Konstantin J. Dedes & Thomas D. Szucs

  • 2010 Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms
    by Joseph Golec & John A. Vernon

  • 2010 Time for Cooperation in Health Economics among the Modelling Community
    by Rene J.G. Arnold & Sean Ekins

  • 2010 Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma: A Pragmatic Trial
    by Edward C.F. Wilson & David Price & Stanley D. Musgrave & Erika J. Sims & Lee Shepstone & Jamie Murdoch & H. Miranda. Mugford & Annie Blyth & Elizabeth F. Juniper & Jon G. Ayres & Stephanie Wolfe & Daryl Freeman & Richard F.T. Gilbert & Elizabeth V. Hillyer & Ian Harvey

  • 2010 Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy: A Pragmatic Trial
    by Edward C.F. Wilson & Erika J. Sims & Stanley D. Musgrave & Lee Shepstone & Annie Blyth & Jamie Murdoch & H. Miranda. Mugford & Elizabeth F. Juniper & Jon G. Ayres & Stephanie Wolfe & Daryl Freeman & Richard F.T. Gilbert & Ian Harvey & Elizabeth V. Hillyer & David Price

  • 2010 Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma
    by Arthur S. Zbrozek & Gary Hudes & Donna Levy & Andrew Strahs & Anna Berkenblit & Robert DeMarinis & Shreekant Parasuraman

  • 2010 Impact of Rapid Methicillin-Resistant Staphylococcus aureus Polymerase Chain Reaction Testing on Mortality and Cost Effectiveness in Hospitalized Patients with Bacteraemia: A Decision Model
    by Jack Brown & Joseph A. Paladino

  • 2010 The Cost of Relapse for Patients with a Manic/Mixed Episode of Bipolar Disorder in the EMBLEM Study
    by Jihyung Hong & Catherine Reed & Diego Novick & Josep Maria. Haro & Frank Windmeijer & Martin Knapp

  • 2010 The State of Health Economic Evaluation Research in Nigeria: A Systematic Review
    by Paul Gavaza & Karen L. Rascati & Abiola O. Oladapo & Star Khoza

  • 2010 Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement: A Systematic Review
    by Alok Kapoor & Warren Chuang & Nila Radhakrishnan & Kenneth J. Smith & Dan Berlowitz & Jodi B. Segal & Jeffrey N. Katz & Elena Losina

  • 2010 Does the Inclusion of a Cost Attribute Result in Different Preferences for the Surgical Treatment of Primary Basal Cell Carcinoma?: A Comparison of Two Discrete-Choice Experiments
    by Brigitte A.B. Essers & Debby van Helvoort-Postulart & Martin H. Prins & Martino Neumann & Carmen D. Dirksen

  • 2010 Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations
    by Stephanie R. Earnshaw & Cheryl L. McDade & Libby K. Black & Christopher F. Bell & Michael W. Kattan

  • 2010 Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis
    by Roisin Adams & Cathal Walsh & Douglas Veale & Barry Bresnihan & Oliver FitzGerald & Michael Barry

  • 2010 Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?
    by Lesley Chim & Patrick J. Kelly & Glenn Salkeld & Martin R. Stockler

  • 2010 Methodological Concerns with Economic Evaluations of Meningococcal Vaccines
    by Teresa L. Kauf

  • 2010 Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: A NICE Single Technology Appraisal
    by Adrian Bagust & Janette Greenhalgh & Angela Boland & Nigel Fleeman & Claire McLeod & Rumona Dickson & Yenal Dundar & Christine Proudlove & Richard Shaw

  • 2010 Economic Content in Medical Journal Advertisements for Medical Devices and Prescription Drugs
    by D. Clay. Ackerly & Seth W. Glickman & Kevin A. Schulman

  • 2010 Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer's Disease: A UK Evaluation Using Discrete-Event Simulation
    by Denis Getsios & Steve Blume & K. Jack. Ishak & Grant D.H. Maclaine

  • 2010 Direct and Indirect Costs of Non-Vertebral Fracture Patients with Osteoporosis in the US
    by Crystal Pike & Howard G. Birnbaum & Matt Schiller & Hari Sharma & Russel Burge & Eric T. Edgell

  • 2010 Health Economic Burden of Patients with Restless Legs Syndrome in a German Ambulatory Setting
    by Richard Dodel & Svenja Happe & Ines Peglau & Geert Mayer & Jrgen Wasem & Jens-Peter Reese & Guido Giani & Max Geraedts & Claudia Trenkwalder & Wolfgang H. Oertel & Karin Stiasny-Kolster

  • 2010 Economic Burden of Multiple Sclerosis: A Systematic Review of the Literature
    by Huseyin Naci & Rachael Fleurence & Julie Birt & Amy Duhig

  • 2010 Alitretinoin for Severe Chronic Hand Eczema: A NICE Single Technology Appraisal
    by Mark Rodgers & Susan Griffin & Mike Paulden & Russell Slack & Steven Duffy & John R. Ingram & Nerys Woolacott & Mark Sculpher

  • 2010 Single Technology Appraisal at the UK National Institute for Health and Clinical Excellence: A Source of Evidence and Analysis for Decision Making Internationally
    by Mark Sculpher

  • 2010 Towards More Consistent Use of Generic Quality-of-Life Instruments
    by Mattias Neyt

  • 2010 Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis
    by Jeroen P. Jansen & Sabine Gaugris & Ernest H. Choy & Andrew Ostor & Julian T. Nash & Wiro Stam

  • 2010 Pharmacoeconomic Evaluation in Ireland: A Review of the Process
    by Lesley Tilson & Aisling OLeary & Cara Usher & Michael Barry

  • 2010 Does the Funding Source Influence the Results in Economic Evaluations?: A Case Study in Bisphosphonates for the Treatment of Osteoporosis
    by Rachael L. Fleurence & D. Eldon. Spackman & Christopher Hollenbeak

  • 2010 Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis: A Critical and Systematic Review
    by William A. Prescott & Fred Doloresco & Jack Brown & Joseph A. Paladino

  • 2010 A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment
    by Jean-Eric Tarride & Robert Hopkins & Gord Blackhouse & James M. Bowen & Matthias Bischof & Camilla Von Keyserlingk & Daria OReilly & Feng Xie & Ron Goeree

  • 2010 Varenicline: A Pharmacoeconomic Review of its Use as an Aid to Smoking Cessation
    by Gillian M. Keating & Katherine A. Lyseng-Williamson

  • 2010 Cost Effectiveness of High-Dose Intravenous Esomeprazole for Peptic Ulcer Bleeding
    by Alan N. Barkun & Viviane Adam & Joseph J.Y. Sung & Ernst J. Kuipers & Joachim Mossner & Dennis Jensen & Robert Stuart & James Y. Lau & Emma Naucler & Jan Kilhamn & Helena Granstedt & Bengt Liljas & Tore Lind

  • 2010 Estimation of a Valuation Function for a Diabetes Mellitus-Specific Preference-Based Measure of Health: The Diabetes Utility Index�
    by Murali Sundaram & Michael J. Smith & Dennis A. Revicki & Lesley-Ann Miller & Suresh Madhavan & Gerry Hobbs

  • 2010 The Cost Effectiveness of Rufinamide in the Treatment of Lennox-Gastaut Syndrome in the UK
    by Agnes Benedict & Lara Verdian & Grant Maclaine

  • 2010 Healthcare Rationing by Proxy: Cost-Effectiveness Analysis and the Misuse of the $50 000 Threshold in the US
    by John F.P. Bridges & Eberechukwu Onukwugha & C. Daniel. Mullins

  • 2010 Measuring Quality of Life for Certain Events versus Pre-Specified Points in Time
    by Mattias Neyt

  • 2010 Can't Get No Satisfaction? Will Pay for Performance Help?: Toward an Economic Framework for Understanding Performance-Based Risk-Sharing Agreements for Innovative Medical Products
    by Adrian Towse & Louis P. Garrison

  • 2010 Access with Evidence Development in the UK: Past Experience, Current Initiatives and Future Potential
    by Andrew Briggs & Karen Ritchie & Elisabeth Fenwick & Kalipso Chalkidou & Peter Littlejohns

  • 2010 Access with Evidence Development: The US Experience
    by Penny E. Mohr & Sean R. Tunis

  • 2010 Access with Evidence Development Schemes: A Framework for Description and Evaluation
    by Christopher J. McCabe & Tania Stafinski & Richard Edlin & Devidas Menon

  • 2010 Funding the Unfundable: Mechanisms for Managing Uncertainty in Decisions on the Introduction of New and Innovative Technologies into Healthcare Systems
    by Tania Stafinski & Christopher J. McCabe & Devidas Menon

  • 2010 Principles of Design of Access with Evidence Development Approaches: A Consensus Statement from the Banff Summit
    by Devidas Menon & Christopher J. McCabe & Tania Stafinski & Richard Edlin

  • 2010 We Know Accurately Only When We Know Little
    by Stuart MacLeod & Craig Mitton

  • 2010 Erlotinib: A Pharmacoeconomic Review of its Use in Advanced Non-Small Cell Lung Cancer
    by Katherine A. Lyseng-Williamson

  • 2010 A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing
    by Lisa M. Meckley & James M. Gudgeon & Jeffrey L. Anderson & Marc S. Williams & David L. Veenstra

  • 2010 Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US
    by Virginia M. Rosen & Douglas C.A. Taylor & Hemangi Parekh & Ankur Pandya & David Thompson & Andreas Kuznik & David D. Waters & Michael Drummond & Milton C. Weinstein

  • 2010 Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma: Long-Term Economic Evaluation
    by Eric Deconinck & Houda Miadi-Fargier & Claude Le. Pen & Pauline Brice

  • 2010 The Cost and Incidence of Prescribing Errors Among Privately Insured HIV Patients
    by Fred J. Hellinger & William E. Encinosa

  • 2010 Adverse Drug Interactions: Moving from Perception to Action
    by Ryan Mayhew & June M. McKoy & Thanh Ha Luu & Isaac Lopez & Melissa Frick & Charles L. Bennett

  • 2010 Should Financial Incentives be Used to Differentially Reward 'Me-Too' and Innovative Drugs?
    by Brita Pekarsky

  • 2010 The Cost Utility of Autologous Chondrocytes Implantation Using ChondroCelect in Symptomatic Knee Cartilage Lesions in Belgium
    by Laetitia Gerlier & Mark Lamotte & Micheline Wille & Peter C. Kreuz & Johan Vanlauwe & Dominique Dubois & Franois M. Meurgey

  • 2010 Measuring the Externality of Antibacterial Use from Promoting Antimicrobial Resistance
    by Klaus Kaier & Uwe Frank

  • 2010 A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States
    by Ifigeneia Mavranezouli

  • 2010 Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices
    by Lizheng Shi & Jinan Liu & Yordanka Koleva & Vivian Fonseca & Anupama Kalsekar & Manjiri Pawaskar

  • 2010 The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions: A Critical Appraisal of Recent Methodological Developments
    by Andrea Manca & Mark J. Sculpher & Ron Goeree

  • 2010 The Economics of a 'Liberated' NHS
    by Nancy J. Devlin

  • 2010 Is There a Role for Pharmacoeconomics in Developing Countries?
    by Babar Zaheer-Ud-Din & Shane Scahill

  • 2010 Methods of Model Calibration: Observations from a Mathematical Model of Cervical Cancer
    by Douglas C.A. Taylor & Vivek Pawar & Denise Kruzikas & Kristen E. Gilmore & Ankur Pandya & Rowan Iskandar & Milton C. Weinstein

  • 2010 An Analysis of NICE's 'Restricted' (or 'Optimized') Decisions
    by Phill ONeill & Nancy J. Devlin

  • 2010 Evaluation of Benefit-Risk
    by Silvio Garattini

  • 2010 New Prescription for the Spanish Drug Sector: Fighting against Public Deficit without Wasting Ammunition
    by Fernando Antoanzas & Pedro Gmez

  • 2010 Cost Effectiveness of Imiquimod 5% Cream Compared with Methyl Aminolevulinate-Based Photodynamic Therapy in the Treatment of Non-Hyperkeratotic, Non-Hypertrophic Actinic (Solar) Keratoses: A Decision Tree Model
    by Edward C.F. Wilson

  • 2010 Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy
    by Mario Eandi & Lorenzo Pradelli & Sergio Iannazzo & Silvia Chiroli & Giuseppe Pontoriero

  • 2010 Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV
    by Teresa L. Kauf & Raymond A. Farkouh & Stephanie R. Earnshaw & Maria E. Watson & Penny Maroudas & Mike G. Chambers

  • 2010 Economic Implications of Sleep Disorders
    by Tracy L. Skaer & David A. Sclar

  • 2010 Cost Effectiveness of Pharmacogenomics: A Critical and Systematic Review
    by William B. Wong & Josh J. Carlson & Rahber Thariani & David L. Veenstra

  • 2010 Generating Evidence for Comparative Effectiveness Research Using More Pragmatic Randomized Controlled Trials
    by C. Daniel. Mullins & Danielle Whicher & Emily S. Reese & Sean Tunis

  • 2010 No Head-to-Head Trial? Simulate the Missing Arms
    by J. Jaime. Caro & K. Jack. Ishak

  • 2010 There's a Reason They Call Them Dummy Variables: A Note on the Use of Structural Equation Techniques in Comparative Effectiveness Research
    by William H. Crown

  • 2010 Comparative Effectiveness Without Head-to-Head Trials: A Method for Matching-Adjusted Indirect Comparisons Applied to Psoriasis Treatment with Adalimumab or Etanercept
    by James E. Signorovitch & Eric Q. Wu & Andrew P. Yu & Charles M. Gerrits & Evan Kantor & Yanjun Bao & Shiraz R. Gupta & Parvez M. Mulani

  • 2010 Managed Care Pharmacy Sees Potential of Comparative Effectiveness Research to Improve Patient Care and Lower Costs
    by Judith Cahill & Neal Learner

  • 2010 Comparative Effectiveness, Personalized Medicine and Innovation: The Path Forward
    by Adrian Thomas & Audrey Phillips & Robert Donnelly & Catherine Tak. Piech

  • 2010 Comparative Effectiveness Research: The View from a Pharmaceutical Company
    by Marc L. Berger & David Grainger

  • 2010 Comparative Effectiveness Research and Personalized Medicine: Catalyzing or Colliding?
    by Robert S. Epstein & J. Russell. Teagarden

  • 2010 Comparative Effectiveness Research and the Psychology of Medical Practice: The Vicissitudes of Knowledge Implementation
    by Jerome P. Kassirer & John B. Wong

  • 2010 Perspective and Desire in Comparative Effectiveness Research: The Relative Unimportance of Mere Preferences, the Central Importance of Context
    by Anthony J. Culyer

  • 2010 Comparative Effectiveness Regulations and Pharmaceutical Innovation
    by John A. Vernon & Joseph H. Golec & J. Stedman. Stevens

  • 2010 Cost-Effectiveness Analysis in Markets with High Fixed Costs
    by David M. Cutler & Keith M. Marzilli. Ericson

  • 2010 Regulatory Benefit-Risk Assessment and Comparative Effectiveness Research: Strangers, Bedfellows or Strange Bedfellows?
    by Louis P. Garrison

  • 2010 The Economics of Comparative Effectiveness Studies: Societal and Private Perspectives and their Implications for Prioritizing Public Investments in Comparative Effectiveness Research
    by David Meltzer & Anirban Basu & Rena Conti

  • 2010 Value-Based Approaches to Healthcare Systems and Pharmacoeconomics Requirements in Asia: South Korea, Taiwan, Thailand and Japan
    by Isao Kamae

  • 2010 International Comparison of Comparative Effectiveness Research in Five Jurisdictions: Insights for the US
    by Adrian R. Levy & Craig Mitton & Karissa M. Johnston & Brian Harrigan & Andrew H. Briggs

  • 2010 Using Comparative Effectiveness Research to Inform Policy and Practice in the UK NHS: Past, Present and Future
    by Kalipso Chalkidou & Tom Walley

  • 2010 Perspectives on Comparative Effectiveness Research: Views from Diverse Constituencies
    by Dave Nellesen & Howard G. Birnbaum & Paul E. Greenberg

  • 2010 Introducing Perspectives on Comparative Effectiveness Research
    by Howard G. Birnbaum & Paul E. Greenberg

  • 2010 Cost Effectiveness of Establishing a Neonatal Screening Programme for Phenylketonuria in Libya
    by Erikas Sladkevicius & Rodney J. Pollitt & Ali Mgadmi & Julian F. Guest

  • 2010 Catastrophic Healthcare Payments and Impoverishment in the Occupied Palestinian Territory
    by Awad Mataria & Firas Raad & Mohammad Abu-Zaineh & Cam Donaldson

  • 2010 The Use of Research Abstracts in Formulary Decision Making by the Joint Oncology Drug Review of Canada
    by Adam V. Weizman & Josh Griesman & Chaim M. Bell

  • 2010 Reducing Uncertainty in Value-Based Pricing Using Evidence Development Agreements: The Case of Continuous Intraduodenal Infusion of Levodopa/Carbidopa (Duodopa) in Sweden
    by Michael Willis & Ulf Persson & York Zoellner & Birgit Gradl

  • 2010 Reforming the English NHS: A Continuing Journey
    by Karen Bloor & Alan Maynard

  • 2010 The Missing Technology: An International Comparison of Human Capital Investment in Healthcare
    by Bianca K. Frogner

  • 2010 Critique of an Economic Evaluation Using the Drummond Checklist
    by Christopher M. Doran

  • 2010 Economic Efficiency of Alcohol Policy
    by Christopher M. Doran & Thameemul A. Jainullabudeen

  • 2010 Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe
    by Alain Denis & Lut Mergaert & Christel Fostier & Irina Cleemput & Steven Simoens

  • 2010 Cost Effectiveness of Long-Acting Risperidone in Sweden
    by Marja Hensen & Bart Heeg & Mickael Lthgren & Ben van Hout

  • 2010 Cost of Illness and Drivers of Cost in Atrial Fibrillation in Sweden and Germany
    by Linus Jnsson & sa Eliasson & John Kindblom & Olle Almgren & Nils Edvardsson

  • 2010 Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007
    by Javier Orofino & Javier Soto & Miguel A. Casado & Itziar Oyagez

  • 2010 Burden and Cost of Hospital Admissions for Vaccine-Preventable Paediatric Pneumococcal Disease and Non-Typable Haemophilus influenzae Otitis Media in New Zealand
    by Richard J. Milne & Stephen Vander Hoorn

  • 2010 Cost Effectiveness of Insulin Glargine plus Oral Antidiabetes Drugs Compared with Premixed Insulin Alone in Patients with Type 2 Diabetes Mellitus in Canada
    by Sandra L. Tunis & Luc Sauriol & Michael E. Minshall

  • 2010 Costs and Consequences of Clopidogrel versus Aspirin for Secondary Prevention of Ischaemic Events in (High-Risk) Atherosclerotic Patients in Sweden: A Lifetime Model Based on the CAPRIE Trial and High-Risk CAPRIE Subpopulations
    by J. Floris S. Logman & Bart M.S. Heeg & Johan Herlitz & Ben A. van Hout

  • 2010 Audit of Diabetes-Dependent Quality of Life (ADDQoL) [Chinese Version for Singapore] Questionnaire: Reliability and Validity among Singaporeans with Type 2 Diabetes Mellitus
    by Swee Sung. Soon & Su Yen. Goh & Yong Mong. Bee & Jiat Ling. Poon & Shu Chuen. Li & Julian Thumboo & Hwee Lin. Wee

  • 2010 The Effect of Protest Zeros on Estimates of Willingness to Pay in Healthcare Contingent Valuation Analysis
    by William M. Fonta & H. Eme. Ichoku & Jane Kabubo-Mariara

  • 2010 Oncologist Preferences for Health States Associated with the Treatment of Advanced Ovarian Cancer
    by Lisa M. Hess & Daniel C. Malone & Grant H. Skrepnek & Pamela G. Reed & Edward Armstrong & Stephen Joel. Coons

  • 2010 Gary Buurman, 1944-2010
    by Stuart Birks

  • 2010 A Systematic Data Review of the Cost of Rehydration Therapy
    by Jay Pershad

  • 2010 Cost Effectiveness of Preventive Screening Programmes for Type 2 Diabetes Mellitus in Germany
    by Thilo M. Schaufler & Malte Wolff

  • 2010 Productivity Loss Resulting from Coronary Heart Disease in Australia
    by Henry Zheng & Fred Ehrlich & Janaki Amin

  • 2010 Healthcare Costs of Atypical Antipsychotic Use for Patients with Bipolar Disorder in a Medicaid Programme
    by Ying Qiu & Alex Z. Fu & Gordon G. Liu & Dale B. Christensen

  • 2010 Public Option and Private Profits: What do Markets Expect?
    by Fabio Milani

  • 2010 Cost Effectiveness of CT Colonography for UK NHS Colorectal Cancer Screening of Asymptomatic Adults Aged 60-69 Years
    by David Lee & Dominic Muston & Alison Sweet & Chris Cunningham & Andrew Slater & Kevin Lock

  • 2010 Willingness to Pay for Maternal Health Outcomes: Are Women Willing to Pay More than Men?
    by Laura Ternent & Paul McNamee & David Newlands & Danielle Belemsaga & Adjima Gbangou & Suzanne Cross

  • 2010 Health System Choice: A Pilot Discrete-Choice Experiment Eliciting the Preferences of British and Australian Citizens
    by Paul A. Scuffham & Jennifer A. Whitty & Matthew Taylor & Ruth C. Saxby

  • 2010 Do Reduced Inpatient Costs Associated with Highly Active Antiretroviral Therapy (HAART) Balance the Overall Cost for HIV Treatment?
    by Paul G. Farnham

  • 2010 Cost-Effectiveness Analysis of Treatments for Premenstrual Dysphoric Disorder
    by Regina Rendas-Baum & Min Yang & Joseph Gricar & Gene V. Wallenstein

  • 2010 Organization and Estimated Patient-Borne Costs of Oral Anticoagulation Therapy in Italy: Results from a Survey
    by Lorenzo Pradelli & Sergio Iannazzo & Orietta Zaniolo & Paola Botrugno

  • 2010 Outpatient Medication Costs of Patients with Cystic Fibrosis in Germany
    by Daniela Eidt-Koch & Thomas O.F. Wagner & Thomas Mittendorf & J.-Matthias Graf von der Schulenburg

  • 2010 The Authors' Reply
    by George Dranitsaris & Sanjay Mehta

  • 2010 Ongoing Pharmaceutical Reforms in France: Implications for Key Stakeholder Groups
    by Catherine Sermet & Veronique Andrieu & Brian Godman & Eric Van Ganse & Alan Haycox & Jean-Pierre Reynier

  • 2010 Oral Therapies for the Treatment of Pulmonary Arterial Hypertension: a Population-Based Cost-Minimization Analysis
    by Marie-Claude Lefebvre & Elke Hunsche

  • 2010 Healthcare Costs in Renal Transplant Recipients Using Branded versus Generic Ciclosporin
    by J. Harold. Helderman & Ning Kang & Antonio P. Legorreta & Judy Y. Chen

  • 2010 Inpatient Costs of Endophthalmitis Evaluated for the Whole of France
    by Xavier Colin & Gilles Berdeaux & Antoine Lafuma & Annie Salvanet-Bouchara & Laurent Kodjikian

  • 2010 Analytical Strategies for Characterizing Chemotherapy Diffusion with Patient-Level Population-Based Data
    by Cami S. Sima & Katherine S. Panageas & Glenn Heller & Deborah Schrag

  • 2010 Is the Societal Approach Wide Enough to Include Relatives?: Incorporating Relatives' Costs and Effects in a Cost-Effectiveness Analysis
    by Thomas Davidson & Lars-ke Levin

  • 2010 Considering the Value Associated with Innovation in Health Technology Appraisal Decisions (Deliberations): A NICE Thing to do?
    by Colin Green

  • 2010 Valeurs du contact et valeurs en contact dans les pratiques du SMS chez les adolescents
    by Raluca MOISE

  • 2010 Media as cultural billboard. A students’ perspective
    by Valentina ROMAN & Alexandra ZBUCHEA

  • 2010 La importancia de la microeconomía schumpeteriana: un análisis de panel para Colombia
    by Jan Ter Wengel & Gilma Beatriz Ferreira & Lorena Salgado & Luis Miguel Suárez

  • 2009 Whitefish: An Economic Primer
    by Arthur J. Hosios & Lawrence B. Smith

  • 2009 Doping, the Inspection Game, and Bayesian Monitoring
    by Roland Kirstein

  • 2009 Free Ride: The Senate Health Bill’s Approach to “Employer Responsibility” Means Some Large Employers Get to Take It Easy
    by Shawn Fremstad

  • 2009 Inequality as Policy: The United States Since 1979
    by John Schmitt

  • 2009 Reimbursement Roulette: The Baucus Bill’s Too Playful Approach to “Play-or-Pay” in Health Care Reform
    by Shawn Fremstad

  • 2009 Employer Responsibility in Health Care Reform: Potential Effects on Low- and Moderate-Income Workers
    by Shawn Fremstad

  • 2009 Rates of Return and Alternative Measures of Capital Input: 14 Countries and 10 Branches, 1971-2005
    by Nicholas Oulton & Ana Rincon-Aznar

  • 2009 Energy demand and energy efficiency in the OECD countries: a stochastic demand frontier approach
    by Massimo Filippini & Lester Hunt

  • 2009 Neo-additive capacities and updating
    by Eichberger, Jürgen & Grant, Simon & Lefort, Jean-Philippe

  • 2009 Performance Benchmarking of Australian and New Zealand Business Regulation - Food Safety
    by Productivity Commission

  • 2009 Using Qualitative Research to Inform the Development of a Comprehensive Outcomes Assessment for Asthma
    by Diane M. Turner-Bowker & Renee N. Saris-Baglama & Michael A. DeRosa & Christine A. Paulsen & Christopher P. Bransfield

  • 2009 How do People with Different Levels of Activation Self-Manage their Chronic Conditions?
    by Anna Dixon & Judith Hibbard & Martin Tusler

  • 2009 Patients' Preferences for Generic and Branded Over-the-Counter Medicines: An Adaptive Conjoint Analysis Approach
    by Merja Halme & Kari Linden & Kimmo Kri

  • 2009 Using the Pediatric Asthma Therapy Assessment Questionnaire to Measure Asthma Control and Healthcare Utilization in Children
    by Gregory B. Diette & Shiva G. Sajjan & Elizabeth A. Skinner & Thomas W. Weiss & Albert W. Wu & Leona E. Markson

  • 2009 First Things First: Difficulty with Current Medications is Associated with Patient Willingness to Add New Ones
    by Brian J. Zikmund-Fisher & Timothy P. Hofer & Mandi L. Klamerus & Eve A. Kerr

  • 2009 Using Self-Regulation Theory to Examine Patient Goals, Barriers, and Facilitators for Taking Medication
    by Suzan N. Kucukarslan & Sheena Thomas & Abraham Bazzi & Deborah Virant-Young

  • 2009 Gender Differences in the Selection of an Action Plan for Patients with Type 2 Diabetes Mellitus
    by Jim Nuovo & Thomas Balsbaugh & Bridget Levich

  • 2009 Behind Closed Doors: What Happens when Patients and Providers Talk about Prostate-Specific Antigen Screening?: Survey of the Effects of a Community-Based Intervention
    by Lauren McCormack & Pamela Williams-Piehota & Carla Bann

  • 2009 Public Involvement in Setting a National Research Agenda: A Mixed Methods Evaluation
    by Sandy Oliver & David G. Armes & Gill Gyte

  • 2009 Development and Validation of a Functional Health Literacy Test
    by Xu-Hao Zhang & Julian Thumboo & Kok-Yong Fong & Shu-Chuen Li

  • 2009 Using the Health Utilities Index in Routine Clinical Care: Process, Feasibility, and Acceptability: A Randomized Controlled Trial
    by Maria-Jose Santana & David H. Feeny

  • 2009 Use of, Satisfaction with, and Willingness to Switch Prescription and Over-The-Counter Treatments for Chronic Urticaria: An Online Survey
    by Donald E. Stull & Sonia Gavriel

  • 2009 A Model of Patient Choice with Mid-Therapy Information
    by William C. Grant & Teresa L. Kauf

  • 2009 Paying for Enhanced Service: Comparing Patients' Experiences in a Concierge and General Medicine Practice
    by Justin M. Ko & David G. Fairchild & Dana G. Safran

  • 2009 Upper Gastrointestinal Symptoms Experienced by Users of Low-Dose Aspirin (Acetylsalicylic Acid) [75-325 mg/day] for Primary and Secondary Coronary Artery Disease Prevention: Perspectives from Patient Focus Groups
    by Mary Kay. Margolis & Elisabeth Srstadius & J�rgen N�sdal & Stephanie Manson & Karin Coyne

  • 2009 The Impact on Patient Health Outcomes of Interventions Targeting the Patient-Physician Relationship
    by Stephen M. Auerbach

  • 2009 Jordan Louviere, PhD: Honoring a Pioneer in the Study of Patient and Citizen Choice
    by Terry Flynn

  • 2009 Personal Health Budgets for the UK NHS: A Revolution for the Patient?
    by Peter Beresford

  • 2009 The Effect of Item Screeners on the Quality of Patient Survey Data: A Randomized Experiment of Ambulatory Care Experience Measures
    by Hector P. Rodriguez & Ted von. Glahn & Angela Li & William H. Rogers & Dana Gelb. Safran

  • 2009 Health-Related Quality of Life and Quality of Life in Type 2 Diabetes: Relationships in a Cross-Sectional Study
    by Murali Sundaram & Jan Kavookjian & Julie Hicks. Patrick

  • 2009 Healthcare Experiences of Limited English-Proficient Asian American Patients: A Cross-Sectional Mail Survey
    by Quyen Ngo-Metzger & Dara H. Sorkin & Russell S. Phillips

  • 2009 Impact of Natalizumab on Patient-Reported Outcomes in a Clinical Practice Setting: A Cross-Sectional Survey
    by Siddhesh A. Kamat & Krithika Rajagopalan & Judith J. Stephenson & Sonalee Agarwal

  • 2009 Incremental 1-Year Medical Resource Utilization and Costs for Patients with Herpes Zoster from a Set of US Health Plans
    by Ronald R. White & Greg Lenhart & Puneet K. Singhal & Ralph P. Insinga & Robbin F. Itzler & James M. Pellissier & Arthur W. Segraves

  • 2009 Utilities of the EQ-5D: Transferable or Not?
    by Saskia Knies & Silvia M.A.A. Evers & Math J.J.M. Candel & Johan L. Severens & Andr J.H.A. Ament

  • 2009 The Importance of Clinical Variables in Comparative Analyses Using Propensity-Score Matching: The Case of ESA Costs for the Treatment of Chemotherapy-Induced Anaemia
    by Daniel Polsky & Daria Eremina & Gregory Hess & Jerrold Hill & Scott Hulnick & Adam Roumm & Joanna L. Whyte & Joel Kallich

  • 2009 Comparing Three Software Tools for Implementing Markov Models for Health Economic Evaluations
    by Petra Menn & Rolf Holle

  • 2009 A Cost-Effectiveness Analysis to Illustrate the Impact of Cost Definitions on Results, Interpretations and Comparability of Pharmacoeconomic Studies in the US
    by Sandra L. Tunis

  • 2009 Methods for Measuring Temporary Health States for Cost-Utility Analyses
    by Davene R. Wright & Eve Wittenberg & J. Shannon. Swan & Rebecca A. Miksad & Lisa A. Prosser

  • 2009 The Role of Patient Preferences in Cost-Effectiveness Analysis: A Conflict of Values?
    by John E. Brazier & Simon Dixon & Julie Ratcliffe

  • 2009 Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women
    by Andrej Rasch & Jan-Marc Hodek & Claus Runge & Wolfgang Greiner

  • 2009 The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the US
    by Jasmina I. Ivanova & Howard G. Birnbaum & Seth Samuels & Matthew Davis & Amy L. Phillips & Dennis Meletiche

  • 2009 Economic Burden of Follicular Non-Hodgkin's Lymphoma
    by Talia Foster & Jeffrey D. Miller & Mark E. Boye & Mason W. Russell

  • 2009 A Decision-Theoretic Framework for the Application of Cost-Effectiveness Analysis in Regulatory Processes
    by Gianluca Baio & Pierluigi Russo

  • 2009 Estimating Drug Costs in Economic Evaluations in Ireland and the UK: An Analysis of Practice and Research Recommendations
    by Dyfrig A. Hughes & Lesley Tilson & Michael Drummond

  • 2009 Case-Control Studies in Pharmacoeconomic Research: An Overview
    by J. Jaime. Caro & Krista F. Huybrechts

  • 2009 Legal and Economic Perspectives Concerning US Government Investigations of Alleged Off-Label Promotion by Drug Manufacturers
    by Paul E. Kalb & Paul E. Greenberg

  • 2009 Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease
    by Andrew P. Yu & Scott Johnson & Si-Tien Wang & Pavel Atanasov & Jackson Tang & Eric Wu & Jingdong Chao & Parvez M. Mulani

  • 2009 Cost-Effectiveness Analysis of Capecitabine Compared with Bolus 5-Fluorouracil/l-Leucovorin for the Adjuvant Treatment of Colon Cancer in Japan
    by Takeru Shiroiwa & Takashi Fukuda & Kojiro Shimozuma & Yasuo Ohashi & Kiichiro Tsutani

  • 2009 Cost Effectiveness of Fondaparinux in Non-ST-Elevation Acute Coronary Syndrome
    by Jaime Latour-Perez & Eva de-Miguel-Balsa

  • 2009 Costs of Illness in a Russian Cohort of Patients with Parkinson's Disease
    by Yaroslav Winter & Sonja von Campenhausen & Georgy Popov & Jens P. Reese & Jens Klotsche & Kai Btzel & Eugene Gusev & Wolfgang H. Oertel & Richard Dodel & Alla Guekht

  • 2009 Economic Evaluations in the EURONHEED: A Comparative Analysis
    by Florencia Hutter & Fernando Antoanzas

  • 2009 Societal and Patient Burden of Fibromyalgia Syndrome
    by Lieven Annemans & Katell Le Lay & Charles Taeb

  • 2009 Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines
    by Natasha K. Stout & Amy B. Knudsen & Chung Yin. Kong & Pamela M. McMahon & G. Scott. Gazelle

  • 2009 Is it Time for Reporting Guidelines for Calibration Methods?
    by Scott B. Cantor

  • 2009 How to Deal with Cost Differences at Baseline
    by Antoinette D.I. van Asselt & Ghislaine A.P.G. van Mastrigt & Carmen D. Dirksen & Arnoud Arntz & Johan L. Severens & Alfons G.H. Kessels

  • 2009 Determinants of Direct Cost Differences among US Employees with Major Depressive Disorders Using Antidepressants
    by Howard G. Birnbaum & Rym Ben-Hamadi & Paul E. Greenberg & Matthew Hsieh & Jackson Tang & Camille Reygrobellet

  • 2009 Converting the SF-12 into the EQ-5D: An Empirical Comparison of Methodologies
    by Ling-Hsiang Chuang & Paul Kind

  • 2009 Economic Outcomes Associated with Microvascular Complications of Type 2 Diabetes Mellitus: Results from a US Claims Data Analysis
    by Elise M. Pelletier & Boyung Shim & Rami Ben-Joseph & J. Jaime. Caro

  • 2009 Holistic Preferences for 1-Year Health Profiles Describing Fluctuations in Health: The Case of Chronic Obstructive Pulmonary Disease
    by Maureen P.M.H. Rutten-van Mlken & Martine Hoogendoorn & Leida M. Lamers

  • 2009 Pharmacoeconomic Considerations in Treating Actinic Keratosis
    by Marjorie V. Neidecker & Mary Lynn. Davis-Ajami & Rajesh Balkrishnan & Steven R. Feldman

  • 2009 Cost Effectiveness of Influenza Vaccination in Older Adults: A Critical Review of Economic Evaluations for the 50- to 64-Year Age Group
    by Anthony T. Newall & Heath Kelly & Stuart Harsley & Paul A. Scuffham

  • 2009 Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs
    by Brian Godman & Ulrich Schwabe & Gisbert Selke & Bjrn Wettermark

  • 2009 Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium
    by Irina Cleemput & Nancy Thiry

  • 2009 The Author's Reply
    by Lieven Annemans, on behalf of the authors

  • 2009 Pharmaceutical Risk-Sharing Agreements
    by Afschin Gandjour

  • 2009 Outcomes Associated with Initial versus Later Vancomycin Use in Patients with Complicated Skin and Skin-Structure Infections
    by Kamal M.F. Itani & Kasem S. Akhras & Robert Stellhorn & Alvaro Quintana & David Budd & Sanjay Merchant

  • 2009 Utility Assessment in Patients with Mental Disorders: Validity and Discriminative Ability of the Time Trade-Off Method
    by Hans-Helmut Knig & Oliver H. Gnther & Matthias C. Angermeyer & Christiane Roick

  • 2009 The Cost of Dementia in Europe: A Review of the Evidence, and Methodological Considerations
    by Linus Jnsson & Anders Wimo

  • 2009 Costing Infectious Disease Outbreaks for Economic Evaluation: A Review for Hepatitis A
    by Jeroen Luyten & Philippe Beutels

  • 2009 The Cost and Impact of Health Conditions on Presenteeism to Employers: A Review of the Literature
    by Alyssa B. Schultz & Chin-Yu Chen & Dee W. Edington

  • 2009 The Future Costs, Risks and Rewards of Drug Development: The Economics of Pharmacogenomics
    by Joseph Cook & Graeme Hunter & John A. Vernon

  • 2009 Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response: A Decision Analysis Based on German Guidelines
    by Uwe Siebert & Gaby Sroczynski & Pamela Aidelsburger & Siegbert Rossol & Jurgen Wasem & Michael P. Manns & John G. McHutchison & John B. Wong

  • 2009 Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder: Results from the MATRIX Study
    by Laura T. Pizzi & Amy Talati & Eric Gemmen & Naomi V. Dahl & Thomas J. Bunz & Peter K. Sand

  • 2009 Cost Effectiveness of Drug-Eluting Stents In Belgian Practice: Healthcare Payer Perspective
    by Mattias Neyt & Chris De Laet & Annemieke De Ridder & Hans Van Brabandt

  • 2009 Willingness to Pay for Cancer Prevention
    by Timothy L. Hunt & Bryan R. Luce & Matthew J. Page & Robin Pokrzywinski

  • 2009 Reviewing the Cost Effectiveness of Rotavirus Vaccination: The Importance of Uncertainty in the Choice of Data Sources
    by Joke Bilcke & Philippe Beutels

  • 2009 Economic and Human Costs of Restless Legs Syndrome
    by Thomas Reinhold & Falk Mller-Riemenschneider & Stefan N. Willich & Bernd Brggenjrgen

  • 2009 Cost Effectiveness of Herpes Zoster Vaccine in Canada
    by Mehdi Najafzadeh & Carlo A. Marra & Eleni Galanis & David M. Patrick & David M. Patrick

  • 2009 Weighting Must Wait: Incorporating Equity Concerns into Cost-Effectiveness Analysis May Take Longer than Expected
    by Allan Wailoo & Aki Tsuchiya & Christopher McCabe

  • 2009 Swimming Upstream: Comparative Effectiveness Research in the US
    by Jeremy A. Greene

  • 2009 Accounting for the Development of Antibacterial Resistance in the Cost Effectiveness of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in the UK
    by Jeroen P. Jansen & Ritesh Kumar & Yehuda Carmeli

  • 2009 Healthcare Costs and Obesity Prevention: Drug Costs and Other Sector-Specific Consequences
    by David R. Rappange & Werner B.F. Brouwer & Rudolf T. Hoogenveen & Pieter H.M. Van Baal

  • 2009 Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
    by Aline Gauthier & Andrea Manca & Susan Anton

  • 2009 Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster
    by Tracy A. Lieu & G. Thomas. Ray & Ismael R. Ortega-Sanchez & Ken Kleinman & Donna Rusinak & Lisa A. Prosser

  • 2009 Cost Effectiveness of Facility-Based Care, Home-Based Care and Mobile Clinics for Provision of Antiretroviral Therapy in Uganda
    by Joseph B. Babigumira & Ajay K. Sethi & Kathleen A. Smyth & Mendel E. Singer

  • 2009 Information Technology Facilitates Cost-Effectiveness Analysis in Developing Countries: An Observational Study of Breast Cancer Chemotherapy in Taiwan
    by Ya-Chen Tina. Shih & I-Wen Pan & Yi-Wen Tsai

  • 2009 Strengthening Cost-Effectiveness Analysis in Thailand through the Establishment of the Health Intervention and Technology Assessment Program
    by Sripen Tantivess & Yot Teerawattananon & Anne Mills

  • 2009 Barriers to Generalizability of Health Economic Evaluations in Latin America and the Caribbean Region
    by Federico Augustovski & Cynthia Iglesias & Andrea Manca & Michael Drummond & Adolfo Rubinstein & Sebastin Garca. Mart

  • 2009 Cost Effectiveness in Low- and Middle-Income Countries: A Review of the Debates Surrounding Decision Rules
    by Samuel D. Shillcutt & Damian G. Walker & Catherine A. Goodman & Anne J. Mills

  • 2009 The Future of Health Technology Assessment in Healthcare Decision Making in Asia
    by Bong-Min Yang

  • 2009 Developing Nations Special Issue
    by Mendel E. Singer

  • 2009 Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
    by Peng Liubao & Wan Xiaomin & Tan Chongqing & Jon Karnon & Chen Gannong & Li Jianhe & Cui Wei & Luo Xia & Cao Junhua

  • 2009 30 Years of Pharmaceutical Cost-Utility Analyses: Growth, Diversity and Methodological Improvement
    by Peter J. Neumann & Chi-Hui Fang & Joshua T. Cohen

  • 2009 A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting
    by Laura McCullagh & Lesley Tilson & Cathal Walsh & Michael Barry

  • 2009 Budget-Impact Analyses: A Critical Review of Published Studies
    by Ewa Orlewska & Laszlo Gulcsi

  • 2009 Economic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation
    by John A. Vernon & Robert Goldberg & Joseph Golec

  • 2009 New Anticoagulants for the Prevention of Deep Venous Thrombosis: Time to Consider Cost Effectiveness?
    by Stavros Apostolakis & Eduard Shantsila & Gregory Y.H. Lip

  • 2009 Demand for Outpatient Healthcare: Empirical Findings from Rural India
    by Sisira Sarma

  • 2009 Cost Savings Associated with Filling a 3-Month Supply of Prescription Medicines
    by Atonu Rabbani & G. Caleb. Alexander

  • 2009 A Comparison of Costs among Patients with Type 2 Diabetes Mellitus Who Initiated Therapy with Exenatide or Insulin Glargine
    by Derek Misurski & Maureen J. Lage & Rosalind Fabunmi & Kristina S. Boye

  • 2009 The Cost Effectiveness of Home-Based Provision of Antiretroviral Therapy in Rural Uganda
    by Elliot Marseille & James G. Kahn & Christian Pitter & Rebecca Bunnell & William Epalatai & Emmanuel Jawe & Willy Were & Jonathan Mermin

  • 2009 Cost Effectiveness of Antiretrovirals - Long Term or Short Term?
    by Steffen Flessa

  • 2009 Assessing Comparative Effectiveness Research in the US
    by Joshua P. Cohen & John F.P. Bridges

  • 2009 Which Barriers Prevent the Efficient Use of Resources in Medical Device Sectors?
    by Steven Simoens

  • 2009 The Economic Value of Primary Prophylaxis Using Pegfilgrastim Compared with Filgrastim in Patients with Breast Cancer in the UK
    by Zhimei Liu & Quan V. Doan & Jennifer Malin & Robert Leonard

  • 2009 Economic Evaluation of Sinfrontal in the Treatment of Acute Maxillary Sinusitis in Adults
    by Kyra C. Kneis & Afschin Gandjour

  • 2009 Short-Term Cost and Health Consequences of Duodenal Levodopa Infusion in Advanced Parkinson's Disease in Sweden: An Exploratory Study
    by Ivar Snb. Kristiansen & Dag Nyholm & Dag Isacson

  • 2009 Financial Risk of the Biotech Industry versus the Pharmaceutical Industry
    by Joseph Golec

  • 2009 Value-Based Insurance Design in Medicare
    by William E. Encinosa

  • 2009 Soft Regulations in Pharmaceutical Policy Making: An Overview of Current Approaches and their Consequences
    by Bjrn Wettermark & Brian Godman & Bengt Jacobsson & Flora M. Haaijer-Ruskamp

  • 2009 Cost Effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis
    by Stephanie R. Earnshaw & Jonathan Graham & MerriKay Oleen-Burkey & Jane Castelli-Haley & Kenneth Johnson

  • 2009 Implementing Differential Pricing for Essential Medicines via Country-Specific Bilateral Negotiated Discounts
    by Ebenezer Kwabena. Tetteh

  • 2009 Aversion to Geographic Inequality and Geographic Variation in Preferences in the Context of Healthcare
    by Carlota Quintal

  • 2009 Comparative Utility of Aripiprazole and Haloperidol in Schizophrenia: Post Hoc Analysis of Two 52-Week, Randomized, Controlled Trials
    by John M. Kane & Edward Kim & Hong J. Kan & Zhenchao Guo & John A. Bates & Richard Whitehead & Andrei Pikalov

  • 2009 Development of a Budget-Impact Model to Quantify Potential Cost Savings from Prescription Opioids Designed to Deter Abuse or Ease of Extraction
    by Alan G. White & Howard G. Birnbaum & Dov B. Rothman & Nathaniel Katz

  • 2009 Oral Therapies for the Treatment of Pulmonary Arterial Hypertension: A Population-Based Cost-Minimization Analysis
    by George Dranitsaris & Sanjay Mehta

  • 2009 Direct Economic Burden of High-Risk and Metastatic Melanoma in the Elderly: Evidence from the SEER-Medicare Linked Database
    by Keith L. Davis & Debanjali Mitra & Srividya Kotapati & Ramy Ibrahim & Jedd D. Wolchok

  • 2009 Cost Effectiveness of Sirolimus-Eluting Stents Compared with Bare Metal Stents in Acute Myocardial Infarction: Insights from the TYPHOON Trial
    by Florence Canoui-Poitrine & Grgoire Jeanblanc & Corinne Alberti & Priscilla Armoogum & Ana Cebrian & Didier Carri & Patrick Henry & Emmanuel Teiger & Michel Slama & Christian Spaulding & Isabelle Durand-Zaleski

  • 2009 Health-Promoting Schools: Evidence for a Holistic Approach to Promoting Health and Improving Health Literacy
    by Albert Lee

  • 2009 Informing Disinvestment through Cost-Effectiveness Modelling: Is Lack of Data a Surmountable Barrier?
    by Jonathan Karnon & Jill Carlton & Carolyn Czoski-Murray & Kevin Smith

  • 2008 Agent-Based Computational Economics: Modeling Economies As Complex Adaptive Systems
    by Tesfatsion, Leigh S.

  • 2008 Modeling Macroeconomies As Open-Ended Dynamic Systems of Interacting Agents
    by LeBaron, Blake & Tesfatsion, Leigh S.

  • 2008 Generic finiteness of equilibrium payoffs for bimatrix games
    by Andreu Mas-Colell

  • 2008 Productivity in the Mining Industry: Measurement and Interpretation
    by Vernon Topp & Leo Soames & Dean Parham & Harry Bloch

  • 2008 Trends in Aged Care Services: some implications
    by Productivity Commission

  • 2008 The Right of Withdrawal in the Treaty of Lisbon: A game theoretic reflection on different decision processes in the EU
    by Susanne Lechner & Renate Ohr

  • 2008 Measuring Poverty and Economic Inclusion: The Current Poverty Measure, the NAS Alternative, and the Case for a Truly New Approach
    by Shawn Fremstad

  • 2008 Performance Benchmarking of Australian Business Regulation: Cost of Business Registrations
    by Productivity Commission

  • 2008 Performance Benchmarking of Australian Business Regulation: Quantity and Quality
    by Productivity Commission

  • 2008 Economic Performance Through Time: A General Equilibrium Model

  • 2008 China: Regional Disparities In Poverty Distribution

  • 2008 Stochastic Demand, Specialization, And Increasing Returns
    by YONG J. YOON

  • 2008 Health-Related Quality-of-Life Outcomes in Patients Treated with Push-Pull OROS Hydromorphone versus Extended-Release Oxycodone for Chronic Hip or Knee Osteoarthritis Pain: A Randomized, Open-Label, Parallel-Group, Multicenter Study
    by Kavita Gajria & Mark Kosinski & Jeff Schein & Shane Kavanagh & Dominique Dubois

  • 2008 How Much Time Do Patients Spend on Outpatient Visits?: The American Time Use Survey
    by Louise B. Russell & Yoko Ibuka & Deborah Carr

  • 2008 The Burden of Restless Legs Syndrome: An Assessment of Work Productivity, Sleep, Psychological Distress, and Health Status Among Diagnosed and Undiagnosed Individuals in an Internet-Based Panel
    by Sheri Fehnel & Laurie Zografos & Tammy Curtice & Hemal Shah & Lori McLeod

  • 2008 Association of Pre-Existing Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients
    by Steven B. Zeliadt & Scott D. Ramsey & Arnold L. Potosky & Neeraj K. Arora & David K. Blough & Ingrid Oakley-Girvan & Ann S. Hamilton & Stephen K. Van Den Eeden & David F. Penson

  • 2008 Preferences of Patients with Advanced Colorectal Cancer for Treatment with Oral or Intravenous Chemotherapy
    by Candida M. Mastroianni & Caterina Viscomi & Silvia Ceniti & Rosanna De Simone & Aldo Filice & Gennaro Gadaleta Caldarola & Stefania Infusino & Caterina Manfredi & Antonio Rea & Claudia Sandomenico & Salvatore Turano & Francesco Serrano & Giovanni Condemi & Carla Cortese & Tullia Prantera & Salvatore Palazzo

  • 2008 Hormonal Contraceptive Users' Self-Reported Benefits, Adverse Reactions, and Fears in 2001 and 2007
    by Miia Tiihonen & Hanna-Mari Leppanen & Anna-Mari Heikkinen & Riitta Ahonen

  • 2008 Obesity and Symptom Burden in Family Medicine Patients
    by James E. Rohrer & Norman H. Rasmussen & Margaret S. Houston & Kurt B. Angstman

  • 2008 Understanding and Assessing the Impact of Alcoholism on Quality of Life: A Systematic Review of the Content Validity of Instruments Used to Assess Health-Related Quality of Life in Alcoholism
    by Matthew D. Reaney & Colin Martin & Jane Speight

  • 2008 Erik Rifkin, PhD: Writer, Researcher, Patient, and Citizen Advocate
    by Jennifer Chang

  • 2008 Association Between Measures of Fatigue and Health-Related Quality of Life in Rheumatoid Arthritis and Osteoarthritis
    by Marita Cross & Helen Lapsley & Annica Barcenilla & Peter Brooks & Lyn March

  • 2008 The Relationship Between Physician Friendliness and Caring, and Patient Satisfaction: Findings from an Internet-Based Survey
    by Adam A. Uhas & Fabian T. Camacho & Steven R. Feldman & Rajesh Balkrishnan

  • 2008 Does Behavioral Bootstrapping Boost Weight Control Confidence?: A Pilot Study
    by James E. Rohrer & Kristin S. Vickers-Douglas & Robert J. Stroebel

  • 2008 Making Patient-Centered Care More Visible: Planetree's Vision
    by Carrie Brady

  • 2008 Honoring the Life of a Pioneer in Patient-Centered Care: Harvey Picker, PhD (1915-2008)
    by Susan B. Frampton & Sara Guastello

  • 2008 Translation and Validation of the Chinese Diabetic Foot Ulcer Scale - Short Form
    by Lan Fong Hui & Daniel Yee-Tak Fong & Michael Yam & Wing Yuk Ip

  • 2008 The Use of Multi-Criteria Decision Analysis Weight Elicitation Techniques in Patients with Mild Cognitive Impairment: A Pilot Study
    by Janine A. van Til & James G. Dolan & Anne M. Stiggelbout & Karin C.G.M. Groothuis & Maarten J. IJzerman

  • 2008 Psychometric Performance of the National Eye Institute 25-Item Visual Function Questionnaire: In Turkish Diabetic Retinopathy Patients
    by Akinci Fevzi & Yildirim Aysegul

  • 2008 A Randomized Study of Electronic Diary versus Paper and Pencil Collection of Patient-Reported Outcomes in Patients with Non-Small Cell Lung Cancer
    by Alistair E. Ring & Kerry A. Cheong & Claire L. Watkins & David Meddis & David Cella & Peter G. Harper

  • 2008 Lillie Shockney: Breast Cancer Survivor, Advocate, and Researcher
    by John F.P. Bridges

  • 2008 When Time is Not on Your Side: Patient Experiences with Waiting for Home Care and Admission to a Nursing or Residential Home
    by N. Job A. van Exel & Marion de Ruiter & Werner B.F. Brouwer

  • 2008 Honoring Pioneers in Patient-Centered Outcomes Research
    by John F.P. Bridges & Christopher I. Carswell

  • 2008 Obesity Modifies the Association of Race/Ethnicity with Medication Adherence in the CARDIA Study
    by Maribel Salas & Catarina I. Kiefe & Pamela J. Schreiner & Yongin Kim & Lucia Juarez & Sharina D. Person & O. Dale Williams

  • 2008 Age and Choice in Health Insurance: Evidence from a Discrete Choice Experiment
    by Karolin Becker & Peter Zweifel

  • 2008 If You Want Patients with Knee Osteoarthritis to Exercise, Tell Them about NSAIDs
    by Liana Fraenkel & Terri Fried

  • 2008 Concordance of Couples' Prostate Cancer Screening Recommendations from a Decision Analysis
    by Scott B. Cantor & Robert J. Volk & Murray D. Krahn & Alvah R. Cass & Jawaria Gilani & Susan C. Weller & Stephen J. Spann

  • 2008 The Role of The Patient in Promoting Patient-Centered Outcomes Research
    by Michael J. Klag & Ellen J. MacKenzie & Christopher I. Carswell & John F.P. Bridges

  • 2008 Subgroups and Heterogeneity in Cost-Effectiveness Analysis
    by Mark Sculpher

  • 2008 Exploring Uncertainty in Cost-Effectiveness Analysis
    by Karl Claxton

  • 2008 Valuing Health States for Use in Cost-Effectiveness Analysis
    by John Brazier

  • 2008 Use of Indirect and Mixed Treatment Comparisons for Technology Assessment
    by Alex Sutton & A.E. Ades & Nicola Cooper & Keith Abrams

  • 2008 Estimating `Costs' for Cost-Effectiveness Analysis
    by Alec Miners

  • 2008 The NICE Cost-Effectiveness Threshold: What it is and What that Means
    by Christopher McCabe & Karl Claxton & Anthony J. Culyer

  • 2008 NICE Methodology for Technology Appraisals: Cutting Edge or Tried and Trusted?
    by Louise Longworth & Carole Longson

  • 2008 NICE Guide to the Methods of Technology Appraisal: Pharmaceutical Industry Perspective
    by Julia Earnshaw & Gavin Lewis

  • 2008 NICE's 2008 Methods Guide: Sensible Consolidation or Opportunities Missed?
    by Mark Sculpher

  • 2008 Trastuzumab: A Pharmacoeconomic Review of its Use in Early Breast Cancer
    by Kate McKeage & Katherine A. Lyseng-Williamson

  • 2008 Demand Forecasting for Preventive AIDS Vaccines: Economic and Policy Dimensions
    by Robert Hecht & Gian Gandhi

  • 2008 Conducting Discrete Choice Experiments to Inform Healthcare Decision Making: A User's Guide
    by Emily Lancsar & Jordan Louviere

  • 2008 Assessing the Impact of Global Price Interdependencies
    by Anke Richter

  • 2008 Modelling Approaches: The Case of Schizophrenia
    by Bart M.S. Heeg & Joep Damen & Erik Buskens & Sue Caleo & Frank de Charro & Ben A. van Hout

  • 2008 Waiting for Reimbursement of New Medicines in Canada: It's Time for a Rethink
    by Brett J. Skinner

  • 2008 Cost-Effectiveness Analyses of Natalizumab (Tysabri(R)) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
    by Ray Gani & Gavin Giovannoni & David Bates & Belinda Kemball & Steve Hughes & John Kerrigan

  • 2008 Generic Entry, Reformulations and Promotion of SSRIs in the US
    by Haiden A. Huskamp & Julie M. Donohue & Catherine Koss & Ernst R. Berndt & Richard G. Frank

  • 2008 Future Drug Prices and Cost-Effectiveness Analyses
    by Martin Hoyle

  • 2008 Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes: A Systematic Review on Content and Adherence to Guidelines
    by Stefan Vegter & Cornelis Boersma & Mark Rozenbaum & Bob Wilffert & GerJan Navis & Maarten J. Postma

  • 2008 The Author's Reply
    by Adam E. Block

  • 2008 Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?
    by Jon Jureidini & Barbara Mintzes & Melissa Raven

  • 2008 Pharmaceutical Risk-Sharing Agreements
    by Joseph P. Cook & John A. Vernon & Richard Manning

  • 2008 Recent National and Regional Drug Reforms in Sweden: Implications for Pharmaceutical Companies in Europe
    by Bjorn Wettermark & Brian Godman & Karolina Andersson & Lars L. Gustafsson & Alan Haycox & Vittorio Bertele'

  • 2008 Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis
    by Dirk Mueller & Eva Weyler & Afschin Gandjour

  • 2008 Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies using the BENESCO Simulation Model: Application to a Population of US Adult Smokers
    by Paul Howard & Christopher Knight & Annabel Boler & Christine Baker

  • 2008 Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada
    by Deborah A. Marshall & Patrick R. Douglas & Michael F. Drummond & George W. Torrance & Stuart MacLeod & Orlando Manti & Lokanadha Cheruvu & Ron Corvari

  • 2008 Cost of Epilepsy: A Systematic Review
    by Adam Strzelczyk & Jens Peter Reese & Richard Dodel & Hajo M. Hamer

  • 2008 Economic Burden of Heart Failure in the Elderly
    by Lawrence Liao & Larry A. Allen & David J. Whellan

  • 2008 Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-alpha Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia
    by Shelby D. Reed & Kevin J. Anstrom & Yanhong Li & Kevin A. Schulman

  • 2008 A Multicentre, Prospective Study to Evaluate Costs of Septic Patients in Brazilian Intensive Care Units
    by Ana M.C. Sogayar & Flavia R. Machado & Alvaro Rea-Neto & Amselmo Dornas & Cintia M.C. Grion & Suzana M.A. Lobo & Bernardo R. Tura & Carla L.O. Silva & Ruy G.R. Cal & Idal Beer & Vilto Michels & Jorge Safi & Marcia Kayath & Eliezer Silva

  • 2008 Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer: A Need for Improved Modelling to Aid Decision Making
    by Lieven Annemans

  • 2008 Economic Evaluations in Rheumatoid Arthritis: A Critical Review of Measures Used to Define Health States
    by Nick Bansback & Roberta Ara & Jonathan Karnon & Aslam Anis

  • 2008 Economic Evaluation of Interventions to Treat Opiate Dependence: A Review of the Evidence
    by Christopher M. Doran

  • 2008 Perspectives on Patient-Reported Outcomes: Content Validity and Qualitative Research in a Changing Clinical Trial Environment
    by Nancy Kline Leidy & Margaret Vernon

  • 2008 Cost-Effectiveness Analysis: Developing Nations Left Behind
    by Mendel E. Singer

  • 2008 Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study
    by Martin Knapp & Frank Windmeijer & Jacqueline Brown & Stathis Kontodimas & Spyridon Tzivelekis & Josep Maria Haro & Mark Ratcliffe & Jihyung Hong & Diego Novick

  • 2008 An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes
    by Scott D. Ramsey & Lauren D. Clarke & Craig S. Roberts & Sean D. Sullivan & Scott J. Johnson & Larry Z. Liu

  • 2008 Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis: Cost-Utility Analysis Using a Markov Model
    by Simon Kreck & Jochen Klaus & Reiner Leidl & Christian von Tirpitz & Alexander Konnopka & Herbert Matschinger & Hans-Helmut Konig

  • 2008 The Use of QALY Weights for QALY Calculations: A Review of Industry Submissions Requesting Listing on the Australian Pharmaceutical Benefits Scheme 2002-4
    by Paul A. Scuffham & Jennifer A. Whitty & Andrew Mitchell & Rosalie Viney

  • 2008 Making a Case for Employing a Societal Perspective in the Evaluation of Medicaid Prescription Drug Interventions
    by Sanjoy Roy & S. Suresh Madhavan

  • 2008 An Overview of Methods and Applications to Value Informal Care in Economic Evaluations of Healthcare
    by Marc A. Koopmanschap & N. Job A. van Exel & Bernard van den Berg & Werner B.F. Brouwer

  • 2008 Zoledronic Acid: A Pharmacoeconomic Review of its Use in the Management of Bone Metastases
    by Kate McKeage & Greg L. Plosker

  • 2008 Community and Patient Values for Preventing Herpes Zoster
    by Tracy A. Lieu & Ismael Ortega-Sanchez & G. Thomas Ray & Donna Rusinak & W. Katherine Yih & Peter W. Choo & Irene Shui & Ken Kleinman & Rafael Harpaz & Lisa A. Prosser

  • 2008 Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens
    by Jeremy Chancellor & Samuel Aballea & Alison Lawrence & Rob Sheldon & Sandrine Cure & Juliette Plun-Favreau & Nick Marchant

  • 2008 Cost-Effectiveness Analyses of Vaccination Programmes: A Focused Review of Modelling Approaches
    by Sun-Young Kim & Sue J. Goldie

  • 2008 Projecting Vaccine Efficacy: Accounting for Geographic Strain Variations
    by Johnie Rose & Mendel E. Singer

  • 2008 Transparency of Economic Evaluations of Health Technologies
    by Joan Rovira

  • 2008 Meandering Down the Road to Transparency
    by Christopher I. Carswell & Joseph A. Paladino

  • 2008 Management of Anaemia: A Critical and Systematic Review of the Cost Effectiveness of Erythropoiesis-Stimulating Agents
    by Mei Sheng Duh & Jennifer R. Weiner & Leigh Ann White & Patrick Lefebvre & Paul E. Greenberg

  • 2008 Having Your Cake and Eating It: Office of Fair Trading Proposal for Funding New Drugs to Benefit Patients and Innovative Companies
    by Brian Godman & Alan Haycox & Ulrich Schwabe & Roberta Joppi & Silvio Garattini

  • 2008 Non-Traditional Settings for Influenza Vaccination of Adults: Costs and Cost Effectiveness
    by Lisa A. Prosser & Megan A. O'Brien & Noelle-Angelique M. Molinari & Katherine H. Hohman & Kristin L. Nichol & Mark L. Messonnier & Tracy A. Lieu

  • 2008 The Burden of Schizophrenia on Caregivers: A Review
    by A. George Awad & Lakshmi N.P. Voruganti

  • 2008 Modelling Methods for Pharmacoeconomics and Health Technology Assessment: An Overview and Guide
    by James E. Stahl

  • 2008 Economic Burden of Psoriatic Arthritis
    by Christoph Ackermann & Arthur Kavanaugh

  • 2008 Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections
    by Robin de Vries & Simon Daenen & Keith Tolley & Axel Glasmacher & Archie Prentice & Sarah Howells & Hariette Christopherson & Lolkje T.W. de Jong-van den Berg & Maarten J. Postma

  • 2008 Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study
    by Alan F. Cruess & Gergana Zlateva & Xiao Xu & Gisele Soubrane & Daniel Pauleikhoff & Andrew Lotery & Jordi Mones & Ronald Buggage & Caroline Schaefer & Tyler Knight & Thomas F. Goss

  • 2008 The Last Decade of Italian Pharmaceutical Policy: Instability or Consolidation?
    by Giovanni Fattore & Claudio Jommi

  • 2008 Dynamic Modelling of Infectious Diseases: An Application to the Economic Evaluation of Influenza Vaccination
    by Roberto Pradas-Velasco & Fernando Antonanzas-Villar & Maria Puy Martinez-Zarate

  • 2008 Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas: A Cost-Utility Analysis
    by Gabriel Rogers & Ruth Garside & Stuart Mealing & Martin Pitt & Rob Anderson & Matthew Dyer & Ken Stein & Margaret Somerville

  • 2008 Cost-Effectiveness Analyses of Hepatitis A Vaccine: A Systematic Review to Explore the Effect of Methodological Quality on the Economic Attractiveness of Vaccination Strategies
    by Andrea M. Anonychuk & Andrea C. Tricco & Chris T. Bauch & Ba' Pham & Vladimir Gilca & Bernard Duval & Ava John-Baptiste & Gloria Woo & Murray Krahn

  • 2008 The New Myth: The Social Value of the QALY
    by Werner Brouwer & Job van Exel & Rachel Baker & Cam Donaldson

  • 2008 Modelling Downstream Effects in the Presence of Technological Change
    by Duncan Mortimer

  • 2008 Does `NICE blight' exist, and if so, why?
    by Alan Haycox

  • 2008 Acknowledgement
    by Adis International Limited

  • 2008 Book Review
    by Adis International Limited

  • 2008 A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy
    by Alec B. O'Connor & Katia Noyes & Robert G. Holloway

  • 2008 Single Technology Appraisals by NICE: Are They Delivering Faster Guidance to the NHS?
    by Leela Barham

  • 2008 Management and Prevention of Diabetic Foot Ulcers and Infections: A Health Economic Review
    by Ivy Chow & Elkin V. Lemos & Thomas R. Einarson

  • 2008 Measuring US Pharmaceutical Industry R&D Spending
    by Joseph Golec & John Vernon

  • 2008 Escitalopram and Duloxetine in Major Depressive Disorder: A Pharmacoeconomic Comparison Using UK Cost Data
    by Alan G. Wade & Jose-Luis Fernandez & Clement Francois & Karina Hansen & Natalya Danchenko & Nicolas Despiegel

  • 2008 Economic Impact and Long-Term Graft Outcomes of Mycophenolate Mofetil Dosage Modifications Following Gastrointestinal Complications in Renal Transplant Recipients
    by Gerardo Machnicki & Jean-Francois Ricci & Daniel C. Brennan & Mark A. Schnitzler

  • 2008 A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B
    by D. Eldon Spackman & David L. Veenstra

  • 2008 A Review of Health-Utility Data for Osteoarthritis: Implications for Clinical Trial-Based Evaluation
    by Hirsch S. Ruchlin & Ralph P. Insinga

  • 2008 The Impact of Influenza on Working Days Lost: A Review of the Literature
    by Martin Keech & Paul Beardsworth

  • 2008 Methods for the Meta-Analysis of Willingness-to-Pay Data: An Overview
    by George Van Houtven

  • 2008 Loss Aversion and Cost Effectiveness of Healthcare Programmes: Whose Aversion Counts Anyway?
    by Johan L. Severens

  • 2008 Loss Aversion and Cost Effectiveness of Healthcare Programmes
    by Afschin Gandjour

  • 2008 The Authors
    by Oren Shavit & Moshe Leshno & Assaf Goldberger & Amir Shmueli & Amnon Hoffman

  • 2008 Assessing the Value of a Future Study
    by Afschin Gandjour

  • 2008 Long-Term Cost-Effectiveness Analysis of Nebivolol Compared with Standard Care in Elderly Patients with Heart Failure: An Individual Patient-Based Simulation Model
    by Guiqing Yao & Nick Freemantle & Marcus Flather & Puvan Tharmanathan & Andrew Coats & Philip A. Poole-Wilson

  • 2008 Costs and Effects of Secondary Prevention with Perindopril in Stable Coronary Heart Disease in Poland: An Analysis of the EUROPA Study Including 1251 Polish Patients
    by W. Ken Redekop & Ewa Orlewska & Pawel Maciejewski & Frans F.H. Rutten & Louis W. Niessen

  • 2008 Multiple Sclerosis in the UK: Service Use, Costs, Quality of Life and Disability
    by Paul McCrone & Margaret Heslin & Martin Knapp & Paul Bull & Alan Thompson

  • 2008 Quality-of-Life Assessment in Rheumatoid Arthritis
    by Anthony S. Russell

  • 2008 Unrelated Medical Costs in Life-Years Gained: Should They be Included in Economic Evaluations of Healthcare Interventions?
    by David R. Rappange & Pieter H.M. van Baal & N. Job A. van Exel & Talitha L. Feenstra & Frans F.H. Rutten & Werner B.F. Brouwer

  • 2008 Funding a Clinical Trial: The Perspective of a Medicines Funder
    by Peter Alsop & Scott Metcalfe & Jackie Evans

  • 2008 Trastuzumab in Early-Stage Breast Cancer: The Question of Treatment Timing
    by Steven Simoens

  • 2008 Effectiveness of a Structured Intensive Weight Loss Program Using Health Educators
    by James E. Rohrer & Harvey D. Cassidy & Diane Dressel & Barbara Cramer

  • 2008 Relationship between the Change in Mental Health and Indicators of Medical Costs in the Prevention of Lifestyle-Related Disease
    by Reiko Ishihara & Chihoko Kame & Akira Babazono

  • 2008 An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis
    by Mickael Hiligsmann & Olivier Ethgen & Olivier Bruyere & Jean-Yves Reginster

  • 2008 Assessing the Barriers to Engaging Challenging Populations in Disease Management Programs: The Medicaid Experience
    by Dylan H. Roby & Gerald F. Kominski & Nadereh Pourat

  • 2008 Health Beliefs and Culture: Essential Considerations for Outcome Measurement
    by Kamaldeep Bhui & Sokratis Dinos

  • 2008 Antimicrobial Stewardship Programs: Role in Optimizing Infectious Disease Outcomes
    by Christine J. Kubin

  • 2008 Information Technology to Support Self-Management in Chronic Care: A Systematic Review
    by Michael R. Solomon

  • 2008 Use of Collaboration to Improve Outcomes in Chronic Disease: An Overview
    by Monica Gilbert & Carole Staley & Sharryn Lydall-Smith & David J. Castle

  • 2008 Is the Rate of Generic Drug Prescribing a Fair Measure for Pay for Performance?
    by Stephen Buetow & Linda Bryant

  • 2008 Acknowledgment
    by Adis International Limited

  • 2008 Evaluation Methods in Disease Management Studies: 2004-07
    by Thomas Wilson & Martin MacDowell & Patricia Salber & Gary Montrose & Carolyn Hamm

  • 2008 Symptom Perspectives: Patient-Professional Differences and Communication
    by Cathy Michaels & Suzanne C. Lareau

  • 2008 Patients with Chronic Obstructive Pulmonary Disease: Between Reality and Expectations - A Patient
    by Wlodzimierz Vlady Rozenbaum

  • 2008 Patients with Alpha-1 Antitrypsin Deficiency: Disease Management Considerations
    by Rick Carter & Brian L. Tiep

  • 2008 Successful Smoking Cessation
    by Gary L. Huber & Vijay K. Mahajan

  • 2008 Clinical Decision Processes and Patient Engagement in Self-Management
    by Jean Bourbeau

  • 2008 Disease Management of Chronic Obstructive Pulmonary Disease from a Disease Management Organization Perspective: Providing Technology and Time to Address Gaps in Care
    by Christobel E. Selecky

  • 2008 Integrated Chronic Obstructive Pulmonary Disease Management in Primary Care
    by Niels H. Chavannes

  • 2008 Disease Management for Chronic Obstructive Pulmonary Disease: A Clinical Strategy
    by Brian L. Tiep & Mary C. Barnett

  • 2008 Asthma as a Model for Chronic Disease Management Programs: The Interplay between Pulmonary Function and Quality of Life
    by Aris C. Garro & Robert B. Klein

  • 2008 Optimizing Disease Management of Chronic Obstructive Pulmonary Disease
    by Philip Corsello & David Tinkelman

  • 2008 Approaches to Chronic Disease and Chronic Care: From Oxymoron to Modern Zeitgeist
    by Anna M. Tacon

  • 2008 The Emerging Chronic Obstructive Pulmonary Disease Epidemic: Clinical Impact, Economic Burden, and Opportunities for Disease Management
    by Rick Carter & Brian L. Tiep & Rebecca E. Tiep

  • 2008 Chronic Obstructive Pulmonary Disease: The Challenge and the Solution
    by Thomas L. Petty

  • 2008 Delivering Diabetes Self-Management Education (DSME) in Primary Care: The Pittsburgh Regional Initiative For Diabetes Education (PRIDE)
    by Linda M. Siminerio & Kristine Ruppert & Sharlene Emerson & Francis X. Solano & Gretchen A. Piatt

  • 2008 Disease Management Programs Targeting Obesity in Children: Setting the Scene for Wellness in the Future
    by Adrienne R. Hughes & John J. Reilly

  • 2008 Community Pharmacy, Disease State Management, and Adherence to Medication: A Review
    by Carol Lyn Armour & Lorraine Smith & Ines Krass

  • 2008 Clinical Pharmacy Services in the Home
    by Linda D. MacKeigan & Lisa M. Nissen

  • 2008 Launch of a National Mandatory Chronic Disease Prevention Program in Japan
    by Atsushi Kobayashi

  • 2008 Measuring Quality in Pay-for-Performance Programs: From `One-Size-Fits-All' Measures to Individual Patient Risk-Reduction Scores
    by Jennifer A. Meddings & Laurence F. McMahon

  • 2008 Pharmacy Continuity of Care: What do Community Pharmacists Need from an Acute Care Hospital to Improve Continuity of Pharmaceutical Care?
    by Cherokee Layson-Wolf & Jill A. Morgan

  • 2008 An Italian Chart for Cardiovascular Risk Estimate Including High-Density Lipoprotein-Cholesterol
    by Alessandro Menotti & Mariapaola Lanti

  • 2008 Clinical and Economic Effects of a Therapeutic Substitution Policy for Proton Pump Inhibitors in Aboriginal Patients in Northern Communities in Canada's Northwest Territories
    by Kathryn Gaebel & Neda Toeg & Mitchell Levine

  • 2008 Why it Pays for Hospitals to Initiate a Heart Failure Disease Management Program
    by Mauricio Velez & Bethany Westerfeldt & Peter S. Rahko

  • 2008 Creating the Virtual Team: Application to Diabetes Mellitus Disease Management
    by Roger Mazze

  • 2008 Pharmacist-Led Interventions for the Management of Cardiovascular Disease: Opportunities and Obstacles
    by Karen J. McConnell & Anne M. Denham & Kari L. Olson

  • 2008 Considerations in Culturally Directed Asthma Disease Management Programs
    by Michelle M. Cloutier

  • 2008 Employee Disease Management in US and Global Workplaces: Integrating Strategies and Expanding their Scope
    by Robin C. Rager & Joseph A. Leutzinger & Jeff A. Hochberg & Wolf Kirsten & David H. Chenoweth

  • 2008 The Potential and Pitfalls of Medicine Management: What Have We Learned So Far?
    by Alison Blenkinsopp & Christine M. Bond

  • 2008 Lessons from Early Experience with Pay for Performance
    by Tim Doran

  • 2008 Disease Management Update
    by Adis International Limited

  • 2008 Intensified Diabetes Care Monitoring and Physician Education: Impact on Outcomes and Costs of Care
    by Ann Donnelly & Prasad Kommareddi & Michael James & Jerry Van Horn & Christopher Zacker & Dan Belletti

  • 2008 Cost Analysis of a Maternity Disease Management Program
    by Gary Stanziano & Niki Istwan

  • 2008 Interdisciplinary Coordination for Breast Healthcare: A Rational Approach to Detection, Diagnosis, and Treatment
    by Benjamin O. Anderson & Cary S. Kaufman & Krystyna D. Kiel & Robert W. Carlson

  • 2008 Disease Management Update
    by Adis International Limited

  • 2008 Nursing Workload Associated with Hospital Patient Care
    by Nicole Mittmann & Soo Jin Seung & Luca F. Pisterzi & Pierre K. Isogai & Donna Michaels

  • 2008 General Pain and Frequency of Medical Visits in Family Medicine: A Retrospective Analysis of Medical Records
    by James E. Rohrer & Stephen P. Merry & Steven C. Adamson & Darryl E. Barnes

  • 2008 Challenges and Applications of the Transtheoretical Model in Patients with Diabetes Mellitus
    by Ana Andres & Juana Gomez & Carmina Saldana

  • 2008 Poor Adherence to Medication in Adults with Rheumatoid Arthritis: Reasons and Solutions
    by Rachel A. Elliott

  • 2008 Challenges Facing Nurse-Led Disease Management for Heart Failure
    by Paul L. Hebert & Jane E. Sisk

  • 2008 Cost-Effectiveness Analysis of Entecavir versus Lamivudine in the First-Line Treatment of Australian Patients with Chronic Hepatitis B
    by Elizabeth Arnold & Yong Yuan & Uchenna Iloeje & Greg Cook

  • 2008 Does Extending Health Insurance Coverage to the Uninsured Improve Population Health Outcomes?
    by James A. Thornton & Jennifer L. Rice

  • 2008 Cost-Effectiveness Analysis of Vaccination against Rotavirus with RIX4414 in France
    by Baudouin Standaert & Nathalie Parez & Bertrand Tehard & Xavier Colin & Bruno Detournay

  • 2008 A Pharmacoeconomic Analysis of Compliance Gains on Antipsychotic Medications
    by Joep Damen & Per-Olof Thuresson & Bart Heeg & Mickael Lothgren

  • 2008 Community-Based Interventions to Promote Increased Physical Activity: A Primer
    by Melissa Bopp & Elizabeth Fallon

  • 2008 The Impact of Direct-to-Consumer Advertised Drugs on Drug Sales in the US and New Zealand
    by Edward Norey & Tessa M. Simone & Shaker A. Mousa

  • 2008 The Impact of Banning Smoking in Workplaces: What are the Early Effects?
    by Shane Allwright

  • 2008 Cost Analysis of Amlodipine versus Enalapril in Patients with Coronary Artery Disease and Normal Blood Pressure: Findings from the CAMELOT Economic Substudy
    by Joseph Menzin & Luke Boulanger & Simon Tang & Kamlesh Thakker & Steven E. Nissen

  • 2008 The Association of Adherence to Antiretroviral Therapy with Healthcare Utilization and Costs for Medical Care
    by Edward M. Gardner & Moises E. Maravi & Cornelis Rietmeijer & Arthur J. Davidson & William J. Burman

  • 2008 Households' Willingness to Pay for a Motorcycle Helmet in Hanoi, Vietnam
    by Khanh H. Pham & Quynh X. Le Thi & Dennis J. Petrie & Jon Adams & Christopher M. Doran

  • 2008 Cost Effectiveness of Ultrasound and Bone Densitometry for Osteoporosis Screening in Post-Menopausal Women
    by Dirk Mueller & Afschin Gandjour

  • 2008 Direct Medical Costs for Type 2 Diabetes Mellitus Complications in the US Commercial Payer Setting: A Resource for Economic Research
    by Elise M. Pelletier & Paula J. Smith & Kristina S. Boye & Derek A. Misurski & Sandra L. Tunis & Michael E. Minshall

  • 2008 Cost Effectiveness of Implantable Cardioverter-Defibrillators for Primary Prevention in a Belgian Context
    by Mattias Neyt & Nancy Thiry & Dirk Ramaekers & Hans Van Brabandt

  • 2008 The Lifetime Cost of Hepatocellular Carcinoma: A Claims Data Analysis from a Medical Centre in Taiwan
    by Hui-Chu Lang & Jaw-Ching Wu & Sang-Hue Yen & Chung-Fu Lan & Shi-Liang Wu

  • 2008 Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia: A 12- and 24-Month Follow-Up from the e-STAR Database in Spain
    by Jose M. Olivares & Alfonso Rodriguez-Martinez & Jose A. Buron & David Alonso-Escolano & Alexander Rodriguez-Morales

  • 2008 Wealth Status and Risky Sexual Behaviour in Ghana and Kenya
    by Kofi Awusabo-Asare & Samuel K. Annim

  • 2008 Differences in Generic Drug Prices between the US and Canada
    by Malcolm Gooi & Chaim M. Bell

  • 2008 Cost Effectiveness of Screen-and-Treat Strategies for Low Bone Mineral Density: How Do We Screen, Who Do We Screen and Who Do We Treat?
    by John T. Schousboe

  • 2008 Means of Knowledge Acquisition of Entrepreneurs and Their Success
    by Barbara Hvalic Erzetic

  • 2007 Agents Come to Bits: Towards a Constructive Comprehensive Taxonomy of Economic Entities
    by Tesfatsion, Leigh S.

  • 2007 Can Australia Match US Productivity Performance?
    by Ben Dolman & Dean Parham & Simon Zheng

  • 2007 Financial Performance of Government Trading Enterprises 2004-05 to 2005-06
    by Productivity Commission

  • 2007 Performance Benchmarking of Australian Business Regulation
    by Productivity Commission

  • 2007 Stability, Specialization And Social Recognition

  • 2007 Editorial

  • 2007 Transaction And Transfer Efficiencies And The Size Of Fdi

  • 2007 Measuring Transaction Costs: Diverging Approaches, Contending Practices
    by NING WANG

  • 2007 The Authors' Reply
    by Dominic P. Tilden & Segundo Mariz & Gillies O'Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos

  • 2007 A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
    by Philip Home & Adrian Bagust & Matthew Taylor & Philip Ambery & Samara Mendes da Costa

  • 2007 Reliability of Medicaid Claims Versus Medical Record Data: In a Cost Analysis of Palivizumab
    by Julie Jacobson Vann & John Feaganes & Steven Wegner

  • 2007 Preferences of Community Pharmacists for Extended Roles in Primary Care: A Survey and Discrete Choice Experiment
    by Anthony Scott & Christine Bond & Jackie Inch & Aileen Grant

  • 2007 Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention
    by Bart M.S. Heeg & Ron J.G. Peters & Marc Botteman & Ben A. van Hout

  • 2007 Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus: Review and Analysis of the Literature
    by Andrew F. Shorr

  • 2007 Modelling Disease Progression in Alzheimer's Disease: A Review of Modelling Methods used for Cost-Effectiveness Analysis
    by Colin Green

  • 2007 The Increasingly Complex Fourth Hurdle for Pharmaceuticals
    by Joshua Cohen & Elly Stolk & Maartje Niezen

  • 2007 Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children: Theoretical and Methodological Considerations
    by Lisa A. Prosser & James K. Hammitt & Ron Keren

  • 2007 A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease
    by Maureen P.M.H. Rutten-van Molken & Floortje E. van Nooten & Marion Lindemann & Manfred Caeser & Peter M.A. Calverley

  • 2007 A Stated Preference Binary Choice Experiment to Explore NICE Decision Making
    by Paul Tappenden & John Brazier & Julie Ratcliffe & James Chilcott

  • 2007 Direct Costs in Patients Hospitalised with Community-Acquired Pneumonia After Non-Response to Outpatient Treatment with Macrolide Antibacterials in the US
    by Joseph A. Paladino & Martin H. Adelman & Jerome J. Schentag & Paul B. Iannini

  • 2007 Healthcare Utilisation and Costs Associated with Adding Montelukast to Current Therapy in Patients with Mild to Moderate Asthma and Co-Morbid Allergic Rhinitis: PRAACTICAL Study
    by Roberto Dal Negro & Peter Piskorz & Roberto Vives & Magda Guilera & Vasilisa Sazonov Kocevar & Xavier Badia

  • 2007 The Contrast and Convergence of Bayesian and Frequentist Statistical Approaches in Pharmacoeconomic Analysis
    by Grant H. Skrepnek

  • 2007 Impact of Pharmaceutical Prior Authorisation Policies: A Systematic Review of the Literature
    by Jaume Puig-Junoy & Ivan Moreno-Torres

  • 2007 When Drugs Don't Work: Economic Assessment of Enhancing Compliance with Interventions Supported by Electronic Monitoring Devices
    by Dyfrig Hughes

  • 2007 Cost-Utility Analysis in China: Differences and Difficulties Compared with Developed Countries
    by Liu Bao Peng & Chong Qing Tan & Xiao Min Wan & Wei Cui

  • 2007 Direct and Indirect Costs Attributable to Alcohol Consumption in Germany
    by Alexander Konnopka & Hans-Helmut Konig

  • 2007 The Use of Disease-Specific Outcome Measures in Cost-Utility Analysis: The Development of Dutch Societal Preference Weights for the FACT-L Scale
    by Leida M. Lamers & Carin A. Uyl-de Groot & Ivonne Buijt

  • 2007 A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma
    by Ya-Chen Tina Shih & Josephine Mauskopf & Rohit Borker

  • 2007 Retrospective Economic and Outcomes Analyses Using Non-US Databases: A Review
    by Lizheng Shi & Eric Q Wu & Meredith Hodges & Andrew Yu & Howard Birnbaum

  • 2007 Cost Considerations in the Treatment of Colorectal Cancer
    by Frank G.A. Jansman & Maarten J. Postma & Jacobus R.B.J. Brouwers

  • 2007 Perspectives on Dynamic Optimisation and Control Theory in Treating Hyperlipidaemia
    by John A. Vernon

  • 2007 Being Led Down the Wrong Garden PATH: the Importance of Knowledge and Facts for the Crossroads
    by Ron Goeree & Daria O'Reilly & Jean-Eric Tarride & Jim Bowen & Gord Blackhouse & Kaitryn Campbell & Rob Hopkins & Morgan Lim & Lisa Patterson

  • 2007 Building Bridges Between Academic Research and Policy Formulation: When Costing Less Means Costing More
    by Amiram Gafni & Stephen Birch

  • 2007 Costs and Benefits of Direct-to-Consumer Advertising: The Case of Depression
    by Adam E. Block

  • 2007 Cost Effectiveness of Oseltamivir Treatment for Patients with Influenza-Like Illness Who Are at Increased Risk for Serious Complications of Influenza: Illustration for The Netherlands
    by Maarten J. Postma & Annoesjka Novak & Huib W.K.F.H. Scheijbeler & Marlene Gyldmark & Marianne L.L. van Genugten & Jan C. Wilschut

  • 2007 Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs: A Retrospective Analysis among Managed Care Patients with Chronic Myelogenous Leukaemia
    by Theodore Darkow & Henry J. Henk & Simu K. Thomas & Weiwei Feng & Jean-Francois Baladi & George A. Goldberg & Alan Hatfield & Jorge Cortes

  • 2007 A Systematic Review of Economic Evaluation Literature in Thailand: Are the Data Good Enough to be Used by Policy-Makers?
    by Yot Teerawattananon & Steve Russell & Miranda Mugford

  • 2007 Estimation, Power and Sample Size Calculations for Stochastic Cost and Effectiveness Analysis
    by S.D. Walter & Amiram Gafni & Stephen Birch

  • 2007 Reform of Prescription Drug Reimbursement and Pricing in the German Social Health Insurance Market: A Comparison of Three Scenarios
    by Stefan Gress & Dea Niebuhr & Uwe May & Jurgen Wasem

  • 2007 Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model
    by J. Alasdair Millar & Michael J. Millward

  • 2007 Economic Evaluation of Treatment Administration Strategies of Ganciclovir for Cytomegalovirus Retinitis in HIV/AIDS Patients in Thailand: A Simulation Study
    by Kanlaya Teerawattananon & Saniorn Iewsakul & Chawewan Yenjitr & Somsanguan Ausayakhun & Watanee Yenjitr & Miranda Mugford & Yot Teerawattananon

  • 2007 Costs of a Community Pharmacist-Led Medicines Management Service for Patients with Coronary Heart Disease in England: Healthcare System and Patient Perspectives
    by Anthony Scott & Michela Tinelli & Christine Bond

  • 2007 The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD): Responsiveness to Change and English Language Validation
    by Peter Wahlqvist & Gordon H. Guyatt & David Armstrong & Alessio Degl'Innocenti & Diane Heels-Ansdell & Samer El-Dika & Ingela Wiklund & Carlo A. Fallone & Lisa Tanser & Sander Veldhuyzen van Zanten & Peggy Austin & Alan N. Barkun & Naoki Chiba & Holger J. Schunemann

  • 2007 Health Utilities Using the EQ-5D in Studies of Cancer
    by A. Simon Pickard & Caitlyn T. Wilke & Hsiang-Wen Lin & Andrew Lloyd

  • 2007 Replace Pharmaceutical Patents Now
    by Earl L. Grinols & James W. Henderson

  • 2007 Book Review
    by Adis International Limited

  • 2007 Therapeutic Use of Granulocyte Colony-Stimulating Factors for Established Febrile Neutropenia: Effect on Costs from a Hospital Perspective
    by Leon E. Cosler & Adi Eldar-Lissai & Eva Culakova & Nicole M. Kuderer & David Dale & Jeffrey Crawford & Gary H. Lyman

  • 2007 Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients: US Healthcare System Perspective
    by Thomas E. Delea & Oleg Sofrygin & Simu K. Thomas & Jean-Francois Baladi & Pradyumna D. Phatak & Thomas D. Coates

  • 2007 Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer
    by Steven B. Zeliadt & David F. Penson

  • 2007 The Economic Implications of Glaucoma: A Literature Review
    by Jordana K. Schmier & Michael T. Halpern & Mechelle L. Jones

  • 2007 Measuring Patient-Reported Outcomes in Solid Organ Transplant Recipients: An Overview of Instruments Developed to Date
    by Irina Cleemput & Fabienne Dobbels

  • 2007 Letter From the Commissioner's Office at the US FDA
    by John A. Vernon

  • 2007 Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada
    by Daniel T. Grima & Melissa F. Thompson & Luc Sauriol

  • 2007 Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients
    by Danielle E.M. Brunenberg & Gwenn E.C. Wetzels & Patricia J. Nelemans & Carmen D. Dirksen & Johan L. Severens & Henri E.J.H. Stoffers & Jan S.A.G. Schouten & Martin H. Prins & Peter W. de Leeuw & Manuela A. Joore

  • 2007 Recombinant Erythropoietin for Chemotherapy-Related Anaemia: Economic Value and Health-Related Quality-of-Life Assessment Using Direct Utility Elicitation and Discrete Choice Experiment Methods
    by Diego F. Ossa & Andrew Briggs & Emma McIntosh & Warren Cowell & Tim Littlewood & Mark Sculpher

  • 2007 Do Drugs Reduce Utilisation of Other Healthcare Resources?
    by Pierre-Yves Cremieux & Pierre Ouellette & Patrick Petit

  • 2007 Enzyme Replacement Therapy in Orphan and Ultra-Orphan Diseases: The Limitations of Standard Economic Metrics as Exemplified by Fabry-Anderson Disease
    by David F. Moore & Markus Ries & Evelyn L. Forget & Raphael Schiffmann

  • 2007 Economic Evaluations of Cholesterol-Lowering Drugs: A Critical and Systematic Review
    by Pearl D. Gumbs & Monique W.M. Verschuren & Aukje K. Mantel-Teeuwisse & Ardine G. de Wit & Anthonius de Boer & Olaf H. Klungel

  • 2007 Economic Evaluation and Decision Making: Reimbursing Trastuzumab in Early-Stage Breast Cancer
    by Steven Simoens

  • 2007 Measuring Preferences for Cost-Utility Analysis: How Choice of Method May Influence Decision-Making
    by Christine M. McDonough & Anna N.A. Tosteson

  • 2007 Is Medication Review by Pharmacists of Any Use?
    by Arnold G. Zermansky & Nick Freemantle

  • 2007 Letter From the Commissioner's Office at the US FDA
    by John A. Vernon

  • 2007 Home-Based Medication Review in Older People: Is it Cost Effective?
    by Margaret Pacini & Richard D. Smith & Edward C.F. Wilson & Richard Holland

  • 2007 Acute/Subacute Herpes Zoster: Healthcare Resource Utilisation and Costs in a Group of US Health Plans
    by Ralph P. Insinga & Robbin F. Itzler & James M. Pellissier

  • 2007 Conjoint Analysis of French and German Parents' Willingness to Pay for Meningococcal Vaccine
    by David Bishai & Roger Brice & Isabelle Girod & Aneta Saleh & Jenifer Ehreth

  • 2007 Disease Burden of Overactive Bladder: Quality-of-Life Data Assessed Using ICI-Recommended Instruments
    by Ramandeep Basra & Con Kelleher

  • 2007 A `League Table' of Contingent Valuation Results for Pharmaceutical Interventions: A Hard Pill to Swallow?
    by Tracey H. Sach & Richard D. Smith & David K. Whynes

  • 2007 Time Preferences for Health in Northern Tanzania: An Empirical Analysis of Alternative Discounting Models
    by Bjarne Robberstad & John Cairns

  • 2007 Reducing the Societal Burden of Depression: A Review of Economic Costs, Quality of Care and Effects of Treatment
    by Julie M. Donohue & Harold Alan Pincus

  • 2007 Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis
    by Mark J.C. Nuijten & Wolfgang Wittenberg & Maximilian Lebmeier

  • 2007 A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
    by Dominic P. Tilden & Segundo Mariz & Gillies O'Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos

  • 2007 Rates and Probabilities in Economic Modelling: Transformation, Translation and Appropriate Application
    by Rachael L. Fleurence & Christopher S. Hollenbeak

  • 2007 Cost Effectiveness of a Pharmacy-Based Coaching Programme to Improve Adherence to Antidepressants
    by Judith E. Bosmans & Oscar H. Brook & Hein P.J. van Hout & Martine C. de Bruijne & Hugo Nieuwenhuyse & Lex M. Bouter & Wim A.B. Stalman & Maurits W. van Tulder

  • 2007 Letter From the Commissioner's Office at the US FDA
    by John A. Vernon

  • 2007 NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors: Was the Right Question Posed? Were the Best Tools Used?
    by Denis Getsios & Kristen Migliaccio-Walle & Jaime J. Caro

  • 2007 When NICE Says No!
    by Alan Haycox

  • 2007 Acknowledgement
    by Adis International Limited

  • 2007 Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events: An Assessment from the Payer's Perspective
    by Bart Heeg & Joep Damen & Ben Van Hout

  • 2007 Economic Evidence at the Local Level: Options for Making it More Useful
    by Kees van Gool & Gisselle Gallego & Marion Haas & Rosalie Viney & Jane Hall & Robyn Ward

  • 2007 Atorvastatin: A Pharmacoeconomic Review of its Use in the Primary and Secondary Prevention of Cardiovascular Events
    by Greg L. Plosker & Katherine A. Lyseng-Williamson

  • 2007 Recombinant Factor VIIa (Eptacog Alfa): A Pharmacoeconomic Review of its Use in Haemophilia in Patients with Inhibitors to Clotting Factors VIII or IX
    by Katherine A. Lyseng-Williamson & Greg L. Plosker

  • 2007 The Economic Impact of Introducing Serotonin-Noradrenaline Reuptake Inhibitors into the Brazilian National Drug Formulary: Cost-Effectiveness and Budget-Impact Analyses
    by Marcio Machado & Michael Iskedjian & Ines A. Ruiz & Thomas R. Einarson

  • 2007 Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B
    by David L. Veenstra & Sean D. Sullivan & Lauren Clarke & Uche H. Iloeje & Eskinder Tafesse & Adrian Di Bisceglie & Kris V. Kowdley & Robert G. Gish

  • 2007 Strategies for the Management of Suspected Heparin-Induced Thrombocytopenia: A Cost-Effectiveness Analysis
    by Amanda R. Patrick & Wolfgang C. Winkelmayer & Jerry Avorn & Michael A. Fischer

  • 2007 Economic Evaluations of Calcineurin Inhibitors in Renal Transplantation: A Literature Review
    by Alec H. Miners & Guiqing Yao & James Raftery & Rod S. Taylor

  • 2007 The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A Structured Review of the Literature
    by Rachael L. Fleurence & Cynthia P. Iglesias & Jeanene M. Johnson

  • 2007 It's Time to Choose the Study Design!: Net Benefit Analysis of Alternative Study Designs to Acquire Information for Evaluation of Health Technologies
    by Oren Shavit & Moshe Leshno & Assaf Goldberger & Amir Shmueli & Amnon Hoffman

  • 2007 Warfarin Pharmacogenetics: Economic Considerations
    by Dyfrig A. Hughes & Munir Pirmohamed

  • 2007 Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin: Economic Comparison in Adult and Adolescent Type 1 Diabetes Mellitus in Australia
    by Neale Cohen & Michael E. Minshall & Lyn Sharon-Nash & Katerina Zakrzewska & William J. Valentine & Andrew J. Palmer

  • 2007 Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK
    by Sorrel E. Wolowacz & Neil Roskell & Steven Kelly & Fiona M. Maciver & Chris S. Brand

  • 2007 Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients
    by Ya-Chen Tina Shih & Nebiyou B. Bekele & Ying Xu

  • 2007 A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD
    by Laura Bojke & Edward Hornby & Mark Sculpher

  • 2007 Valuing Children's Health: A Comparison of Cost-Utility Analyses for Adult and Paediatric Health Interventions in the US
    by Joseph A. Ladapo & Peter J. Neumann & Ron Keren & Lisa A. Prosser

  • 2007 Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions: Why Uncertainty About the Outcome, Estimate and Willingness to Pay Matters
    by Jeffrey S. Hoch & Carolyn S. Dewa

  • 2007 Ninth Annual Disease Management Leadership Forum and First Disease Management Association of America-National Association of Manufacturers Integrated Care Summit: Las Vegas, Nevada, 16-19 September 2007
    by Ginny-Louise MacKay

  • 2007 Cost-Effectiveness Analysis of a Pharmacy Asthma Care Program in Australia
    by Adam Gordois & Carol Armour & Martha Brillant & Sinthia Bosnic-Anticevich & Deborah Burton & Lynne Emmerton & Ines Krass & Bandana Saini & Lorraine Smith & Kay Stewart

  • 2007 Nurse Practitioner-Based Diabetes Care Management: Impact of Telehealth or Telephone Intervention on Glycemic Control
    by Karen Chang & Rita Davis & Judy Birt & Pete Castelluccio & Peter Woodbridge & David Marrero

  • 2007 Patient and Physician Factors Contributing to Poor Outcomes in Patients with Asthma and COPD
    by Adrian Gillissen & Hubertus Wirtz & Uwe Juergens

  • 2007 Health Support of People with Disabilities in South Australia: Innovations in Policy and Practice
    by David Caudrey & Marguerite Dissinger

  • 2007 Disease Management of Chronic Heart Failure in the Elderly: Issues and Options
    by Ken McDonald

  • 2007 Acknowledgment
    by Adis International Limited

  • 2007 Disease Management Update
    by Adis International Limited

  • 2007 Consensus Development and Application of ICD-9-CM Codes for Defining Chronic Illnesses and their Complications
    by Ariel Linden & Thomas J. Biuso & Gopal Allada & Alan F. Barker & Joaquin Cigarroa & Sai Praveen Haranath & Diana Rinkevich & Karl Stajduhar

  • 2007 Obesity and Medical Visits in Family Medicine: A Retrospective Analysis of Medical Records
    by James E. Rohrer & Steven C. Adamson & Joseph W. Furst

  • 2007 Health Coaching as an Intervention in Health Management Programs
    by Susan W. Butterworth & Ariel Linden & Wende McClay

  • 2007 Selection of Proton Pump Inhibitors for Formulary Inclusion: Making Decisions Based on Appropriate Criteria
    by Stephen W. Nissen & Keith M. Olsen

  • 2007 Health Plan Employer Data and Information Set (HEDIS(R)) Criteria to Determine the Quality of Asthma Care in Children: What Are the Limitations?
    by Harold J. Farber & Michael Schatz

  • 2007 Perspectives on Premenstrual Syndrome/Premenstrual Dysphoric Disorder: Outcomes From a Meeting of the Latin America Experts Group
    by Luis Bahamondes & Santiago Cordova-Eguez & Jose Enrique Pons & Lee Shulman

  • 2007 Disease Management Update
    by Adis International Limited

  • 2007 The Role of Medication Adherence as a Determinant of Blood Pressure Control in a Managed Care Population
    by Nilay D. Shah & MaryAnn E. Steiner & Lee C. Vermeulen & Lawrence A. Fleming & Patrick R. Cory

  • 2007 Consumer-Directed Health Plans and the Chronically Ill
    by Stephen T. Parente & Jon B. Christianson & Roger Feldman

  • 2007 Measuring the Quality of Healthcare: The Connection between Structure, Process, and Outcomes of Care, Using the Example of Myocardial Infarction Treatment in Germany
    by Ansgar Wubker

  • 2007 Evaluation of an Online Relapse Prevention Program for Bipolar Disorder: An Overview of the Aims and Methodology of a Randomized Controlled Trial
    by Caryl Barnes & Robin Harvey & Philip Mitchell & Michael Smith & Kay Wilhelm

  • 2007 Physician-Patient e-Visit Programs: Implementation and Appropriateness
    by Pamela Whitten & Lorraine Buis & Brad Love

  • 2007 Disease Management Programs for Glaucoma: Has the Vision Become a Reality?
    by Lawrence D. Goldberg

  • 2007 Disease Management Update
    by Adis International Limited

  • 2007 Psychoeducational Approaches to Medication Adherence in Patients with Bipolar Disorder
    by Martha Sajatovic & Peijun Chen & Philipp Dines & Edwin R. Shirley

  • 2007 Treating Allergic Asthma with Omalizumab
    by Paul P. Belliveau & Monina R. Lahoz

  • 2007 Design, Measurement, and Evaluation of an Education Strategy in the Hospital Setting to Combat Antimicrobial Resistance: Theoretical Considerations and a Practical Example
    by Celine Pulcini & Sally Crofts & Diane Campbell & Peter Davey

  • 2007 Implementation of an HPV-Vaccination Program: Key Factors for Success
    by Shalini L. Kulasingam

  • 2007 Disease Management and the Medical Home Model: Competing or Complementary?
    by Vincent Kuraitis

  • 2007 Abandoning the UK NHS?
    by Tony Clive Hockley

  • 2007 The Role of Spirometry in Evaluating Therapeutic Responses in Advanced COPD
    by Pierantonio Laveneziana & Denis E. O'Donnell

  • 2007 The Rise of Specialty Pharmacy Costs: Issues for Providers, Payers, and Patients
    by Steve B. Miller & Tracy A. Hoffman & Jonah C. Houts & Jane L. Miller & Britton L. Pim & Andrew Behm

  • 2007 Exploring Disease Management Programs for Diabetes Mellitus: Proposal of a Novel Hybrid Model
    by Kerri L. Cavanaugh & Richard O. White & Russell L. Rothman

  • 2007 Physician Prescribing and Medicare Part D: Closing the Gaps
    by William H. Shrank

  • 2007 Disease Management Update
    by Adis International Limited

  • 2007 Patient-Motivated Prevention of Lifestyle-Related Disease in Japan: A Randomized, Controlled Clinical Trial
    by Akira Babazono & Chihoko Kame & Reiko Ishihara & Eiji Yamamoto & Alan L. Hillman

  • 2007 Techniques for Measuring Medication Adherence in Hypertensive Patients in Outpatient Settings: Advantages and Limitations
    by Jay Hawkshead & Marie A. Krousel-Wood

  • 2007 Initiatives to Promote Effective Self-Care Skills in Children and Adolescents with Diabetes Mellitus
    by Barbara J. Anderson & Britta Svoren & Lori Laffel

  • 2007 Estimating the Effect of Regression to the Mean in Health Management Programs
    by Ariel Linden

  • 2007 Disease Management Update
    by Adis International Limited

  • 2007 Spotlight on the Pharmacoeconomics of Candesartan Cilexetil in Chronic Heart Failure and Hypertension
    by Greg L. Plosker & Susan J. Keam

  • 2007 The Impact of Nebulized Levalbuterol on Health Care Payments for Elderly Asthma and Chronic Obstructive Pulmonary Disease Patients in Medicaid Plans
    by Ronald J. Ozminkowski & Shaohung Wang & Stacey R. Long

  • 2007 Estimating the Impact of a Congestive Heart Failure Disease Management Program on Prescription Drug Use: A State Medicaid Program
    by Anthony C. Moscoso & Matthew J. Strand & Gregory D. Berg & Gary K. Grunwald

  • 2007 Hypertension Home Telemonitoring: Current Evidence and Recommendations for Future Studies
    by Mirou Jaana & Guy Pare & Claude Sicotte

  • 2007 Use of the Pre-Post Method to Measure Cost Savings in Disease Management: Issues and Implications
    by Ariel Linden

  • 2007 Initiatives and Barriers to Adopting Health Information Technology: A US Perspective
    by Henry A. DePhillips

  • 2007 The Special Economic Allocations Law and its role in the oil fiscal income distribution (1998-2006)
    by Gladys Cáceres F. & Helena Hernández V.

  • 2007 Factores estratégicos de éxito de las empresas de inserción
    by José Luis Retolaza Ávalos & Maite Ruiz Roqueñi & Andrés Araujo de la Mata

  • 2007 Données individuelles et implications macroéconomiques
    by .

  • 2006 Handbook of Computational Economics, Vol. 2: Agent-Based Computational Economics
    by Tesfatsion, Leigh & Judd, Kenneth L.

  • 2006 Financial Performance of Government Trading Enterprises 2000-01 to 2004-05
    by Productivity Commission

  • 2006 Principle of Uncertain Future
    by Alexander Harin

  • 2006 A Rational Irrational Man?
    by Alexander Harin

  • 2006 Operational identification of the complete class of superlative index numbers: an application of Galois theory
    by William Barnett & Ki-Hong Choi

  • 2006 A Guide for Newcomers to Agent-Based Modeling in the Social Sciences
    by Axelrod, Robert & Tesfatsion, Leigh

  • 2006 Agent-Based Computational Modeling And Macroeconomics
    by Tesfatsion, Leigh

  • 2006 Diversity Of Specialization Patterns, Schur Convexity And Transference: A Note On The Measurement Of The Division Of Labor

  • 2006 The Role Of Expectations In A Specialization-Driven Growth Model With Endogenous Technology Choice

  • 2006 Domestic And Global Sourcing

  • 2006 Output Set, Convexity, Specialization And Trade In The Absence Of Comparative Advantages

  • 2006 Theoretical Difficulties With Transaction Cost Measurement

  • 2006 Introduction

  • 2006 Recollections Of Xiaokai

  • 2006 Xiaokai Yang At Monash
    by IAN WILLS

  • 2006 Reflections Of Xiaokai Yang
    by MEI WEN

  • 2006 Xiaokai Yang: Some Recollections

  • 2006 Xiaokai Yang: An Economist Defined By One Big Idea

  • 2006 Xiaokai Yang'S Contribution

  • 2006 My Friend Xiaokai Yang, The Mozart Of Economic Theory

  • 2006 My Acquaintance With Xiaokai

  • 2006 Reminiscence Of Xiaokai Yang
    by KE LI

  • 2006 Reflection On Xiaokai Yang

  • 2006 In Memory Of Xiaokai

  • 2006 Love Of Variety And Scale Implications: An Empirical Evaluation

  • 2006 Division Of Labour, Specialization, And Theft Behavior — A General Equilibrium Analysis Of "Hobbes' Jungle"
    by KE LI

  • 2006 A Three-Good Overlapping-Generations General Equilibrium Efficient Business Cycle Model
    by JULAN DU

  • 2006 Endogenous Specialization, Endogenous Transaction Costs, And The Theory Of The Firm

  • 2006 The Authors' Reply
    by Adrian A. Bagust & Marc Evans & Sophie Beale & Philip Home & Andrew Perry & Murray Stewart & Arran Shearer & Alan Martin & Lisa Hulme & Andreas Liebl & Oliver Schoeffski & Anita Goertz & Javier Ampudia-Blasco & Belen Martinez-Lage & Isabel Perez Escolano & Gonzalo Paris

  • 2006 Modelling Lifetime Metabolic Progression and Cost Effectiveness of Treatment Strategies for Type 2 Diabetes
    by Andrew J. Palmer & Craig J. Currie

  • 2006 Missing Data Imputation in Quality-of-Life Assessment: Imputation for WHOQOL-BREF
    by Ting Hsiang Lin

  • 2006 Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia: Cost Effectiveness and Risk Sharing
    by John H. Wlodarczyk & Leslie G. Cleland & Anne M. Keogh & Keith D. McNeil & Kate Perl & Robert G. Weintraub & Trevor J. Williams

  • 2006 Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996-2003
    by Yue-Chune Lee & Ming-Chin Yang & Yu-Tung Huang & Chien-Hsiang Liu & Sun-Bing Chen

  • 2006 Cost-of-Illness Studies: A Review of Current Methods
    by Ebere Akobundu & Jing Ju & Lisa Blatt & C. Daniel Mullins

  • 2006 Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework: Some Considerations
    by Emma McIntosh

  • 2006 The Value of Thinly Spread QALYs
    by Duncan Mortimer

  • 2006 Accuracy versus Transparency in Pharmacoeconomic Modelling: Finding the Right Balance
    by David M. Eddy

  • 2006 US FDA Guidance: Apropos of PROs
    by Paul Kind

  • 2006 National-Level Purchasing of Expensive Drugs is Increasing Pressure on the Hospital Drug Budget
    by Slobodan M. Jankovic & Nebojsa Milivojevic

  • 2006 Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada
    by Michele Kohli & Cheryl Attard & Annette Lam & Daniel Huse & John Cook & Chantal Bourgault & Evo Alemao & Donald Yin & Michael Marentette

  • 2006 Costs of Inflammatory Bowel Disease in Germany
    by Renee Stark & Hans-Helmut Konig & Reiner Leidl

  • 2006 A Multi-Country Health Economic Evaluation of Highly Concentrated N-3 Polyunsaturated Fatty Acids in Secondary Prevention after Myocardial Infarction
    by Mark Lamotte & Lieven Annemans & Pawel Kawalec & York Zoellner

  • 2006 Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease
    by Virginia L. Priest & Evan J. Begg & Sharon J. Gardiner & Christopher M.A. Frampton & Richard B. Gearry & Murray L. Barclay & David W.J. Clark & Paul Hansen

  • 2006 A Comparative Review of Health-Related Quality-of-Life Measures for Use in HIV/AIDS Clinical Trials
    by Darren J. Clayson & Diane J. Wild & Paul Quarterman & Isabelle Duprat-Lomon & Maria Kubin & Stephen Joel Coons

  • 2006 Prostaglandin Analogues for the Treatment of Glaucoma and Ocular Hypertension: A Systematic Review of Economic Evidence
    by Michelle Orme & Annabel Boler

  • 2006 Cost Effectiveness of Leukotriene Modifiers in Adults with Asthma
    by Pamela C. Heaton

  • 2006 Clopidogrel: A Pharmacoeconomic Review of its Use in Patients with Non-ST Elevation Acute Coronary Syndromes
    by Katherine A. Lyseng-Williamson & Greg L. Plosker

  • 2006 Cost Effectiveness of Budesonide/Formoterol for Maintenance and Reliever Therapy versus Salmeterol/Fluticasone plus Salbutamol in the Treatment of Asthma
    by Gunnar Johansson & Emma B. Andreasson & Per E. Larsson & Claus F. Vogelmeier

  • 2006 Tapering Off Benzodiazepines in Long-Term Users: An Economic Evaluation
    by Richard C. Oude Voshaar & Paul F.M. Krabbe & Wim J.M.J. Gorgels & Eddy M.M. Adang & Anton J.L.M. van Balkom & Eloy H. van de Lisdonk & Frans G. Zitman

  • 2006 Usefulness of the Audit of Diabetes-Dependent Quality-of-Life (ADDQoL) Questionnaire in Patients with Diabetes in a Multi-Ethnic Asian Country
    by Hwee-Lin Wee & Chee-Eng Tan & Su-Yen Goh & Shu-Chuen Li

  • 2006 Hepatitis C: Cost of Illness and Considerations for the Economic Evaluation of Antiviral Therapies
    by John B. Wong

  • 2006 Cost of Lung Cancer: A Methodological Review
    by Laurent Molinier & Christophe Combescure & Cristos Chouaid & Jean-Pierre Daures & Bruno Housset & Didier Fabre & Alain Grand & Alain Vergnenegre

  • 2006 Developing Health-Related Quality-of-Life Instruments for Use in Asia: The Issues
    by Yin Bun Cheung & Julian Thumboo

  • 2006 Economic Models of Antiretroviral Therapy: Searching for the Optimal Strategy
    by Fred J. Hellinger

  • 2006 NICE Says No to Inhaled Insulin: What Lessons Should We Learn?
    by Nick Freemantle

  • 2006 The Authors' Reply
    by Colin Green & Joanna Picot & Emma Loveman & Andrea Takeda & Jo Kirby & Andrew Clegg

  • 2006 Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer's Disease
    by Nick Bosanquet & Andrew Yeates

  • 2006 Is the Childhood Asthma Questionnaire a Good Measure of Health-Related Quality of Life of Asthmatic Children in Asia?: Validation Among Paediatric Patients with Asthma in Singapore
    by Lee-Yee Chong & Oh-Moh Chay & Li Shu-Chuen

  • 2006 Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients: A Pharmacoeconomic Analysis
    by George Dranitsaris & Mark Vincent & Mark Crowther

  • 2006 Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients: Modelling Study from the Hospital Perspective in Germany
    by Peter K. Schadlich & Michael Kentsch & Manfred Weber & Wolfgang Kammerer & Josef Georg Brecht & Vijay Nadipelli & Eduard Huppertz

  • 2006 The Effects of Type 1 Diabetes and its Long-Term Complications on Physical and Mental Health Status
    by Jarmo Hahl & Helena Hamalainen & Tuula Simell & Olli Simell

  • 2006 The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy
    by George W. Carides & Shahnaz Shahinfar & Erik J. Dasbach & William F. Keane & William C. Gerth & Charles M. Alexander & William H. Herman & Barry M. Brenner & the RENAAL Investigators

  • 2006 Healthcare Rationing in Spain: Framework, Descriptive Analysis and Consequences
    by Rosa Rodriguez-Monguio & Fernando Antonanzas Villar

  • 2006 Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy: Implications for Decision Making
    by Cornelis Boersma & Jarir Atthobari & Ron T. Gansevoort & Lolkje T.W. de Jong-Van den Berg & Paul E. de Jong & Dick de Zeeuw & Lieven J.P. Annemans & Maarten J. Postma

  • 2006 The Authors' Reply
    by Lawrence D. Goldberg & John G. Walt

  • 2006 Cost Considerations in the Medical Management of Glaucoma in the US: Estimated Yearly Costs and Cost Effectiveness of Bimatoprost Compared with Other Medications
    by Javier Soto

  • 2006 Letrozole: A Pharmacoeconomic Review of its Use in Postmenopausal Women with Breast Cancer
    by Christopher Dunn & Susan J. Keam

  • 2006 Economic Evaluation of Weekly Epoetin Alfa versus Biweekly Darbepoetin Alfa for Chemotherapy-Induced Anaemia: Evidence from a 16-Week Randomised Trial
    by Shelby D. Reed & Jasmina I. Radeva & Davey B. Daniel & Samir H. Mody & Jamie B. Forlenza & R. Scott McKenzie & Kevin A. Schulman

  • 2006 Comprehensive Decision-Analytic Model and Bayesian Value-of-Information Analysis: Pentoxifylline in the Treatment of Chronic Venous Leg Ulcers
    by Cynthia P. Iglesias & Karl Claxton

  • 2006 Encouraging Smokers to Quit: The Cost Effectiveness of Reimbursing the Costs of Smoking Cessation Treatment
    by Janneke Kaper & Edwin J. Wagena & Constant P. van Schayck & Johan L. Severens

  • 2006 Cost Effectiveness of Increasing the Dose Intensity of Chemotherapy with Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: Based on Data from the Medical Research Council LU19 Trial
    by Laura Bojke & Mark Sculpher & Richard Stephens & Wendi Qian & Nick Thatcher & David Girling

  • 2006 Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus: A Systematic Literature Review
    by Sylvia M.C. Vijgen & Mirjam Hoogendoorn & Caroline A. Baan & G. Ardine de Wit & Wien Limburg & Talitha L. Feenstra

  • 2006 Accounting for Tastes: A German Perspective on the Inclusion of Patient Preferences in Healthcare
    by Florian Vogt & David L.B. Schwappach & John F.P. Bridges

  • 2006 The Authors' Reply
    by Richard J. Milne & Kathy H. Heaton-Brown & Paul Hansen & David Thomas & Vernon Harvey & Alison Cubitt

  • 2006 Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women
    by Stephanie Land

  • 2006 Productivity Costs in Health-State Valuations: Does Explicit Instruction Matter?
    by Marieke Krol & Werner Brouwer & Pedram Sendi

  • 2006 A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy
    by Aslam H. Anis & Huiying Sun & Sonia Singh & John Woolcott & Bohdan Nosyk & Marc Brisson

  • 2006 Post-Exposure Influenza Prophylaxis with Oseltamivir: Cost Effectiveness and Cost Utility in Families in the UK
    by Beate Sander & Frederick G. Hayden & Marlene Gyldmark & Louis P. Garrison

  • 2006 Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment: A Review and Consolidation of Quality Assessment
    by Zoe Philips & Laura Bojke & Mark Sculpher & Karl Claxton & Su Golder

  • 2006 Optimal Assignment of Treatments to Health States Using a Markov Decision Model: An Introduction to Basic Concepts
    by Mohan V. Bala & Josephine A. Mauskopf

  • 2006 Economic and Developmental Considerations for Pharmacogenomic Technology
    by John A. Vernon & Scott J. Johnson & W. Keener Hughen & Antonio Trujillo

  • 2006 The Burden of Age-Related Macular Degeneration
    by Jordana K. Schmier & Mechelle L. Jones & Michael T. Halpern

  • 2006 Bernard S. Bloom, PhD
    by Henry A. Glick

  • 2006 Rationing of Drugs for Rare Diseases
    by Dyfrig Hughes

  • 2006 Bimatoprost: A Pharmacoeconomic Review of its Use in Open-Angle Glaucoma and Ocular Hypertension
    by Greg L. Plosker & Susan J. Keam

  • 2006 The Authors' Reply
    by Paul Kind & Sue Macran

  • 2006 Eliciting Social Preference Weights for Functional Assessment of Cancer Therapy-Lung Health States
    by A. Simon Pickard & Deborah Dobrez & David Cella

  • 2006 Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women
    by Richard J. Milne & Kathy H. Heaton-Brown & Paul Hansen & David Thomas & Vernon Harvey & Alison Cubitt

  • 2006 Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer's Disease and Other Dementias
    by Jerrold Hill & Howard Fillit & Simu K. Thomas & Sobin Chang

  • 2006 Cost Considerations in the Medical Management of Glaucoma in the US: Estimated Yearly Costs and Cost Effectiveness of Bimatoprost Compared with Other Medications
    by Lawrence D. Goldberg & John Walt

  • 2006 Cost Effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen Therapy: The UK Perspective
    by Jonathan Karnon & Thomas Delea & Stephen R.D. Johnston & Robert Smith & Jane Brandman & Jennifer Sung & Paul E. Goss

  • 2006 Trends in Outpatient Prescription Drug Use and Related Costs in the US: 1998-2003
    by Diane K. Wysowski & Laura A. Governale & Joslyn Swann

  • 2006 Aromatase Inhibitors in Breast Cancer: A Review of Cost Considerations and Cost Effectiveness
    by Jonathan Karnon

  • 2006 Less is More: Medicines that Require Less Frequent Administration Improve Adherence, but Are They Better?
    by Dyfrig Hughes

  • 2006 How Much is the Cost of Visual Impairment: the Author's Reply
    by Antoine Lafuma

  • 2006 How Much is the Cost of Visual Impairment: Caveat Emptor
    by Catherine Meads & Chris Hyde

  • 2006 Evaluation of Non-Medical Costs Associated with Visual Impairment in Four European Countries: France, Italy, Germany and the UK
    by Antoine Lafuma & Antoine Brezin & Stefania Lopatriello & Klaus Hieke & Julia Hutchinson & Viviane Mimaud & Gilles Berdeaux

  • 2006 The Long-Term Cost Effectiveness of Treatments for Benign Prostatic Hyperplasia
    by Rachael L. DiSantostefano & Andrea K. Biddle & John P. Lavelle

  • 2006 A Multi-Country Economic Evaluation of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease
    by Mark Lamotte & Lieven Annemans & Thomas Evers & Maria Kubin

  • 2006 Combination Vaccine Against Invasive Meningococcal B and Pneumococcal Infections: Potential Epidemiological and Economic Impact in The Netherlands
    by Jasper M. Bos & Hans C. Rumke & Robert Welte & Lodewijk Spanjaard & Loek van Alphen & Maarten J. Postma

  • 2006 Differential Effects of Atypical versus Typical Antipsychotic Medication on Earnings of Schizophrenia Patients: Estimates from a Prospective Naturalistic Study
    by David Salkever & Eric Slade & Mustafa Karakus

  • 2006 Sociodemographic Differences in Quality of Life in Rheumatoid Arthritis
    by Erik J. Groessl & Theodore G. Ganiats & Andrew J. Sarkin

  • 2006 Better Analysis for Better Decisions: Has Pharmacoeconomics Come of Age?
    by Michael Drummond & Mark Sculpher

  • 2006 Economic Evaluation of Rivastigmine in Patients with Parkinson's Disease Dementia
    by Andrew R. Willan & Ron Goeree & Eleanor M. Pullenayegum & Christopher McBurney & Gordon Blackhouse

  • 2006 Cost Effectiveness of Bemiparin Sodium versus Unfractionated Heparin and Oral Anticoagulants in the Acute and Long-Term Treatment of Deep Vein Thrombosis
    by Antonio Gomez-Outes & Eduardo Rocha & Javier Martinez-Gonzalez & Vijay V. Kakkar

  • 2006 Evaluation of the Cost Effectiveness of Sirolimus versus Tacrolimus for Immunosuppression Following Renal Transplantation in the UK
    by Phil McEwan & Simon Dixon & Keshwar Baboolal & Pete Conway & Craig J. Currie

  • 2006 Interstitial Cystitis: Cost, Treatment and Co-morbidities in an Employed Population
    by Eric Q. Wu & Howard Birnbaum & Milena Mareva & Andrew Parece & Zihong Huang & David Mallett & Haya Taitel

  • 2006 Incorporating Carer Effects into Economic Evaluation
    by Simon Dixon & Mel Walker & Sam Salek

  • 2006 Too Important to Ignore: Informal Caregivers and Other Significant Others
    by Werner B.F. Brouwer

  • 2006 Costs of Irritable Bowel Syndrome in the UK and US
    by Stefanie Maxion-Bergemann & Frank Thielecke & Florian Abel & Rito Bergemann

  • 2006 Bayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis
    by A.E. Ades & Mark Sculpher & Alex Sutton & Keith Abrams & Nicola Cooper & Nicky Welton & Guobing Lu

  • 2006 The Authors' Reply
    by J.M. Bos & M.J. Postma & L. Annemans

  • 2006 Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies
    by Stuart Birks

  • 2006 Candesartan Cilexetil: A Pharmacoeconomic Review of its Use in Chronic Heart Failure and Hypertension
    by Greg L. Plosker & Susan J. Keam

  • 2006 Association of Co-Morbidities with Prescribing Patterns and Cost Savings: Olanzapine versus Risperidone for Schizophrenia
    by Wei Yu & Xinhua S. Ren & Austin F. Lee & Lawrence Herz & Yu-Hui Huang & Lewis E. Kazis

  • 2006 Cost Effectiveness of Tumour Necrosis Factor-alpha Inhibitors as First-Line Agents in Rheumatoid Arthritis
    by James R. Spalding & Joel Hay

  • 2006 Generic Health-Related Quality-of-Life Assessment in Children and Adolescents: Methodological Considerations
    by Ulrike Ravens-Sieberer & Michael Erhart & Nora Wille & Ralf Wetzel & Jennifer Nickel & Monika Bullinger

  • 2006 Assessing Generalisability in Model-Based Economic Evaluation Studies: A Structured Review in Osteoporosis
    by Hege Urdahl & Andrea Manca & Mark J. Sculpher

  • 2006 Letter From the Commissioner's Office at the US FDA
    by John A. Vernon

  • 2006 Do Pharmacogenomic Tests Provide Value to Policy Makers?
    by Ya-Chen Tina Shih & Lajos Pusztai

  • 2006 Acknowledgement
    by Adis International Limited

  • 2006 Economic Evaluation in the US: What is the Missing Link?
    by Peter J. Neumann & Sean D. Sullivan

  • 2006 Economic Evaluations in the Canadian Common Drug Review
    by Andreas Laupacis

  • 2006 Building Bridges Between Academic Research and Policy Formulation: The PRUFE Framework - an Integral Part of Ontario's Evidence-Based HTPA Process
    by Ron Goeree & Leslie Levin

  • 2006 Economic Evaluation and Decision Making in the UK
    by Martin J. Buxton

  • 2006 Information Created to Evade Reality (ICER): Things We Should Not Look to for Answers
    by Stephen Birch & Amiram Gafni

  • 2006 `Lost in Translation': Accounting for Between-Country Differences in the Analysis of Multinational Cost-Effectiveness Data
    by Andrea Manca & Andrew R. Willan

  • 2006 Analysis Sans Frontieres: Can We Ever Make Economic Evaluations Generalisable Across Jurisdictions?
    by Mark J. Sculpher & Michael F. Drummond

  • 2006 Pharmacoeconomics and Pharmacoepidemiology: Curious Bedfellows or a Match Made in Heaven?
    by Andrew H. Briggs & Adrian R. Levy

  • 2006 Utility Measurement in Healthcare: The Things I Never Got To
    by George W. Torrance

  • 2006 Using Value of Information Analysis to Prioritise Health Research: Some Lessons from Recent UK Experience
    by Karl P. Claxton & Mark J. Sculpher

  • 2006 Recent Developments in Decision-Analytic Modelling for Economic Evaluation
    by Milton C. Weinstein

  • 2006 Better Analysis for Better Decisions: Facing Up to the Challenges
    by Michael F. Drummond & Mark J. Sculpher

  • 2006 Hospitalisation Costs of Cystic Fibrosis
    by Jonas Schreyogg & Helge Hollmeyer & Miriam Bluemel & Doris Staab & Reinhard Busse

  • 2006 Disability and Quality of Life in Post-Traumatic Stress Disorder: Impact of Drug Treatment
    by Soraya Seedat & Christine Lochner & Bavanisha Vythilingum & Dan J. Stein

  • 2006 Single-Inhaler Combination Therapy for Asthma: A Review of Cost Effectiveness
    by Manabu Akazawa & David A. Stempel

  • 2006 Therapeutic Options for the Prevention and Treatment of Postoperative Nausea and Vomiting: A Pharmacoeconomic Review
    by Jean Lachaine

  • 2006 Should We Abandon QALYs as a Resource Allocation Tool?
    by Sandeep Vijan

  • 2006 QALYs: Are They Helpful to Decision Makers?
    by Maurice McGregor & J. Jaime Caro

  • 2006 The Generalisability of Pharmacoeconomic Studies: Issues and Challenges Ahead
    by James M. Mason & Anne R. Mason

  • 2006 Anticoagulation for Stroke Prevention: High Effectiveness, More Cost Benefit?
    by Eduard Shantsila & Timothy Watson & Gregory Y.H. Lip

  • 2006 The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the US
    by Patrick W. Sullivan & Thomas W. Arant & Samuel L. Ellis & Heather Ulrich

  • 2006 The Initial Validation of a Markov Model for the Economic Evaluation of (New) Treatments for Rheumatoid Arthritis
    by Paco M.J. Welsing & Johan L. Severens & Margriet Hartman & Anke M. van Gestel & Piet L.C.M. van Riel & Roland F.J.M. Laan

  • 2006 2006 Disease Management Leadership Forum Meeting Report: Denver, Colorado, 2-5 December 2006
    by Julie A. Meek

  • 2006 Economic Analysis of a Telemedicine Intervention to Improve Glycemic Control in Patients with Diabetes Mellitus: Illustration of a Novel Analytic Method
    by James M. Mason & Robert J. Young & John P. New & J. Martin Gibson & Andrew F. Long & Tina Gambling & Tim Friede

  • 2006 Psychiatric Drug Use Among Patients of a Community Mental Health Service: Patterns and Implications
    by Natasa Gisev & J. Simon Bell & Andrew J. McLachlan & Manoranjenni Chetty & Timothy F. Chen

  • 2006 Combination Therapy for Asthma: Perspectives of the Patient, Provider, and Payer
    by Harold J. Farber & James Glauber

  • 2006 Targeted Screening and Treatment of Chronic Kidney Disease: Lessons Learned from the Kidney Early Evaluation Program
    by Joseph A. Vassalotti & Leslie Gracz-Weinstein & Monica R. Gannon & Wendy Weinstock Brown

  • 2006 Using Nicotine Replacement Therapy to Assist in Reducing Cigarette Consumption before Quitting: Another Strategy for Smoking Cessation?
    by Hayden McRobbie & Robyn Whittaker & Christopher Bullen

  • 2006 Putting a Public Health Face on Clinical Practice: Potential for Using an Infectious Disease Management Model for Chronic Disease Prevention
    by Donald O. Fedder & Harsha Desai & Migle Maciunskaite

  • 2006 Acknowledgment
    by Adis International Limited

  • 2006 Disease Management Update
    by Adis International Limited

  • 2006 The Role of Peginterferon alpha-2a (40kD) Plus Ribavirin in the Management of Chronic Hepatitis C Mono-Infection
    by Dene Simpson & Monique P. Curran

  • 2006 The Impact of Open Access to Atypical Antipsychotics on Treatment Costs for Medi-Cal Patients with Bipolar Disorder
    by Sangeeta Narayan & Kimberly L. Sterling & Jeffrey S. McCombs

  • 2006 Internet-Based Smoking Cessation Initiatives: Availability, Varieties, and Likely Effects on Outcomes
    by Anna M. McDaniel & Renee M. Stratton

  • 2006 Preparing for and Responding to Bioterrorist Attacks: The Role of Disease Management Initiatives
    by R. Gregory Evans & Steven J. Lawrence

  • 2006 Disease Management and Its Implications for Outpatient Physician Practice: A Memo for Physicians
    by Jaan Sidorov

  • 2006 Disease Management Update
    by Adis International Limited

  • 2006 Impact of a Diabetes Disease Management Program by Race and Ethnicity
    by Verna L. Welch & Natalia Vukshich Oster & Julie A. Gazmararian & Kimberly Rask & Laura Schild & Charles Cutler & Claire Spettell & Michael Reardon

  • 2006 Disease Management of the Frail Elderly Population
    by Stuart Levine & Judy Y. Reyes & Randy Schwartz & Dave Schmidt & Tim Schwab & Moon Leung

  • 2006 Poor Adherence to Anti-inflammatory Medication in Asthma: Reasons, Challenges, and Strategies for Improved Disease Management
    by Rachel A. Elliott

  • 2006 Developing a Specialist Patient Program for Migraine
    by Ann Turner

  • 2006 Adherence to Antipsychotic Treatment in Schizophrenia: What Role Does Cognitive Behavioral Therapy Play in Improving Outcomes?
    by Gary Donohoe

  • 2006 Measuring the Economic Value of Disease Management Programs
    by Don Fetterolf

  • 2006 In Search of Financial Savings from Disease Management: Applying the Number-Needed-to-Decrease Analysis to a Diabetic Population
    by Ariel Linden & Thomas J. Biuso

  • 2006 Disease Management Update
    by Adis International Limited

  • 2006 Community Direct Access Service for Early Detection and Treatment of Clinical Deterioration: Effectiveness and Impact on the Workload Pattern of a Hospital-Based Heart Failure Unit
    by Carmel Conlon & Christina O'Loughlin & Mark Ledwidge & Kenneth McDonald

  • 2006 Analysis of Factors Affecting Patient Satisfaction: Focus on Asthma Patients
    by Bayram Sahin & Mehtap Tatar

  • 2006 Impact of Telehealth on Healthcare Utilization by Congestive Heart Failure Patients
    by Craig A. Lehmann & Nancy Mintz & Jean Marie Giacini

  • 2006 Evaluation of an Asthma Disease Management Program in a Medicaid Population
    by Alice Lind & Louise Kaplan & Gregory D. Berg

  • 2006 Telemedicine for Diabetes Care
    by Toree H. Malasanos

  • 2006 Removing Prescription Charges for Patients with Mental Health Disorders: Would it Improve Patient Outcomes in the UK?
    by Ellen I. Schafheutle

  • 2006 Physician Voluntary Reporting Program
    by David W. Plocher

  • 2006 The Economic Burden of End-Stage Renal Disease with Hyperphosphatemia: A Study of Florida Medicaid
    by Annesha White & Folakemi Odedina & Hong Xiao & Ellen Campbell & Richard Segal

  • 2006 Process Optimization by Means of a Computerized Process Simulation Model in Cardiac Surgery
    by Richard Feyrer & Udo Kunzmann & Michael Weyand & Robert Cesnjevar

  • 2006 Promoting the Implementation of Best-Practice Guidelines Using a Matrix Tool: Focus on Cancer Care
    by Karen Luxford & David Hill & Richard Bell

  • 2006 Type 2 Diabetes Mellitus Treatment Patterns and Healthcare Costs in the Elderly Population
    by Gary Erwin & Shrividya Iyer & Rukmini Rajagopalan & James Astuto & Patricia Wilson & Justin Schaneman & Nathan Kleinman

  • 2006 Prescription to Over-the-Counter Switch of Second-Generation Antihistamines (Loratadine): A Review of Its Impact on Healthcare Costs and Resource Utilization
    by Kavita V. Nair

  • 2006 Disease Management Update
    by Adis International Limited

  • 2006 Management of Schizophrenia: Defining the Role of Long-Acting Injectable Risperidone
    by Monique P. Curran & Gillian M. Keating

  • 2006 The Cost of Lung Cancer Management in France from the Payor's Perspective
    by Alain Vergnenegre & Laurent Molinier & Christophe Combescure & Jean-Pierre Daures & Bruno Housset & Christos Chouaid

  • 2006 Population-Based Disease Management in the German Statutory Health Insurance: Implementation and Preliminary Results
    by Stephanie A.K. Stock & Marcus Redaelli & Karl W. Lauterbach

  • 2006 Clinical and Behavioral Impact of Implementing Community-Based Diabetes Disease Management in Japan
    by Hiroyuki Sakamaki & Shunya Ikeda & Naoki Ikegami & Michiko Norimoto & Shigemitsu Moriwaki

  • 2006 An Evaluation of the Factors Associated with Statin Dose Management and Low-Density Lipoprotein-Cholesterol Goal Attainment
    by Caron Ory & Christina Fontes & Setareh A. Williams & Gerald M. Borok & Kenneth McDonough & Eunice Chang

  • 2006 Disease Management for Hypertension: A Pilot Cluster Randomized Trial of 67 Australian General Practices
    by Deborah A. Turnbull & Justin J. Beilby & Tahereh Ziaian & Farooq Qureshi & Mark Nelson & Anne L. Tonkin & John E. Marley

  • 2006 Worksite Disease Management Programs for Depression: Potential Employer Benefits
    by Diane E. Steffick & John C. Fortney & Jeffrey L. Smith & Jeffrey M. Pyne

  • 2006 Access to Prescription Drugs: The Case of Medicaid
    by Peter J. Cunningham

  • 2006 The Author's Reply
    by Joshua Cohen

  • 2006 Comparing Patient Access to Pharmaceuticals in the UK and US
    by Joel W. Hay

  • 2006 Comparison of Individual and Group Valuation of Health State Scenarios across Communities in West Africa
    by Anayo Fidelis Akunne & John F.P. Bridges & Mamadou Sanon & Rainer Sauerborn

  • 2006 Maximising Responses to Discrete Choice Experiments: A Randomised Trial
    by Joanna Coast & Terry N. Flynn & Chris Salisbury & Jordan Louviere & Tim J. Peters

  • 2006 Impact of Cross-Reference Pricing on Pharmaceutical Prices: Manufacturers' Pricing Strategies and Price Regulation
    by Tom Stargardt & Jonas Schreyogg

  • 2006 Analysis of Healthcare Financing, Supply and Utilisation Trends in the New EU Countries
    by Jane E. Ruseski

  • 2006 Handling Value Added Tax (VAT) in Economic Evaluations: Should Prices Include VAT?
    by Mickael Bech & Terkel Christiansen & Dorte Gyrd-Hansen

  • 2006 Quality and Cost in Healthcare: A Relationship Worth Examining
    by Craig Mitton & Francois Dionne & Stuart Peacock & Sam Sheps

  • 2006 Acknowledgement
    by Adis International Limited

  • 2006 Patients' Preferences for Healthcare System Reforms in Hungary: A Conjoint Analysis
    by Baktygul Akkazieva & Laszlo Gulacsi & Agnes Brandtmuller & Marta Pentek & John F.P. Bridges

  • 2006 Comparing Patient Access to Pharmaceuticals in the UK and US
    by Joshua Cohen & Catherine Cairns & Cherie Paquette & Laura Faden

  • 2006 Community-Based Youth Tobacco Control Interventions: Cost Effectiveness of the Full Court Press Project
    by Hana Ross & Lisa M. Powell & Joseph E. Bauer & David T. Levy & Richard M. Peck & Hye-Ryeon Lee

  • 2006 Modelling the Costs and Outcomes of Changing Rates of Screening for Alcohol Misuse by GPs in the Australian Context
    by Marian Shanahan & Anthony Shakeshaft & Richard P. Mattick

  • 2006 To Retain or Remove User Fees?: Reflections on the Current Debate in Low- and Middle-Income Countries
    by Chris D. James & Kara Hanson & Barbara McPake & Dina Balabanova & Davidson Gwatkin & Ian Hopwood & Christina Kirunga & Rudolph Knippenberg & Bruno Meessen & Saul S. Morris & Alexander Preker & Yves Souteyrand & Abdelmajid Tibouti & Pascal Villeneuve & Ke Xu

  • 2006 Estimating Technical Efficiency in the Hospital Sector with Panel Data: A Comparison of Parametric and Non-Parametric Techniques
    by Luigi Siciliani

  • 2006 Supplier-Induced Demand: Reconsidering the Theories and New Australian Evidence
    by Jeffrey R.J. Richardson & Stuart J. Peacock

  • 2006 How Cost-of-Illness Studies Can be Made More Useful for Illicit Drug Policy Analysis
    by Timothy J. Moore & Jonathan P. Caulkins

  • 2006 Centralising Drug Review to Improve Coverage Decisions: Economic Lessons From (and For) Canada
    by Steve Morgan & Meghan McMahon & Craig Mitton

  • 2006 Factors Associated with Physicians' Choice of Working Sector: A National Longitudinal Survey in Finland
    by Terhi Kankaanranta & Jari Vainiomaki & Ville Autio & Hannu Halila & Harri Hyppola & Mauri Isokoski & Santero Kujala & Esko Kumpusalo & Kari Mattila & Irma Virjo & Jukka Vanska & Pekka Rissanen

  • 2006 Australian General Practice: Where Have the GP Services Gone?
    by Ian McRae

  • 2006 A Macroeconomic Approach to Evaluating Policies to Contain Antimicrobial Resistance: A Case Study of Methicillin-Resistant Staphylococcus aureus (MRSA)
    by Richard D. Smith & Milton Yago & Michael Millar & Joanna Coast

  • 2006 Recycling Blood: Sharing the Benefits of Cell Salvage
    by Bernard Crotty

  • 2006 Using Economic Analyses for Local Priority Setting: The Population Cost-Impact Approach
    by Richard F. Heller & Islay Gemmell & Edward C.F. Wilson & Richard Fordham & Richard D. Smith

  • 2006 The Relationship between Ex Ante Mortality Risk and End-of-Life Medical Costs
    by David H. Howard & Steven D. Culler & Benjamin G. Druss & Kenneth E. Thorpe

  • 2006 Genetic Health Technology and Economic Evaluation: A Critical Review
    by James Jarrett & Miranda Mugford

  • 2006 Methodological Aspects in the Assessment of Treatment Effects in Observational Health Outcomes Studies
    by Josep Maria Haro & Stathis Kontodimas & Miguel Angel Negrin & Mark Ratcliffe & David Suarez & Frank Windmeijer

  • 2006 Health Reform, Equity and Primary Healthcare: Taking Off the Make-Up
    by Stephen Thomas & Okore Okorafor & Sandi Mbatsha

  • 2006 Impact of Price-Deregulation on Market Outcomes - The Case of Chimney Sweep Services in Slovenia
    by Egon Žižmond

  • 2006 Antecedentes y posibles ventajas y desventajas del Tratado de Libre Comercio - TLC para un país como Colombia
    by Francisco Giraldo Izasa

  • 2006 La nueva Macroeconomía Clásica y el Equilibrio General: una visión crítica
    by Bernard Guerrien

  • 2005 Fair Behavior and Inflation Persistence
    by Seidel, Gerald

  • 2005 Reform of Building Regulation
    by Productivity Commission

  • 2005 Scientific Revolution. A Farewell to EconWPA
    by Alexander Harin

  • 2005 Stochastic Market Sharing, Partial Communication and Collusion
    by Heiko Gerlach

  • 2005 Gains and losses. The same or different choices?
    by Alexander Harin

  • 2005 A new approach to solve old problems
    by Alexander Harin

  • 2005 The Governance of Occupational Pension Funds and the Politico- Economic Implications: The Case of Austria
    by Stefan W. Schmitz

  • 2005 Raison d'être et spécificités de la firme bancaire : pourquoi la banque n'est-elle pas une entreprise comme les autres ?
    by dhafer saidane

  • 2005 Optimal Taxation of Gambling and Lotto
    by Walther Herbert

  • 2005 Financial Performance of Government Trading Enterprises 1999-00 to 2003-04
    by Productivity Commission

  • 2005 Trends in Australian Agriculture
    by Productivity Commission

  • 2005 U.S. Inequality: Debt Constraints or Incomplete Markets?
    by Juan Carlos Cordoba

  • 2005 Explaining de facto Judicial Independence
    by Bernd Hayo and Stefan Voigt

  • 2005 Common Shocks and Relative Compensation Schemes
    by Martine Quinzii & Michael Magill

  • 2005 Walrasian Sequential Equilibrium, Bounded Rationality, And Social Experiments

  • 2005 Why Has Inequality Increased In China? Toward A Theory Of International Matching
    by E. MASKIN

  • 2005 Natural Equality, Increasing Returns, And Economic Progress: A Reinterpretation Of Adam Smith'S System

  • 2005 New Classical Economics: Towards A New Paradigm For Economics?

  • 2005 Division Of Labour And Transaction Costs: Toward A Research Agenda

  • 2005 Division Of Labour And Transaction Costs: An Introduction

  • 2005 Book Review
    by Adis International Limited

  • 2005 Linezolid: A Pharmacoeconomic Review of its Use in Serious Gram-Positive Infections
    by Greg L. Plosker & David P. Figgitt

  • 2005 Cost Effectiveness of Dalteparin for Preventing Venous Thromboembolism in Abdominal Surgery
    by Adrienne Heerey & Sanjeev Suri

  • 2005 Cost-Benefit Analysis of Vaccination against Tick-Borne Encephalitis among French Troops
    by Guillaume Desjeux & Laurent Galoisy-Guibal & Cyrille Colin

  • 2005 A Systematic Review of Patient-Reported Outcome Instruments Measuring Sleep Dysfunction in Adults
    by Emily Beth Devine & Zafar Hakim & Jesse Green

  • 2005 Economic Implications of Biological Therapies for Crohn's Disease: Review of Infliximab
    by Keith Bodger

  • 2005 The Role of Economic Evaluation in Vaccine Decision Making: Focus on Meningococcal Group C Conjugate Vaccine
    by Robert Welte & Caroline L. Trotter & W. John Edmunds & Maarten J. Postma & Philippe Beutels

  • 2005 The Authors' Reply
    by Anthony O'Hagan & Christopher McCabe & Ron Akehurst & Alan Brennan & Andrew Briggs & Karl Claxton & Elisabeth Fenwick & Dennis Fryback & Mark Sculpher & David Spiegelhalter & Andrew Willan

  • 2005 Incorporation of Uncertainty in Health Economic Modelling Studies
    by Mark Nuijten

  • 2005 An Economic Evaluation of Rizatriptan in the Treatment of Migraine
    by Melissa Thompson & Marek Gawel & Brigitte Desjardins & Nicole Ferko & Daniel Grima

  • 2005 Cost of Illness and its Predictors for Parkinson's Disease in Germany
    by Annika E. Spottke & Martin Reuter & Olaf Machat & Bernhard Bornschein & Sonja von Campenhausen & Karin Berger & Rudolf Koehne-Volland & Jurgen Rieke & Alexander Simonow & Dirk Brandstaedter & Uwe Siebert & Wolfgang H. Oertel & Gudrun Ulm & Richard Dodel

  • 2005 Economic Evaluation of Temozolomide in the Treatment of Recurrent Glioblastoma Multiforme
    by Janne A. Martikainen & Akseli Kivioja & Taru Hallinen & Pia Vihinen

  • 2005 Societal Discounting of Health Effects in Cost-Effectiveness Analyses: The Influence of Life Expectancy
    by Suzanne Polinder & Willem Jan Meerding & Job van Exel & Werner Brouwer

  • 2005 Parent-Proxy EQ-5D Ratings of Children with Attention-Deficit Hyperactivity Disorder in the US and the UK
    by Louis S. Matza & Kristina Secnik & Sally Mannix & F. Randy Sallee

  • 2005 Granulocyte Colony-Stimulating Factor for Chemotherapy-Induced Neutropenia in Patients with Small Cell Lung Cancer: The 40% Rule Revisited
    by Elizabeth A. Calhoun & Glen T. Schumock & June M. McKoy & Simon Pickard & Karen A. Fitzner & Elizabeth A. Heckinger & Eowyn F. Powell & Kathyrn R. McCaffrey & Charles L. Bennett

  • 2005 Pharmaceutical Policy regarding Generic Drugs in Belgium
    by Steven Simoens & Kristien De Bruyn & Marc Bogaert & Gert Laekeman

  • 2005 Real-World Trials to Answer Real-World Questions
    by Nick Freemantle & Lawrence Blonde & Bjorn Bolinder & Robert A. Gerber & F.D. Richard Hobbs & Luc Martinez & Stuart Ross

  • 2005 The Authors' Reply
    by Andrew Moore & Ceri Phillips & Elke Hunsche & James Pellissier & Simone Crespi

  • 2005 Economic Evaluation of Etoricoxib versus Non-Selective NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis Patients in the UK
    by Eduardo Carracedo-Martinez

  • 2005 Costs and Medical Care Consequences Associated with the Diagnosis of Peripheral Arterial Disease
    by Kristen Migliaccio-Walle & J. Jaime Caro & Khajak J. Ishak & Judith A. O'Brien

  • 2005 Economic Assessment of Adjustable Maintenance Treatment with Budesonide/Formoterol in a Single Inhaler versus Fixed Treatment in Asthma
    by Bernd Bruggenjurgen & Dagmar Selim & Peter Kardos & Kai Richter & Claus Vogelmeier & Stephanie Roll & Wolfgang Meyer-Sabellek & Roland Buhl & Stefan N Willich

  • 2005 Introducing Economic Evaluation as a Policy Tool in Korea: Will Decision Makers get Quality Information?: A Critical Review of Published Korean Economic Evaluations
    by Kun-Sei Lee & Werner B.F. Brouwer & Sang-Il Lee & Hye-Won Koo

  • 2005 The State of Patient-Reported Outcomes in Atrial Fibrillation: A Review of Current Measures
    by Karin Coyne & Mary Kay Margolis & Susan Grandy & Peter Zimetbaum

  • 2005 Evaluating Health-Related Quality-of-Life Studies in Paediatric Populations: Some Conceptual, Methodological and Developmental Considerations and Recent Applications
    by Mirella De Civita & Dean Regier & Abul H. Alamgir & Aslam H. Anis & Mark J. FitzGerald & Carlo A. Marra

  • 2005 Price Differentiation and Transparency in the Global Pharmaceutical Marketplace
    by David B. Ridley

  • 2005 Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies
    by J.M. Bos & Maarten J. Postma & Lieven Annemans

  • 2005 Development of an Economic Model to Assess the Cost Effectiveness of Treatment Interventions for Chronic Obstructive Pulmonary Disease
    by Michael Spencer & Andrew H. Briggs & Ronald F. Grossman & Laureen Rance

  • 2005 The Cost Effectiveness of Infliximab for Severe Treatment-Resistant Rheumatoid Arthritis in the UK
    by Marco Barbieri & John B. Wong & Michael Drummond

  • 2005 Pharmacoeconomic Evaluation of Antidepressants: A Critical Appraisal of Methods
    by Sheikh Usman Iqbal & Mark Prashker

  • 2005 Bipolar Disorder and Health-Related Quality of Life: Review of Burden of Disease and Clinical Trials
    by Dennis A. Revicki & Louis S. Matza & Emuella Flood & Andrew Lloyd

  • 2005 Remission from Depression: A Review of Venlafaxine Clinical and Economic Evidence
    by Donald Han & Edward C.Y. Wang

  • 2005 The Economics of Topical Immunomodulators for the Treatment of Atopic Dermatitis
    by William Abramovits & Mark Boguniewicz & Amy S. Paller & Diane L. Whitaker-Worth & Mary M. Prendergast & Michael Tokar & Kuo B. Tong

  • 2005 Health Utilities in Alzheimer's Disease and Implications for Cost-Effectiveness Analysis
    by Peter J. Neumann

  • 2005 Incorporation of Uncertainty in Health Economic Modelling Studies
    by Anthony O'Hagan & Christopher McCabe & Ron Akehurst & Alan Brennan & Andrew Briggs & Karl Claxton & Elisabeth Fenwick & Dennis Fryback & Mark Sculpher & David Spiegelhalter & Andrew Willan

  • 2005 On Pharmacogenomics and Cost-Effectiveness Analysis at the Individual Level
    by Mohan V. Bala & Gary A. Zarkin

  • 2005 Cost Effectiveness of Imatinib Compared with Interferon-alpha or Hydroxycarbamide for First-Line Treatment of Chronic Myeloid Leukaemia
    by Kim Dalziel & Ali Round & Ruth Garside & Ken Stein

  • 2005 Reductions in Anaemia and Fatigue are Associated with Improvements in Productivity in Cancer Patients Receiving Chemotherapy
    by Ernst Berndt & Joel Kallich & Anne McDermott & Xiao Xu & Howard Lee & John Glaspy

  • 2005 Economic Evaluation of Levetiracetam as an Add-On Therapy in Patients with Refractory Epilepsy
    by Lucie Blais & Odile Sheehy & Jean-Marc Saint-Hilaire & Gilles-Pierre Bernier & Philippe Godfroid & Jacques LeLorier

  • 2005 Economic Considerations in the Prescribing of Third-Generation Antidepressants
    by Stuart Montgomery & John J. Doyle & Lee Stern & Christopher R. McBurney

  • 2005 The Health-Related Quality of Life and Economic Burden of Constipation
    by Cheryl Dennison & Manishi Prasad & Andrew Lloyd & Samir K. Bhattacharyya & Ravinder Dhawan & Karin Coyne

  • 2005 Valuing Patient and Caregiver Time: A Review of the Literature
    by Jennifer E. Tranmer & Denise N. Guerriere & Wendy J. Ungar & Peter C. Coyte

  • 2005 Does Pharmacogenomics Provide an Ethical Challenge to the Utilisation of Cost-Effectiveness Analysis by Public Health Systems?
    by Adam La Caze

  • 2005 Effects of Antidepressants on Quality of Life in Women with Premenstrual Dysphoric Disorder
    by Ellen W. Freeman

  • 2005 Willingness to Pay for a QALY: Theoretical and Methodological Issues
    by Dorte Gyrd-Hansen

  • 2005 Quality Control in the Regulation of Pharmaceuticals
    by Alan Maynard

  • 2005 Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide for Rheumatoid Arthritis in Germany: II. The Contribution of Leflunomide to Efficiency
    by Peter K. Schadlich & Henning Zeidler & Angela Zink & Erika Gromnica-Ihle & Matthias Schneider & Christoph Straub & Josef G. Brecht & Eduard Huppertz

  • 2005 Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide in Rheumatoid Arthritis in Germany: I. Selected DMARDs and Patient-Related Costs
    by Peter K. Schadlich & Henning Zeidler & Angela Zink & Erika Gromnica-Ihle & Matthias Schneider & Christoph Straub & Josef G. Brecht & Eduard Huppertz

  • 2005 Cost Effectiveness of Budesonide/Formoterol in a Single Inhaler for COPD Compared with Each Monocomponent Used Alone
    by Claes-Goran Lofdahl & Asa Ericsson & Klas Svensson & Emma Andreasson

  • 2005 Health-Related QOL in Acute Exacerbations of Chronic Bronchitis and Chronic Obstructive Pulmonary Disease: A Review of the Literature
    by Helen Doll & Marc Miravitlles

  • 2005 Review of the Cost Effectiveness of Immunisation Strategies for the Control of Epidemic Meningococcal Meningitis
    by Mark A. Miller & Cathryn K. Shahab

  • 2005 Pharmacoeconomic Analyses Using Discrete Event Simulation
    by J. Jaime Caro

  • 2005 Future Challenges for the Economic Evaluation of Healthcare: Patient Preferences, Risk Attitudes and Beyond
    by John F.P. Bridges

  • 2005 Meningococcal Vaccination: Cui Bono?
    by Thomas D. Szucs

  • 2005 Cost-Effectiveness Model Of Long-Acting Risperidone in Schizophrenia in the US
    by Natalie C. Edwards & Marcia F.T. Rupnow & Chris L. Pashos & Marc F. Botteman & Ronald J. Diamond

  • 2005 The Case of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Rheumatoid Arthritis: A Budget Impact Analysis
    by Jan Sorensen & Lis S. Andersen

  • 2005 A Pharmacoeconomic Evaluation of Statins in the Treatment of Hypercholesterolaemia in the Primary Care Setting in Spain
    by Pedro J. Tarraga-Lopez & Angel Celada-Rodriguez & Miguel Cerdan-Oliver & Juan Solera-Albero & Jose M Ocana-Lopez & Mateo A. Lopez-Cara & Jaime De Miguel-Clave

  • 2005 Oral Serotonin Receptor Agonists: A Review of Their Cost Effectiveness in Migraine
    by Jennifer H. Lofland & David B. Nash

  • 2005 International Variation in Resource Utilisation and Treatment Costs for Rheumatoid Arthritis: A Systematic Literature Review
    by Hubertus Rosery & Rito Bergemann & Stefanie Maxion-Bergemann

  • 2005 The Economic Impact of Neuropsychiatric Symptoms in Alzheimer's Disease: Can Drugs Ease the Burden?
    by Daniel L. Murman & Christopher C. Colenda

  • 2005 Penny and Pound Wise: Pharmacoeconomics from a Governmental Perspective
    by Mike F. van Oostenbruggen & Ronald B. Jansen & Katja Mur & Huib Kooijman

  • 2005 The Relationship between Productivity and Health-Related QOL: An Exploration
    by Werner B.F. Brouwer & Willem-Jan Meerding & Leida M. Lamers & Johan L. Severens

  • 2005 EMEA: For Patients or For Industry?
    by Silvio Garattini

  • 2005 Memantine: A Pharmacoeconomic Review of its Use in Moderate-to-Severe Alzheimer's Disease
    by Greg L. Plosker & Katherine A. Lyseng-Williamson

  • 2005 The Impact of Anaemia and its Treatment on Employee Disability and Medical Costs
    by Ernst Berndt & William Crown & Joel Kallich & Stacey Long & Xue Song & Gary H. Lyman

  • 2005 Cost-Minimisation Analysis of Sivelestat for Acute Lung Injury Associated with Systemic Inflammatory Response Syndrome
    by Naoki Aikawa & Seitaro Fujishima & Makoto Kobayashi & Shozo Matsuoka & Taira Abiru

  • 2005 Evaluation of the Cost Effectiveness of Escitalopram versus Venlafaxine XR in Major Depressive Disorder
    by Jose-Luis Fernandez & Stuart Montgomery & Clement Francois

  • 2005 Providing Systematic Guidance in Pharmacoeconomic Guidelines for Analysing Costs
    by Philip Jacobs & Arto Ohinmaa & Bruce Brady

  • 2005 Cost Effectiveness of Treating Low HDL-Cholesterol in the Primary Prevention of Coronary Heart Disease
    by Joel W. Hay & Kimberly L. Sterling

  • 2005 The Case for Stratified Cost-Effectiveness Analysis by Baseline Health-Related QOL: Theory and Sensitivity Analysis
    by Joseph Schaafsma

  • 2005 The Diffusion of Health Economics Knowledge in Europe: The EURONHEED (European Network of Health Economics Evaluation Database) Project
    by Gerard de Pouvourville & Philippe Ulmann & John Nixon & Stephanie Boulenger & Julie Glanville & Michael Drummond

  • 2005 The Friction-Cost Method: Replacement for Nothing and Leisure for Free?
    by Werner B.F. Brouwer & Marc A. Koopmanschap

  • 2005 Friction-Cost Method as an Alternative to the Human-Capital Approach in Calculating Indirect Costs
    by Howard Birnbaum

  • 2005 Comorbidities and Costs of Adult Patients Diagnosed with Attention-Deficit Hyperactivity Disorder
    by Kristina Secnik & Andrine Swensen & Maureen J. Lage

  • 2005 A Randomised Trial of the Cost Effectiveness of Buprenorphine as an Alternative to Methadone Maintenance Treatment for Heroin Dependence in a Primary Care Setting
    by Anthony H. Harris & Elena Gospodarevskaya & Alison J. Ritter

  • 2005 Q-TWiST Analysis of Cyclophosphamide, Epirubicin, Fluorouracil versus Cyclophosphamide, Methotrexate, Fluorouracil Treatment for Premenopausal Women with Node-Positive Breast Cancer
    by Davide Radice & Alberto Redaelli

  • 2005 Household-Based Costs and Benefits of Vaccinating Healthy Children in Daycare Against Influenza Virus: Results from a Pilot Study
    by Maria Pisu & Martin I. Meltzer & Eugene S. Hurwitz & Michael Haber

  • 2005 Measuring Productivity Changes in Economic Evaluation: Setting the Research Agenda
    by Marc Koopmanschap & Alex Burdorf & Karin Jacob & Willem Jan Meerding & Werner Brouwer & Hans Severens

  • 2005 A Review of the Costs of Managing Childhood Epilepsy
    by Ettore Beghi & Barbara Frigeni & Massimiliano Beghi & Paola De Compadri & Livio Garattini

  • 2005 Pharmacoeconomic Impact of Non-Compliance with Statins
    by Andrew M. Peterson & William F. McGhan

  • 2005 Role of Pharmacoeconomic Analysis in R&D Decision Making: When, Where, How?
    by Paul Miller

  • 2005 Rizatriptan: A Pharmacoeconomic Review of its Use in the Acute Treatment of Migraine
    by Paul L. McCormack & Rachel H. Foster

  • 2005 Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer's Disease
    by Colin Green & Joanna Picot & Emma Loveman & Andrea Takeda & Jo Kirby & Andrew Clegg

  • 2005 Pramipexole and Levodopa in Early Parkinson's Disease: Dynamic Changes in Cost Effectiveness
    by Katia Noyes & Andrew W. Dick & Robert G. Holloway & The Parkinson Study Group

  • 2005 A Willingness-To-Pay Assessment of Parents' Preference for Shorter Duration Treatment of Acute Otitis Media in Children
    by Delphine Gueylard Chenevier & Jacques LeLorier

  • 2005 Estimating Mean Total Costs in the Presence of Censoring: A Comparative Assessment of Methods
    by Tracey A. Young

  • 2005 Willingness to Pay for Inhaled Insulin: A Contingent Valuation Approach
    by Hamid Sadri & Linda D. MacKeigan & Lawrence A. Leiter & Thomas R. Einarson

  • 2005 Cost-Effectiveness Acceptability Curves and a Reluctance to Lose
    by Johan L. Severens & Danielle E.M. Brunenberg & Elisabeth A.L. Fenwick & Bernie O'Brien & Manuela A. Joore

  • 2005 No Room for Kinkiness in a Public Healthcare System
    by Jack Dowie

  • 2005 The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development - The Authors' Reply
    by Joseph A. DiMasi & Cherie Paquette

  • 2005 Comment on _The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development_
    by Aidan Hollis

  • 2005 Acknowledgement
    by Adis International Limited

  • 2005 The Importance of Drug Adverse Effects Compared with Seizure Control for People with Epilepsy: A Discrete Choice Experiment
    by Andrew Lloyd & Emma McIntosh & Martin Price

  • 2005 Economic Evaluation of Three Two-Drug Chemotherapy Regimens in Advanced Non-Small-Cell Lung Cancer
    by Niels Neymark & Pilar Lianes & Egbert F. Smit & Jan P. van Meerbeeck

  • 2005 Eliciting Social Preference Weights for Functional Assessment of Cancer Therapy-Lung Health States
    by Paul Kind & Susan Macran

  • 2005 Acute Pyelonephritis Among Adults: Cost of Illness and Considerations for the Economic Evaluation of Therapy
    by Patricia Brown & Moran Ki & Betsy Foxman

  • 2005 Assessing the Annual Economic Burden of Preventing and Treating Anogenital Human Papillomavirus-Related Disease in the US: Analytic Framework and Review of the Literature
    by Ralph P. Insinga & Erik J. Dasbach & Elamin H. Elbasha

  • 2005 Antiviral Agents for Influenza: A Comparison of Cost-Effectiveness Data
    by Larry D. Lynd & Ron Goeree & Bernie J. O'Brien

  • 2005 Economic Evaluations of Healthcare Programmes and Decision Making: The Influence of Economic Evaluations on Different Healthcare Decision-Making Levels
    by Marieke E. van Velden & Johan L. Severens & Annoesjka Novak

  • 2005 Reporting Pharmacoeconomic Evaluations
    by C.I. Carswell & J.A. Paladino

  • 2005 Pharmacological Management of Overactive Bladder: A Systematic and Critical Review of Published Economic Evaluations
    by Denis Getsios & Wissam El-Hadi & Ingrid Caro & J. Jaime Caro

  • 2005 Measuring Health-Related Quality of Life in Older Patient Populations: A Review of Current Approaches
    by Anne Hickey & Maja Barker & Hannah McGee & Ciaran O'Boyle

  • 2005 Transparency in Economic Evaluations
    by Suzanne Hill

  • 2005 Eplerenone: A Pharmacoeconomic Review of its Use in Patients with Post-Myocardial Infarction Heart Failure
    by Katherine F. Croom & Greg L. Plosker

  • 2005 Financial Impact of Two Different Ways of Evaluating Early Virological Response to Peginterferon-alpha-2b Plus Ribavirin Therapy in Treatment-Naive Patients with Chronic Hepatitis C Virus Genotype 1
    by Maria Buti & Miguel A. Casado & Leslie Fosbrook & Rafael Esteban

  • 2005 Economic Analysis of On-Demand Maintenance Therapy with Proton Pump Inhibitors in Patients with Non-Erosive Reflux Disease
    by Dyfrig A. Hughes & Keith Bodger & Peter Bytzer & Dirk de Herdt & Dominique Dubois

  • 2005 Using Policy Simulation to Predict Drug Plan Expenditure when Planning Reimbursement Changes
    by Colin R. Dormuth & Sean Burnett & Sebastian Schneeweiss

  • 2005 The Cost Effectiveness of Orlistat in a 1-Year Weight-Management Programme for Treating Overweight and Obese Patients in Sweden: A Treatment Responder Approach
    by Peter Hertzman

  • 2005 Cost Effectiveness of a Clinical Decision Support System Based on the Recommendations of the European Society of Cardiology and Other Societies for the Management of Hypercholesterolemia: Report of a Cluster-Randomized Trial
    by Albert Cobos & Jordi Vilaseca & Cesar Asenjo & Juan Pedro-Botet & Emilia Sanchez & Alicia Val & Eva Torremade & Cristina Espinosa & Salvador Bergonon

  • 2005 Consumer Knowledge of the Impact of a Change in Prescription Drug Benefit Design
    by Roger Feldman & Jean Abraham & Linda Davis & Caroline Carlin

  • 2005 Utilization and Medical Care Expenditures in Patients with Chronic Obstructive Pulmonary Disease: A Managed Care Claims Data Analysis
    by Kristina S. Yu-Isenberg & Ann Vanderplas & Eunice Y. Chang & Hemal Shah

  • 2005 Education and Phone Follow-Up in Postmenopausal Women at Risk for Osteoporosis: Effects on Calcium Intake, Exercise Frequency, and Medication Use
    by John T. Schousboe & Rowan C. DeBold & Linda S. Kuno & Thomas W. Weiss & Ya-Ting Chen & Thomas A. Abbott

  • 2005 Efficiency of Interventions in HIV Infection, 1994-2004
    by Guy Harling & Robin Wood & Eduard J. Beck

  • 2005 How Should Functionally Equivalent Drugs be Reimbursed?: A Retrospective Analysis of Reimbursement for Epoetin-alpha and Darbepoetin-alpha in 2001-3 and the Cost Implications for CMS
    by Panos G. Kanavos & Omer R. Saka

  • 2005 Acknowledgment
    by Adis International Limited

  • 2005 US FDA Drug Classification System
    by Alan J. Johnson & Edward Fleegler & Gregory D. Berg

  • 2005 Management of Hormone-Responsive Postmenopausal Breast Cancer: Defining the Role of Anastrozole
    by Lynda R. Wiseman & Lesley J. Scott

  • 2005 Clinical and Utilization Outcomes for a Heart Failure Care Support Program: A Matched-Cohort Study
    by Alan Johnson & Gregory Berg & Edward Fleegler & Jeanne Lehn

  • 2005 Predicted Effects of a New Combination Vaccine on Childhood Immunization Coverage Rates and Vaccination Activities
    by Allen S. Meyerhoff & David P. Greenberg & R. Jake Jacobs

  • 2005 Evaluation and Treatment of Depression in Managed Care (Part II): Quality Improvement Programs
    by Christy L. Beaudin & Teresa L. Kramer

  • 2005 Evaluation and Treatment of Depression (Part I): Benefits for Patients, Providers, and Payors
    by Teresa L. Kramer & Christy L. Beaudin & Carol R. Thrush

  • 2005 Using the Internet in Asthma Management: Current Concepts and Challenges
    by Ashok M. Patel

  • 2005 Cost of Acute Myocardial Infarction in Hong Kong
    by Vivian W.Y. Lee & Wai Kwong Chan & Nelson L.C. Lam & Kenneth K.C. Lee

  • 2005 Impact of Bipolar Disorder on Employers: Rationale for Workplace Interventions
    by Leslie B. Montejano & Ron Z. Goetzel & Ronald J. Ozminkowski

  • 2005 The Performance Gap between Clinical Trials and Patient Treatment for Dyslipidemia: A Comprehensive Review
    by Joseph J. Saseen & Setareh A. Williams & Robert J. Valuck & John C. O'Donnell & Kenneth McDonough

  • 2005 The Challenge of Suicide Prevention: An Overview of National Strategies
    by Martin Anderson & Rachel Jenkins

  • 2005 Impact of Coaching Patients on Coronary Risk Factors: Lessons from The COACH Program
    by Margarite J. Vale & Michael V. Jelinek & James D. Best

  • 2005 Use of Short-Acting Insulin Secretagogues for Type 2 Diabetes Mellitus: Considerations for National Health Systems
    by Maribel Salas & Jamie Banks

  • 2005 Impact of Practice Changes on an Antiretroviral Budget in an HIV Care Program
    by Hartmut B Krentz & M. John Gill

  • 2005 Work Loss, Healthcare Utilization, and Costs among US Employees with Chronic Pain
    by Laura T. Pizzi & Chureen T. Carter & Jamie B. Howell & Susan M. Vallow & Albert G. Crawford & Evan D. Frank

  • 2005 Psychoeducational Programs for Patients with Epilepsy
    by Theodor W. May & Margarete Pfafflin

  • 2005 Economic, Patient Preference, and Health-Related Quality of Life Considerations for Intranasal Corticosteroids in Allergic Rhinitis: Implications for Managed Care
    by Gireesh V. Gupchup & Matthew E. Borrego & Richard Santos & Bijal M. Shah

  • 2005 Evaluating Disease Management Program Effectiveness: An Introduction to the Bootstrap Technique
    by Ariel Linden & John L. Adams & Nancy Roberts

  • 2005 Impact of Insurance Coverage on the Use and Effects of Smoking Cessation Medications
    by Leif I. Solberg

  • 2005 Consultation-Liaison Psychiatry: Advantages for Healthcare Systems
    by James A. Bourgeois & Donald M. Hilty & Mark E. Servis & Robert E. Hales

  • 2005 Prescription to Over-the-Counter Switching of Drugs: Methodological Issues and Implications for Non-Sedating Antihistamines
    by John A. Rizzo & Ronald J. Ozminkowski & Ron Z. Goetzel

  • 2005 Effectiveness of Interventions to Increase Adherence to Statin Therapy
    by Jacqueline Muller-Nordhorn & Stefan N. Willich

  • 2005 Management of Metastatic Colorectal Cancer: Defining the Role of Capecitabine
    by Lynda R. Wiseman & Katherine A. Lyseng-Williamson

  • 2005 Examining the Association Between Preventive Screenings and Subsequent Health Services Utilization by Patients with Type 2 Diabetes Mellitus
    by Fevzi Akinci & Joseph S. Coyne & Joni Minear & Kenn Daratha & Dan Simonson

  • 2005 Identifying Future High-Healthcare Users: Exploring the Value of Diagnostic and Prior Utilization Information
    by Amy K. Rosen & Fei Wang & Maria E. Montez & Carter C. Rakovski & Dan R. Berlowitz & Jaime C. Lucove

  • 2005 Using Propensity Scores to Construct Comparable Control Groups for Disease Management Program Evaluation
    by Ariel Linden & John L. Adams & Nancy Roberts

  • 2005 Walking for the Management of Obesity
    by Mikael Fogelholm

  • 2005 Impact of a Clinical Decision Support System on the Management of Patients with Hypercholesterolemia in the Primary Healthcare Setting
    by Alex Bassa & Miguel del Val & Albert Cobos & Eva Torremade & Salvador Bergonon & Carlos Crespo & Max Brosa & Silvia Munio & Cristina Espinosa

  • 2005 Early Intervention in Psychosis: Rationale and Evidence for Effectiveness
    by Bethan Reading & Max Birchwood

  • 2005 Telemanagement in Chronic Heart Failure: A Review
    by Ruth M. Kleinpell & Boaz Avitall

  • 2005 Clinical Outcomes Associated with Pharmacist Involvement in Patients with Dyslipidemia: A Review
    by L. Brian Cross & Andrea S. Franks

  • 2005 Non-Pharmacological Treatments for Chronic Pain: A Disease Management Context
    by Dennis C. Turk & Bill McCarberg

  • 2005 Drug-Eluting Stents in the Management of Coronary Artery Disease: Implications for Payors and Hospitals
    by James B. Hermiller

  • 2005 The Incremental Cost Effectiveness of Withdrawing Pulmonary Artery Catheters from Routine Use in Critical Care
    by Katherine Stevens & Christopher McCabe & Carys Jones & Joanne Ashcroft & Sheila Harvey & Kathy Rowan

  • 2005 Determining Priority for Liver Transplantation: A Comparison of Cost per QALY and Discrete Choice Experiment-Generated Public Preferences
    by Julie Ratcliffe & Martin Buxton & Tracey Young & Louise Longworth

  • 2005 The Cost Effectiveness of Universal versus Selective Newborn Screening for Sickle Cell Disease in the US and the UK: A Critique
    by Scott D. Grosse & Richard S. Olney & Mary Ann Baily

  • 2005 The Australian Health Policy Changes of 1999 and 2000: An Evaluation
    by Sandra Hopkins & Peter Zweifel

  • 2005 What Value Health?: A Review of Health State Values Used in Early Technology Assessments for NICE
    by Ken Stein & Alison Fry & Ali Round & Ruairidh Milne & John Brazier

  • 2005 How to Present the Business Case for Healthcare Quality to Employers
    by Sean Nicholson & Mark V. Pauly & Daniel Polsky & Catherine M. Baase & Gary M. Billotti & Ronald J. Ozminkowski & Marc L. Berger & Claire E. Sharda

  • 2005 Should Patients Have a Greater Role in Valuing Health States?
    by John Brazier & Ron Akehurst & Alan Brennan & Paul Dolan & Karl Claxton & Chris McCabe & Mark Sculpher & Aki Tsuchyia

  • 2005 Acknowledgement
    by Stuart Birks & Gary Buurman

  • 2005 Book Review
    by Adis International Limited

  • 2005 Drug Costs Developments after Patent Expiry of Enalapril, Fluoxetine and Ranitidine: A Study Conducted for the Netherlands
    by Cornelis Boersma & Rogier M. Klok & Jasper M. Bos & Mark Naunton & Paul B. van den Berg & Lolkje T.W. de Jong-van den Berg & Maarten J. Postma

  • 2005 Barriers to the Equitable Funding of Primary Healthcare in South Africa
    by Stephen Thomas & Okore A. Okorafor & Sandi Mbatsha

  • 2005 Methodological Challenges Posed by Economic Evaluations of Early Childhood Intervention Programmes
    by Stavros Petrou & Ron Gray

  • 2005 Can We Use Contingent Valuation to Assess the Demand for Childhood Immunisation in Developing Countries?: A Systematic Review of the Literature
    by Raymond Y.T. Yeung & Richard D. Smith

  • 2005 Prisoner Healthcare Co-Payment Policy: A Cost-Cutting Measure that Might Threaten Inmates' Health
    by Niyi Awofeso

  • 2005 Can Privatising Selected Services Benefit the Public Healthcare System?: The Greek Case
    by Dimitris Niakas & Mamas Theodorou & Lycurgus Liaropoulos

  • 2005 The Chinese Pharmaceutical Market at the Crossroads: Pro-Competition Solutions to Improve Access, Quality and Affordability
    by Y. Richard Wang

  • 2005 The Infrastructure of Obesity and the Obesity Epidemic: Implications for Public Policy
    by Kenneth R. Stanton & Zoltan J. Acs

  • 2005 The Impact of Deficit Reduction on the Nursing Labour Market in Canada: Unintended Consequences of Fiscal Reform
    by Marko Vujicic & Robert G. Evans

  • 2005 What is Required to Evaluate the Impact of Pharmaceutical Reference Pricing?
    by Jaume Puig-Junoy

  • 2005 Using Contingent Choice Methods to Assess Consumer Preferences About Health Plan Design
    by M. Susan Marquis & Melinda Beeuwkes Buntin & Kanika Kapur & Jill M. Yegian

  • 2005 Handling Missing Data in Patient-Level Cost-Effectiveness Analysis alongside Randomised Clinical Trials
    by Andrea Manca & Stephen Palmer

  • 2005 Comparing the Preferences of Health Professionals and Members of the Public for Setting Healthcare Priorities: Experiences from Australia
    by Virginia Wiseman

  • 2005 Procedural Justice in Public Healthcare Resource Allocation
    by Aki Tsuchiya & Luis Silva Miguel & Richard Edlin & Allan Wailoo & Paul Dolan

  • 2005 Prescribing Incentive Schemes: A Useful Approach?
    by Anne R. Mason & Michael F. Drummond & Jane A. Hunter & Adrian K. Towse & Jonathan Cooke

  • 2005 Medicare Coverage and Reimbursement of Outpatient Prescription Drugs in the US: History, Recent Changes and Outlook for the Future
    by Sharon Forrest & Mireille M Goetghebeur & Joel Hay

  • 2005 A Wolf Dressed in Sheep's Clothing: Perhaps Quality Measures are Just Unmeasured Severity
    by John F.P. Bridges & Avi Dor & Michael Grossman

  • 2005 Untangling the Debate Surrounding Strategies for Achieving Sustainable High Coverage of Insecticide-Treated Nets
    by Warren Stevens

  • 2005 Decentralisation Strategies and Provider Incentives in Healthcare: Evidence from the English National Health Service
    by Russell Mannion & Maria Goddard & Michael Kuhn & Angela Bate

  • 2005 Using Value of Information Analysis to Inform Publicly Funded Research Priorities
    by Laura Ginnelly & Karl Claxton & Mark J. Sculpher & Sue Golder

  • 2005 Affordability of Medicines and Patients' Cost-Reducing Behaviour: Empirical Evidence Based on SUR Estimates from Italy and the UK
    by Vincenzo Atella & Ellen Schafheutle & Peter Noyce & Karen Hassell

  • 2005 Key Performance Indicators for the Implementation of Social Health Insurance
    by Guy Carrin & Chris James

  • 2005 Impact of Demographic Changes on Healthcare Expenditures and Funding in the EU
    by Afschin Gandjour & Juliette Greb & Eckart Bomsdorf & Karl Wilhelm Lauterbach

  • 2004 Explaining Sunday shop policies
    by Elbert Dijkgraaf & Raymond Gradus

  • 2004 Trends in Australian Manufacturing
    by Productivity Commission

  • 2004 Road Pricing, Traffic Congestion and Economic Welfare: A Note
    by Ingo_Böbel & Casimir_de_Rham

  • 2004 The level of satisfaction with life: evidence gathered among women from Greater Montevideo
    by Maximo Rossi & Marisa Bucheli

  • 2004 Evaluation of the Mutual Recognition Schemes
    by Productivity Commission

  • 2004 Asymmetric Information and the Demand for Health Care - the Case of Double Moral Hazard
    by Udo Schneider

  • 2004 The Estonian ICT Manufacturing and Software Industry: Current State and Future Outlook
    by Tarmo Kalvet

  • 2004 Bureaucratic corruption and macroeconomic performance
    by Ingrid Ott

  • 2004 Fashion Statement
    by Ted Temzelides

  • 2004 When Promotions Induce Good Managers to Be Lazy
    by Antoine Renucci & Frédéric Loss

  • 2004 Constitutional Rules
    by Francesco Giovannoni & Toke S. Aidt

  • 2004 Overconfidence in Economic Contests
    by Munetomo Ando

  • 2004 A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism: Use in Patients Undergoing Major Orthopaedic Surgery
    by Sean D. Sullivan & Bruce L. Davidson & Susan R. Kahn & James E. Muntz & Gerry Oster & Gary Raskob

  • 2004 The Burden of Migraine in Spain: Beyond Direct Costs
    by Xavier Badia & Sol Magaz & Laura Gutierrez & Jordi Galvan

  • 2004 A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer
    by Jeremy Holmes & David Dunlop & Lindsay Hemmett & Peter Sharplin & Uday Bose

  • 2004 Cost Effectiveness and Cost Utility of Adjuvant Interferon alpha in Cutaneous Melanoma: A Review
    by Ralph Crott

  • 2004 Global Registries for Measuring Pharmacoeconomic and Quality-of-Life Outcomes: Focus on Design and Data Collection, Analysis and Interpretation
    by Lisa Kennedy & Ann-Marie Craig

  • 2004 Outcome Measures for Pharmacoeconomics Education
    by Vittorio Maio & Jennifer H. Lofland

  • 2004 Psychometric and Utility-Based Measures of Health Status of Asthmatic Patients with Different Disease Control Level
    by Agota Szende & Klas Svensson & Elisabeth Stahl & Agnes Meszaros & Gyula Y. Berta

  • 2004 An Economic Evaluation of Fluvastatin used for the Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention in the UK
    by Paul A. Scuffham & Stephen Chaplin

  • 2004 Growth Hormone Therapy and Quality of Life in Adults and Children
    by Deborah J. Radcliffe & Joseph S. Pliskin & J.B. Silvers & Leona Cuttler

  • 2004 Pharmacogenomics and the Evolution of Healthcare: Is it Time for Cost-Effectiveness Analysis at the Individual Level?
    by Mohan V. Bala & Gary A. Zarkin

  • 2004 The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics
    by Christopher R. Flowers & David Veenstra

  • 2004 Cost Effectiveness of Peginterferon alpha-2a Plus Ribavirin versus Interferon alpha-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C. The Authors' Reply
    by Sean D. Sullivan & Kavita Patel & Jesse Green

  • 2004 Cost Effectiveness of Peginterferon alpha-2a Plus Ribavirin versus Interferon alpha-2b Plus Ribavirin as Initial Therapy for Treatment-Naive
    by Miguel Arguedas

  • 2004 Drotrecogin Alfa (Activated): A Pharmacoeconomic Review of its Use in Severe Sepsis
    by James E. Frampton & Rachel H. Foster

  • 2004 Management and Costs of Treating Lung Cancer Patients in a University Hospital
    by Konstantin J. Dedes & Thomas D. Szucs & Stephan Bodis & Markus Joerger & Adam Lowy & Erich W. Russi & Hans C. Steinert & Walter Weder & Rolf A. Stahel

  • 2004 Economic Evaluations of Treatments for Systemic Fungal Infections: A Systematic Review of the Literature
    by Simon Dixon & Emma McKeen & Margaret Tabberer & Suzy Paisley

  • 2004 Adherence to Guidelines for Community-Acquired Pneumonia: Does it Decrease Cost of Care?
    by Patricia D. Brown

  • 2004 Repaglinide: A Pharmacoeconomic Review of its Use in Type 2 Diabetes Mellitus
    by Greg L. Plosker & David P. Figgitt

  • 2004 Measuring Treatment Preferences and Willingness to Pay for Docetaxel in Advanced Ovarian Cancer
    by George Dranitsaris & Julia Elia-Pacitti & Wayne Cottrell

  • 2004 Economic Implications of Treatment-Resistant Depression Among Employees
    by Paul Greenberg & Patricia K. Corey-Lisle & Howard Birnbaum & Maryna Marynchenko & Ami Claxton

  • 2004 The Economic Burden of Allergic Rhinitis: A Critical Evaluation of the Literature
    by Shelby D. Reed & Todd A. Lee & Douglas C. McCrory

  • 2004 Bernard J. O'Brien, BA, MSc, PhD
    by Deborah A. Freund

  • 2004 Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective
    by Kurt Neeser & Georg Lubben & Uwe Siebert & Wendelin Schramm

  • 2004 Cost Effectiveness of Representatives of Three Classes of Antidepressants Used in Major Depression in the UK
    by Alan Lenox-Smith & Pete Conway & Chris Knight

  • 2004 Pharmacoeconomic Analysis of Amphotericin B Lipid Complex versus Liposomal Amphotericin B in the Treatment of Fungal Infections
    by Joseph L. Kuti & Srividya Kotapati & Peter Williams & Blair Capitano & Charles H. Nightingale & David P. Nicolau

  • 2004 How Often Do Sensitivity Analyses for Economic Parameters Change Cost-Utility Analysis Conclusions?
    by Bruce R. Schackman & Heather Taffet Gold & Patricia W. Stone & Peter J. Neumann

  • 2004 Longitudinal versus Cross-Sectional Methodology for Estimating the Economic Burden of Breast Cancer: A Pilot Study
    by C. Daniel Mullins & Junling Wang & Jesse L. Cooke & Lisa Blatt & Claudia R. Baquet

  • 2004 Economic Impact of Respiratory Syncytial Virus-Related Illness in the US: An Analysis of National Databases
    by L. Clark Paramore & Vincent Ciuryla & Gabrielle Ciesla & Larry Liu

  • 2004 The NICE Reference Case Requirement: More Pain for What, if Any, Gain?
    by Amiram Gafni & Stephen Birch

  • 2004 The NICE Reference Case Requirement: Implications for Drug Manufacturers and Health Systems
    by Paul C. Langley

  • 2004 Cost Effectiveness of Peginterferon alpha-2a Plus Ribavirin versus Interferon alpha-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C
    by Sean D. Sullivan & Antonio Craxi & Alfredo Alberti & Giovanni Giuliani & Claudio De Carli & Neil Wintfeld & Kavita K. Patel & Jesse Green

  • 2004 Development and Validation of an Acceptability and Satisfaction Questionnaire for a Contraceptive Vaginal Ring, NuvaRing(R)
    by Annoesjka Novak & Christine de la Loge & Linda Abetz

  • 2004 A
    by Manishi Prasad & Peter Wahlqvist & Rich Shikiar & Ya-Chen Tina Shih

  • 2004 Aggressive Non-Hodgkin
    by Stephen M. Beard & Lucy Wall & Louise Gaffney & Fiona Sampson

  • 2004 Psychometric Validation of the National Eye Institute Visual Function Questionnaire - 25 (NEI VFQ-25) French Version: In a Population of Patients Treated for Ocular Hypertension and Glaucoma
    by Jean-Phillipe Nordmann & Muriel Viala & Kate Sullivan & Benoit Arnould & Gilles Berdeaux

  • 2004 Cost Effectiveness of Interventions for Lateral Epicondylitis: Results from a Randomised Controlled Trial in Primary Care
    by Ingeborg B.C. Korthals-de Bos & Nynke Smidt & Maurits W. van Tulder & Maureen P.M.H. Rutten-van Molken & Herman J. Ader & Danielle A.W.M. van der Windt & Willem J.J. Assendelft & Lex M. Bouter

  • 2004 A Review of Health-Related Workplace Productivity Loss Instruments
    by Jennifer H. Lofland & Laura Pizzi & Kevin D. Frick

  • 2004 Cost-of-Illness Studies in Diabetes Mellitus
    by Lorraine Ettaro & Thomas J. Songer & Ping Zhang & Michael M. Engelgau

  • 2004 Education in Pharmacoeconomics: An International Multidisciplinary View
    by Karen L. Rascati & Michael F. Drummond & Lieven Annemans & Peter G. Davey

  • 2004 Cost of Stress Urinary Incontinence: A Claims Data Analysis
    by Howard G. Birnbaum & Stephanie A. Leong & Emily F. Oster & Kraig Kinchen & Peter Sun

  • 2004 Health Economic Evaluation of Non-Melanoma Skin Cancer and Actinic Keratosis
    by Mitchell K. Higashi & David L. Veenstra & Paul C. Langley

  • 2004 The Generation Gap: Differences Between Children and Adults Pertinent to Economic Evaluations of Health Interventions
    by Ron Keren & Susmita Pati & Chris Feudtner

  • 2004 Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature. The Authors' Reply
    by Nancy Thiry & Philippe Beutels & Pierre Van Damme & Eddy Van Doorslaer

  • 2004 Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature
    by Thomas Hammerschmidt & Kurt Banz & Stefan Wagenpfeil & Albrecht Neiss & Peter Wutzler

  • 2004 Infliximab: A Pharmacoeconomic Review of its Use in Rheumatoid Arthritis
    by Katherine A. Lyseng-Williamson & Rachel H. Foster

  • 2004 Cost-Effective Strategies in the Prevention of Diabetic Nephropathy
    by Jonathan D. Rippin & Anthony H. Barnett & Stephen C. Bain

  • 2004 Allocation of Resources Between Smoking Cessation Methods and Lovastatin Treatment of Hypercholesterolaemia: Based on Cost Effectiveness and the Social Welfare Function
    by Pedro Plans-Rubio

  • 2004 A Multicentre Study of Patient Survival, Disability, Quality of Life and Cost of Care: Among Patients with AIDS in Northern Italy
    by Andrea Tramarin & Stefano Campostrini & Maarten J. Postma & Guido Calleri & Keith Tolley & Nicoletta Parise & Fausto de Lalla

  • 2004 Why Did Drug Spending Increase During the 1990s?: A Decomposition Based on Swedish Data
    by Ulf-G. Gerdtham & Douglas Lundin

  • 2004 Assessing the Value of Antipsychotics for Treating Schizophrenia: The Importance of Evaluating and Interpreting the Clinical Significance of Individual Service Costs
    by Sandra L. Tunis & Haya Ascher-Svanum & Michael Stensland & Bruce J. Kinon

  • 2004 The Economic Implications of Non-Adherence after Renal Transplantation
    by Irina Cleemput & Katrien Kesteloot & Yves Vanrenterghem & Sabina De Geest

  • 2004 The Effect of Cost Construction Based on Either DRG or ICD-9 Codes or Risk Group Stratification on the Resulting Cost-Effectiveness Ratios
    by Elinor C.G. Chumney & Andrea K. Biddle & Kit N. Simpson & Morris Weinberger & Kathryn M. Magruder & William N. Zelman

  • 2004 Discrete Choice Experiment to Derive Willingness To Pay for Methyl Aminolevulinate Photodynamic Therapy Versus Simple Excision Surgery in Basal Cell Carcinoma
    by Adele Weston & Patrick FitzGerald

  • 2004 Economic Costs to Business of the HIV/AIDS Epidemic
    by Gordon G. Liu & Jeff J. Guo & Scott R. Smith

  • 2004 Valuing Prevention Through Economic Evaluation: Some Considerations Regarding the Choice of Discount Model for Health Effects with Focus on Infectious Diseases
    by Jasper M. Bos & Philippe Beutels & Lieven Annemans & Maarten J. Postma

  • 2004 Acknowledgement
    by Adis International Limited

  • 2004 Cost Effectiveness of Raloxifene in the Treatment of Osteoporosis in Sweden: An Economic Evaluation Based on the MORE Study
    by Fredrik Borgstrom & Olof Johnell & John A. Kanis & Anders Oden & David Sykes & Bengt Jonsson

  • 2004 Relative Cost Effectiveness of Depo-Provera(R), Implanon(R), and Mirena(R) in Reversible Long-Term Hormonal Contraception in the UK
    by Susan J. Varney & Julian F. Guest

  • 2004 Validation of the Work and Health Interview
    by Walter F. Stewart & Judith A. Ricci & Carol Leotta & Elsbeth Chee

  • 2004 Measurement of Health-Related QOL in Diabetes Mellitus
    by Ken Watkins & Cathleen M. Connell

  • 2004 Reconciliation of Economic Concerns and Health Policy: Illustration of an Equity Adjustment Procedure Using Proportional Shortfall
    by Elly A. Stolk & Gijs van Donselaar & Werner B.F. Brouwer & Jan J.V. Busschbach

  • 2004 Etanercept: A Pharmacoeconomic Review of its Use in Rheumatoid Arthritis
    by Katherine A. Lyseng-Williamson & Greg L. Plosker

  • 2004 Use and Cost of Antiretrovirals in France 1995-2000: An Analysis Based on the Medical Dossier on Human Immunodeficiency (release 2) Database
    by Yves A. Flori & Marc le Vaillant

  • 2004 Cost-Effectiveness Analysis of Extended-Release Formulations of Oxybutynin and Tolterodine for the Management of Urge Incontinence
    by Dyfrig A. Hughes & Dominique Dubois

  • 2004 Clinical and Economic Impact of Epoetins in Cancer Care
    by Monia Marchetti & Giovanni Barosi

  • 2004 Economic Impact of Migraine and Other Episodic Headaches in France: Data from the GRIM2000 Study
    by Andre Pradalier & Jean-Paul Auray & Abdelkader El Hasnaoui & Kazem Alzahouri & Jean-Francois Dartigues & Gerard Duru & Patrick Henry & Michel Lanteri-Minet & Christian Lucas & Guy Chazot & Anne-Francois Gaudin

  • 2004 Does Seropositivity for Helicobacter pylori Antibodies Increase Outpatient Costs for Gastric and Duodenal Ulcer or Inflammation?
    by Akira Babazono & Motonobu Miyazaki & Hiroshi Une & Eiji Yamamoto & Toshihide Tsuda & Yoshio Mino & Alan L. Hillman

  • 2004 Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events: Economic Evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective
    by Peter K. Schadlich & Josef G. Brecht & Badrudin Rangoonwala & Eduard Huppertz

  • 2004 Cost Effectiveness of ACE Inhibitor Treatment for Patients with Type 1 Diabetes Mellitus
    by Frederick B. Dong & Stephen W. Sorensen & Diane L. Manninen & Theodore J. Thompson & Venkat Narayan & Carlyn E. Orians & Edward W. Gregg & Richard C. Eastman & Erik J. Dasbach & William H. Herman & Jeffrey M. Newman & Andrew S. Narva & David J. Ballard & Michael M. Engelgau

  • 2004 Comparisons of Hypertension-Related Costs from Multinational Clinical Studies
    by C. Daniel Mullins & Mirko Sikirica & Viran Seneviratne & Jeonghoon Ahn & Kasem S. Akhras

  • 2004 The Costs and Benefits of Community Thrombolysis for Acute Myocardial Infarction: A Decision-Analytic Model
    by Luke Vale & Harvey Steffens & Cam Donaldson

  • 2004 Cost-Benefit Analysis of First-Generation Antihistamines in the Treatment of Allergic Rhinitis
    by Patrick W. Sullivan & Sheryl L. Follin & Michael B. Nichol

  • 2004 Pharmacoeconomic Burden of Undertreating Hypertension
    by Luca Degli Esposti & Giorgia Valpiani

  • 2004 Pharmacoeconomic Implications of New Therapies in Sepsis
    by Kelly A. Wood & Derek C. Angus

  • 2004 Pharmacoeconomic Analysis of Bemiparin and Enoxaparin as Prophylaxis for Venous Thromboembolism in Total Knee Replacement Surgery
    by Jesus Honorato & Antonio Gomez-Outes & Antonio Navarro-Quilis & Javier Martinez-Gonzalez & Eduardo Rocha & Andre Planes

  • 2004 Cost Effectiveness of Ibutilide With Prophylactic Magnesium in the Treatment of Atrial Fibrillation
    by Craig I. Coleman & James S. Kalus & C. Michael White & Anne P. Spencer & James P. Tsikouris & Jenny O. Chung & Kenneth W. Kenyon & Martin Ziska & Jeffrey Kluger & Prabashni Reddy

  • 2004 A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries
    by Robert Welte & Talitha Feenstra & Hans Jager & Reiner Leidl

  • 2004 Varicella Vaccination in Italy: An Economic Evaluation of Different Scenarios
    by Laurent Coudeville & Alain Brunot & Carlo Giaquinto & Carlo Lucioni & Benoit Dervaux

  • 2004 Acute Rhinosinusitis: A Pharmacoeconomic Review of Antibacterial Use
    by Jean-Blaise Wasserfallen & Francoise Livio & Giorgio Zanetti

  • 2004 Transferability of Economic Evaluation Results
    by Fernando Antonanzas

  • 2004 Cost Effectiveness of Fluticasone Propionate Plus Salmeterol Versus Fluticasone Propionate Plus Montelukast in the Treatment of Persistent Asthma
    by Richard D. OConnor & Harold Nelson & Rohit Borker & Amanda Emmett & Priti Jhingran & Kathleen Rickard & Paul Dorinsky

  • 2004 Economic Aspects of Severe Sepsis: A Review of Intensive Care Unit Costs, Cost of Illness and Cost Effectiveness of Therapy
    by Hilmar Burchardi & Heinz Schneider

  • 2004 Assessing the Use of Retrospective Databases in Conducting Economic Evaluations of Drugs: The Case of Asthma
    by Fredrik Berggren

  • 2004 Incorporation of Statistical Uncertainty in Health Economic Modelling Studies Using Second-Order Monte Carlo Simulations
    by Mark J.C. Nuijten

  • 2004 Resource Use and Cost of Care for Patients Hospitalised with Community Acquired Pneumonia: Impact of Adherence to Infectious Diseases Society of America Guidelines
    by Joanne J. Orrick & Richard Segal & Thomas E. Johns & Wayne Russell & Feng Wang & Donald D. Yin

  • 2004 Healthcare Costs with Tiotropium Plus Usual Care versus Usual Care Alone Following 1 Year of Treatment in Patients with Chronic Obstructive Pulmonary Disorder (COPD)
    by Mitchell Friedman & Shailendra S. Menjoge & Susan F. Anton & Steven Kesten

  • 2004 Economic Aspects of Pneumococcal Pneumonia: A Review of the Literature
    by Diana De Graeve & Philippe Beutels

  • 2004 Effect of Second-Generation Antipsychotics on Employment and Productivity in Individuals with Schizophrenia: An Economic Perspective
    by Mauro Percudani & Corrado Barbui & Michele Tansella

  • 2004 The Measurement of Contingent Valuation for Health Economics
    by Ahmed M. Bayoumi

  • 2004 On Cost Effectiveness and Sample Size in Clinical Trials. The Author's Reply
    by Martin E. Backhouse

  • 2004 On Cost Effectiveness and Sample Size in Clinical Trials
    by Augustinus A.M. Hart & Marcel G.W. Dijkgraaf

  • 2004 Warfarin in the Secondary Prevention of Thromboembolism in Atrial Fibrillation: Impact of Bioavailability on Costs and Outcomes
    by Nicole Mittmann & Paul I. Oh & Scott E. Walker & William R. Bartle

  • 2004 Economic Assessment of the Secondary Prevention of Ischaemic Stroke with Dipyridamole plus Aspirin (Aggrenox(R)/Asasantin(R)) in France
    by Jean-Pierre Marissal & Bernard Selke

  • 2004 Economic Evaluation of Etoricoxib versus Non-Selective NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis Patients in the UK
    by Andrew Moore & Ceri Phillips & Elke Hunsche & James Pellissier & Simone Crespi

  • 2004 From Randomised Clinical Trials to Clinical Practice: A Pragmatic Cost-Effectiveness Analysis of Paclitaxel in First-Line Therapy for Advanced Ovarian Cancer
    by Samuel Limat & Marie-Christine Woronoff-Lemsi & Celine Menat & Anne Madroszyk-Flandin & Yacine Merrouche

  • 2004 An Economic Model of 2-Hour Post-Dose Ciclosporin Monitoring in Renal Transplantation
    by Paul A. Keown & Bryce Kiberd & Robert Balshaw & Shideh Khorasheh & Carlo Marra & Philip Belitsky & Zoltan Kalo

  • 2004 Effectiveness, Quality of Life, and Cost of Caring for Children in France with Recurrent Acute Rhinopharyngitis Managed by Homeopathic or Non-Homeopathic General Practitioners: A Pragmatic, Prospective Observational Study
    by Melanie Trichard & Gilles Chaufferin & Christian Dubreuil & Nicolas Nicoloyannis & Gerard Duru

  • 2004 The Burden of Osteoporosis and the Case for Disease Management
    by William D. Fraser

  • 2004 Long-Term Drug Treatment of GERD: Economic Issues for Formulary Decision Makers
    by James Chan & Theodore R. Levin

  • 2004 Development of a Regionalized, Comprehensive Care Network for Pediatric Sickle Cell Disease to Improve Access to Care in a Rural State
    by Lee M. Hilliard & Mary H. Maddox & Shenghui Tang & Thomas H. Howard

  • 2004 Socioeconomic Implications of Long-Term Warfarin Use
    by Joseph Menzin & Talia Foster & Rebecca Audette

  • 2004 Improving Treatment Regimen Adherence in Coronary Heart Disease by Targeting Patient Types
    by Robin S. Turpin & Jeffrey B. Simmons & Janice F. Lew & Charles M. Alexander & Marie A. Dupee & Patricia Kavanagh & Ellen R. Cameron

  • 2004 Thiazolidinediones for Diabetes Mellitus: Considerations for Reimbursements by Third-Party Payors
    by Andrew J. Palmer & William J. Valentine & Joshua A. Ray

  • 2004 Barrett
    by Deepak V. Gopal & Mark Reichelderfer & Eric A. Gaumnitz & Josephine Harter & Blair A. Jobe

  • 2004 Acknowledgments
    by Adis International Limited

  • 2004 Management of Benign Prostatic Hyperplasia: Defining the Role of Tamsulosin
    by Katherine F. Croom & Antona J. Wagstaff

  • 2004 Caring for Hypertension on Initiation: Costs and Effectiveness (CHOICE): A Naturalistic Design and Rationale for the Study of Patterns of Care in Hypertension
    by Jaime J. Caro & Norman Hollenberg & Joseph D Jackson & Krista A Payne & Gil LItalien

  • 2004 Overview of Disease Management Approaches: Implications for Corporate-Sponsored Programs
    by Shirley A. Musich & Alyssa B. Schultz & Wayne N. Burton & Dee W. Edington

  • 2004 National Performance Measures for Diabetes Mellitus Care: Implications for Health Care Providers
    by Fevzi Akinci & Joseph Coyne & Bernard Healey & Joni Minear

  • 2004 Pulmonary Rehabilitation Programs: Improving Outcomes in Elderly Patients with COPD
    by Jorg D. Leuppi & Roland M. Bingisser

  • 2004 Impact of a Migraine Disease Management Program: Humanistic Outcomes
    by Henry X. Hu & Glen D. Solomon & Kathleen Conboy & Lisa Deml & Leona E. Markson

  • 2004 Economic Benefits of Including Environmental Issues as a Component of Comprehensive Asthma Care: A Managed Care Perspective
    by Doug Brugge & James Hyde & Bonnie H. Weinbach & Jonathan I. Levy & Suzanne Steinbach

  • 2004 Reducing the Incidence of Type 2 Diabetes Mellitus: A Healthcare Plan and Program Implementation Perspective
    by Nicolaas P. Pronk & Jackie Boucher & Robert W. Jeffery & Nancy E. Sherwood & Raymond Boyle

  • 2004 Opportunities for Pharmacists to Aid in the Management of Acid-Peptic Disorders
    by C. Wayne Weart & Harry Leider

  • 2004 Specialist and Generalist Care for Type 1 Diabetes Mellitus: Differential Impact on Processes and Outcomes
    by Janice C. Zgibor & Trevor J. Orchard

  • 2004 Short-Term Aggressive Disease Management Programs for Heart Failure: Effect on Drug Utilization, Clinical Outcomes, and Costs
    by Kwame O. Akosah & Stephanie Carothers

  • 2004 Performance Measurement of Disease Management Programs: Examination of Recent Guidelines
    by Barry M. Zajac

  • 2004 Spotlight on Eptifibatide in Percutaneous Coronary Intervention and Acute Coronary Syndromes
    by Greg L. Plosker & Tim Ibbotson

  • 2004 A Surveillance System for the Real-Time Reporting of Influenza Activity
    by Helmut Uphoff & Irena Groniewicz & Marc Soriano & Isabel Burckhardt-Batista

  • 2004 Dosing Patterns of Anti-TNF Therapy in Patients with Rheumatoid Arthritis in a Managed Care Setting
    by Karen Stockl & Manal Jarrar & Neeta Tandon

  • 2004 The Costs of Non-Adherence to Oral Antihyperglycemic Medication in Individuals with Diabetes Mellitus and Concomitant Diabetes Mellitus and Cardiovascular Disease in a Managed Care Environment
    by T. Jeffrey White & Ann Vanderplas & Eunice Chang & Christopher M. Dezii & Geoffrey D. Abrams

  • 2004 Atypical Antipsychotics as First-Line Treatments for Schizophrenia: Advantages for Stakeholders in the UK Healthcare System
    by Ann M. Mortimer

  • 2004 Optimizing Drug Prescribing in Managed Care Populations: Improving Clinical and Economic Outcomes
    by Rachel Czubak & Jasmine Tucker & Barbara J. Zarowitz

  • 2004 The Department of Health (England) Action Plan for Improving Services for People with Epilepsy: Will It Improve Quality of Care?
    by Frank M.C. Besag

  • 2004 Improvements in Asthma Pharmacotherapy and Self-Management: An Example of a Population-Based Disease Management Program
    by Richard A. Feifer & Robert R. Verbrugge & Mona Khalid & Rebecca Levin & Gwendolyn B. OKeefe & Ronald E. Aubert

  • 2004 Impact of Three-Tier Pharmacy Benefit Structures on Consumer Attitudes, Pharmacy, Medical Utilization and Costs: A Critical Review
    by Kavita V. Nair & Robert J. Valuck

  • 2004 Impact of Guidelines on Healthcare from the Patient and Payor Perspective: Example of the American Pain Society Guidelines
    by Bill McCarberg

  • 2004 Management of Overactive Bladder: Defining the Role of Extended-Release Tolterodine
    by Susan J. Keam & Caroline M. Perry

  • 2004 Management of Genital Herpes: Defining the Role of Valaciclovir
    by Antona J. Wagstaff & Susan J. Keam & David P. Figgitt

  • 2004 Employer-Based Disease Management Programs in Cancer: Experience to Date
    by Frederick C. Lee

  • 2004 Management of Mild to Moderate Alzheimer Disease: Defining the Role of Rivastigmine
    by Greg L. Plosker & Gillian M. Keating

  • 2004 Management of Parkinson Disease: Defining the Role of Ropinirole
    by David Murdoch & Susan M. Cheer & Antona J. Wagstaff

  • 2004 Prevention and Treatment of Osteoporosis in Postmenopausal Women: Defining the Role of Alendronate
    by Susan J. Keam & Greg L. Plosker

  • 2004 Adalimumab for Rheumatoid Arthritis: Considerations for Reimbursement by Third-Party Payors
    by Leo van de Putte & Michael B. Nichol

  • 2004 Nurses
    by Erik Magnus Saether

  • 2004 Burning a Hole in the Budget: Tobacco Spending and its Crowd-Out of Other Goods
    by Susan H. Busch & Mireia Jofre-Bonet & Tracy A. Falba & Jody L. Sindelar

  • 2004 Income-Related Inequality in the Use of Dental Services in Finland
    by Lien Nguyen & Unto Hakkinen

  • 2004 Tackling Regional Health Inequalities in France by Resource Allocation: A Case for Complementary Instrumental and Process-Based Approaches?
    by Martine M. Bellanger & Alain Jourdain

  • 2004 Consumer Mobility in Social Health Insurance Markets: A Five-Country Comparison
    by Trea Laske-Aldershof & Erik Schut & Konstantin Beck & Stefan Gress & Amir Shmueli & Carine Van de Voorde

  • 2004 Senior Citizens and the Burden of Prescription Drug Outlays: What Lessons for the Medicare Prescription Drug Benefit?
    by Panos Kanavos & Marin Gemmill

  • 2004 How Much Might Universal Health Insurance Reduce Socioeconomic Disparities in Health?: A Comparison of the US and Canada
    by Sandra L. Decker & Dahlia K. Remler

  • 2004 Is Patient Choice an Effective Mechanism to Reduce Waiting Times?
    by Diane Dawson & Rowena Jacobs & Steve Martin & Peter Smith

  • 2004 Do Patients Always Prefer Quicker Treatment?: A Discrete Choice Analysis of Patients
    by Peter Burge & Nancy Devlin & John Appleby & Charlene Rohr & Jonathan Grant

  • 2004 Guest Editorial
    by Adam Oliver

  • 2004 Aggregating Public Preferences for Healthcare: Putting Theory into Practice
    by Virginia Wiseman

  • 2004 Examining Within-Country Variation of Maternity Costs in the Context of a Multicountry, Multicentre Randomised Controlled Trial
    by Guy Hutton & Julia Fox-Rushby & Miranda Mugford & Jadsada Thinkhamrop & Bandit Thinkhamrop & Ana Maria Galvez & Manuel Alvarez

  • 2004 Medicare Payment Policy and the Controversy over Hospital Cost Shifting
    by Rick Mayes & Jason S. Lee

  • 2004 Listening to the Decision Makers: Sustainability of PBMA in Alberta
    by Craig Mitton & San Patten & Cam Donaldson

  • 2004 Productivity Research and Healthcare Delivery Innovation
    by Karen Eggleston & Jerome Grossman & David Cutler

  • 2004 Observations on Health Financing Reform in the Republic of Georgia, 1996-2002
    by Kees Schaapveld & Grant Rhodes

  • 2004 Calculating Society
    by Jeff Richardson & Richard D. Smith

  • 2004 Healthcare Expenditure and Ageing: A Comment
    by J. Francois Outreville

  • 2004 EQ-5D versus SF-6D in an Older, Chronically Ill Patient Group
    by Karen Gerard & Tricia Nicholson & Mark Mullee & Raj Mehta & Paul Roderick

  • 2004 The Use of Probabilistic Decision Models in Technology Assessment: The Case of Total Hip Replacement
    by Andrew Briggs & Mark Sculpher & Jill Dawson & Ray Fitzpatrick & David Murray & Henrik Malchau

  • 2004 Improving Road Safety and Residential Quality of Life: Evaluating the Automated Wayside Horn System
    by Roy E. Lucke & Richard A. Raub & Thomas E. Thunder

  • 2004 The Economics of Prevention in a Post-Managed-Care Environment
    by Cyril F. Chang & Teresa M. Waters & David M. Mirvis

  • 2004 Should We Maximise QALYs?: A Debate with Respect to Peak-End Evaluation
    by Adam Oliver

  • 2004 Do Interventions to Increase Income Improve the Health of the Poor in Developed Economies and Are Such Policies Cost Effective?
    by Anne Ludbrook & Kathy Porter

  • 2004 Modelling the Ability of Risk Adjusters to Reduce Adverse Selection in Managed Care
    by Randall S. Stafford & Donglin Li & Roger B. Davis & Lisa I. Iezzoni

  • 2004 Comparing Utility Scores Before and After Hearing-Aid Provision: Results According to the EQ-5D, HUI3 and SF-6D
    by Garry R. Barton & John Bankart & Adrian C. Davis & Quentin A. Summerfield

  • 2004 Driver Perception Response Time During the Signal Change Interval
    by Pin-Kai Goh & Yiik-Diew Wong

  • 2004 A Tribute to the Life and Work of Bernie O
    by John F.P. Bridges

  • 2004 The Value of Life and Accident Costing: A Willingness-to-Pay Study Amongst Motorcyclists in Malaysia
    by Mohd Y. Mohd Fauzi & Mohd N. Nor Ghani & Radin S. Radin Umar & Hashim Ahmad Hariza

  • 2004 Healthcare Payment Incentives: A Comparative Analysis of Reforms in Taiwan, South Korea and China
    by Karen Eggleston & Chee-Ruey Hsieh

  • 2004 The Impact of Physician Payment Methods on Raising the Efficiency of the Healthcare System: An International Comparison
    by Steven Simoens & Antonio Giuffrida

  • 2004 The Reliability of Willingness to Pay for Changes in Health Status
    by Richard D. Smith

  • 2004 Road Safety and Accident Prevention
    by Richard Tay

  • 2004 An Alternative Approach to Resource Allocation: Weighted Capacity to Benefit Plus MESH Infrastructure
    by Gavin Mooney & Shane Houston

  • 2004 Self-Reported Effectiveness of Double-Fine Zones as a Speed Control Measure
    by Barnie Jones & Kevin Haas & Alan Kirk & Andrew Griffith

  • 2004 Editorial Foreword
    by Adis International Limited

  • 2003 The Impact of Insurance Fraud Detection Systems
    by Jörg Schiller

  • 2003 The Impact of Insurance Fraud Detection Systems
    by Joerg Schiller

  • 2003 Radiocommunications
    by Productivity Commission

  • 2003 University Resourcing: Australia in an International Context
    by Productivity Commission

  • 2003 Growth in the “New Economy”: U.S. Bandwidth Use and Pricing Across the 1990s
    by Douglas A. Galbi

  • 2003 Productivity Commission Submission to the Review of Pricing Arrangements in Residential Aged Care
    by Productivity Commission

  • 2003 International benchmarking of container stevedoring
    by Productivity Commission

  • 2003 Rescuing Patients from the Rule of Efficiency: A Need to Debate the
    by Sophia Kessabi & Richard de Abreu Lourenco & Michael Wonder

  • 2003 Direct Treatment Costs for Patients with Lung Cancer from First Recurrence to Death in France
    by Anne-Chantal Braud & Christine Levy-Piedbois & Pascal Piedbois & Youri Piedbois & Alain Livartovski & Beatrice Le Vu & Jean Tredaniel & Francois Reboul & Yvelise Brewer & Said Talbi & Francois Blanchon & Britta Paschen & Isabelle Durand-Zaleski

  • 2003 Economic Evaluation of Norethisterone Acetate/Ethinylestradiol (FemHRT(R)) for Women with Menopausal Symptoms
    by Douglas Coyle & Ann Cranney & Peter Tugwell

  • 2003 The Comparative Medical Costs of Atherothrombotic Disease in European Countries
    by Emile Levy & Sylvie Gabriel & Jerome Dinet

  • 2003 Assessing the Economic Impact of Adverse Drug Effects
    by Rosa Rodriguez-Monguio & Maria Jose Otero & Joan Rovira

  • 2003 Costs of Bipolar Disorder
    by Leah S. Kleinman & Ana Lowin & Emuella Flood & Gian Gandhi & Eric Edgell & Dennis A. Revicki

  • 2003 Cost Effectiveness of Pneumococcal Vaccination for Infants and Children with the Conjugate Vaccine PnC-7 in Germany
    by Christa Claes & Johann-Matthias Graf von der Schulenburg

  • 2003 The Cost Effectiveness of ACE Inhibitors as First-Line Antihypertensive Therapy
    by Alain J. Nordmann & Murray Krahn & Alexander G. Logan & Gary Naglie & Allan S. Detsky

  • 2003 Labour Force Participation Among Individuals with Hepatitis C in the US
    by Philip Jacobs & Ying Chu Ng & Tania Stafinski & Roger Dodd & Bryce Larke & Winnie Wong

  • 2003 The Economics of Screening and Treatment in Type 2 Diabetes Mellitus
    by Maria Raikou & Alistair McGuire

  • 2003 Quality of Life and Economic Considerations in the Management of Prostate Cancer
    by Marco Turini & Alberto Redaelli & Paola Gramegna & Davide Radice

  • 2003 A Stochastic Economic Evaluation of Letrozole versus Tamoxifen as a First-Line Hormonal Therapy: For Advanced Breast Cancer in Postmenopausal Patients
    by Jon Karnon & Trefor Jones

  • 2003 Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus
    by Andreas Maetzel & Jorg Ruof & Melva Covington & Anne Wolf

  • 2003 Using Gross National Product to Calculate Acceptable Immunisation Costs: Deploying Cost-Effectiveness Calculations in Reverse
    by Vineet Tyagi & Saroj K. Singh & Ashu Sawhney & Vikas Taneja & Jacob M. Puliyel

  • 2003 Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery
    by Sean D. Sullivan & Susan R. Kahn & Bruce L. Davidson & Lars Borris & Patrick Bossuyt & Gary Raskob

  • 2003 Cytomegalovirus Infection in Solid Organ Transplantation: Economic Implications
    by Ananya Das

  • 2003 Pharmaceutical Care Programmes for the Elderly: Economic Issues
    by Grainne E. Crealey & Ian K. Sturgess & James C. McElnay & Carmel M. Hughes

  • 2003 Factors Affecting UK Primary-Care Costs of Managing Patients with Asthma over 5 Years
    by Roben Das Gupta & Julian F. Guest

  • 2003 Cost Effectiveness of Nasal Budesonide versus Surgical Treatment for Nasal Polyps
    by Fredrik Berggren & Leif Johansson

  • 2003 Peginterferon alpha-2a (40kD) [Pegasys(R)] Improves HR-QOL Outcomes Compared with Unmodified Interferon alpha-2a [Roferon(R)-A]: In Patients with Chronic Hepatitis C
    by Jens Rasenack & Stefan Zeuzem & S. Victor Feinman & E. Jenny Heathcote & Michael Manns & Eric M. Yoshida & Mark G. Swain & Edward Gane & Moises Diago & Dennis A. Revicki & Amy Lin & Neil Wintfeld & Jesse Green

  • 2003 Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer's Disease
    by Anders Wimo & Bengt Winblad & Albrecht Stoffler & Yvonne Wirth & Hansjorg Mobius

  • 2003 The Cost Effectiveness of Two New Antiepileptic Therapies in the Absence of Direct Comparative Data: A First Approximation
    by Ben A. van Hout & Dennis D. Gagnon & Pauline Mcnulty & Anthony O'Hagan

  • 2003 Cost Effectiveness of Alendronate (Fosamax(R)) for the Treatment of Osteoporosis and Prevention of Fractures
    by Olof Johnell & Bengt Jonsson & Linus Jonsson & Dennis Black

  • 2003 A Simulation Model for Estimating Direct Costs of Type 1 Diabetes Prevention
    by Jarmo Hahl & Tuula Simell & Antti Kupila & Paivi Keskinen & Mikael Knip & Jorma Ilonen & Olli Simell

  • 2003 Ontario's Formulary Committee: How Recommendations Are Made
    by Anne M. PausJenssen & Peter A. Singer & Allan S. Detsky

  • 2003 A Study of Influenza and Influenza-Related Complications among Children in a Large US Health Insurance Plan Database
    by Jeanne Loughlin & Nick Poulios & Pavel Napalkov & Yann Wegmuller & Arnold S. Monto

  • 2003 Unit Costs of Inpatient Hospital Days
    by Jan B. Oostenbrink & Tineke Buijs-Van der Woude & Michel van Agthoven & Marc A. Koopmanschap & Frans F.H. Rutten

  • 2003 Cost Comparisons of Pharmacological Strategies in Open-Heart Surgery
    by Prabashni Reddy & Jessica Song

  • 2003 Health-Related Quality-of-Life Assessments in Patients with Advanced Cancer of the Prostate
    by Jan Adolfsson

  • 2003 Specialist Nurse Management Programmes: Economic Benefits in the Management of Heart Failure
    by Simon Stewart & John D. Horowitz

  • 2003 Bedside Rapid Flu Test and Zanamivir Prescription in Healthy Working Adults: A Cost-Benefit Analysis
    by Michael Schwarzinger & Bruno Housset & Fabrice Carrat

  • 2003 Cost-Minimisation Study of Dorzolamide versus Brinzolamide in the Treatment of Ocular Hypertension and Primary Open-Angle Glaucoma: In Four European Countries
    by Jeanfrancois Rouland & Claude Lepen & Carlos Gouveiapinto & Patrizia Berto & Gilles Berdeaux

  • 2003 A Meta-Analysis of Quality-of-Life Estimates for Stroke
    by Tammy O. Tengs & Ting H. Lin

  • 2003 The Burden of Age-Related Macular Degeneration: Results of a Cohort Study in Two French Referral Centres
    by Julia Bonastre & Claude Le Pen & Gisele Soubrane & Gabriel Quentel

  • 2003 Treatment of Atopic Dermatitis and Impact on Quality of Life: A Review with Emphasis on Topical Non-Corticosteroids
    by Roman Schiffner & Julia Schiffner-Rohe & Michael Landthaler & Wilhelm Stolz

  • 2003 NICE Methodological Guidelines and Decision Making in the National Health Service in England and Wales
    by Amiram Gafni & Stephen Birch

  • 2003 European Healthcare Policies for Controlling Drug Expenditure
    by Silvia M. Ess & Sebastian Schneeweiss & Thomas D. Szucs

  • 2003 Discounting in Cost-Utility Analysis of Healthcare Interventions: Reassessing Current Practice
    by Brian J. Cohen

  • 2003 Cost Effectiveness and Cost Utility of Acetylcysteine versus Dimethyl Sulfoxide for Reflex Sympathetic Dystrophy
    by Hiske E.M. van Dieten & Roberto S.G.M. Perez & Maurits W. van Tulder & Jaap J. de Lange & Wouter W.A. Zuurmond & Herman J. Ader & Hindrik Vondeling & Maarten Boers

  • 2003 Economic Implications of the Use of Basiliximab in Addition to Triple Immunosuppressive Therapy in Renal Allograft Recipients: A UK Perspective
    by Stephen J. Walters & Malcolm Whitfield & Ronald L. Akehurst & James B. Chilcott

  • 2003 Cost Analysis of Ropinirole versus Levodopa in the Treatment of Parkinson's Disease
    by Michael Iskedjian & Thomas R. Einarson

  • 2003 Cost of Illness of Atopic Dermatitis in Children: A Societal Perspective
    by Andrew S. Kemp

  • 2003 Comparative Cost Effectiveness of Angiotensin II Receptor Blockers in a US Managed Care Setting: Olmesartan Medoxomil Compared with Losartan, Valsartan, and Irbesartan
    by W. Robert Simons

  • 2003 Potential Costs and Effects of the National Service Framework for Coronary Heart Disease in the UK
    by Venanzio Vella

  • 2003 Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies
    by Niklas Zethraeus & Magnus Johannesson & Bengt Jonsson & Mickael Lothgren & Magnus Tambour

  • 2003 Economic Evaluations of Varicella Vaccination Programmes: A Review of the Literature
    by Nancy Thiry & Philippe Beutels & Pierre Van Damme & Eddy Van Doorslaer

  • 2003 Generic Clozapine: A Cost-Saving Alternative to Brand Name Clozapine?
    by Gordon Tse & Deborah Thompson & Ric M. Procyshyn

  • 2003 An Evaluation of the Cost Effectiveness of Drotrecogin Alfa (Activated) Relative to the Number of Organ System Failures
    by Madeline Betancourt & Peggy S. McKinnon & R. Michael Massanari & Salmaan Kanji & David Bach & John W. Devlin

  • 2003 The Health Economics of Bladder Cancer: A Comprehensive Review of the Published Literature
    by Marc F. Botteman & Chris L. Pashos & Alberto Redaelli & Benjamin Laskin & Robert Hauser

  • 2003 Economic Evaluations of Granulocyte Colony-Stimulating Factor: In the Prevention and Treatment of Chemotherapy-Induced Neutropenia
    by Marc Esser & Helmut Brunner

  • 2003 Development and Validation of the Diabetic Foot Ulcer Scale-Short Form (DFS-SF)
    by Carla M. Bann & Sheri E. Fehnel & Dennis D. Gagnon

  • 2003 The Cost Effectiveness of Tacrolimus versus Microemulsified Cyclosporin: A 10-Year Model of Renal Transplantation Outcomes
    by Michelle E. Orme & Wieslaw A. Jurewicz & Nagappan Kumar & Tracy L. McKechnie

  • 2003 Economic Implications of Attention-Deficit Hyperactivity Disorder for Healthcare Systems
    by Cynthia L. Leibson & Kirsten Hall Long

  • 2003 Screening, Prevention and Socioeconomic Costs Associated with the Treatment of Colorectal Cancer
    by Alberto Redaelli & Carole W. Cranor & Gary J. Okano & Pat Ray Reese

  • 2003 Pharmaceutical Expenditure and Therapeutic Value of New Medicines in Spain
    by Josep Darba

  • 2003 Escitalopram: A Pharmacoeconomic Review of its Use in Depression
    by Katherine F. Croom & Greg L. Plosker

  • 2003 The Cost Effectiveness of Apligraf(R) Treatment of Diabetic Foot Ulcers
    by W. Ken Redekop & Joseph McDonnell & Paul Verboom & Kornelia Lovas & Zoltan Kalo

  • 2003 Cost-Utility Analysis of Survival with Epoetin-Alfa versus Placebo in Stage IV Breast Cancer
    by Silas C. Martin & Dennis D. Gagnon & Lucy Zhang & Carsten Bokemeyer & Marinus Van Marwijk Kooy & Ben van Hout

  • 2003 Costs and Cost Effectiveness of Low Molecular Weight Heparins and Platelet Glycoprotein IIb/IIIa Inhibitors: In the Management of Acute Coronary Syndromes
    by Nick Bosanquet & Bengt Jonsson & Keith A.A. Fox

  • 2003 Reductions in Individual Work Productivity Associated with Type 2 Diabetes Mellitus
    by Jill E. Lavigne & Charles E. Phelps & Alvin Mushlin & Wayne M. Lednar

  • 2003 Indirect Costs in Ambulatory Patients with HIV/AIDS in Spain: A Pilot Study
    by Juan Oliva & Cesar Roa & Juan del Llano

  • 2003 Methods to Analyse Cost Data of Patients Who Withdraw in a Clinical Trial Setting
    by Jan B. Oostenbrink & Maiwenn J. Al & Maureen P.M.H. Rutten-van Molken

  • 2003 Heartburn in Patients with Gastro-Oesophageal Reflux Disease in Germany and Sweden: A Study on Patients
    by Roger Jones & Silke Horbach & Peter Sander & Tina Ryden-Bergsten

  • 2003 Frequency of Hospitalisations and Inpatient Care Costs of Manic Episodes: In Patients with Bipolar I Disorder in France
    by Marie de Zelicourt & Roland Dardennes & Helene Verdoux & Gian Gandhi & Babak Khoshnood & Eric Chomette & Marie-Laure Papatheodorou & Eric T. Edgell & Christian Even & Francis Fagnani

  • 2003 Evaluating Minimal Clinically Important Differences for the Acne-Specific Quality of Life Questionnaire
    by Lori D. McLeod & Sheri E. Fehnel & Jane Brandman & Tara Symonds

  • 2003 Cost-Effectiveness League Tables: Valuable Guidance for Decision Makers?
    by Josephine Mauskopf & Frans Rutten & Warren Schonfeld

  • 2003 Prevention of Recurrent Rhinopharyngitis in At-Risk Children in France: A Cost-Effectiveness Model for a Nonspecific Immunostimulating Bacterial Extract (OM-85 BV)
    by Jean-Jacques Pessey & Francoise Megas & Benoit Arnould & Florence Baron-Papillon

  • 2003 A Cost Comparison of Oral Tegafur Plus Uracil/Folinic Acid and Parenteral Fluorouracil for Colorectal Cancer in Canada
    by Jean A. Maroun & Carl Asche & Francoise Romeyer & Jayanti Mukherjee & Christine Cripps & Amit Oza & Jamie R. Skillings & Jacques Letarte

  • 2003 Pharmacoeconomics of Cholinesterase Inhibitors in the Treatment of Alzheimer
    by Linus Jonsson

  • 2003 Cystic Fibrosis: Cost of Illness and Considerations for the Economic Evaluation of Potential Therapies
    by Christian Krauth & Noushin Jalilvand & Tobias Welte & Reinhard Busse

  • 2003 Inhaled Salmeterol/Fluticasone Propionate Combination: A Pharmacoeconomic Review of its Use in the Management of Asthma
    by Katherine A. Lyseng-Williamson & Greg L. Plosker

  • 2003 The Incorporation of Potential Confounding Variables in Markov Models
    by Mark J.C. Nuijten & Frans Rutten

  • 2003 Quality of Life in Patients with Rheumatoid Arthritis: Which Drugs Might Make a Difference?
    by Barbara Blumenauer & Ann Cranney & Jennifer Clinch & Peter Tugwell

  • 2003 Practical Aspects of Designing and Conducting Pharmacoeconomic Studies in Japan
    by Jim Doherty & Keiko Sato

  • 2003 Eptifibatide: A Pharmacoeconomic Review of its Use in Percutaneous Coronary Intervention and Acute Coronary Syndromes
    by Greg L. Plosker & Tim Ibbotson

  • 2003 Validation of Expert Opinion in Identifying Comorbidities Associated with Atopic Dermatitis/Eczema
    by Charles N. Ellis & Lynn A. Drake & Mary M. Prendergast & William Abramovits & Mark Boguniewicz & C. Ralph Daniel & Mark Lebwohl & Seth R. Stevens & Diane L. Whitaker-Worth & Kuo B. Tong

  • 2003 Defining Monetary Values for Quality of Life Improvements: An Exploratory Study
    by Jean Lachaine & Claudine Laurier & Andre-Pierre Contandriopoulos

  • 2003 Recurrent Genital Herpes Treatments and Their Impact on Quality of Life
    by Mathijs H. Brentjens & Kimberly A. Yeung-Yue & Patricia C. Lee & Stephen K. Tyring

  • 2003 Integer/Linear Mathematical Programming Models: A Tool for Allocating Healthcare Resources
    by Stephanie R. Earnshaw & Susan L. Dennett

  • 2003 Economic Model of First-Line Drug Strategies to Achieve Recommended Glycaemic Control in Newly Diagnosed Type 2 Diabetes Mellitus
    by Joe W. Ramsdell & Seth N. Braunstein & Jennifer M. Stephens & Christopher F. Bell & Marc F. Botteman & Scott T. Devine

  • 2003 Can Sequential Administration Minimise the Cost of High Dose Chemotherapy?: An Economic Assessment in Inflammatory Breast Cancer
    by Patricia Marino & Anne-Gaelle Le Corroller & Thao Palangie & Maud Janvier & Michel Fabbro & Laurent Molinier & Thierry Delozier & Alain Livartowski & Jean-Paul Moatti & Patrice Viens

  • 2003 Cost Evaluation of Basiliximab Treatment for Renal Transplant Patients in Japan
    by Tomonori Hasegawa & Hidehiko Imai & Sunao Miki

  • 2003 The Impact of Treatment for Gastro-Oesophageal Reflux Disease on Health-Related Quality of Life: A Literature Review
    by Manishi Prasad & Anne M. Rentz & Dennis A. Revicki

  • 2003 A Role for Two-Stage Pharmacoeconomic Appraisal?: Is There a Role for Interim Approval of a Drug for Reimbursement Based on Modelling Studies with Subsequent Full Approval Using Phase III Data?
    by Suzanne Hill & Nick Freemantle

  • 2003 Lower Respiratory Tract Infections: Impact on the Workplace
    by Howard G. Birnbaum & Melissa Morley & Stephanie Leong & Paul Greenberg & Gene L. Colice

  • 2003 Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin in Patients with Acute Coronary Syndrome in Poland: Modelling Study from the Hospital Perspective
    by Ewa Orlewska & Andrzej Budaj & Dariusz Tereszkowski-Kaminski

  • 2003 Consumer Preference for Dinoprostone Vaginal Gel Using Stated Preference Discrete Choice Modelling
    by Susan J. Taylor & Carol L. Armour

  • 2003 Cost Effectiveness of Adding Folinic Acid to Fluorouracil Plus Levamisole as Adjuvant Chemotherapy in Patients with Colon Cancer in Germany
    by Brigitta U.M. Monz & Hans-Helmut Konig & Reiner Leidl & Ludger Staib & Karl-Heinrich Link

  • 2003 Determinants of Drug Costs in Hospitalised Patients with Haemophilia: Impact of Recombinant Activated Factor VII
    by Jean Philippe Galanaud & Nathalie Pelletier-Fleury & Helene Logerot-Lebrun & Thierry Lambert

  • 2003 Olanzapine versus Risperidone in the Treatment of Schizophrenia: A Comparison of Costs among Texas Medicaid Recipients
    by Karen L. Rascati & Michael T. Johnsrud & M. Lynn Crismon & Maureen J. Lage & Beth L. Barber

  • 2003 Disease Management Update
    by Adis International Limited

  • 2003 Validation of the Pneumonia Severity Index Among Patients Treated at Home or in the Hospital
    by Brian S. Armour & Stephen R. Pitts & M. Melinda Pitts & Jennifer Wike & Linda Alley & Jeff Etchason

  • 2003 School-Based Prevention Programs for Eating Disorders: Achievements and Opportunities
    by Riccardo Dalle Grave

  • 2003 Comprehensive Case Management Models For Pulmonary Tuberculosis
    by Patrick Chaulk & Vahe A. Kazandjian

  • 2003 What is the Return on Investment Associated with Diabetes Disease Management?: A Report from One Managed Care Organization in Pennsylvania, USA
    by Jaan Sidorov & Peter Paulick & Lila Sobel

  • 2003 A Review of Telemedicine and Asthma
    by Claire Wainwright & Richard Wootton

  • 2003 The MELD System for Liver Allocation: Implications for Patients and Payors
    by Richard B. Freeman

  • 2003 Certification for Disease-Specific Care Programs
    by Charles A. Mowll

  • 2003 Disease Management Update
    by Adis International Limited

  • 2003 New Biochemical Tools for Diagnosing Acute Coronary Syndromes: Impact on Patient Outcomes and Resource Utilization in Hospitals
    by W. Frank Peacock & Fred Wilson

  • 2003 Acute Care for Elders Units: Practical Considerations for Optimizing Health Outcomes
    by Robert M. Palmer & Steven R. Counsell & Seth C. Landefeld

  • 2003 Supporting Herbal Resource Needs for Health Plan Members: Complementary and Alternative Medicine by Telephone
    by Jodi A. Chaffin & Jolene J. Thoennes & Jackie L. Boucher & Nicolaas P. Pronk

  • 2003 Improving the Health Status of US Working Adults with Type 2 Diabetes Mellitus: A Review
    by Fevzi Akinci & Bernard J. Healey & Joseph S. Coyne

  • 2003 Chronic Disease Management: A Definition And Systematic Approach To Component Interventions
    by Susan L. Norris & Russell E. Glasgow & Michael M. Engelgau & Patrick J. OConnor & David McCulloch

  • 2003 Disease Management Update
    by Adis International Limited

  • 2003 Utilization and Financial Outcomes of an Asthma Disease Management Program Delivered to Medicaid Members: Results of a Three-Group Comparison Study
    by Alan E. Johnson & Ming Yin & Gregory Berg

  • 2003 Cost Effectiveness of Diabetes Mellitus Management Programs: A Health Plan Perspective
    by Todd Gilmer & Patrick J. OConnor

  • 2003 The Role of Evidence-Based Medicine in Disease Management
    by Paul H. Keckley

  • 2003 Diabetes Self-Management Education Research: An International Review of Intervention Methods, Theories, Community Partnerships and Outcomes
    by Leonard Jack, Jr

  • 2003 How Can Social Workers Improve Outcomes and Costs in Disease Management?
    by Nancy Claiborne & Henry Vandenburgh

  • 2003 Disease Management Update
    by Adis International Limited

  • 2003 Identifying Future High-Cost Cases Through Predictive Modeling
    by Yang Zhao & Arlene S. Ash & John Haughton & Benjamin McMillan

  • 2003 Disease Management of Migraine and the Importance of Stratified Care
    by Richard B. Lipton & Marcelo E. Bigal & Wsalter F. Stewart

  • 2003 Screening for Depression in Patients with Chronic Illness: Why and How?
    by Jeffrey M. Davis & Christine M. Gershtein

  • 2003 Disease Management Programs in the Geriatric Setting: Practical Considerations
    by Kenneth J. Steinman & Michael A. Steinman & Theodore I. Steinman

  • 2003 Medicaid Disease Management Programs: Findings from Three Leading US State Programs
    by Jeann L. Gillespie & Louis F. Rossiter

  • 2003 Disease Management Update
    by Adis International Limited

  • 2003 A Comparative Cost Analysis of Participating versus Non-Participating Somatizing Patients Referred to a Behavioral Medicine Group in a Health Maintenance Organization
    by Steven E. Locke & Patricia Ford & Thomas McLaughlin

  • 2003 Educating the Public About Stroke: Role in Improving Outcomes
    by Richard N. Bradley

  • 2003 Disease-Specific Self-Management Programs in Patients with Advanced Chronic Obstructive Pulmonary Disease: A Comprehensive and Critical Evaluation
    by Jean Bourbeau

  • 2003 Health Screening and Health Promotion Programs for the Elderly
    by Adam Drewnowski & Elaine Monsen & Diana Birkett & Susan Gunther & Susan Vendeland & Jeff Su & Gillian Marshall

  • 2003 Telemedicine from the Payor Perspective: Considerations for Reimbursement Decisions
    by Pamela Whitten & Emily Kuwahara

  • 2003 Can Genomics Deliver on the Promise of Improved Outcomes and Reduced Costs?: Background and Recommendations for Health Insurers
    by Marc S. Williams

  • 2003 Disease Management Update
    by Adis International Limited

  • 2003 Estimating Influenza-Related Hospital Admissions in Children and Adults: A Time Series Analysis
    by Paul A. Scuffham

  • 2003 Active Management of Patients with Chronic Renal Insufficiency: The Effect on Hospital Days During the Initial Hemodialysis Period
    by Ilan Zawadzki & Moshe Fridman & Wing Chan & Seonyoung Ryu

  • 2003 Importance of Cultural Sensitivity in Therapeutic Transactions: Considerations for Healthcare Providers
    by Oyedeji Ayonrinde

  • 2003 The Effectiveness of Asthma Nurse Intervention: The Need for Change
    by Christine Wrench & Alyn H. Morice

  • 2003 Structured Outpatient Education and Treatment Programs for Patients with Diabetes Mellitus and/or Hypertension: The German Experience
    by Monika Gruesser & Karola Hoffstadt & Viktor Joergens

  • 2003 Teledermatology Can Produce High-Quality Care at Low Cost
    by Keng Chen & Stephen Shumack & Richard Wootton

  • 2003 Disease Management Update
    by Adis International Limited

  • 2003 Spotlight on Insulin Lispro in Diabetes Mellitus This Spotlight is derived from abstract and summary text of an Adis Pharmacoeconomic Drug Evaluation originally published in full in PharmacoEconomics 2002; 20 (14): 989-1025
    by Christopher J. Dunn & Greg L. Plosker

  • 2003 Results of a Men's Urological Health Screening Program at Lockheed Martin Aeronautical Systems
    by Pamella Thomas & Ron Z. Goetzel & Ronald J. Ozminkowski & Vahan S. Kassabian & David C. Schutt

  • 2003 Antidepressant Treatment Patterns and Success Rates in a Managed Care Organization
    by Edward P. Armstrong

  • 2003 Electronic Management Systems in Diabetes Mellitus: Impact on Patient Outcomes
    by Riccardo Bellazzi

  • 2003 Designing and Evaluating Health Promotion Programs: Simple Rules for a Complex Issue
    by Nicolaas P. Pronk

  • 2003 Physician Financial Incentives in Managed Care: Resource Use, Quality and Cost Implications
    by Brian S. Armour & Mmelinda Pitts

  • 2003 An Overview of Community Pharmacist Interventions: Assessing Cost-Effectiveness and Patients' Willingness To Pay
    by Shu Chuen Li

  • 2003 Interdisciplinary Team-Based Disease Management of Heart Failure
    by Thomas G. Di Salvo & Lynne Warner Stevenson

  • 2003 Assessment Methods for Patient-Reported Outcomes
    by Michael R. Hufford & Saul Shiffman

  • 2003 Ethical Considerations in Disease Management: A Managed Care Perspective
    by Robert A. Baldor

  • 2003 Disease Management Update
    by Adis International Limited

  • 2003 Spotlight on Galantamine in Alzheimer's Disease This Spotlight is derived from abstract and summary text of an Adis Drug Evaluation originally published in full in PharmacoEconomics 2002; 20 (13): 919-942
    by Katherine A. Lyseng-Williamson & Greg L. Plosker

  • 2003 Assessing Beneficiary Health Outcomes and Disease Management Initiatives in Medicare
    by Samuel C. Haffer & Sonya E. Bowen & Erin Dowd Shannon & Brenda M. Fowler

  • 2003 Economic Impact of Patient Adherence with Antidepressant Therapy Within a Managed Care Organization
    by T. Jeffrey White & Ann Vanderplas & Caron Ory & Christopher M. Dezii & Eunice Chang

  • 2003 Determinants of Quality of In-Hospital Care for Patients with Acute Coronary Syndromes
    by Ian A. Scott

  • 2003 Reducing Racial and Ethnic Disparities in Disease Management to Improve Health Outcomes
    by Dennis P. Andrulis

  • 2003 Predictive Modeling in Health Plans
    by Randy C. Axelrod & David Vogel

  • 2003 Long-Term Care Insurance in Japan: Its Frameworks, Issues and Roles
    by Kiyomi Asahara & Yumiko Momose & Sachiyo Murashima

  • 2003 Acknowledgment
    by Adis International Limited

  • 2003 Management of Rheumatoid Arthritis: Defining the Role of Leflunomide
    by Christopher I. Carswell & Caroline M. Perry & Tim Ibbotson

  • 2003 Clinical and Utilization Outcomes for a Pediatric and Adolescent Telephonic Asthma Care Support Program: A Propensity Score-Matched Cohort Study
    by Gregory D. Berg & Alan Johnson & Edward Fleegler

  • 2003 Impact of Antimicrobial Control Programs on Patient Outcomes: Pharmacy Perspective
    by David T. Bearden & George P. Allen

  • 2003 Health Outcomes Assessment in Cancer: Current Measurement Strategies and Recommendations for Improvement
    by William F. Lawrence & Carolyn M. Clancy

  • 2003 The Approaches to Schizophrenia Communication (ASC) Tool: Including the Patient Perspective in Treatment
    by Albana M. Dassori & Alexander L. Miller & Peter J. Weiden

  • 2003 Specialist Nurse-Led Intervention in Outpatients with Congestive Heart Failure: Impact on Clinical and Economic Outcomes
    by Nicholas D. Palmer & Barbara Appleton & Erwin A. Rodrigues

  • 2003 Management of Postmenopausal Osteoporosis: Defining the Role of Raloxifene
    by Keri Wellington & Greg L. Plosker

  • 2003 Antibacterials for Viral Respiratory Infections: Results of a Physician-Based Intervention in a Predominantly Preferred Provider Organization Setting
    by John Berthiaume & Helen O. Chernicoff & Jaok J. Kim & Richard S. Chung & Roberta C. Pang & Antonio P. Legorreta

  • 2003 Global Efforts for Reducing the Burden of Smoking
    by Frank J. Chaloupka & Prabhat Jha & Marlo A. Corrao & Vera Luiza da Costa e Silva & Hana Ross & Christina C. Ciecierski & Derek Yach

  • 2003 Provider Training and Education in Disease Management: Current and Innovative Technology
    by Myra L. Muramoto & Jean Campbell & Zenen Salazar

  • 2003 Long-Term Effects of Second-Generation Cholinesterase Inhibitors on Clinical Outcomes and Costs of Alzheimer
    by J. Jaime Caro & Denis Getsios

  • 2003 A Schema for Effective Osteoporosis Management: Outcomes of the Geisinger Health System Osteoporosis Program
    by Eric D. Newman

  • 2003 A minőség figyelembevételének szükségessége az egyensúlyi állapot meghatározásában
    by Vörös, József

  • 2003 Business ethics, corporate social responsibility and corporate governance: a review and summary critique
    by John Donaldson & Irene Fafaliou

  • 2002 Agent-Based Computational Economics: Growing Economies from the Bottom Up
    by Tesfatsion, Leigh S.

  • 2002 Economic Agents and Markets As Emergent Phenomena
    by Tesfatsion, Leigh S.

  • 2002 Skill and Australia's productivity surge
    by Paula Barnes & Sharon Kennard

  • 2002 Productivity and the structure of employment
    by Paula Barnes & Rick Johnson & Anthony Kulys & Scott Hook

  • 2002 The role of training and innovation in workplace performance
    by Patrick Laplagne & Leonie Bensted

  • 2002 Financial Performance Government Trading Enterprises 1996-97 to 2000-01
    by Productivity Commission

  • 2002 A Minskian Analysis of Financial Crisis in Developing Countries
    by Susan K. Schroeder

  • 2002 Assessment of Health Economics in Alzheimer's Disease (AHEAD): Treatment with Galantamine in Sweden
    by Frances B. Garfield & Denis Getsios & J. Jaime Caro & Anders Wimo & Bengt Winblad

  • 2002 Cost Effectiveness of Treatment of Parkinson's Disease with Entacapone in the United States
    by Cynthia S. Palmer & Mark J.C. Nuijten & Jordana K. Schmier & Prasun Subedi & Edward H. Snyder

  • 2002 Direct Medical Cost of Managing Deep Vein Thrombosis According to the Occurrence of Complications
    by Judith A. O'Brien & Jaime J. Caro

  • 2002 Cost Effectiveness of Tinzaparin Sodium Versus Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis
    by J. Jaime Caro & Denis Getsios & Ingrid Caro & Judith A. O'Brien

  • 2002 Reference-Based Pricing Schemes: Effect on Pharmaceutical Expenditure, Resource Utilisation and Health Outcomes
    by Lisa L. Ioannides-Demos & Joseph E. Ibrahim & John J. McNeil

  • 2002 On-Demand and Intermittent Therapy for Gastro-Oesophageal Reflux Disease: Economic Considerations
    by John M. Inadomi

  • 2002 Economic Benefits of Amlodipine Treatment in Patients with Coronary Artery Disease
    by Roman Casciano & John J. Doyle & John Chen & Steve Arikian & Julian Casciano & Heather Kugel & Raul Arocho

  • 2002 Stroke Rehabilitation Services to Accelerate Hospital Discharge and Provide Home-Based Care: An Overview and Cost Analysis
    by Craig Anderson & Cliona Ni Mhurchu & Paul M. Brown & Kristie Carter

  • 2002 Ready-to-Use Injection Preparations versus Conventional Reconstituted Admixtures: Economic Evaluation in a Real-Life Setting
    by Phillipe van der Linden & Jacques Douchamps & Claude Schmitt & Dominique Forget

  • 2002 Cost-Effective Approaches to the Treatment of Community-Acquired Pneumonia in the Era of Resistance
    by Joseph L. Kuti & Blair Capitano & David P. Nicolau

  • 2002 Methods for Claims-Based Pharmacoeconomic Studies in Psychosis
    by Frank Gianfrancesco & Ruey-Hua Wang & Ramy Mahmoud & Richard White

  • 2002 Cost Effectiveness of Paclitaxel/Cisplatin Compared with Cyclophosphamide/Cisplatin in the Treatment of Advanced Ovarian Cancer in Belgium
    by Niels Neymark & Thierry Gorlia & Ines Adriaenssen & Benoit Baron & Martine Piccart

  • 2002 A Model to Estimate the Cost Benefit of an Occupational Vaccination Programme for Influenza with Influvac(R) in the UK Use of the tradename is for product identification purposes only and does not imply endorsement
    by Roben Das Gupta & Julian F. Guest

  • 2002 Limitations of the Methods Used for Calculating Quality-Adjusted Life-Year Values
    by Gerard Duru & Jean Paul Auray & Ariel Beresniak & Michel Lamure & Abby Paine & Nicolas Nicoloyannis

  • 2002 Health-Related Quality of Life and Cost Impact of Irritable Bowel Syndrome in a UK Primary Care Setting
    by Ron L. Akehurst & John E. Brazier & Nigel Mathers & Caroline O'Keefe & Eva Kaltenthaler & Anne Morgan & Maria Platts & Stephen J. Walters

  • 2002 Standardisation of Costs: The Dutch Manual for Costing in Economic Evaluations
    by Jan B. Oostenbrink & Marc A. Koopmanschap & Frans F.H. Rutten

  • 2002 Homocyst(e)ine and Coronary Heart Disease: Pharmacoeconomic Support for Interventions to Lower Hyperhomocyst(e)inaemia
    by Brahmajee K. Nallamothu & A. Mark Fendrick & Gilbert S. Omenn

  • 2002 Use of Healthcare Services by Patients Treated with Risperidone Versus Conventional Antipsychotic Agents
    by Frank Gianfrancesco & Michael B. Durkin & Ramy Mahmoud & Ruey-Hua Wang

  • 2002 Reporting Heterogeneity in the Measurement of Health and Health-Related Quality of Life
    by Amir Shmueli

  • 2002 Estimating the Effect of Changes in Body Mass Index on Health State Preferences
    by Zafar Hakim & Anne Wolf & Louis P. Garrison

  • 2002 A Fair Innings for NICE?
    by Nick Freemantle & Karen Bloor & Joanne Eastaugh

  • 2002 Cost Effectiveness of Treatments for Amyotrophic Lateral Sclerosis: A Review of the Literature
    by Gary Ginsberg & Serena Lowe

  • 2002 Sickle Cell Anaemia: Epidemiology and Cost of Illness
    by Paul J. Nietert & Marc D. Silverstein & Miguel R. Abboud

  • 2002 The Cost of Gastro-Oesophageal Reflux Disease, Dyspepsia and Peptic Ulcer Disease in Sweden
    by Lars Agreus & Lars Borgquist

  • 2002 The Practice of Splitting Tablets: Cost and Therapeutic Aspects
    by John Bachynsky & Cheryl Wiens & Krystal Melnychuk

  • 2002 Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer
    by M. Lees & M. Aristides & N. Maniadakis & J. McKendrick & N. Botwood & D. Stephenson

  • 2002 Cost Effectiveness of Oral Terbinafine (Lamisil(R)) Compared with Oral Fluconazole (Diflucan(R)) in the Treatment of Patients with Toenail Onychomycosis
    by Heini Salo & Markku Pekurinen

  • 2002 Economic Considerations Related to Providing Adequate Pain Relief for Women in Labour: Comparison of Epidural and Intravenous Analgesia
    by Cecil Huang & Alex Macario

  • 2002 Quality-of-Life Assessment in Osteoporosis: Health-Status and Preference-Based Measures
    by Anna N.A. Tosteson & Cristina S. Hammond

  • 2002 Cost Effectiveness of Esomeprazole Compared with Omeprazole in the Acute Treatment of Patients with Reflux Oesophagitis in the UK
    by Peter Wahlqvist & Ola Junghard & Andy Higgins & Jonathan Green

  • 2002 Cost Effectiveness of Proton Pump Inhibitors in Gastro-Oesophageal Reflux Disease Without Oesophagitis: Comparison of On-Demand Esomeprazole with Conventional Omeprazole Strategies
    by Peter Wahlqvist & Ola Junghard & Andy Higgins & Jonathan Green

  • 2002 Assessment of the Relationship Between Measures of Disease Severity, Quality of Life, and Willingness to Pay in Asthma
    by Alan J. Zillich & Karen Blumenschein & Magnus Johannesson & Patricia Freeman

  • 2002 Putting Your Money Where Your Mouth Is: Willingness to Pay for Dental Gel
    by Debora Matthews & Angela Rocchi & Amiram Gafni

  • 2002 Enoxaparin: A Pharmacoeconomic Review of its Use in the Prevention and Treatment of Venous Thromboembolism and in Acute Coronary Syndromes
    by David Bergqvist

  • 2002 A Monte Carlo Simulation for Modelling Outcomes of AIDS Treatment Regimens
    by Anke Richter & Brett Hauber & Kit Simpson & Josephine A. Mauskopf & Dongping Yin

  • 2002 Economic Value of Thrombolysis with Adjunctive Abciximab in Patients with Subacute Peripheral Arterial Occlusion
    by Stephan H. Duda & Gunnar Tepe & Mohan Bala & Oliver Luz & Gerhard Ziemer & Kenneth Ouriel & Benjamin Pusich & Jakub Wiskirchen & Claus D. Claussen & Kurt Banz

  • 2002 Economic Evaluation of Triflusal and Aspirin in the Treatment of Acute Myocardial Infarction
    by Josep Darba & Inaki Izquierdo & Caridad Pontes & Carlos Navas & Joan Rovira

  • 2002 Development of an Economic Model to Assess the Cost Effectiveness of Asthma Management Strategies
    by Martin J. Price & Andrew H. Briggs

  • 2002 Intermittent Claudication: Pharmacoeconomic and Quality-of-Life Aspects of Treatment
    by Gregorio Brevetti & Roberta Annecchini & Roxanna Bucur

  • 2002 Acute Exacerbations of Chronic Bronchitis: A Pharmacoeconomic Review of Antibacterial Use
    by Stephen Morris & Pippa Anderson & Debra E. Irwin

  • 2002 Optimising Drug Utilisation in Long Term Care
    by Kate L. Lapane & Carmel M. Hughes

  • 2002 Cost-Effectiveness Analysis of Stratified Versus Stepped Care Strategies for Acute Treatment of Migraine: The Disability in Strategies for Care (DISC) Study
    by Mark Sculpher & David Millson & David Meddis & Lynne Poole

  • 2002 Design, Analysis and Presentation of Multinational Economic Studies: The Need for Guidance
    by Francis Pang

  • 2002 Tamoxifen Plus Chemotherapy versus Tamoxifen Alone as Adjuvant Therapies for Node-Positive Postmenopausal Women with Early Breast Cancer: A Stochastic Economic Evaluation
    by Jonathan Karnon & Jackie Brown

  • 2002 Health-Related Quality of Life in a UK-Based Population of Men with Erectile Dysfunction
    by Julian F. Guest & Roben Das Gupta

  • 2002 Cost-Effectiveness Analysis of Exemestane Compared with Megestrol in Advanced Breast Cancer: A Model for Europe and Australia
    by Peter Lindgren & Bengt Jonsson & Alberto Redaelli & Davide Radice

  • 2002 Pharmacy Benefit Management: Enhancing the Applicability of Pharmacoeconomics for Optimal Decision Making
    by C. Daniel Mullins & Junling Wang

  • 2002 Economic Comparison of Leflunomide and Methotrexate in Patients with Rheumatoid Arthritis: An Evaluation Based on a 1-Year Randomised Controlled Trial
    by Andreas Maetzel & Vibeke Strand & Peter Tugwell & George Wells & Claire Bombardier

  • 2002 Economic Impact of Low Dose Polyethylene Glycol 3350 Plus Electrolytes Compared with Lactulose in the Management of Idiopathic Constipation in the UK
    by Angela H. Christie & Pearl Culbert & Julian F. Guest

  • 2002 Antihypertensive Treatment with and without Benazepril in Patients with Chronic Renal Insufficiency: A US Economic Evaluation
    by Thomas J. Hogan & William J. Elliott & Arnold H. Seto & George L. Bakris

  • 2002 Onychomycosis: Health-Related Quality of Life Considerations
    by James W. Shaw & Vijay N. Joish & Stephen Joel Coons

  • 2002 Economic Evaluation of Vaccination Programmes: A Consensus Statement Focusing on Viral Hepatitis
    by Philippe Beutels & W. John Edmunds & Fernando Antonanzas & G. Ardine de Wit & David Evans & Rachel Feilden & A. Mark Fendrick & Gary M. Ginsberg & Henry A. Glick & Eric Mast & Marc Pechevis & Eddy K.A. Van Doorslaer & Ben A. van Hout

  • 2002 Health State Preference Assessment in Diabetic Peripheral Neuropathy
    by Sean D. Sullivan & Doris P. Lew & E. Beth Devine & Zafar Hakim & Gayle E. Reiber & David L. Veenstra

  • 2002 Use of Randomised Controlled Trials for Producing Cost-Effectiveness Evidence: Potential Impact of Design Choices on Sample Size and Study Duration
    by Martin E. Backhouse

  • 2002 Quality of Life in Patients with Epilepsy and Impact of Treatments
    by Patrizia Berto

  • 2002 Developing the Revised NICE Appraisal Technical Guidance to Manufacturers and Sponsors: Opportunity or Threat?
    by Rod S. Taylor & John Hutton & Anthony J. Culyer

  • 2002 Insulin Lispro: A Pharmacoeconomic Review of its Use in Diabetes Mellitus
    by Christopher J. Dunn & Greg L. Plosker

  • 2002 Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin in the Secondary Prevention of Acute Coronary Syndrome
    by Max Brosa & Carlos Rubio-Terres & Ibrahim Farr & Vijay Nadipelli & Jenaro Froufe

  • 2002 Pharmacoeconomic Considerations in Assessing and Selecting Congestive Heart Failure Therapies
    by Emile Levy & Pierre Levy

  • 2002 Theoretical Arguments for the Discounting of Health Consequences: Where Do We Go from Here?
    by Angelina Lazaro

  • 2002 Galantamine: A Pharmacoeconomic Review of its Use in Alzheimer's Disease
    by Katherine A. Lyseng-Williamson & Greg L. Plosker

  • 2002 Cost-Effectiveness Comparison of Salmeterol/Fluticasone Propionate versus Montelukast in the Treatment of Adults with Persistent Asthma
    by Ketan Sheth & Rohit Borker & Amanda Emmett & Kathleen Rickard & Paul Dorinsky

  • 2002 The Annual Societal Cost of Alcohol Misuse in Scotland
    by Susan J. Varney & Julian F. Guest

  • 2002 The Cost to the United Kingdom National Health Service of Managing Erectile Dysfunction: The Impact of Sildenafil and Prescribing Restrictions
    by Edward C.F. Wilson & Emma S. McKeen & Paul A. Scuffham & Martin C.J. Brown & Kevan Wylie & Geoff Hackett

  • 2002 The Economic Costs of Early Stage Prostate Cancer
    by Christopher S. Saigal & Mark S. Litwin

  • 2002 Combining a Budgetary-Impact Analysis and a Cost-Effectiveness Analysis Using Decision-Analytic Modelling Techniques
    by Mark J.C. Nuijten & Frans Rutten

  • 2002 Costs and Effectiveness of Using Coumarins Before, During and After Coronary Angioplasty
    by Jurrien M. ten Berg & Johannas C. Kelder & Thys H.W. Plokker & Ben A. van Hout

  • 2002 UK Department of Health Guidance on Prescribing for Impotence Following the Introduction of Sildenafil: Potential to Contain Costs in the Average Health Authority District
    by Martin Ashton-Key & Michael Sadler & Byron Walmsley & Simon Holmes & Sarah Randall & Michael H. Cummings

  • 2002 Cost-Effectiveness Comparison of Tizanidine and Baclofen in the Management of Spasticity
    by David N. Rushton & Adam C. Lloyd & Pippa M. Anderson

  • 2002 Long Term Cost-of-Illness in Stroke: An International Review
    by Krista A. Payne & Krista F. Huybrechts & Jjaime Caro & Traci J. Craig Green & Wendy S. Klittich

  • 2002 Vision-Specific Instruments for the Assessment of Health-Related Quality of Life and Visual Functioning: A Literature Review
    by Mary Kay Margolis & Karin Coyne & Tessa Kennedy-Martin & Timothy Baker & Oliver Schein & Dennis A. Revicki

  • 2002 Cost Effectiveness of Asthma Management Strategies
    by Mike Thomas & John Haughney & David Price

  • 2002 The Impact of Health Economics on Healthcare Delivery: A Health Economist's Perspective: A Primary Care Response
    by David Kernick

  • 2002 Conjoint Analysis of a New Chemotherapy: Willingness to Pay and Preference for the Features of Raltitrexed versus Standard Therapy in Advanced Colorectal Cancer
    by Mike Aristides & Jack Chen & Mark Schulz & Eve Williamson & Stephen Clarke & Kaye Grant

  • 2002 Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia
    by Alexander H. Miners & Caroline A. Sabin & Keith H. Tolley & Christine A. Lee

  • 2002 Burden of Illness in Irritable Bowel Syndrome Comparing Rome I and Rome II Criteria
    by Xavier Badia & Fermin Mearin & Agustin Balboa & Eva Baro & Ellen Caldwell & Mercedes Cucala & Manuel Diaz-Rubio & Arturo Fueyo & Julio Ponce & Mentse Roset & Nicholas J. Talley

  • 2002 Valuation of Symptomatic Hepatitis A in Adults: Estimates Based on Time Trade-Off and Willingness-To-Pay Measurement
    by R Jake Jacobs & Ronald J. Moleski & Allen S. Meyerhoff

  • 2002 Cost Effectiveness of Implantable Cardioverter Defibrillator Therapy versus Drug Therapy for Patients at High Risk of Sudden Cardiac Death
    by Marian A. Spath & Bernie J. O'Brien

  • 2002 Prospective Study Designs in Outcomes Research: The Case of Migraine
    by Elizabeth A. Rothermich & Meryl I. Brod & Warren H. Schonfeld & Clayton R. Rowland & Baltazar Gomez-Mancilla

  • 2002 Mycophenolate Mofetil: A Pharmacoeconomic Review of its Use in Solid Organ Transplantation
    by Melissa Young & Greg L. Plosker

  • 2002 Economic Analysis of Filgrastim Use for Patients with Acute Myeloid Leukaemia in the UK: A Comparison of Collection Methods of Resource Use Data
    by Bo Standaert & Janet Goldstone & Z. John Lu & Moshe Haim Erder & John Liu Yin

  • 2002 The Cost Effectiveness of Chlorofluorocarbon-Free Beclomethasone Dipropionate in the Treatment of Chronic Asthma: A Cost Model Based on a 1-Year Pragmatic, Randomised Clinical Study
    by David Price & John Haughney & Martin Duerden & Charles Nicholls & Charlotte Moseley

  • 2002 Cost of Illness of Crohn's Disease
    by Keith Bodger

  • 2002 Disease Management Update
    by Adis International Limited

  • 2002 Cost-Benefit Analysis of Vaccination Against Influenza of Employees from an Academic Medical Centre
    by Wilma Parlevliet & Corianne de Borgie & Gerard Frijstein & Henk-Jan Guchelaar

  • 2002 An Independent Practice Association-Supported Disease Management Program: Impact on Patients with Coronary Artery Disease
    by Miriam Cannon-Wagner & Diane S. Soule & David R. Walker & Richard P. Vance

  • 2002 The Influence of Socioeconomic and Psychological Factors on Patient Adherence to Self-Management Strategies: Lessons Learned in Asthma
    by John Kolbe

  • 2002 Disease Management and the Application of Privacy Guidelines
    by Marybeth Regan

  • 2002 Pulmonary Rehabilitation Programs: Outcomes in Patients with Chronic Obstructive Pulmonary Disease
    by Nicolino Ambrosino

  • 2002 National Service Framework for Older People: Will Access to Health Services for Elderly Patients Improve?
    by Sumeet Chadha & John Young

  • 2002 Disease Management Update
    by Adis International Limited

  • 2002 Prevalence and Management of Anemia Among Patients with Chronic Kidney Disease in a Health Maintenance Organization
    by Annamaria T. Kausz & Earl P. Steinberg & Allen R. Nissenson & Brian J.G. Pereira

  • 2002 Methods Aimed at Improving Asthma Care and Outcomes Management: A Case Study
    by Felicia C. Allen-Ramey & Gregory B. Diette & Robert C. McDonald & Elizabeth A. Skinner & Donald M. Steinwachs & Albert W. Wu

  • 2002 Migraine Prophylaxis in Managed Care Organizations: Unclear Role in Disease Management Programs
    by Jennifer H. Lofland & Purna K. Lakhia

  • 2002 Supporting Patient Care by Using Innovative Information Technology: A Case Study from Clinical Psychiatry
    by Elske Ammenwerth & Frauke Ehlers & Ulrike Kutscha & Ansgar Kutscha & Ronald Eichstadter & Franz Resch

  • 2002 Building the Outcomes-Based Formulary
    by Brian T. Sweet & Marcus D. Wilson & William J. Waugh & Andrea D. Hess & Joshua J. Spooner

  • 2002 Managed Drug Use in Assisted Living and Home Care Settings: Who Benefits?
    by Stephen M. Setter & David Alexander Sclar & Brian J. Gates

  • 2002 Disease Management Programs: The Second Generation
    by Paul S. Shelton

  • 2002 Disease Management Update
    by Adis International Limited

  • 2002 Management of Erectile Dysfunction: Defining the Role of Sildenafil
    by Katherine A. Lyseng-Williamson & Antona J. Wagstaff

  • 2002 The Role of Different Types of Health Insurance on Access and Utilization of Antihypertensive Drugs: An Empirical Study in a US Hypertensive Population
    by Christine Huttin

  • 2002 Community Mental Health Services for Individuals with Intellectual Disabilities: Issues and Approaches to Optimizing Outcomes
    by Angela Hassiotis

  • 2002 Preventing Relapse of Psychotic Illness: Role of Self-Monitoring of Prodromal Symptoms
    by Lisa Hewitt & Max Birchwood

  • 2002 Disease Management Update
    by Adis International Limited

  • 2002 Management of Type 2 Diabetes Mellitus: Defining the Role of Nateglinide
    by Christopher I. Carswell & Christine R. Culy & Caroline M. Perry

  • 2002 A Formulary Analysis of Angiotensin II Antagonists in a UK Teaching Hospital
    by Andrew P. Moore & Nigel M. Wheeldon & Mike Jennings

  • 2002 Models of Palliative Care Service Delivery: What is Most Cost Effective?
    by Nick Bosanquet

  • 2002 Lymphedema After Surgery for Cancer: The Role of Patient Support Groups in Patient Therapy
    by Stanley G. Rockson

  • 2002 Health Promotion for Individuals with Disabilities: The Need for a Transitional Model in Service Delivery
    by James H. Rimmer

  • 2002 Antibacterials and Acute Exacerbation of Chronic Bronchitis: Issues for Formulary Decision Makers
    by Alan Chock & Vera Gong & Christopher J. Destache

  • 2002 Disease Management Update
    by Adis International Limited

  • 2002 Management of Relapsing-Remitting Multiple Sclerosis: Defining the Role of Subcutaneous Recombinant Interferon-beta-1a (Rebif(R)) Use of a tradename is for product identification purposes only, and does not imply endorsement
    by Katherine A. Lyseng-Williamson & Greg L. Plosker

  • 2002 New Trends in Patient Monitoring
    by Senen Barro & Jesus Presedo & Paulo Felix & Daniel Castro & Jose Antonio Vila

  • 2002 Integration of Case and Disease Management: Why and How?
    by Margaret A. Radzwill

  • 2002 Telemedicine, Outcomes and Policy Decisions
    by Arto Ohinmaa & David Hailey

  • 2002 Disease Management Update
    by Adis International Limited

  • 2002 Spotlight on Paclitaxel in Ovarian Cancer The full text of this article was published in PharmacoEconomics 2001; 19 (12): 1227-1259
    by Melissa Young & Greg L. Plosker

  • 2002 Excess Healthcare Costs Associated with Excess Health Risks in Diseased and Non-Diseased Health Risk Appraisal Participants
    by Shirley Musich & Timothy McDonald & David Hirschland & Dee W. Edington

  • 2002 Standardized Telephonic Case Management in a Hispanic Heart Failure Population: An Effective Intervention
    by Barbara Riegel & Beverly Carlson & Dale Glaser & Zoe Kopp & Tomas E. Romero

  • 2002 The Potential Impact of Measuring Healthcare Quality on Pharmaceutical-Related Costs and Outcomes
    by William L. Roper & R. Tamara Hodlewsky & Hugh Tilson & Kathleen N. Lohr & William H. Campbell

  • 2002 The Emerging Role of the Consumer in Pharmaceutical Pricing Decisions
    by Elinor C. Chumney & Kit N. Simpson

  • 2002 Pharmacy Benefit Managers' Role in Facilitating Medicare Beneficiary Access to Pharmaceutical Care
    by Joshua Cohen & Jennifer Chee

  • 2002 Risks and Benefits of the Use of Capitation Formulae in Primary Care
    by Azeem Majeed

  • 2002 Pharmaceutical Company Websites as Sources of Information for Consumers: How Appropriate and Informative Are They?
    by Kathleen M. Griffiths & Helen Christensen & Kimberley Evans

  • 2002 Disease Management Update
    by Adis International Limited

  • 2002 Piperacillin/Tazobactam in Moderate to Severe Bacterial Infections The full text of this article was published in PharmacoEconomics 2001; 19 (11): 1135-1175
    by Melissa Young & Greg L. Plosker

  • 2002 Use of the Internet by Patients with Chronic Illness
    by Richard W. Millard & Patricia A. Fintak

  • 2002 Employer Role in Integrative Workplace Health Management: A New Model in Progress
    by Cordia Chu & Sophie Dwyer

  • 2002 Development of a Migraine Disease Management Initiative in a Managed Care Plan
    by Glen D. Solomon & Henry X. Hu & Rick Simmons & Kathleen Conboy & Rob Jeddeloh & Marie Eastburn

  • 2002 The Fifth Vital Sign: Cornerstone of a New Pain Management Strategy
    by Hildegarde J. Berdine

  • 2002 Utilizing an Intranet in Disease Management
    by Marybeth Regan

  • 2002 Role of Family Physicians in Implementing Asthma Self-Management Programs
    by Bart P.A. Thoonen & Chris van Weel

  • 2002 Outcomes Associated with a Disease Management Program for End-Stage Renal Disease
    by Allen R. Nissenson

  • 2002 Clinical and Economic Implications of Non-Adherence to HAART in HIV Infection
    by Alissa Scalera & Ahmed M. Bayoumi & Paul Oh & Nancy Risebrough & Neil Shear & Alice Lin-in Tseng

  • 2002 Integrating Healthcare Standards and Performance Measurement
    by Richard G. Koss & Linda S. Hanold & Jerod M. Loeb

  • 2002 Effective Utilization of Pharmacoeconomics for Decision Makers
    by Judith D. Bentkover & Ron Corey

  • 2002 Disease Management Update
    by Adis International Limited

  • 2002 Spotlight on Paclitaxel in Non-Small Cell Lung Cancer The full text of this article was published in PharmacoEconomics 2001; 19 (11): 1111-1134
    by Greg L. Plosker & Miriam Hurst

  • 2002 The Development of a Tool to Assess Quality of Cost Estimates
    by Philip Jacobs & Greg Finlayson & Ben Faienza & Murray Brown & Betty Newson & Nadine MacLean

  • 2002 Role of Parent Training in the Effective Management of Attention-Deficit/Hyperactivity Disorder
    by Thomas J. Power & Heather F. Russell & Stephen L. Soffer & Jessica Blom-Hoffman & Suzanne M. Grim

  • 2002 Practical Considerations for the Design and Evaluation of Disease Education and Management Programs in the Workplace
    by Seth Serxner & David Anderson

  • 2002 Worksite Health Promotion: A Critical Investment
    by Bruce Sherman

  • 2002 An HMO-Sponsored Primary Care-Based Disease Management and Case Management Initiative: Economic and Selected Clinical Outcomes
    by Jaan Sidorov & Franz Joseph Fisher & Sabrina Girolami & Otto Wolke

  • 2002 Disease Management Update: From the World Literature
    by Adis International Limited

  • 2002 Management of Acute Bacterial Exacerbations of Chronic Bronchitis: Defining the Role of Moxifloxacin
    by Harinder S. Malhotra & Caroline M. Perry & Douglas Ormrod

  • 2002 Management of Alzheimer's Disease: Defining the Role of Donepezil
    by Tim Ibbotson & Karen L. Goa

  • 2002 Management of Rheumatoid Arthritis: Defining the Role of Etanercept
    by Gillian M. Keating & Blair Jarvis

  • 2002 Improved Diabetes Control Through a Provider-Based Disease Management Program
    by Rose Maljanian & Neil Grey & Ilene Staff & Marisol Cruz-Marino-Aponte

  • 2002 Disease Management Update
    by Adis International Limited

  • 2002 Spotlight on Mycophenolate Mofetil in Solid Organ Transplantation This Spotlight is derived from abstract and summary text of an Adis Pharmacoeconomic Drug Evaluation originally published in full in PharmacoEconomics 2002; 20 (10): 675-713
    by Melissa Young & Greg L. Plosker

  • 2002 Strategies for Pharmacists in the Implementation of Diabetes Mellitus Management Programs: New Roles in Primary and Collaborative Care
    by Gloria J. Nichols-English & Melanie Provost & Dayin Koompalum & Hua Chen & Masood Athar

  • 2002 Rural Psychiatry: Special Issues and Models of Service Delivery
    by Fiona Judd & Caitlin Fraser & Margaret Grigg & Joseph Scopelliti & Gene Hodgins & Adrian Donoghue & John Humphreys

  • 2002 On the Evaluation of Drug Benefits Policy Changes with Longitudinal Claims Data: Concepts of Income-Based Deductibles and Issues Related to Causal Inference
    by Sebastian Schneeweiss & Malcolm Maclure & Colin Dormuth

  • 2002 Point of Care Testing: Potential for Tracking Disease Management Outcomes
    by Christopher P. Price

  • 2002 Clinical Guidelines in Disease Management
    by Albert I. Wertheimer & Nicole M. Chaney

  • 2002 Disease Management Update
    by Adis International Limited

  • 2002 An Empirical Model for the Development of Disease Management Programs in General Practice: A Case Study Using Hypertension
    by Deborah A. Turnbull & Helen Mensforth & Justin J. Beilby & John E. Marley & Farooq Qureshi & Anne L. Tonkin

  • 2002 Patients Diagnosed with Irritable Bowel Syndrome: Medical Record Validation of a Claims-Based Identification Algorithm
    by Antonio P. Legorreta & Jean-Francois Ricci & Mike Markowitz & Priti Jhingran

  • 2002 The Relationship of Diabetes Mellitus Performance Indicators with Self-Reported Health and Patient Satisfaction
    by David P. Nau & Ritesh N. Kumar

  • 2002 Guidelines and Care Management Issues for People with Alzheimer's Disease and Other Dementias
    by Katie Maslow & John Selstad & Susan J. Denman

  • 2002 The Effects of the Internet on Pharmaceutical Consumers and Providers
    by Francois M.H.M. Dupuits

  • 2002 Telemedicine Screening for Diabetic Retinopathy: Improving Patient Access to Care
    by Kanagasingam Yogesan & Ian J. Constable & Ian Chan

  • 2002 Disease Management Update
    by Adis International Limited

  • 2002 Management of Parkinson's Disease: Defining the Role of Entacapone
    by Tim Ibbotson & Karen L. Goa

  • 2002 Improving Patient Outcomes with Tools for Asthma Self-Monitoring: A Review of the Literature
    by Timothy R. Myers

  • 2002 A Complex System Perspective on Medication Compliance: Information for Healthcare Providers
    by Simon Rietveld & Jos M. Koomen

  • 2002 Evaluating Disease Management Programs
    by David R. Walker & Byron K. McKinney & Miriam Cannon-Wagner & Richard P. Vance

  • 2002 The Developing Role of Pharmacists in Patient Access to Emergency Contraception
    by Judith A. Soon & Marc Levine & Mary H.H. Ensom & Jacqueline S. Gardner & Hilary M. Edmondson & David W. Fielding

  • 2001 Agent-Based Computational Economics: A Guide to the Literature
    by Tesfatsion, Leigh

  • 2001 Introduction to the Special Issue on Agent-Based Computational Economics
    by Tesfatsion, Leigh S.

  • 2001 Introduction to the Special Issue on Agent-Based Computational Economics
    by Tesfatsion, Leigh S.

  • 2001 Guest Editorial: Agent-Based Modeling of Evolutionary Economic Systems
    by Tesfatsion, Leigh S.

  • 2001 Modéliser la suburbanisation . Succès et limites de la microéconomie urbaine
    by BOITEUX-ORAIN, Céline & HURIOT, Jean-Marie

  • 2001 Ein wertschöpfungsbasierter Ansatz der einzelwirtschaftlichen Verteilungstheorie. Bilanzpolitik und Arbeitsrecht als institutionalisierte Verhandlungsrestriktionen
    by Florian Turk

  • 2001 A Multinational Study to Measure the Value that Patients with Cancer Place on Improved Emesis Control Following Cisplatin Chemotherapy
    by George Dranitsaris & Pauline Leung & Renoto Ciotti & Ana Ortega & Maria Spinthouri & Lycurgus Liaropoulos & Roberto Labianca & Antonello Quadri

  • 2001 The Cost of Palliative Care for Hepatocellular Carcinoma in Hong Kong
    by Anthony T.C. Chan & Philip Jacobs & Winnie Yeo & Maria Lai & Clarke B. Hazlett & Tony S.K. Mok & Thomas W.T. Leung & Wan Y. Lau & Philip J. Johnson

  • 2001 The Economics of HIV Vaccines: Projecting the Impact of HIV Vaccination of Infants in Sub-Saharan Africa
    by Jasper M. Bos & Maarten J. Postma

  • 2001 Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke: A Canadian Healthcare Perspective
    by Shannon E. Sinclair & Luciana Frighetto & Peter S. Loewen & Rubina Sunderji & Philip Teal & Susan C. Fagan & Carlo A. Marra

  • 2001 Different Approaches To Valuing the Lost Productivity of Patients with Migraine
    by Jennifer H. Lofland & Julie C. Locklear & Kevin D. Frick

  • 2001 Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in Sweden: Analysis Using Data from the Cardiac Insufficiency Bisoprolol Study II Trial
    by Mattias Ekman & Niklas Zethraeus & Bengt Jonsson

  • 2001 Impact of Allergic Rhinitis Treatment on Quality of Life
    by Anju Tripathi & Roy Patterson

  • 2001 Cost-Effectiveness Analysis of Dopamine Agonists in the Treatment of Parkinson's Disease in Japan
    by Takuro Shimbo & Kenji Hira & Manabu Takemura & Tsuguya Fukui

  • 2001 Cost-Efficacy Analysis of Fluticasone Propionate versus Zafirlukast in Patients with Persistent Asthma
    by Rogelio Menendez & Richard H. Stanford & Lisa Edwards & Christopher Kalberg & Kathleen Rickard

  • 2001 Quality of Life and Utility in Patients with Non-Small Cell Lung Cancer
    by Sabrina Trippoli & Monica Vaiani & Carlo Lucioni & Andrea Messori

  • 2001 Incremental Cost Analysis of Ambulatory Clinic and Home-Based Intravenous Therapy for Patients with Multiple Myeloma
    by Peter C. Coyte & Mark J. Dobrow & Larry Broadfield

  • 2001 Cost Effectiveness in Canada of a Multidrug Prepackaged Regimen (Hp-PAC(R)) Use of tradenames is for product identification only and does not imply endorsement. for Helicobacter pylori Eradication
    by Karen Agro & Gordon Blackhouse & Ron Goeree & Andrew R. Willan & Jia-Qing Huang & Richard H. Hunt & Bernie J. O'Brien

  • 2001 The Cost Effectiveness of Stratified Care in the Management of Migraine
    by Paul Williams & Andrew J. Dowson & Alan M. Rapoport & James Sawyer

  • 2001 A Review of the Direct Costs of Rheumatoid Arthritis: Managed Care versus Fee-for-Service Settings
    by Deborah P. Lubeck

  • 2001 The Impact of Health Economics on Healthcare Delivery: The Health Economists' Perspective
    by Ruth McDonald & Alan Haycox & Tom Walley

  • 2001 Pharmacoeconomic Fellowships: The Need for Outcome Measures
    by Vittorio Maio & Tammy K. Girts & Jennifer H. Lofland & David B. Nash

  • 2001 Iatrogenic Cost Factors Incorporating Mild and Moderate Adverse Events in the Economic Comparison of Aceclofenac and Other NSAIDs
    by Francesc Peris & Eduard Martinez & Xavier Badia & Max Brosa

  • 2001 Cost Effectiveness of Becaplermin in the Treatment of Diabetic Foot Ulcers in Four European Countries
    by Ola Ghatnekar & Ulf Persson & Michael Willis & Knut Odegaard

  • 2001 Emerging Role of Pharmacoeconomics in the Research and Development Decision-Making Process
    by Joseph A. Dimasi & Erol Caglarcan & Maria Wood-Armany

  • 2001 Economic and Health-Related Quality of Life Considerations of New Therapies in Parkinson's Disease
    by Linda M. Rubenstein & Andrea DeLeo & Elizabeth A. Chrischilles

  • 2001 A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs
    by Sherine E. Gabriel & Douglas Coyle & Larry W. Moreland

  • 2001 Highly Active Antiretroviral Therapy: Pharmacoeconomic Issues in the Management of HIV Infection
    by Pedram Sendi & Andrew J. Palmer & Amiram Gafni & Manuel Battegay

  • 2001 Torasemide: A Pharmacoeconomic Review of its Use in Chronic Heart Failure
    by Melissa Young & Greg L. Plosker

  • 2001 International Validation of the CLAU-S Quality-of-Life Questionnaire for Use in Patients with Intermittent Claudication
    by Patrick Marquis & Sylvie Comte & Philippe Lehert

  • 2001 An Epidemiological Approach to Assess the Economic Burden of NSAID-Induced Gastrointestinal Events in The Netherlands
    by Ronald M.C. Herings & Olaf H. Klungel

  • 2001 Quality of Life in Irritable Bowel Syndrome
    by Richard Lea & Peter J. Whorwell

  • 2001 An Economic Overview of Chronic Obstructive Pulmonary Disease
    by Hirsch S. Ruchlin & Erik J. Dasbach

  • 2001 Developing Guidance for Budget Impact Analysis
    by Paul Trueman & Michael Drummond & John Hutton

  • 2001 The Cost Effectiveness of Tapered versus Abrupt Discontinuation of Oral Cyclosporin Microemulsion for the Treatment of Psoriasis
    by Leona Hakkaart-van Roijen & Paul Verboom & W. Ken Redekop & Karien R. Touw & Frans F.H. Rutten

  • 2001 Cost Effectiveness of Desirudin Compared with a Low Molecular Weight Heparin in the Prevention of Deep Vein Thrombosis after Total Hip Replacement Surgery
    by Lars-Ake Levin & David Bergqvist

  • 2001 Gastrointestinal-Related Healthcare Resource Usage Associated with a Fixed Combination of Diclofenac and Misoprostol versus Other NSAIDs
    by Elham Rahme & Lawrence Joseph & Sheldon X. Kong & Douglas J. Watson & James M. Pellissier & Jacques LeLorier

  • 2001 Cost Effectiveness of Nasal Calcitonin in Postmenopausal Women: Use of Cochrane Collaboration Methods for Meta-Analysis Within Economic Evaluation
    by Douglas Coyle & Ann Cranney & Karen M. Lee & Vivian Welch & Peter Tugwell

  • 2001 Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada
    by Michael Iskedjian & Thomas R. Einarson & Bernie J. O'Brien & J. Gaston De Serres & Ron Gold & Ian M. Gemmill & Natalie Milkovich & Andrew Rosner

  • 2001 Economic Evaluation of Systemic Treatments for Cytomegalovirus Retinitis in Patients with AIDS
    by Todd A. Lee & Sean D. Sullivan & David L. Veenstra & Scott D. Ramsey & Patrick J.K. Steger & Raffaele Malinverni & Andreas M. Pleil & Todd Williamson

  • 2001 Cost Effectiveness of Selective Decontamination of the Digestive Tract in Liver Transplant Patients
    by Petra J. van Enckevort & Jan H. Zwaveling & Jan T. Bottema & John K. Maring & Ids J. Klompmaker & Maarten J.H. Slooff & Elisabeth M. Ten Vergert

  • 2001 The Cost of Inadequate Prescriptions for Hypolipidaemic Drugs
    by Luisa Cabello Ballesteros & M. Isabel Fernandez San Martin & Teresa Sanz Cuesta & Esperanza Escortell Mayor & Carmen Lopez Bilbao

  • 2001 Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension: Economic Evaluation of Ramipril Efficacy In Nephropathy (REIN) Study for Germany from the Perspective of Statutory Health Insurance
    by Peter K. Schadlich & Josef Georg Brecht & Massimo Brunetti & Eva Pagano & Badrudin Rangoonwala & Eduard Huppertz

  • 2001 The Lifetime Cost of Bipolar Disorder in the US: An Estimate for New Cases in 1998
    by Charles E. Begley & John F. Annegers & Alan C. Swann & Christopher Lewis & Sharon Coan & William B. Schnapp & Lynda Bryant-Comstock

  • 2001 Cost Considerations in the Use of Anaesthetic Drugs
    by Ian Smith

  • 2001 Hip Fracture Prevention: Cost-Effective Strategies
    by Peter Vestergaard & Lars Rejnmark & Leif Mosekilde

  • 2001 Lifestyle Drugs: Determining Their Value and Who Should Pay
    by Devora Mitrany

  • 2001 Efavirenz: A Pharmacoeconomic Review of its Use in HIV Infection
    by Greg L. Plosker & Caroline M. Perry & Karen L. Goa

  • 2001 Cost-Effectiveness Analysis of n-3 Polyunsaturated Fatty Acids (PUFA) after Myocardial Infarction: Results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial
    by Maria Grazia Franzosi & Massimo Brunetti & Roberto Marchioli & Rosa Maria Marfisi & Gianni Tognoni & Franco Valagussa

  • 2001 Cost Effectiveness of Continuous Terbinafine Compared with Intermittent Itraconazole in the Treatment of Dermatophyte Toenail Onychomycosis: An Analysis Based on Results from the L.I.ON. Study
    by Ronald Jansen & W. Ken Redekop & Frans F.H. Rutten

  • 2001 Cost-Benefit Analysis of a Haemophilus Influenzae Type B Meningitis Prevention Programme in The Philippines
    by M. Rhona M.T. Limcangco & Carol L. Armour & Eugene G. Salole & Susan J. Taylor

  • 2001 The Cost of Treatment of Alzheimer's Disease in The Netherlands: A Regression-Based Simulation Model
    by Joseph McDonnell & W. Ken Redekop & Nicole van der Roer & Elles Goes & Annemieke Ruitenberg & Jan J.V. Busschbach & Monique M.B. Breteler & Frans F.H. Rutten

  • 2001 Augmenting Reference Pricing of Pharmaceuticals in New Zealand with Strategic Cross-Product Agreements
    by Alan Woodfield

  • 2001 Symptom and Health-Related Quality-of-Life Measures for Use in Selected Gastrointestinal Disease Studies: A Review and Synthesis of the Literature
    by Anne M. Rentz & Carmelina Battista & Elyse Trudeau & Robert Jones & Patricia Robinson & Sheldon Sloan & Sonika Mathur & Lori Frank & Dennis A. Revicki

  • 2001 Pharmacoeconomics of Hypertension Management: The Place of Combination Therapy
    by Ettore Ambrosioni

  • 2001 On Individual Preferences and Aggregation in Economic Evaluation in Healthcare
    by Bengt Liljas & Bjorn Lindgren

  • 2001 Rivastigmine: A Pharmacoeconomic Review of its Use in Alzheimer's Disease
    by Harriet M. Lamb & Karen L. Goa

  • 2001 Cost-Effectiveness Analysis of Inhaled Zanamivir in the Treatment of Influenza A and B in High-Risk Patients
    by Adrian D. Griffin & Andrew S. Perry & Douglas M. Fleming

  • 2001 Cost-Benefit Analysis of Active Vaccination Campaigns Against Hepatitis A Among Daycare Centre Personnel in Israel
    by Gabriel Chodick & Yehuda Lerman & Tamar Peled & Hava Aloni & Shai Ashkenazi

  • 2001 Cost of Treatment for Onychomycosis: Data from a 9-Month Observational Study
    by David M. Stier & Curt Henke & Jeff Schein & Joe Doyle & Warren H. Schonfeld & Jeanette Broering

  • 2001 Cost Effectiveness of Emedastine versus Levocabastine in the Treatment of Allergic Conjunctivitis in 7 European Countries
    by Carlos Gouveia Pinto & Antoine Lafuma & Francis Fagnani & Mark J.C. Nuijten & Gilles Berdeaux

  • 2001 Economic Burden of Chronic Obstructive Pulmonary Disease: Impact of New Treatment Options
    by Mitchell Friedman & Daniel E. Hilleman

  • 2001 Workplace Productivity: A Review of the Impact of Migraine and its Treatment
    by Paul Stang & Roger Cady & Alice Batenhorst & Lynn Hoffman

  • 2001 Influenza: Cost of Illness and Considerations in the Economic Evaluation of New and Emerging Therapies
    by Peter Cram & Susan G. Blitz & Arnold Monto & A. Mark Fendrick

  • 2001 Cost-Effectiveness Analysis of Pneumococcal Vaccination for Elderly Individuals in The Netherlands
    by Maarten J. Postma & Marielouise A. Heijnen & Johannes C. Jager

  • 2001 Usefulness of US Cost-of-Illness Studies in Healthcare Decision Making
    by Bernard S. Bloom & Douglas J. Bruno & Daniel Y. Maman & Ravi Jayadevappa

  • 2001 The Multinational Impact of Migraine Symptoms on Healthcare Utilisation and Work Loss
    by William C. Gerth & George W. Carides & Erik J. Dasbach & W. Hester Visser & Nancy C. Santanello

  • 2001 Health-Related Quality of Life (HR-QOL) and Regulatory Issues: An Assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) Recommendations on the Use of HR-QOL Measures in Drug Approval
    by Giovanni Apolone & Gianfranco De Carli & Massimo Brunetti & Silvio Garattini

  • 2001 A Review of Health-Related Quality-of-Life Measures in Stroke
    by Beatrice A. Golomb & Barbara G. Vickrey & Ron D. Hays

  • 2001 Changing Therapeutic Regimens in Benign Prostatic Hyperplasia: Clinical and Economic Considerations
    by Herman J. Stoevelaar & Joseph McDonnell

  • 2001 Quality-of-Life Assessment in Comparative Therapeutic Trials and Causal Structure Considerations in Peripheral Occlusive Arterial Disease
    by Philippe Lehert

  • 2001 Direct-to-Consumer Promotion of Prescription Drugs: Economic Implications for Patients, Payers and Providers
    by Steven D. Findlay

  • 2001 Economic Analysis of Initial HIV Treatment: Efavirenz- versus Indinavir-Containing Triple Therapy
    by J. Jaime Caro & Judith A. O'Brien & Kristen Migliaccio-Walle & Gabriel Raggio

  • 2001 Cost Efficacy of Tazobactam/Piperacillin versus Imipenem/Cilastatin in the Treatment of Intra-Abdominal Infection
    by Eva Susanne Dietrich & Bjorn Schubert & Winfried Ebner & Franz Daschner

  • 2001 A General Model of the Effects of Sleep Medications on the Risk and Cost of Motor Vehicle Accidents and its Application to France
    by Joseph Menzin & Kathleen M. Lang & Pierre Levy & Emile Levy

  • 2001 Dermatan Sulfate versus Unfractionated Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Surgery for Cancer: A Cost-Effectiveness Analysis
    by Ermanno Attanasio & Pierluigi Russo & Gabriella Carunchio & Luciano Caprino

  • 2001 Glycoprotein IIb/IIIa Receptor Therapy in Percutaneous Coronary Intervention and Non-ST-Segment Elevation Acute Coronary Syndromes: Estimating the Economic Implications
    by William B. Hillegass & Anne R. Newman & Dominic L. Raco

  • 2001 Enteroviral Meningitis: Cost of Illness and Considerations for the Economic Evaluation of Potential Therapies
    by T.V. Parasuraman & Kathleen Frenia & Jose Romero

  • 2001 The Cost of HIV Treatment and Care: A Global Review
    by Eduard J. Beck & Alec H. Miners & Keith Tolley

  • 2001 Paclitaxel: A Pharmacoeconomic Review of its Use in the Treatment of Ovarian Cancer
    by Melissa Young & Greg L. Plosker

  • 2001 Direct Costs of Schizophrenia in Italian Community Psychiatric Services
    by Livio Garattini & Carlotta Rossi & Fabrizio Tediosi & Cesare Cornaggia & Giampiero Covelli & Corrado Barbui & Fabio Parazzini

  • 2001 Economic Evaluation of Collagenase-Containing Ointment and Hydrocolloid Dressing in the Treatment of Pressure Ulcers
    by Elvira Muller & Martin W.F. van Leen & Rito Bergemann

  • 2001 Incremental Cost Effectiveness of Prophylaxis for Cytomegalovirus Disease in Patients with AIDS
    by John H. Kempen & Kevin D. Frick & Douglas A. Jabs

  • 2001 Accounting for Noncompliance in Pharmacoeconomic Evaluations
    by Dyfrig A. Hughes & Adrian Bagust & Alan Haycox & Tom Walley

  • 2001 Piperacillin/Tazobactam: A Pharmacoeconomic Review of its Use in Moderate to Severe Bacterial Infections
    by Melissa Young & Greg L. Plosker

  • 2001 Paclitaxel: A Pharmacoeconomic Review of its Use in Non-Small Cell Lung Cancer
    by Greg L. Plosker & Miriam Hurst

  • 2001 Cost-Effectiveness Analysis and the Consistency of Decision Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996)
    by Bethan George & Anthony Harris & Andrew Mitchell

  • 2001 Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK
    by Ruth E. Brown & John Hutton & Anita Burrell

  • 2001 Quality-of-Life Assessment in Patients with Benign Prostatic Hyperplasia: Effects of Various Interventions
    by Jose-Emilio Batista-Miranda & Marta De la Cruz Diez & Pedro Arano Bertran & Humberto Villavicencio

  • 2001 Economic Evaluations During Early (Phase II) Drug Development: A Role for Clinical Trial Simulations?
    by Dyfrig A. Hughes & Tom Walley

  • 2001 Which Antifungal Agent for Onychomycosis?: A Pharmacoeconomic Analysis
    by Vijay N. Joish & Edward P. Armstrong

  • 2001 Formulary Restriction of Selective Serotonin Reuptake Inhibitors for Depression: Potential Pitfalls
    by Paula L. Hensley & H. George Nurnberg

  • 2001 A Cost-Cost Study Comparing Etanercept with Infliximab in Rheumatoid Arthritis
    by Mark J.C. Nuijten & Peter Engelfriet & Klaas Duijn & George Bruijn & David Wierz & Marc Koopmanschap

  • 2001 Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis: Ontario Ministry of Health Perspective
    by John K. Marshall & James M. Pellissier & Cheryl L. Attard & Sheldon X. Kong & Michael A. Marentette

  • 2001 Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson's Disease: Impact of Motor Fluctuations and Dyskinesias
    by Richard C. Dodel & Karin Berger & Wolfgang H. Oertel

  • 2001 Barrett's Oesophagus: A Review of Costs of the Illness
    by Miguel R. Arguedas & Mohamad A. Eloubeidi

  • 2001 This Month's News
    by Adis International Limited

  • 2001 Combining Utility Measurements: Exploring Different Approaches
    by Denise E. Bonds & Kenneth A. Freedberg

  • 2001 Management of Pharmaceutical Resources for the Primary Prevention of Coronary Heart Disease in Catalonia (Spain) Based on Efficiency and Equity
    by Pedro Plans-Rubio

  • 2001 Measuring and Managing Health Outcomes and Quality of Care in End-Stage Renal Disease
    by Kraig S. Kinchen & Neil R. Powe

  • 2001 Improving Quality of Life for Patients with Angina Pectoris: A Team Approach to Disease Management
    by Margaret E. Cupples & Martin Dempster

  • 2001 Improving the Use of Data Sources in Disease Management Programs
    by Jacob Abarca & Edward P. Armstrong

  • 2001 This Month's News
    by Adis International Limited

  • 2001 Healthcare Reform and Disease Management in Italy: Promoting the Effectiveness and Appropriateness of Health Service Use
    by Roberto Grilli & Andrea Donatini & Francesco Taroni

  • 2001 Disease Management Programs for Hepatitis C: A Team Approach to Setting Goals
    by Raymond S. Koff

  • 2001 Effective Employer-Vendor Partnerships: Encouraging Positive Disruptive Innovations in Healthcare
    by Julie A. Meek & Vince Kuraitis

  • 2001 Patient-Centered Healthcare: The Role of the Internet
    by Dixie B. Baker

  • 2001 This Month's News
    by Adis International Limited

  • 2001 Management of Advanced Breast Cancer: Defining the Role of Anastrozole
    by Gillian M. Keating & Karen L. Goa

  • 2001 Hepatitis C Screening and Treatment versus Liver Transplantation: A Financial Option Appraisal and Commissioning Model for Purchasers
    by Nevil Batra

  • 2001 Implementation of Guidelines for Diagnosing and Treating Hypertension
    by Finlay A. McAlister & Raj Padwal

  • 2001 Disability Prevention: New Paradigm for the Management of Occupational Back Pain
    by Patrick Loisel & Marie-Jose Durand & Diane Berthelette & Nicole Vezina & Raymond Baril & Denis Gagnon & Christian Lariviere & Claude Tremblay

  • 2001 This Month's News
    by Adis International Limited

  • 2001 Insulin Therapy in Patients with Type 2 Diabetes Mellitus: Shared Care Versus Secondary Outpatient Care in The Netherlands
    by Raymond C.W. Hutubessy & Hindrik Vondeling & Jeroen J.J. de Sonnaville & Louisa P. Colly & Jan L..J. Smit & Robert J. Heine

  • 2001 Improved Bone Health Behavior Using Community Pharmacists as Educators: The Geisinger Health System Community Pharmacist Osteoporosis Education Program
    by Eric D. Newman & Philip Hanus

  • 2001 Early Recognition and Intervention: The Key to Success in the Treatment of Schizophrenia?
    by Jan Olav Johannessen

  • 2001 Neonatal Care Management: An Integrated Approach
    by Michael N. Musci & John J. Esslinger & Michael Kornhauser

  • 2001 Sickle Cell Disease Screening Programs: Integration Into Managed Care
    by Sally C. Davies & Lola Oni

  • 2001 This Month's News
    by Adis International Limited

  • 2001 Management of Colorectal Cancer: Defining the Role of Raltitrexed
    by Anna J. Matheson & Stuart Noble

  • 2001 Analysis of Antidepressant Use Through Hierarchical Disease Analysis: Using a Managed Care Administrative Database
    by Edward P. Armstrong

  • 2001 The National Lung Health Education Program and Managed Care: The Importance of Early Identification and Intervention in Chronic Obstructive Pulmonary Disease
    by Thomas L. Petty

  • 2001 The Internet as a Resource for Consumer Healthcare
    by Deborah Lewis & Kimberly Behana

  • 2001 This Month's News
    by Adis International Limited

  • 2001 Management of Chronic Hepatitis B: Defining the Role of Lamivudine
    by Blair Jarvis & Caroline M. Perry

  • 2001 Risperidone, Haloperidol and Clozapine in the South Carolina Medicaid Program: A Comparative Analysis of Utilisation and Expenditure
    by Kenneth M. Shermock & M. Kay Sadik & Chris M. Kozma & Anne-Marie Sesti & C.E. Reeder

  • 2001 The Role of the Patient in Maximizing Efficacy of Drug Therapy in Migraine
    by William Pryse-Phillips

  • 2001 Maximizing Treatment Outcome in Depression: Strategies to Overcome Social Stigma and Noncompliance
    by Glen L. Stimmel

  • 2001 This Month's News
    by Adis International Limited

  • 2001 Analysis of Asthma-Related Costs and Patterns of Resource Utilization in a Managed-Care Population
    by Edward P. Armstrong & Kem Krueger & Paul C. Langley

  • 2001 Assertive Community Treatment for People with Severe Mental Illness: Critical Ingredients and Impact on Patients
    by Gary R. Bond & Robert E. Drake & Kim T. Mueser & Eric Latimer

  • 2001 Utilizing and Integrating the Internet in Disease Management
    by Marybeth Regan

  • 2001 Managing Patients with Diabetes Mellitus and Mental Health Problems: Administrative and Clinical Challenges
    by Barbara H. Warren & Cynthia K. Crews & Martina M. Schulte

  • 2001 Role of the Workplace in Migraine Disease Management
    by Leon J. Warshaw & Wayne N. Burton & William J. Schneider

  • 2001 Behavioral Aspects of Arthritis and Rheumatic Disease Self-Management
    by Julie J. Keysor & Shannon S. Currey & Leigh F. Callahan

  • 2001 Training Issues in the Use of Inhalers
    by Martin Duerden & David Price

  • 2001 Pharmaceutical Restrictions: Possible Effect on Patient/Physician Buy-In of Disease Management Programs
    by C. Daniel Mullins & Simu K. Thomas & David S. Roffman

  • 2001 Community-Acquired Pneumonia and its Management: The Role of Levofloxacin
    by Caroline M. Perry & Karen L. Goa

  • 2001 Trends in the Rate of Self-Report and Diagnosis of Erectile Dysfunction in the United States 1990-1998: Was the Introduction of Sildenafil an Influencing Factor?
    by Tracy L. Skaer & David A. Sclar & Linda M. Robison & Richard S. Galin

  • 2001 Cost Effectiveness of Antibacterial Restriction Strategies in a Tertiary Care University Teaching Hospital
    by Caterina Tsiata & Vassilis Tsekouras & Antonis Karokis & John Starakis & Harry P. Bassaris & Mihalis Maragoudakis & Athanasios T. Skoutelis

  • 2001 Health Utility Attributes for Chronic Conditions
    by Nicole Mittmann & Derek Chan & Kostas Trakas & Nancy Risebrough

  • 2001 Data Warehousing Solutions and Internet Initiatives in the Disease Management Era: Important Issues to Consider
    by Alejandro Jaramillo

  • 2001 This Month's News
    by Adis International Limited

  • 2001 Management of Diabetes Mellitus: Defining the Role of Insulin Lispro Mix75/25 (Humalog(R) Mix75/25(TM))
    by Christine R. Culy & Blair Jarvis

  • 2001 Increased National Cholesterol Education Program (NCEP) Goal Attainment: Outcome Assessment of Department of Defense Conversion to Cerivastatin and Simvastatin
    by Dennis Beaudoin & Emery Spaar & Susan Pitman Lowenthal & Karen C. Chung

  • 2001 Primary Care Clinic-Based Chronic Disease Care: Features of Successful Programs
    by Patrick J. O'Connor & JoAnn M. Sperl-Hillen & Nicolaas P. Pronk & Terry Murray

  • 2001 Optimizing the Delivery of Effective Diabetes Care: An English Perspective
    by Abdu Mohiddin & Martin Gulliford

  • 2001 Health Plans and Disease Management: Threats and Opportunities
    by Karen Ignagni

  • 2001 This Month's News
    by Adis International Limited

  • 2001 Cost and Cost Effectiveness of Venous and Pressure Ulcer Protocols of Care
    by Morris D. Kerstein & Eric Gemmen & Lia van Rijswijk & Courtney H. Lyder & Tania Phillips & George Xakellis & Katharine Golden & Catherine Harrington

  • 2001 Unique Co-Operative Worksite-Based Osteoporosis Project: Employer, Healthcare Plan and Pharmaceutical Company Combine Efforts to Screen and Manage Women at Risk
    by Larry K. Cantley & Cheryl Summers & David E. Rice

  • 2001 Treatment Expectations in Hypertension: Implications for Patients Enrolled in Disease Management Programs
    by Debbie Cohen & Raymond Townsend & Mark Miani & David Bernard

  • 2001 A Fully Integrated Clinical Information System to Support Management of End-Stage Renal Disease: Design and Implementation
    by William D. Mattern & Sue Scott

  • 2001 The Role of Mental Health Patient Organizations in Disease Management: Focus on the US National Depressive and Manic-Depressive Association
    by Lydia Lewis

  • 2001 This Month's News
    by Adis International Limited

  • 2001 Chronic Obstructive Pulmonary Disease in a Managed-Care Setting
    by Steven Kesten

  • 2001 Technology-Based Disease Management: A Low-Cost, High-Value Solution for the Management of Chronic Disease
    by Wally H. Gomaa & Thomas Morrow & Pieter Muntendam

  • 2001 Comparing Smoking Cessation Interventions for Work-Site Disease Management
    by Todd Greenwood

  • 2001 Implementing Change: It's as Hard as it Looks
    by Caren Heller & Ahsan Arozullah

  • 2001 Work Productivity in Psychiatry: Trends in Interventions and Outcomes
    by Pamela L. Moriearty & Eugene Oulvey & Karen Lee

  • 2001 Specialty Pharmacies: Filling a Unique Position in the Disease Management Industry
    by Thomas Morrow

  • 2001 Broad Disease Management Interventions: Reducing Health Care Costs for Plan Members with Congestive Heart Failure
    by Joel C. Hoffman

  • 2000 Potential Savings in the Cost of Caring for Alzheimer's Disease: Treatment with Rivastigmine
    by A. Brett Hauber & Josephine A. Mauskopf & Edward H. Snyder

  • 2000 Potential Savings in the Cost of Caring for Alzheimer's Disease: Treatment with Rivastigmine
    by Karen W. Linkins & John R. Lloyd & Gregory O. Hjelmstad & Holly J. Strausbaugh

  • 2000 Inhaled Salmeterol/Fluticasone Propionate Combination: A Pharmacoeconomic Review of its Use in the Management of Asthma
    by Anthony Markham & Julie C. Adkins

  • 2000 Association between Abciximab and Length of Stay in Intensive Care for Patients Undergoing Percutaneous Coronary Intervention: A 2-Stage Econometric Model in a Naturalistic Setting
    by Maureen J. Lage & Beth L. Barber & Mohan Bala & Patrick L. McCollam & Daniel E. Ball

  • 2000 Olanzapine versus Risperidone: A Prospective Comparison of Clinical and Economic Outcomes in Schizophrenia
    by Eric T. Edgell & Scott W. Andersen & Bryan M. Johnstone & Brian Dulisse & Dennis Revicki & Alan Breier

  • 2000 Effectiveness of Eletriptan in Reducing Time Loss Caused by Migraine Attacks
    by Nicholas E.J. Wells & Timothy J. Steiner

  • 2000 Stratified Administration of Serotonin 5-HT3 Receptor Antagonists (Setrons) for Chemotherapy-Induced Emesis: Economic Implications
    by Lisa A. Sanchez & Mark Holdsworth & Sylvia B. Bartel

  • 2000 The Single Market for Pharmaceuticals in the European Union in Light of European Court of Justice Rulings
    by Panos Kanavos

  • 2000 Economic Analysis of Long Term Reversible Contraceptives: Focus on Implanon(R)
    by Ceri J. Phillips

  • 2000 Economic Analysis of Long Term Reversible Contraceptives: Focus on Implanon(R)
    by Pekka Rissanen

  • 2000 Inhaled Fluticasone Propionate: A Pharmacoeconomic Review of its Use in the Management of Asthma
    by Harriet M. Lamb & Christine R. Culy & Diana Faulds

  • 2000 Economic Impact of Tibolone Compared with Continuous-Combined Hormone Replacement Therapy: In the Management of Postmenopausal Women with Climacteric Symptoms in the UK
    by Jonathan M. Plumb & Julian F. Guest

  • 2000 Cost-Effectiveness Analysis of Topical Calcipotriol versus Short- Contact Dithranol: In the Treatment of Mild to Moderate Plaque Psoriasis
    by Darren M. Ashcroft & Alain Li Wan Po & Hywel C. Williams & Christopher E.M. Griffiths

  • 2000 Economic Impact of Increased Clinical Intervention Rates in Community Pharmacy: A Randomised Trial of the Effect of Education and a Professional Allowance
    by Shalom I. Benrimoj & Jane H. Langford & Geoffrey Berry & David Collins & Roberta Lauchlan & Kay Stewart & Michael Aristides & Matthew Dobson

  • 2000 Cost Analysis of an Adult Outpatient Parenteral Antibiotic Therapy (OPAT) Programme: A Canadian Teaching Hospital and Ministry of Health Perspective
    by Amy O. Wai & Luciana Frighetto & Carlo A. Marra & Emily Chan & Peter J. Jewesson

  • 2000 Health-Related Quality-of-Life Measurement in Hypertension: A Review of Randomised Controlled Drug Trials
    by Isabelle Cote & Jean-Pierre Gregoire & Jocelyne Moisan

  • 2000 HIV-1 Drug Resistance Genotyping: A Review of Clinical and Economic Issues
    by Carine Chaix-Couturier & Christopher Holtzer & Kathryn A. Phillips & Isabelle Durand-Zaleski & John Stansell

  • 2000 The Concept of Clinically Meaningful Difference in Health-Related Quality of Life Research: How Meaningful is it?
    by Ron D. Hays & J. Michael Woolley

  • 2000 Cocaine Medications, Cocaine Consumption and Societal Costs
    by William S. Cartwright

  • 2000 The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS
    by Aslam H. Anis & Daphne Guh & Robert S. Hogg & Xiao-Hua Wang & Benita Yip & Kevin J.P. Craib & Michael V. O'Shaughnessy & Martin T. Schechter & Julio S.G. Montaner

  • 2000 Cost Effectiveness of Acute Imipramine Therapy versus Two Imipramine Maintenance Treatment Regimens for Panic Disorder
    by Matig R. Mavissakalian & Jordana K. Schmier & Jennifer A. Flynn & Dennis A. Revicki

  • 2000 Cost Effectiveness of Cephalosporin Monotherapy and Aminoglycoside/ Ureidopenicillin Combination Therapy: For the Treatment of Febrile Episodes in Neutropenic Patients
    by Joseph A. Paladino & Debra A. Fong & Alan Forrest & Reuben Ramphal

  • 2000 Cost Effectiveness of Human Immunodeficiency Virus Postexposure Prophylaxis for Healthcare Workers
    by Dewey C. Scheid & Robert M. Hamm & Kevin W. Stevens

  • 2000 Socioeconomic Issues Affecting the Treatment of Obesity in the New Millennium
    by Louis F. Martin & Alex Robinson & Barbara J. Moore

  • 2000 Cost Effectiveness of Therapies for Atrial Fibrillation: A Review
    by Mark P. Teng & Edward Catherwood & Daniel P. Melby

  • 2000 The Impact of Health Economics on Healthcare Delivery: A Primary Care Perspective
    by David P. Kernick

  • 2000 Glipizide: A Review of the Pharmacoeconomic Implications of the Extended-Release Formulation in Type 2 Diabetes Mellitus
    by Rachel H. Foster & Greg L. Plosker

  • 2000 The Economic Value of a New Insulin Preparation, Humalog(R) Mix 25(TM): Measured by a Willingness-To-Pay Approach
    by George Dranitsaris & Christopher J. Longo & Loren D. Grossman

  • 2000 Cost Effectiveness of Abciximab During Routine Medical Practice
    by Shelby Ogilvie Reed & C. Daniel Mullins & Laurence S. Magder

  • 2000 Cost Implications for the Use of Inhaled Anti-Inflammatory Medications in the Treatment of Asthma
    by Ronald J. Ozminkowski & Shaohung Wang & William D. Marder & John Azzolini & David Schutt

  • 2000 Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal Transplantation: Comparing Valaciclovir Prophylaxis with Current Practice
    by Josephine A. Mauskopf & Anke Richter & Lieven Annemans & Grant Maclaine

  • 2000 Costs of Deep Foot Infections in Patients with Diabetes Mellitus
    by Gunnel Ragnarson Tennvall & Jan Apelqvist & Magnus Eneroth

  • 2000 The Epidemic of Alzheimer's Disease: How Can We Manage the Costs?
    by Neil Johnson & Tim Davis & Nick Bosanquet

  • 2000 The Need for an Iterative Process for Assessing Economic Outcomes Associated with SSRIs
    by Tracy L. Skaer & David A. Sclar & Linda M. Robison & Richard S. Galin

  • 2000 Antiviral Therapies for Herpes Zoster Infections: Are They Economically Justifiable?
    by Kenneth J. Smith & Mark S. Roberts

  • 2000 Economic Assessment of the Secondary Prevention of Ischaemic Events with Lysine Acetylsalicylate
    by Jean-Pierre Marissal & Bernard Selke & Therese Lebrun

  • 2000 Economic Evaluations of Influenza Vaccination in Healthy Working-Age Adults: Employer and Society Perspective
    by Susan C. Wood & Van Hung Nguyen & Claudia Schmidt

  • 2000 Cost Effectiveness of Epoetin-alpha to Augment Preoperative Autologous Blood Donation in Elective Cardiac Surgery
    by Douglas Coyle & Karen M. Lee & Dean A. Fergusson & Andreas Laupacis

  • 2000 Differences in Attitudes, Knowledge and Use of Economic Evaluations in Decision-Making in The Netherlands: The Dutch Results from the EUROMET Project
    by Jeannette E.F. Zwart-van Rijkom & Hubertus G.M. Leufkens & Jan J.V. Busschbach & Andre W. Broekmans & Frans F.H. Rutten

  • 2000 Pharmacoeconomic Analysis of Antidepressants for Major Depressive Disorder in the United Kingdom
    by Hugh Freeman & Steve Arikian & Alan Lenox-Smith

  • 2000 Clinical Trials and the New Good Clinical Practice Guideline in Japan: An Economic Perspective
    by Shunsuke Ono & Yasuo Kodama

  • 2000 Patient Compliance with Drug Therapy in Schizophrenia: Economic and Clinical Issues
    by Eva Lindstrom & Kerstin Bingefors

  • 2000 Economic Issues in the Prevention of Vertical Transmission of HIV
    by A.E. Ades & Julie Ratcliffe & Diana M. Gibb & Mark J. Sculpher

  • 2000 Economic Evaluation of Enoxaparin Sodium versus Heparin in Unstable Angina: A French Sub-Study of the ESSENCE Trial
    by Bruno Detournay & Xavier Huet & Francois Fagnani & Gilles Montalescot

  • 2000 The Impact of Pituitary Adenoma on Morbidity: Increased Sick Leave and Disability Retirement in a Cross-Sectional Analysis of Swedish National Data
    by Bjorn Jonsson & Bo Nilsson

  • 2000 Health-Related Quality of Life in Asymptomatic Patients with HIV: Evaluation of the SF-36 Health Survey in Italian Patients
    by Fabio Arpinelli & Giovanni Visona & Raffaele Bruno & Gianfranco Decarli & Giovanni Apolone

  • 2000 Using Economic Evaluations to Make Formulary Coverage Decisions: So Much for Guidelines
    by Aslam H. Anis & Yves Gagnon

  • 2000 Long Term Treatment of Multiple Sclerosis with Interferon-beta May Be Cost Effective
    by Malcolm Kendrick & K. Ian Johnson

  • 2000 A Review of Alternative Approaches to Healthcare Resource Allocation
    by Stavros Petrou & Jane Wolstenholme

  • 2000 Social Phobia: Epidemiology and Cost of Illness
    by Joshua D. Lipsitz & Franklin R. Schneier

  • 2000 Introduction to the Pharmacoeconomics of Herbal Medicines
    by Peter A.G.M. De Smet & Gouke Bonsel & Ary Van der Kuy & Yechiel A. Hekster & Marja H. Pronk & Mark J.A. Brorens & Jacques H.M. Lockefeer & Mark J.C. Nuijten

  • 2000 Cost of Illness in Adult Patients with Hypopituitarism
    by Christer Ehrnborg & Leona Hakkaart-Van Roijen & Bjorn Jonsson & Frans F.H. Rutten & Bengt-Ake Bengtsson & Thord Rosen

  • 2000 Cost Effectiveness of Zanamivir for the Treatment of Influenza in a High Risk Population in Australia
    by Josephine A. Mauskopf & Sheryl C. Cates & Adrian D. Griffin & Deirdre M. Neighbors & Sarah C. Lamb & Carolyn Rutherford

  • 2000 Costs for Acute Myocardial Infarction in a Tertiary Care Centre and Nationwide in France
    by Olivier Montagne & Carine Chaix & Alain Harf & Alain Castaigne & Isabelle Durand-Zaleski

  • 2000 Cost-Effectiveness Analysis of Pneumococcal Vaccination of Adults and Elderly Persons in Belgium
    by Diana De Graeve & Geert Lombaert & Herman Goossens

  • 2000 Low-Flow Anaesthesia: Does it have Potential Pharmacoeconomic Consequences?
    by Stefan Suttner & Joachim Boldt

  • 2000 A Critical Review of Published Economic Modelling Studies in Depression
    by Michael T. Jones & Paul C. Cockrum

  • 2000 Expert Judgement in Pharmacoeconomic Studies: Guidance and Future Use
    by Christopher Evans & Bruce Crawford

  • 2000 Disease Management: A Global Cost-Containing Initiative?
    by Karen Bloor & Alan Maynard

  • 2000 Mirtazapine: A Pharmacoeconomic Review of its Use in Depression
    by Kristin J. Holm & Blair Jarvis & Rachel H. Foster

  • 2000 Testing the Validity of Cost-Effectiveness Models
    by Chris McCabe & Simon Dixon

  • 2000 Handling Uncertainty in Cost-Effectiveness Models
    by Andrew H. Briggs

  • 2000 Assessing Quality in Decision Analytic Cost-Effectiveness Models: A Suggested Framework and Example of Application
    by Mark Sculpher & Elisabeth Fenwick & Karl Claxton

  • 2000 Modelling in Health Economic Evaluation: What is its Place? What is its Value?
    by Alan Brennan & Ron Akehurst

  • 2000 Decision Analytic Modelling in the Economic Evaluation of Health Technologies: A Consensus Statement
    by Adis International Limited

  • 2000 Healthcare Costs of Patients with Heart Failure Treated with Torasemide or Furosemide
    by Kevin T. Stroupe & Melissa M. Forthofer & D. Craig Brater & Michael D. Murray

  • 2000 Cost-Effectiveness Analysis of Lamivudine for the Treatment of Chronic Hepatitis B
    by Steven J. Crowley & David Tognarini & Paul V. Desmond & Michael Lees

  • 2000 Cost Effectiveness of Competing Strategies to Prevent or Treat GORD-Related Dysphagia
    by Amnon Sonnenberg

  • 2000 Cost Analysis of the Treatment of Schizophrenia in the UK: A Simulation Model Comparing Olanzapine, Risperidone and Haloperidol
    by Stephen Almond & Owen O'Donnell

  • 2000 Initial Treatment Choice in Depression: Impact on Medical Expenditures
    by Eric T. Edgell & Timothy R. Hylan & JoLaine R. Draugalis & Stephen Joel Coons

  • 2000 Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy: A Comparison of Raltitrexed and Fluorouracil plus Folinic Acid
    by Mark Sculpher & Michael K. Palmer & Anne Heyes

  • 2000 Potential Savings in the Cost of Caring for Alzheimer's Disease: Treatment with Rivastigmine
    by A. Brett Hauber & Ari Gnanasakthy & Edward H. Snyder & Mohan V. Bala & Anke Richter & Josephine A. Mauskopf

  • 2000 Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio
    by Anthony O'Hagan & John W. Stevens & Jacques Montmartin

  • 2000 Economic Burden of Irritable Bowel Syndrome: Proposed Strategies to Control Expenditures
    by Michael Camilleri & Donald E. Williams

  • 2000 Cost Effectiveness of Combination HIV Therapy: 3 Years Later
    by Richard D. Moore

  • 2000 The Importance of Achieving Additional Drug Benefits at a Reasonable Cost: A Review of the Fluoxetine Years
    by Nick Freemantle & James Mason

  • 2000 Household Income Losses Associated With Ischaemic Heart Disease For US Employees
    by Jeph Herrin & Charles B. Cangialose & Stephen J. Boccuzzi & William S. Weintraub & David J. Ballard

  • 2000 The Cost Effectiveness of Misoprostol Prophylaxis Alongside Long Term Nonsteroidal Anti-Inflammatory Drugs: Implications of the MUCOSA Trial
    by Peter J. Davey & Eric Meyer

  • 2000 Economics of the Antithymocyte Globulins Thymoglobulin(R) and Atgam(R) in the Treatment of Acute Renal Transplant Rejection
    by Mark A. Schnitzler & Robert S. Woodward & Jeffrey A. Lowell & Leah Amir & Timothy J. Schroeder & Gary G. Singer & Daniel C. Brennan

  • 2000 Assessing Health Utilities in Schizophrenia: A Feasibility Study
    by Lakshmi N. Voruganti & A. George Awad & L. Kola Oyewumi & Leonardo Cortese & Sandra Zirul & Ravinder Dhawan

  • 2000 Evaluating the Potential
    by Eric L. Eisenstein & Eric D. Peterson & James G. Jollis & Barbara E. Tardiff & Robert M. Califf & J. David Knight & Daniel B. Mark

  • 2000 Clinical and Economic Factors Important to Anaesthetic Choice for Day-Case Surgery
    by Edmond I. Eger & Paul F. White & Martin S. Bogetz

  • 2000 ACE Inhibitors after Myocardial Infarction: Clinical and Economic Considerations
    by Andrew P. Davie

  • 2000 Bridging Decision Analytic Modelling with a Cross-Sectional Study: Application to Parkinson's Disease
    by Mark J.C. Nuijten

  • 2000 Economic Analysis of Long Term Reversible Contraceptives: Focus on Implanon(R)
    by Ceri J. Phillips

  • 2000 Cost-of-Illness of Epilepsy in Italy: Data from a Multicentre Observational Study (Episcreen)
    by P. Berto & P. Tinuper & S. Viaggi

  • 2000 Impact of Zanamivir Treatment on Productivity, Health Status and Healthcare Resource Use in Patients with Influenza
    by Fred Y. Aoki & Douglas M. Fleming & Adrian D. Griffin & Loretto A. Lacey & Sally Edmundson

  • 2000 Pharmacoeconomics and Clinical Practice Guidelines: A Survey of Attitudes in Swedish Formulary Committees
    by Anders Anell & Patrick Svarvar

  • 2000 The Costs of Pharmacological Treatment for Major Depression: The Italian Prospective Multicentre Observational Incidence-Based Study
    by Rosanna Tarricone & Giovanni Fattore & Simone Gerzeli & Giulio Serra & Cristina Taddei & Mauro Percudani

  • 2000 Valuing Health-Related Quality of Life: A Review of Health State Valuation Techniques
    by Colin Green & John Brazier & Mark Deverill

  • 2000 Pharmacoeconomic Considerations in Treating Ovarian Cancer
    by Diane Bodurka-Bevers & Charlotte C. Sun & David M. Gershenson

  • 2000 New Generation Aromatase Inhibitors in Breast Cancer: Weighing Out Potential Costs and Benefits
    by Gerald M. Higa

  • 2000 Diagnosis Related Group Costs in a Regulated Environment: A Note About Their Economic Interpretation
    by Claude Le Pen & Gilles Berdeaux

  • 2000 Economic Cost of Male Erectile Dysfunction Using a Decision Analytic Model: For a Hypothetical Managed-Care Plan of 100 000 Members
    by Howard L. Tan

  • 2000 The Cost of Urinary Incontinence in Italian Women: A Cross-Sectional Study
    by Fabrizio Tediosi & Fabio Parazzini & Angela Bortolotti & Livio Garattini

  • 2000 Use and Cost of Hospital and Community Service Provision for Children with HIV Infection at an English HIV Referral Centre
    by Eduard J. Beck & Sundhiya Mandalia & Rebecca Griffith & Jeni Beecham & M. D. Sam Walters & Mary Boulton & David L. Miller

  • 2000 Economic Evaluation of Specific Immunotherapy Versus Symptomatic Treatment of Allergic Rhinitis in Germany
    by Peter K. Schadlich & Josef G. Brecht

  • 2000 A Comparative Review of Generic Quality-of-Life Instruments
    by Stephen Joel Coons & Sumati Rao & Dorothy L. Keininger & Ron D. Hays

  • 2000 Estimating the Long Term Cost Savings from the Treatment of Alzheimer's Disease: A Modelling Approach
    by Peter J. Neumann

  • 2000 Formulary Management of Low Molecular Weight Heparins
    by William E. Wade & Bradley C. Martin & Jeffrey A. Kotzan & William J. Spruill & Marie A. Chisoholm & Matthew Perri

  • 2000 Management of Acute Repetitive Seizures: Defining the Role of Rectal Diazepam Gel
    by Matthew N. Lowe & Katharine J. Palmer & Michelle I. Wilde

  • 2000 Management of Acute Otitis Media: Defining the Role of Cefuroxime Axetil
    by Harriet M. Lamb & Caroline M. Spencer

  • 2000 Self-Management of Epilepsy: A Review of the Concept and Its Outcomes
    by Janice M. Buelow & Joyce Johnson

  • 2000 The Role of Minimal- and No-Contact Behavioural Treatments in Migraine: A Review of Efficacy and Cost Effectiveness
    by Lisa Scharff & Joseph Etherage

  • 2000 Healthcare Reforms in Germany: Managed Care, An Opportunity?
    by Reinhard Rychlik & Karin Guntertgomann & Anne Kilburg & Jeffrey B. Frazier

  • 2000 Epoetin Alfa Drug Use Evaluation Using A Software System: Lessons Learned
    by Edward P. Armstrong & Ruth E. Cherrick

  • 2000 Economic Evaluations of Influenza Vaccination in the Elderly: Impact on Public Health Policy
    by Susan C. Wood & Van Hung Nguyen & Claudia Schmidt

  • 2000 Recombinant Human Erythropoietin as an Alternative to Blood Transfusion in Cancer-Related Anaemia
    by Andreas Engert

  • 2000 An Integrated Model for the Management of Co-Occurring Psychiatric and Substance Disorders in Managed-Care Systems
    by Kenneth Minkoff

  • 2000 Outcome Measures of Efficacy Associated with a Web-Enabled Asthma Self-Management Programme: Findings from a Quasi-Experiment
    by Martin Atherton

  • 2000 Targeting High Utilisers: Predictive Validity of a Screening Questionnaire
    by Julie A. Meek & Brenda L. Lyon & Frederick E. May & Wendy D. Lynch

  • 2000 Interventions for Families of Individuals with Schizophrenia: Maximising Outcomes for their Relatives
    by Phyllis Solomon

  • 2000 Breast Cancer Epidemiology, Prevention and Costs of Care: Implications for Disease Management Programmes
    by K. Robin Yabroff & Ruth Brown & Michael Halpern

  • 2000 The Role of Community Health Information Networks in Disease Management
    by Francois M.H.M. Dupuits

  • 2000 The Value of Disease Management: Approaching the Industrialisation of Modern Medicine
    by Marc L. Berger & Peter Nebenfuhr & Richard K. Murray

  • 2000 Economic Impact of an Asthma Education Programme on Medical Care Utilisation
    by Dong-Churl Suh & Soungkook Shin & Robert M. Voytovich & Allan Zimmerman

  • 2000 Smoking Cessation: The Contribution of Community Pharmacy
    by James C. McElnay & Terry A. Maguire & Ashlinn Drummond & Carmel M. Hughes

  • 2000 Dynamic Assessment in Disease Management
    by Ira S. Nash

  • 2000 Screening and Brief Intervention in the Management of Early Problem Drinkers: Integration into Healthcare Settings
    by Vania Modestolowe & Ava Boornazian

  • 2000 Disease Management as a Part of Total Health and Productivity Management
    by Ron Z. Goetzel & Ronald J. Ozminkowski

  • 2000 Management of Narcolepsy: Defining the Role of Modafinil
    by Alison M. Comer & Caroline M. Spencer

  • 2000 Recent Developments for Optimal End-Points in Rheumatoid Arthritis Clinical Studies
    by Esmeralda T.H. Molenaar & Maarten Boers & Peter M. Brooks & Lee Simon & Vibeke Strand & Peter Tugwell

  • 2000 Managing Influenza in Primary Care: A Practical Guide to Clinical Diagnosis
    by Rene Snacken

  • 2000 Lipid Clinics as Disease Management Programmes in the United States: Essential Elements and Practical Considerations
    by Ralph L. Laforge

  • 2000 Potential Role of Telecommunication Technologies in the Management of Chronic Health Conditions
    by Joseph Finkelstein & Robert H. Friedman

  • 2000 Medical Savings Account Plans: A Patient-Centred Approach to Medical Insurance
    by David T. Springer

  • 2000 Modification of Albumin Use Pattern After an Educational Intervention
    by Veronica De Miguel & Emilio Vargas & Antonio Portoles & Miguel Puerro & Ana Isabel Terleira & Alfonso Moreno

  • 2000 Cost Estimates for Chronic Diseases
    by Jean Woo & Clive Cockram

  • 2000 Psychosocial Components of Asthma Management in Children
    by Shari L. Wade

  • 2000 Impact of Disease and Health Management Strategies on Formulary Design and Management
    by Michael Toscani & Dong Churl Suh & Brent Benedict

  • 2000 The Economics of Hepatitis B Virus Vaccination: An Analysis of Cost-Effectiveness Results for Switzerland
    by Pascal Zurn & Guy Carrin & Jean-Pierre Danthine & Raoul Kammerlander & Mark Kane

  • 2000 Quality-of-Care Indicators for HIV/AIDS
    by Albert W. Wu & Allen Gifford & Steven Asch & Susan E. Cohn & Samuel A. Bozzette & Robin Yurk

  • 2000 Performance Measurement and Management of Healthcare Professionals: Some Topical Issues
    by Martin N. Marshall & Huw T.O. Davies

  • 2000 Electronic Point-of-Care Prescribing: Writing the `Script'
    by Gordon Schiff & David W. Bates

  • 2000 Management of Hypertension in Patients with Diabetes Mellitus: Defining the Role of Lisinopril
    by Blair Jarvis & Caroline M. Spencer

  • 2000 Formulary Management of Eradication Therapies for Helicobacter pylori: Drug Selection by Means of the SOJA Method
    by Robert Janknegt & Leopold G.J.B. Engels

  • 2000 Computer-Assisted Drug Therapy Problem Notification
    by Ronald A. Lyon & Yvette J. Crockell & Nancy P. England

  • 2000 Developments in Influenza Prevention and Treatment: A Managed Care Perspective
    by Arnold S. Monto & A. Mark Fendrick

  • 2000 Challenging Current Asthma Treatment Guidelines: Improved Control of Asthma Symptoms with Nebulised Budesonide in Patients with Severe Asthma Receiving Continuous Oral Steroids
    by Kevin C. Connolly & Michael D. Peake & David M.G. Halpin & Lynda Golightly & Marlyn L. Turbitt

  • 2000 The Management of Women at High Risk of Experiencing Hereditary Breast and Ovarian Cancer: The Lahey Guidelines
    by Kevin S. Hughes & Constance A. Roche & Timothy Whitney & Robert McLellan

  • 2000 Technology-Based Advances in the Management of Depression: Focus on the COPE(TM) Program
    by John H. Greist & Deborah J. Osgood-Hynes & Lee Baer & Isaac M. Marks

  • 2000 Assessing the Economic Impact of Telemedicine
    by David M. Hailey & Bernard L. Crowe

  • 2000 A Population-Based Approach to Asthma Disease Management
    by Pamela J. Algatt-Bergstrom & Leona E. Markson & Richard K. Murray & Marc L. Berger

  • 2000 Management of Major Depression in the Workplace: Impact on Employee Work Loss
    by Howard G. Birnbaum & Pierre Y. Cremieux & Paul E. Greenberg & Ronald C. Kessler

  • 2000 The Health Hero(R) Online Service: A New Internet-Based Communications Platform for Disease Management, Case Management and Performance Measurement
    by Michael A. O'Connell & Julie Cheitlin Cherry

  • 2000 Designing and Developing Effective Disease Management Programmes: Key Decisions for Programme Success
    by Ann Scheck McAlearney

  • 2000 Performance-Based Contracts and Provider Efficiency: The State of the Art
    by Mingshan Lu & Cam Donaldson

  • 2000 Patients' Views on Healthcare: A Driving Force for Improvement in Disease Management
    by Michel Wensing & Richard Grol

  • 2000 Management of Dyslipidaemias: The Role of Simvastatin
    by Karen M. Hvizdos & Karen L. Goa

  • 2000 The Role of Home Infusion Therapy in Haemophilia: A Disease Management Perspective
    by Erik Berntorp & Stefan Lethagen

  • 2000 Interactive Internet Web Sites: A Potentially Powerful Tool for Disease Management
    by David W. Bulger & Chris Reeves

  • 2000 The Patient's Responsibility for Optimum Healthcare
    by Douglas P. Olsen

  • 2000 The Patient Perspective as an Integral Part of Diabetes Disease Management
    by Kathleen M. Rayman & Geraldine C. Ellison

  • 2000 Monitoring Outcomes of Care in Older People in a UK Community Setting: The North East Fife Outcomes Project
    by Petra Kliempt & Danny Ruta

  • 2000 Health and Disease Management Within an Academic Health System
    by David B. Bernard & Kenneth D. Coburn & Mark A. Miani

  • 2000 Achieving Patient Buy-In and Long Term Compliance with Antihypertensive Treatment
    by Frances B. Garfield & J. Jaime Caro

  • 2000 Medicare Risk Plans and Disease Management Vendors: Present and Future Relationships
    by Sam Forman

  • 1999 A C++ Platform for the Evolution of Trade Networks
    by McFadzean, David & Tesfatsion, Leigh S.

  • 1999 A Theory of Diversity
    by Nehring,K. und C.Puppe

  • 1999 Optimal all-pay auction when signals are correlated
    by Paulo Klinger Monteiro

  • 1999 How information shapes cities: theory and facts
    by GUILLAIN, Rachel & HURIOT, Jean-Marie

  • 1999 Asymmetries of information in centralized order-driven markets
    by BOCCARD, Nicolas & CALCAGNO, Riccardo

  • 1999 Acamprosate: Pharmacoeconomic Implications of Therapy
    by Rachel H. Foster & Karen J. McClellan

  • 1999 Abciximab: A Pharmacoeconomic Review of its Use in Percutaneous Coronary Revascularisation
    by Christopher J. Dunn & Rachel H. Foster

  • 1999 Annual Cost of Erectile Dysfunction to UK Society
    by Jonathan M. Plumb & Julian F. Guest

  • 1999 Economic Evaluation of Long Term Management Strategies for Erosive Oesophagitis
    by Ron Goeree & Bernie O'Brien & Richard Hunt & Gordon Blackhouse & Andrew Willan & Jan Watson

  • 1999 Health Economics in the Canadian Pharmaceutical Industry
    by Lila Assiff & Michael R. Pollock & Patricia Manzi & Ben Faienza & Devidas Menon

  • 1999 The Effect of Generic Competition on Prescription to Over-the-Counter Switching
    by Christopher S. Hollenbeak

  • 1999 Managing Pharmaceutical Expenditure while Increasing Access: The Pharmaceutical Management Agency (PHARMAC) Experience
    by Richard Braae & Wayne McNee & David Moore

  • 1999 Diagnosis and Management of Osteomyelitis: Decision Analytic and Pharmacoeconomic Considerations
    by Manouche Tavakoli & Peter Davey & Benedict A. Clift & Huw T. O. Davies

  • 1999 Measuring Quality of Life in Paediatric Patients
    by Melinda A. Connolly & Jeffrey A. Johnson

  • 1999 The Doctor-Patient Relationship and Prescribing Patterns: A View from Primary Care
    by Doug T. Steinke & Thomas M. MacDonald & Peter G. Davey

  • 1999 Cost-Effectiveness Analysis of Antiplatelet Therapy in the Prevention of Recurrent Stroke in the UK: Aspirin, Dipyridamole and Aspirin-Dipyridamole
    by Mike Chambers & John Hutton & John Gladman

  • 1999 Economic Impact of Providing Workplace Influenza Vaccination: A Model and Case Study Application at a Brazilian Pharma-Chemical Company
    by Emmanuel Burckel & Talat Ashraf & Jose P. Galvao de Sousa Filho & Eduardo Forleo Neto & Hubert Guarino & Caio Yauti & Fernando de Barros Barreto & Louis Champion

  • 1999 Cost Effectiveness of Ciprofloxacin plus Metronidazole versus Imipenem-Cilastatin in the Treatment of Intra-Abdominal Infections
    by Daniel J. Walters & Joseph S. Solomkin & Joseph A. Paladino

  • 1999 Cost Effectiveness of Amphotericin B plus G-CSF Compared with Amphotericin B Monotherapy: Treatment of Presumed Deep-Seated Fungal Infection in Neutropenic Patients in the UK
    by Terry N. Flynn & Stephen M. Kelsey & Dena L. Hazel & Julian F. Guest

  • 1999 Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin for Acute Coronary Syndromes: A Canadian Hospital Perspective
    by Robert M. Balen & Carlo A. Marra & Peter J. Zed & Marc Cohen & Luciana Frighetto

  • 1999 Cost Effectiveness of Fluticasone Propionate and Flunisolide in the Treatment of Corticosteroid-Naive Patients with Moderate Asthma
    by Timm Volmer & Adrian Kielhorn & Hans H. Weber & Karl J. Wiessmann

  • 1999 Economic Evaluation of Ciprofloxacin Compared with Usual Antibacterial Care for the Treatment of Acute Exacerbations of Chronic Bronchitis in Patients Followed for 1 Year
    by George Torrance & Valery Walker & Ronald Grossman & Jayanti Mukherjee & David Vaughan & Jacques La Forge & Noel Lampron

  • 1999 Cost Effectiveness of Omeprazole and Ranitidine in Intermittent Treatment of Symptomatic Gastro-Oesophageal Reflux Disease
    by Nils-Olov Stalhammar & Jonas Carlsson & Robert Peacock & Stefan Mullerlissner & Marcandre Bigard & Gabriele B. Porro & Julio Ponce & James Hosie & Mairi Scott & Donald G. Weir & Claire Fulton & Keith Gillon & Karna D. Bardhan

  • 1999 Linking Health-Related Quality-of-Life Indicators to Large National Data Sets
    by John A. Rizzo & Jody L. Sindelar

  • 1999 Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care: Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia
    by Pierre-Yves Cremieux & Stan N. Finkelstein & Ernst R. Berndt & Jeffrey Crawford & Mitchell B. Slavin

  • 1999 Real World Designs in Economic Evaluation: Bridging the Gap Between Clinical Research and Policy-Making
    by Rob Baltussen & Reiner Leidl & Andre Ament

  • 1999 Measuring the Effects of Medication Use on Health-Related Quality of Life in Patients with Rheumatoid Arthritis: A Review
    by Michael B. Nichol & Ann S. M. Harada

  • 1999 Pharmacoeconomics and Health Policy: Current Applications and Prospects for the Future
    by Paul E. Greenberg & Almudena Arcelus & Howard G. Birnbaum & Pierre-Yves Cremieux & Jacques LeLorier & Pierre Ouellette & Mitchell B. Slavin

  • 1999 A Review of Quality of Life in Alzheimer's Disease: Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects. The Authors Reply
    by Sam S. Salek & Melvyn D. Walker & Anthony J. Bayer

  • 1999 A Review of Quality of Life in Alzheimer's Disease: Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects
    by Stephen P. McKenna & Lynda C. Doward

  • 1999 Costs of Mini Mental State Examination-Related Cognitive Impairment
    by Linus Jonsson & Peter Lindgren & Anders Wimo & Bengt Jonsson & Bengt Winblad

  • 1999 Costs Associated with Symptomatic Systolic Heart Failure
    by Peter G. Davey & Peter B. Clarkson & Alex McMahon & Thomas M. MacDonald

  • 1999 Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK
    by Mark Nuijten & Liebeth Meester & Franz Waibel & Suzanne Wait

  • 1999 Economic Evaluation of the Treatment of Chronic Wounds: Hydroactive Wound Dressings in Combination with Enzymatic Ointment Versus Gauze Dressings in Patients with Pressure Ulcer and Venous Leg Ulcer in Germany
    by Rito Bergemann & Karl W. Lauterbach & Wolfgang Vanscheidt & Klaus-Dieter Neander & Reinhard Engst

  • 1999 Decision Analysis of Histamine H2-Receptor Antagonist Maintenance Therapy Versus Helicobacter pylori Eradication Therapy: A Randomised Controlled Trial in Patients with Continuing Pain After Duodenal Ulcer
    by Manouche Tavakoli & Andrzej T. Prach & Mo Malek & David Hopwood & Bernard W. Senior & Frank E. Murray

  • 1999 Clinical and Economic Considerations of Empirical Antibacterial Therapy of Febrile Neutropenia in Cancer
    by George Dranitsaris

  • 1999 Therapeutic Options in the Treatment of Multiple Myeloma: Pharmacoeconomic and Quality-of-Life Considerations
    by Finn Wisloff & Nina Gulbrandsen & Erik Nord

  • 1999 Herbal Remedies: Issues in Licensing and Economic Evaluation
    by Darren M. Ashcroft & Alain Li Wan Po

  • 1999 Decreased Medical Expenditures for Care of HIV-Seropositive Patients: The Impact of Highly Active Antiretroviral Therapy at a US Veterans Affairs Medical Center
    by Larry Mole & Kimberly Ockrim & Mark Holodniy

  • 1999 Cost Effectiveness of Helicobacter pylori Eradication Therapies in Patients with Duodenal Ulcer: An Analysis of Triple Therapy Versus Two Dual Therapy Alternatives
    by Gunnel R. Tennvall & Anna Norinder & Bo Ohlin

  • 1999 Patient-Level Estimates of the Cost of Complications in Diabetes in a Managed-Care Population
    by Scott D. Ramsey & Katherine Newton & David Blough & David K. McCulloch & Nirmala Sandhu & Edward H. Wagner

  • 1999 Pharmacotherapeutic Circles: Results of an 18-Month Peer-Review Prescribing-Improvement Programme for General Practitioners
    by Liselotte von Ferber & Jurgen Bausch & Ingrid Koster & Ingrid Schubert & Peter Ihle

  • 1999 A Review of Quality-of-Life Evaluations in Patients with Congestive Heart Failure
    by Colin Berry & John McMurray

  • 1999 Formulary Management of Proton Pump Inhibitors
    by Michael F. Byrne & Frank E. Murray

  • 1999 Formulary Submission Guidelines for Blue Cross and Blue Shield of Colorado and Nevada: Structure, Application and Manufacturer Responsibilities
    by Paul C. Langley

  • 1999 Choice of Cost-Effectiveness Measure in the Economic Evaluation of Cholesterol-Modifying Pharmacotherapy: An Illustrative Example Focusing on the Primary Prevention of Coronary Heart Disease in Canada
    by Stephen Morris & Ed Godber

  • 1999 Cost Comparison of Antibacterial Therapies for Serious Infections: A New Zealand 3-Hospital Study
    by W. Guy Scott & Helen M. Scott & Seton Henderson & Alison Inder & Joanne Sanders & Ruth Spearing & Colin McArthur & James Judson & Bartrum Baker & Peter Hicks & Philippa Cotterell

  • 1999 The Influence of Hospital-Based Prescribers on Prescribing in General Practice
    by John Feely & Robert Chan & John McManus & Brendan O'Shea

  • 1999 Estimating Long Term Cost Savings from Treatment of Alzheimer's Disease: A Modelling Approach
    by Paul Fenn & Alastair Gray

  • 1999 Cost Effectiveness of Riluzole in Amyotrophic Lateral Sclerosis
    by Andrea Messori & Sabrina Trippoli & Paola Becagli & Gaetano Zaccara

  • 1999 Review of Quality-of-Life Evaluations in Patients with Angina Pectoris
    by Afschin Gandjour & Karl W. Lauterbach

  • 1999 A Review of Quality-of-Life Evaluations in Prostate Cancer
    by Sunshine D. Sommers & Scott D. Ramsey

  • 1999 Challenges to the Economic Evaluation of New Biotechnological Interventions in Healthcare
    by James Mason

  • 1999 Donepezil: Pharmacoeconomic Implications of Therapy
    by Rachel H. Foster & Greg L. Plosker

  • 1999 The Pharmacoeconomics of Hormone Replacement Therapy
    by David J Torgerson & David M Reid

  • 1999 Diclofenac/Misoprostol: Pharmacoeconomic Implications of Therapy
    by Greg L. Plosker & Harriet M. Lamb

  • 1999 Incremental Cost-Effectiveness Analysis of Intravenous Ganciclovir Versus Oral Ganciclovir in the Maintenance Treatment of Newly Diagnosed Cytomegalovirus Retinitis in Patients with AIDS
    by Anita Rachlis & Fiona Smaill & Valery Walker & Lorraine Hotchkies & Amy Jones

  • 1999 Cost of Illness and Disease Severity in a Cohort of French Patients with Parkinson's Disease
    by Claude Le Pen & Suzanne Wait & Frederic Moutard-Martin & Max Dujardin & Marc Ziegler

  • 1999 Economic Analysis of Carboplatin Versus Cisplatin in Lung and Ovarian Cancer
    by Zeba M. Khan & Karen L. Rascati & Jim M. Koeller

  • 1999 Measuring Sensitivity in Pharmacoeconomic Studies: Refining Point Sensitivity and Range Sensitivity by Incorporating Probability Distributions
    by Mark J.C. Nuijten

  • 1999 Benefit Valuation in Economic Evaluation of Cancer Therapies: A Systematic Review of the Published Literature
    by Jackie Brown & Mark Sculpher

  • 1999 Using Healthcare Claims Data for Outcomes Research and Pharmacoeconomic Analyses
    by Howard G. Birnbaum & Pierre Y. Cremieux & Paul E. Greenberg & Jacques LeLorier & JoAnn Ostrander & Laura Venditti

  • 1999 A Review of Quality of Life in Alzheimer's Disease: Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects
    by Sam S. Salek & Melvyn D. Walker & Anthony J. Bayer

  • 1999 A Review of Quality of Life in Alzheimer's Disease: Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects
    by Marianne Greer & Helma Monteban

  • 1999 Olanzapine: A Pharmacoeconomic Review of its Use in Schizophrenia
    by Rachel H. Foster & Karen L. Goa

  • 1999 Cost of Schizophrenia to UK Society: An Incidence-Based Cost-of-Illness Model for the First 5 Years Following Diagnosis
    by Julian F. Guest & Ron F. Cookson

  • 1999 Costs of Diabetes: A Methodological Analysis of the Literature
    by Eva Pagano & Massimo Brunetti & Fabrizio Tediosi & Livio Garattini

  • 1999 A Model to Compute the Medical Cost of Patients in Intensive Care
    by Carine Chaix & Isabelle Durand-Zaleski & Corinne Alberti & Christian Brun-Buisson

  • 1999 Hospital Selection for Unit Cost Estimates in Multicentre Economic Evaluations: Does the Choice of Hospitals Make a Difference?
    by Ron Goeree & Amiram Gafni & Mary Hannah & Terri Myhr & Gordon Blackhouse

  • 1999 Standard Cost Lists for Healthcare in Canada: Issues in Validity and Inter-Provincial Consolidation
    by Philip Jacobs & Noralou P. Roos

  • 1999 Angiotensin Converting Enzyme (ACE) Inhibitors and Heart Failure: The Consequences of Underprescribing
    by Fredrik Andersson & Charles Cline & Tina Ryden-Bergsten & Leif Erhardt

  • 1999 Outstanding Regulatory Aspects in the European Pharmaceutical Market
    by Panos Kanavos & Elias Mossialos

  • 1999 Direct Costs of Hip Fractures in Patients Over 60 Years of Age in Belgium
    by Jean-Yves Reginster & Pierre Gillet & Wafa Ben Sedrine & Geoffrey Brands & Olivier Ethgen & Cecile defroidmont & Christiane Gosset

  • 1999 Medical Resource Use and Cost of Venlafaxine or Tricyclic Antidepressant Therapy: Following Selective Serotonin Reuptake Inhibitor Therapy for Depression
    by Robert I. Griffiths & Erin M. Sullivan & Richard G. Frank & Michael J. Strauss & Robert J. Herbert & Jon Clouse & Howard H. Goldman

  • 1999 Reconciling Decision Models With the Real World: An Application to Anaemia of Renal Failure
    by Ya-Chen Tina Shih & Teresa L. Kauf

  • 1999 Clinical and Economic Outcomes of Olanzapine Compared With Haloperidol for Schizophrenia: Results From a Randomised Clinical Trial
    by Susan H. Hamilton & Dennis A. Revicki & Eric T. Edgell & Laura A. Genduso & Gary Tollefson

  • 1999 The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals
    by Judith L. Glennie & George W. Torrance & Jean Francois Baladi & Catherine Berka & Eleanor Hubbard & Devidas Menon & Nick Otten & Marc Riviere

  • 1999 Counting the Costs of Drug-Related Adverse Events
    by T. Jeffrey White & Annet Arakelian & Jay P. Rho

  • 1999 Prescribing at the Interface Between Primary and Secondary Care in the UK: Towards Joint Formularies?
    by Martin Duerden & Tom Walley

  • 1999 Pharmacoeconomic Evaluation in the Real World: Effectiveness Versus Efficacy Studies
    by Dennis A. Revicki & Lori Frank

  • 1999 Vinorelbine in Advanced Non-Small Cell Lung Cancer: A Pharmacoeconomic Review
    by Allan J. Coukell & Stuart Noble & Diana Faulds

  • 1999 Cost Analysis of the Treatment of Severe Spinal Spasticity With a Continuous Intrathecal Baclofen Infusion System
    by M. Postma & Dettie Oenema & Symon Terpstra & Jelte Bouma & Hannah Kuipersupmeijer & Michiel J. Staal & Berry J. Middel

  • 1999 Applying Epidemiology-Based Outcomes Research to Clinical Decision-Making: A Hypothetical Model of Biotechnology Therapy in Gram-Negative Sepsis
    by Edward C.Y. Wang & Thaddeus H. Grasela & Cynthia A. Walawander

  • 1999 Treatment of Locally Advanced Pancreatic Carcinoma in Sweden: A Health Economic Comparison of Palliative Treatment With Best Supportive Care Versus Palliative Treatment With Gemcitabine in Combination With Best Supportive Care
    by Gunnel Ragnarsont Tennvall & Nils Wilking

  • 1999 Utility Scores for Chronic Conditions in a Community-Dwelling Population
    by Nicole Mittmann & Kostas Trakas & Nancy Risebrough & Barbara A. Liu

  • 1999 Recent Advances in the Methods of Cost-Benefit Analysis in Healthcare: Matching the Art to the Science
    by Emma McIntosh & Cam Donaldson & Mandy Ryan

  • 1999 Methodological Hurdles in Conducting Pharmacoeconomic Analyses
    by J. Douglasrizzo & Neil R. Powe

  • 1999 The Clinical and Economic Potential of Cyclosporin Drug Interactions
    by Jill E. Martin & A. Jamal Daoud & Timothy J. Schroeder & M. Royfirst

  • 1999 Costs of Peripheral Blood Progenitor Cell Transplantation Using Whole Blood Mobilised by Filgrastim as Compared With Autologous Bone Marrow Transplantation in Non-Hodgkin's Lymphoma
    by Carin A. Uyl-de Groot & Gert J. Ossenkoppele & Ivanne Buijt & Peter C. Huijgens

  • 1999 Pharmaceutical Price Regulation: A Study on the Impact of the Rate-of-Return Regulation in the UK
    by Joan-Ramon Borrell

  • 1999 Simvastatin After Orthotopic Heart Transplantation: Costs and Consequences
    by Karl J. Krobot & Klaus Wenke & Bruno Reichart

  • 1999 New Drugs for Osteoporosis: Comparison of the Costs and Required Returns With Those of Other Drugs Intended for Long-Term Use
    by Martin Edwards

  • 1999 Under-Utilisation of beta-Blockers After Acute Myocardial Infarction: Pharmacoeconomic Implications
    by W. David Bradford & Jersey Chen & Harlan M. Krumholz

  • 1999 Patient Self-Reports in Pharmacoeconomic Studies: Their Use and Impact on Study Validity
    by Christopher Evans & Bruce Crawford

  • 1999 The Economics of Multiple Sclerosis: Distribution of Costs and Relationship to Disease Severity
    by Amy Nicole Grudzinski & Zafar Hakim & Emily R. Cox & J. Lyle Bootman

  • 1999 Pharmacoeconomic Consequences of Variable Patient Compliance With Prescribed Drug Regimens
    by John Urquhart

  • 1999 Primary Care Purchasing: Are Integrated Primary Care Provider/Purchasers the Way Forward?
    by Stephen Peckham

  • 1999 Approaches to Missing Data Inference Results from CaPSURE: An Observational Study of Patients with Prostate Cancer
    by Deborah P. Lubeck & David J. Pasta & Scott C. Flanders & James M. Henning

  • 1999 Cost Effectiveness of Recombinant Human Insulin-Like Growth Factor I Therapy in Patients with ALS
    by Stacey J. Ackerman & Erin M. Sullivan & Kathleen M. Beusterien & Howard M. Natter & Deborah F. Gelinas & Donald L. Patrick

  • 1999 Pharmacoeconomic Considerations in Treating Patients With Acute Leukaemia
    by Viggo Jonsson & Mogen Mork Hansen & Per Ljungman & Stein Kaasa

  • 1999 Health-Related Quality-of-Life Measurement in Patients with Parkinson's Disease
    by Crispin Jenkinson & Ray Fitzpatrick & Viv Peto

  • 1999 Determining Clinically Important Differences in Health Status Measures: A General Approach with Illustration to the Health Utilities Index Mark II
    by Greg Samsa & David Edelman & Margaret L. Rothman & G. Rhys Williams & Joseph Lipscomb & David Matchar

  • 1999 The Effect of Managed Care on Prescription Drug Costs and Benefits
    by Alan Lyles & Francis B. Palumbo

  • 1999 Valuing Health-Related Quality of Life: Issues and Controversies
    by Paul Dolan

  • 1999 Economic Evaluation of Antibacterials in the Treatment of Acute Sinusitis
    by Claudine Laurier & Jean Lachaine & Murray Ducharme

  • 1999 Willingness to Pay as a Measure of Health Benefits
    by Mohan V. Bala & Josephine A. Mauskopf & Lisa L. Wood

  • 1999 Cost Analysis of 2 Empiric Antibacterial Regimens Containing Glycopeptides for the Treatment of Febrile Neutropenia in Patients with Acute Leukaemia
    by Giampaolo Bucaneve & Francesco Menichetti & Albano Del Favero

  • 1999 Cost-Benefit Analysis of Haemophilus influenzae Type b Vaccination in Children in Spain
    by F. Javier Jimenez & Pilar Guallar-Castillon & Carlos Rubio Terres & Eliseo Guallar

  • 1999 Pharmacoeconomics of Lipid-Lowering Agents for Primary and Secondary Prevention of Coronary Artery Disease
    by Joel W. Hay & Winnie M. Yu & Talat Ashraf

  • 1999 Evaluating Health-Related Quality-of-Life Outcomes in Patients with Congestive Heart Failure: A Review of Recent Randomised Controlled Trials
    by Nancy K. Leidy & Anne M. Rentz & Teresa M. Zyczynski

  • 1999 The Use of Meta-Analysis in Cost-Effectiveness Analysis: Issues and Recommendations
    by Sanjay Saint & David L. Veenstra & Sean D. Sullivan

  • 1999 Behavioural Medicine Group Intervention for High-Utilising Somatising Patients: Evaluation Across 7 Unrelated Healthcare Organisations
    by Steven E. Locke & Pauline P. Chan & Debra S. Morley & Caroline C. McLeod & Matthew A. Budd & Marcia Orlowski

  • 1999 Law and Disorder: Critical Legal Issues in Disease Management
    by James M. Jacobson & James M. Jorling & Neela A. Paykel

  • 1999 Implementing Disease Management Programmes within an Integrated Delivery System
    by Neal Friedman & Linda Skogmo & Pat Aruffo

  • 1999 Integrating Systems of Care: Responding to the Demand
    by Rufus Howe

  • 1999 Playing Disease Management Numbers Games
    by Robert E. Stone

  • 1999 Helping Cure Healthcare Systems: Changing Minds and Behaviour
    by James O. Prochaska & Janice M. Prochaska

  • 1999 Gaining Physician Buy-In for Disease Management Initiatives
    by Harry L. Leider

  • 1999 Episodes of Care: A Tool for Measuring the Impact of Healthcare Services on Cost and Quality
    by Edward Bassin

  • 1999 `Build versus Buy' in Disease Management: Separating Fact from Myth
    by Alfred Lewis

  • 1999 Point-of-Care Testing in Oral Anticoagulant Monitoring: Implications for Patient Management
    by Jennifer Sickels & Jennifer Elston Lafata & Jack E. Ansell

  • 1999 Disease Management by Prevention: The Prospects for Diabetic Retinopathy
    by Emily Y. Chew

  • 1999 Patient Compliance and its Impact on Treatment Outcomes
    by Laura T. Pizzi & Joseph E. Biskupiak

  • 1999 Enhancing Outcomes Research: The Experience of a Community Pharmacist Research Network
    by R. Leon Longe & A. Thomas Taylor & William E. Wade & William J. Spruill

  • 1999 Case Management: Transforming to Meet the Demands of an Evolving Healthcare System
    by Marianne E. Weiss

  • 1999 The Pros and Cons of Covering Lifestyle Drugs
    by Debi Reissman

  • 1999 Management of Community-Acquired Pneumonia: The Role of Clarithromycin
    by Julia A. Barman Balfour & Harriet M. Lamb

  • 1999 Guidelines for Glomerulonephritis: Their Importance in Diagnosis and Designing a Management Strategy
    by Edith Renoult & Luc Frimat & Michele Kessler

  • 1999 Cancer and Disease Management: Indications for Action
    by Marybeth Regan

  • 1999 What is the Role of Stroke Units in Overall Care?
    by Joanne V. Hickey & James C. Grotta

  • 1999 Community-Based Prevention and Chronic Disease Self-Management Programmes: Problems, Praises and Pitfalls
    by Mark Daniel & Lawrence W. Green

  • 1999 Treatment of Pneumonias in a Managed-Care Organisation: The Impact of a Treatment Guideline Promotion on Physician Prescribing Behaviour
    by Edward P. Armstrong & Paul C. Langley

  • 1999 Self-Management Services: Their Role in Disease Management
    by Jessie Gruman & Michael VonKorff

  • 1999 Wellness Programmes: Primary-Care Medicine
    by Sarita Verma & Evelyn Forsyth & Leslie Flynn

  • 1999 Selecting a Vendor for Disease Management Programmes
    by Harry L. Leider

  • 1999 Does Telemedicine Have a Role to Play in Disease Management?
    by John Craig & Maria Loane & Richard Wootton

  • 1999 Management of Patients with Cystic Fibrosis: Defining the Role of Inhaled Tobramycin
    by Harriet M. Lamb & Karen L. Goa

  • 1999 The Burden of Asthma Symptoms and the Positive Role of Patient Management
    by Edward C.Y. Wang & Kathryn A. Gaebel

  • 1999 Principles of Perioperative Antibacterial Prophylaxis: Management of Surgical Site Infections
    by John Bohnen

  • 1999 Carve-Outs: Their Place in Disease Management
    by Marybeth Regan

  • 1999 Guidelines for General Practitioners: Approaches for Managing the Information Influx for Effective Disease Management
    by David Pencheon

  • 1999 Epidemiology of Helicobacter pylori Infection: Disease Management Implications for Peptic Ulcer Disease
    by Hoda M. Malaty & David Y. Graham

  • 1999 Management Strategies for Ensuring Adequate Analgesia in Children
    by Melanie Lux & Chris L. Algren & John T. Algren

  • 1999 Disease State Management Programmes: Approaches and Applications
    by Mark G. Fuller

  • 1999 The Role of the Pharmacist in the Management of HIV/AIDS
    by Anthony J. Zappa

  • 1999 Optimising the Patient's Role: An Essential Component in Disease Management
    by Scott MacStravic

  • 1999 Hospital Length of Stay for Schizophrenia: Is Primary Payer an Influencing Factor?
    by David A. Sclar & Linda M. Robison & Tracy L. Skaer & Richard S. Galin

  • 1999 The Caregiver as Part of the Dementia Management Team
    by Steven M. Albert

  • 1999 Management of Acute Ischaemic Stroke: Recommended Practice Guidelines as a Component of Disease Management
    by Soren Paaske Johnsen & Steen Elkjaer Husted & Anne Thomassen

  • 1999 Patient Education in Asthma: Impact of Nurse Educators
    by Margot F. Underwood & Shirley G. Revitt & Stephen K. Field & Robert L. Cowie

  • 1999 An Inner-City Asthma Disease Management Initiative: Results of an Outcomes Evaluation
    by Rose Maljanian & Scott Wolf & John Goethe & Patricia Hernandez & Sheryl Horowitz

  • 1999 Direct-To-Consumer Advertising: Impact on Patient Expectations Regarding Disease Management
    by Joel Lexchin

  • 1999 Evaluation of Patients with Hypertension: Diagnosis, Screening and Risk Stratification
    by Michael Barenbrock & Martin Hausberg & Claus Spieker

  • 1999 Phased Competency: A New Model to Prepare Nurses for Enhanced Roles In Diabetes Disease Management
    by Linda L. Edwards

  • 1999 Practical Strategies to Increase Patient Education Effectiveness in a Disease State Management Programme
    by Marian Ryan Henry

  • 1999 Actual Costs Versus Diagnostic-Related Group Reimbursements for Unstable Angina: An Important Distinction for Effective Disease Management
    by Claudio Brunelli & Gian Paolo Bezante & Alberto Pasdera & Paolo Spallarossa & Maria Rosalia Merello & Pier Rossettin & Franco Zorzet & Salvatore Caponnetto

  • 1999 The Role of Behavioural Treatment in the Management of Insomnia
    by Chien-Ming Yang & Arthur J. Spielman

  • 1999 Outcomes, Outcomes Research and Disease Management: A View from the UK
    by Tom Walley

  • 1999 Use of Guidelines in the Management of Patients With Glaucoma
    by Paul Lee

  • 1999 Management of Advanced Non-Small Cell Lung Cancer: The Potential Role of Gemcitabine
    by Stuart Noble & Diana Faulds

  • 1999 Costs and Benefits of Prevention and Disease Management
    by Shirley A. Musich & Wayne N. Burton & Dee W. Edington

  • 1999 Design, Development and Implementation of a Multidisciplinary Diabetes Disease Management Programme
    by Robert E. Stone

  • 1999 Baseline Assessment of an Inner City Population Enrolled in an Asthma Disease Management Programme: Data for Continuous Programme Improvement
    by Rose Maljanian & John W. Goethe & Scott A. Wolf & Laura R. Triano & Patricia Hernandez

  • 1999 Message Tailoring: An Essential Component for Disease Management
    by David W. Bulger & Amy B. Smith

  • 1999 The Annual Cost of Chronic Obstructive Pulmonary Disease to the UK's National Health Service
    by Julian F. Guest

  • 1999 A Comparison of a Budesonide-Based and a Beclomethasone/Prednisolone-Based Management Strategy for the Treatment of Severe Asthma in General Practice
    by Govindaraj Mohan & Kevin A. MacLusky & Clifford C. Godley & Pamela L. Todd

  • 1999 Guidelines for the Diagnosis and Treatment of Meningococcal Meningitis
    by Bjorn-Erik Kristiansen & Trond Flaegstad

  • 1999 Diabetes Mellitus: Disease Management in a Multispecialty Group Practice
    by Jeremy M. Gleeson & Michael Foris & Marjorie Cypress & Donna J. Rodriguez & Neal Friedman & Martha Kent

  • 1999 Management of Febrile Episodes in Neutropenic Patients: Defining the Role of Meropenem
    by Harriet M. Lamb & Karen L. Goa

  • 1999 Management of Community-Acquired Pneumonia: Defining the Role of Azithromycin
    by Nishan S. Gunasekara & Julia A. Barman Balfour

  • 1999 Use of Surgical Procedures in the Treatment of Epilepsy: Interventions and Outcomes
    by John T. Langfitt & Kathryn Bronstein

  • 1999 The Burden of Obesity and Its Sequelae
    by Jacob C. Seidell

  • 1999 Measuring Outcomes in Alzheimer's Disease Research: Assessment of the Effectiveness of Interventions
    by Stacey Wood & Jeffrey L. Cummings

  • 1998 On the paradox of efficiency improvement at the micro level and Productivity Slowdown at the macro level: The case of Efficient Inventory Control
    by Thomas Cool

  • 1998 Teaching Agent-Based Computational Economics to Graduate Students
    by Tesfatsion, Leigh S.

  • 1998 Common Errors and Controversies in Pharmacoeconomic Analyses
    by Stephen Palmer & Sarah Byford

  • 1998 Common Errors and Controversies in Pharmacoeconomic Analyses
    by Javier Soto

  • 1998 A Short Term Cost-Effectiveness Model for Oral Antidiabetic Medicines in Europe
    by Sheila Hood & Lieven Annemans & Maureen Rutten-van Molken

  • 1998 A Short Term Cost-Effectiveness Model for Oral Antidiabetic Medicines in Europe
    by Linda D. MacKeigan

  • 1998 Cyclosporin Microemulsion (Neoral(R)) Use of trade name is for product identification, and does not imply endorsement.: A Pharmacoeconomic Review of its Use Compared with Standard Cyclosporin in Renal and Hepatic Transplantation
    by Allan J. Coukell & Greg L. Plosker

  • 1998 Fosphenytoin: Pharmacoeconomic Implications of Therapy
    by Stephen M. Holliday & Paul Benfield & Greg L. Plosker

  • 1998 Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma
    by Maureen P.M.H. Rutten-van Molken & Eddy K.A. van Doorslaer & M. Denise Till

  • 1998 Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction: Economic Evaluation of the Acute Infarction Ramipril Efficacy (AIRE) Study for Germany from the Perspective of Statutory Health Insurance
    by Peter K. Schadlich & Eduard Huppertz & Josef Georg Brecht

  • 1998 The Use and Cost of HIV Service Provision in England in 1996
    by Eduard J. Beck & Keith Tolley & Amanda Power & Sundhiya Mandalia & Philippa Rutter & Junichi Izumi & Jeni Beecham & Alistair Gray & David Barlow & Philippa Easterbrook & Martin Fisher & John Innes & George Kinghorn & Bibhat Mandel & Anton Pozniak & Allan Tang & David Tomlinson & Ian Williams

  • 1998 Insomnia, Health-Related Quality of Life and Healthcare Resource Consumption: A Study of Managed-Care Organisation Enrollees
    by Hind T. Hatoum & Sheldon X. Kong & Christopher M. Kania & Josephine M. Wong & Wallace B. Mendelson

  • 1998 A Review of Quality of Life in Alzheimer's Disease: Part 2: Issues in Assessing Drug Effects
    by Sam S. Salek & Melvyn D. Walker & Antony J. Bayer

  • 1998 Thrombolysis, Stroke Units and Other Strategies for Reducing Acute Stroke Costs
    by Theodore H. Wein & Susan L. Hickenbottom & Andrei V. Alexandrov

  • 1998 Are Mental Health Services Losing Out in the US Under Managed Care?
    by Dale L. Johnson

  • 1998 Economic Evaluation of Nimesulide Versus Diclofenac in the Treatment of Osteoarthritis in Greece
    by Lycurgus Liaropoulos & Maria Spinthouri & Theodore Ignatiades & Georgia Ifandi & Fanis Katostaras & Emmanuel Diamantopoulos

  • 1998 Cost Effectiveness of Multi-Therapy Treatment Strategies in the Prevention of Vertebral Fractures in Postmenopausal Women with Osteoporosis
    by Andrew J. Rosner & Daniel T. Grima & George W. Torrance & Cathy Bradley & Jonathan D. Adachi & Rolf J. Sebaldt & Donald J. Willison

  • 1998 Cost Effectiveness of Pramipexole in Parkinson's Disease in the US
    by Thomas J. Hoerger & Mohan V. Bala & Clayton Rowland & Marianne Greer & Elizabeth A. Chrischilles & Robert G. Holloway

  • 1998 Urge Incontinence: Quality of Life and Patients' Valuation of Symptom Reduction
    by Richard M. O'Conor & Magnus Johannesson & Steven L. Hass & Gisela Kobelt-Nguyen

  • 1998 A Review of Quality of Life in Alzheimer's Disease: Part 1: Issues in Assessing Disease Impact
    by Melvyn D. Walker & Sam S. Salek & Antony J. Bayer

  • 1998 A Review of the Economics of the Prevention and Control of Rabies: Part 2: Rabies in Dogs, Livestock and Wildlife
    by Martin I. Meltzer & Charles E. Rupprecht

  • 1998 Pharmaceutical Reference Prices: How do They Work in Practice?
    by Michael Dickson & Heinz Redwood

  • 1998 Willingness To Pay: What's in a Name?
    by Amiram Gafni

  • 1998 Docetaxel: A Pharmacoeconomic Review of its Use in the Treatment of Metastatic Breast Cancer
    by Harriet M. Lamb & Lynda R. Wiseman

  • 1998 Cost Effectiveness of Fluvoxamine in the Treatment of Recurrent Depression in France
    by Mark Nuijten & Lionel Hadjadjeba & Christopher Evans & John van den Berg

  • 1998 Threshold Analysis of Helicobacter pylori Therapy
    by Amnon Sonnenberg

  • 1998 A Method to Select an Instrument for Measurement of HR-QOL for Cross-Cultural Adaptation Applied to Dermatology
    by Adolfo Ga de Tiedra & Joan Mercadal & Xavier Badia & Jose Ma Mascaro & Rafael Lozano

  • 1998 The Burden of Illness of Hypopituitary Adults with Growth Hormone Deficiency
    by Leona Hakkaart-van Roijen & Albert Beckers & Achille Stevenaert & Frans F.H. Rutten

  • 1998 Economic Impact of Aminoglycoside Toxicity and its Prevention Through Therapeutic Drug Monitoring
    by Richard L. Slaughter & Diane M. Cappelletty

  • 1998 A Review of the Economics of the Prevention and Control of Rabies: Part 1: Global Impact and Rabies in Humans
    by Martin I. Meltzer & Charles E. Rupprecht

  • 1998 The Problem of Protocol Driven Costs in Pharmacoeconomic Analysis
    by Douglas Coyle & Karen M. Lee

  • 1998 Mega-Mergers in the Pharmaceutical Industry: In Whose Interests?
    by Alain Li Wan Po

  • 1998 Does Managed Care Fuel Pharmaceutical Industry Growth?
    by Michael D. Murray & Frank W. Deardorff

  • 1998 Methodological Quality of Economic Modelling Studies: A Case Study with Hepatitis B Vaccines
    by Michelle Wilde

  • 1998 Costs and Effects Associated with a Community Pharmacy-Based Smoking-Cessation Programme
    by Grainne E. Crealey & James C. McElnay & Terry A. Maguire & Ciaran O'Neill

  • 1998 Cost Effectiveness of Immunoprophylaxis in the Prevention of Recurrent Infectious Rhinitis in Adults
    by Gilles Berdeaux & Antoine Lafuma & Anne-Marie Perruchet & Francis Fagnani

  • 1998 The Economic Impact of Parkinson`s Disease: An Estimation Based on a 3-Month Prospective Analysis
    by Richard C. Dodel & Marikka Singer & Rudolf Kohne-Volland & Thomas Szucs & Bernard Rathay & Erich Scholz & Wolfgang H. Oertel

  • 1998 Cost Analysis of Palliative Care for Terminally Ill Cancer Patients in the UK After Switching from Weak to Strong Opioids
    by Julian F. Guest & Warren M. Hart & Ronald F. Cookson

  • 1998 Outcomes of Pharmacological and Surgical Treatment for Obesity
    by Jennifer Cerulli & Margaret Malone

  • 1998 Reporting Format for Economic Evaluation: Part II: Focus on Modelling Studies
    by C. Nuijten & Marja H. Pronk & Mark J. A. Brorens & Yechiel A. Hekster & Jacques H. M. Lockefeer & Peter A. G. M. de Smet & Gouke Bonsel & Ary van der Kuy

  • 1998 Methodological Quality of Economic Modelling Studies: A Case Study with Hepatitis B Vaccines
    by Tom Jefferson & Vittorio Demicheli

  • 1998 The Need for Pharmacoeconomic Evaluations in the NHS
    by John P. Griffin

  • 1998 Pravastatin: A Pharmacoeconomic Review of its use in Primary and Secondary Prevention of Coronary Heart Disease
    by Allan J. Coukell & Michelle I. Wilde

  • 1998 Cost Effectiveness of Screening for Subclinical Hypothyroidism in the Elderly: A Decision-Analytical Model
    by Massimo Bona & Ferruccio Santini & Giovanni Rivolta & Enzo Grossi & Roberto Grilli

  • 1998 Quality of Life Following a Change in Therapy for Diabetes Mellitus
    by Mirjana Pibernik-Okanovic & Silvija Szabo & Zeljko Melko

  • 1998 Choice of NSAID and Management Strategy in Rheumatoid Arthritis and Osteoarthritis: The Impact on Costs and Outcomes in the UK
    by Chris J. McCabe & Ron L. Akehurst & Jeff Kirsch & Malcolm Whitfield & Martin Backhouse & Anthony D. Woolf & David L. Scott & Paul Emery & Ian Haslock

  • 1998 A Review of the Pharmacoeconomics of Pharmaceutical Care
    by Richard J. Plumridge & Richard E. Wojnar-Horton

  • 1998 Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS: An Overview and Methodological Discussion
    by Kenneth A. Freedberg & A. David Paltiel

  • 1998 Reporting Format for Economic Evaluation: Part I: Application to the Dutch Healthcare System
    by Mark J.C. Nuijten & Mark J.A. Brorens & Yechiel A. Hekster & Ary van der Kuy & Jacques H. M. Lockefeer & Per A.G.M. de Smet & Gouke Bonsel & Marja H. Pronk

  • 1998 The Role of Clinical Pathways in Reducing the Economic Burden of Stroke
    by Douglas J. Lanska

  • 1998 Update on Clinical Research Summit in US
    by Jay Moskowitz & James N. Thompson

  • 1998 Cost-of-Illness Studies: Useful for Health Policy?
    by Marc A. Koopmanschap

  • 1998 Risperidone: A Pharmacoeconomic Review of its Use in Schizophrenia
    by Rachel H. Foster & Karen L. Goa

  • 1998 The Use of Decision-Analytical Modelling in Economic Evaluation of Patch Testing in Allergic Contact Dermatitis
    by Rukmini Rajagopalan & Roger T. Anderson & Syam Sarma & Carol Retchin & John Jones

  • 1998 A New Product Pricing Model Using Intracorporate Market Perceptions to Extract the Value of Additional Information
    by Robert S. Woodward & Leah Amir & Mark A. Schnitzler & Daniel C. Brennan

  • 1998 The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients: A Comparison of Atorvastatin, Simvastatin, Lovastatin and Fluvastatin
    by Michael J. Koren & Dean G. Smith & Donald B. Hunninghake & Michael H. Davidson & James M. McKenney & Stuart R. Weiss & Helmut G. Schrott & Robert W. Jr Henley & Perry Tresh & Richard W. McLain & Rebecca G. Bakker-Arkema & Donald M. Black

  • 1998 The Economics of TRACE: A Cost-Effectiveness Analysis of Trandolapril in Postinfarction Patients with Left Ventricular Dysfunction
    by Claude LePen & Herve Lilliu & Thomas Keller & Sylvie Fiessinger

  • 1998 Cost Effectiveness of Coronary Heart Disease Prevention Strategies in Adults
    by Adalsteinn D. Brown & Alan M. Garber

  • 1998 The Impact of Managed Care on Clinical Research
    by Martin McKee & Elias Mossialos

  • 1998 `The Pros and Cons of a Single Euro-Price for Drugs' and `The Economics of Parallel Trade'
    by Patricia Danzon & Adrian Towse

  • 1998 `The Pros and Cons of a Single Euro-Price for Drugs' and `The Economics of Parallel Trade'
    by Joan Rovira

  • 1998 The Role of Pharmacoeconomic Evaluations in Disease Management
    by Kenneth Chang & David Nash

  • 1998 A Reappraisal of Economic Evaluation of Pharmaceuticals: Science or Marketing?
    by Michael F. Drummond

  • 1998 The Cost Effectiveness of Acamprosate in the Treatment of Alcoholism in Germany: Economic Evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study
    by Peter K. Schadlich & Josef Georg Brecht

  • 1998 MSQ: Migraine-Specific Quality-of-Life Questionnaire: Further Investigation of the Factor Structure
    by Priti Jhingran & Sonia M. Davis & Lisa M. LaVange & David W. Miller & Ronald W. Helms

  • 1998 Modelling the Potential Economic Impact of Viral Load-Driven Triple Drug Combination Antiretroviral Therapy
    by Aslam H. Anis & Robert S. Hogg & Xiao-hua Wang & Benita Yip & Anita Palepu & Julio S. G. Montaner & Michael V. O'Shaughnessy & Martin T. Schechter

  • 1998 The Influence of Ill-Health Experience on the Valuation of Health
    by Xavier Badia & Michael Herdman & Paul Kind

  • 1998 Socioeconomics of a Global Leprosy Eradication Programme
    by Sharad S. Naik & Ramaswamy Ganapati

  • 1998 The Economic Burden of Migraine to Society
    by Michel D. Ferrari

  • 1998 Common Errors and Controversies in Pharmacoeconomic Analyses
    by Sarah Byford & Stephen Palmer

  • 1998 The Dilemma of New Drugs: Are Costs Rising Faster than Effectiveness?
    by James Mason & Nick Freemantle

  • 1998 Cost Effectiveness of Early Treatment with Oral Aciclovir in Adult Chickenpox Presented in part at the Society of General Internal Medicine 16th Annual Meeting: 1993 Apr; Washington DC
    by Kenneth J. Smith & Mark S. Roberts

  • 1998 Cost-Effectiveness Analysis of Treatments to Reduce Cholesterol Levels, Blood Pressure and Smoking for the Prevention of Coronary Heart Disease: Evaluative Study Carried Out in Spain
    by Pedro Plans-Rubio

  • 1998 Economic Evaluation of Multiple Sclerosis in the UK, Germany and France
    by N. Murphy & C. Confavreux & J. Haas & N. Konig & E. Roullet & M. Sailer & M. Swash & C. Young & J.-L. Merot

  • 1998 The Economic Cost of Multiple Sclerosis in Sweden in 1994
    by Freddie Henriksson & Bengt Jonsson

  • 1998 Assessing the Willingness of Parents to Pay for Reducing Postoperative Emesis in Children
    by Lara Diez

  • 1998 Cost Analysis of the Treatment of Schizophrenia in the UK: A Comparison of Olanzapine and Haloperidol
    by Stephen Almond & Owen O'Donnell

  • 1998 How to Calculate Indirect Costs in Economic Evaluations
    by Bengt Liljas

  • 1998 How to Calculate Indirect Costs in Economic Evaluations
    by Werner B.F. Brouwer & Marc A. Koopmanschap

  • 1998 Fluoxetine: A Pharmacoeconomic Review of its Use in Depression
    by Michelle I. Wilde & Paul Benfield

  • 1998 Linking the Health Utilities Index to National Medical Expenditure Survey Data
    by John A. Rizzo & Steven Pashko & Rebecca Friedkin & John Mullahy & Jody L. Sindelar

  • 1998 Predicting Hospitalisation of Patients with Diabetes Mellitus: An Application of the Bayesian Discriminant Analysis
    by Samir K. Bhattacharyya

  • 1998 Economic Analysis of Fluconazole versus Amphotericin B for the Treatment of Candidemia in Non-Neutropenic Patients
    by George Dranitsaris & Peter Phillips & Coleman Rotstein & Anitasha Puodziunas & Steve Shafran & Gary Garber & Fiona Smaill & Irving Salit & Mark Miller & Kurt Williams & John Conly & Joel Singer & Steve Ioannou

  • 1998 Should Antibacterials Be Deregulated?
    by Joan Rovira & Montserrat Figueras & Josep L. Segu

  • 1998 The Use of the Bootstrap Statistical Method for the Pharmacoeconomic Cost Analysis of Skewed Data
    by Alain Desgagne & Anne-Marie Castilloux & Jean-Francois Angers & Jacques LeLorier

  • 1998 Reassessing the Relevance of Pharmacoeconomic Analyses in Formulary Decisions
    by Jeffrey A. Johnson & Erwin Friesen

  • 1998 Pharmacoeconomic Analysis of 3 Treatment Strategies for Cytomegalovirus Retinitis in Patients with AIDS
    by Robert I. Griffiths & Giselle C. Bleecker & Douglas A. Jabs & Douglas T. Dieterich & Laura Coleson & Debbie Winters & Richard Wolitz & Earl P. Steinberg

  • 1998 Evaluation of the Potential Clinical and Economic Effects of Bodyweight Stabilisation with Acarbose in Patients with Type 2 Diabetes Mellitus: A Decision-Analytical Approach
    by Kurt Banz & Rolf Dinkel & Markolf Hanefeld & Uta Schwanebeck

  • 1998 Antidepressant Selection and Use and Healthcare Expenditures: An Empirical Approach
    by William H. Crown & Timothy R. Hylan & Laurie Meneades

  • 1998 Valuation of EuroQOL (EQ-5D) Health States in an Adult US Sample
    by Jeffrey A. Johnson & Stephen Joel Coons & Alex Ergo & George Szava-Kovats

  • 1998 The Use of QALY and Non-QALY Measures of Health-Related Quality of Life: Assessing the State of the Art
    by Mark Deverill & John Brazier & Colin Green & Andrew Booth

  • 1998 An Introduction to Markov Modelling for Economic Evaluation
    by Andrew Briggs & Mark Sculpher

  • 1998 The (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses: Fact or Fallacy?
    by Cam Donaldson

  • 1998 The Role of Government and Private Insurers in Guiding and Implementing Pharmacoeconomic Analyses
    by Deborah A. Freund & Bryan R. Luce

  • 1998 Meropenem: A Pharmacoeconomic Review of its Use in Serious Infections
    by Stephen M. Holliday & Paul Benfield

  • 1998 Economic Evaluation of Insulin Lispro versus Neutral (Regular) Insulin Therapy Using a Willingness-To-Pay Approach
    by Peter Davey & David Grainger & Jamie MacMillan & Narayan Rajan & Mike Aristides & Matthew Dobson

  • 1998 Cost-Effectiveness Analysis of Early Lisinopril Use in Patients With Acute Myocardial Infarction: Results From GISSI-3 Trial
    by Maria Grazia Franzosi & Aldo Pietro Maggioni & Eugenio Santoro & Gianni Tognoni & Emanuele Cavalieri

  • 1998 Average Annual Drug Cost and its Determinants in a Population Based Cohort of HIV-Positive Adult Men and Women
    by Aslam H. Anis & Robert S. Hogg & Benita Yip & Xiao-hua Wang & Julio S. G. Montaner & Michael V. O'Shaughnessy & Martin T. Schechter

  • 1998 A Short Term Cost-Effectiveness Model For Oral Antidiabetic Medicines in Europe
    by Sheila C. Hood & Lieven Annemans & Maureen Rutten -van Molken

  • 1998 The Selection of Data Sources For Use in Modelling Studies
    by Mark J.C. Nuijten

  • 1998 The Economics of Parallel Trade
    by Patricia M. Danzon

  • 1998 Applications of Modelling Studies
    by Mark J.C. Nuijten & John Starzewski

  • 1998 The Role of Cost-Consequence Analysis in Healthcare Decision-Making
    by Josephine A. Mauskopf & John E. Paul & David M. Grant & Andy Stergachis

  • 1998 The Pros and Cons of a Single `Euro-Price' For Drugs
    by Adrian Towse

  • 1998 Cost of an Outbreak of Hepatitis A in Puglia, Italy
    by Carlo Lucioni & Vincenzo Cipriani & Silvio Mazzi & Michele Panunzio

  • 1998 Pharmacoeconomic Analysis of Oral Antifungal Therapies Used to Treat Dermatophyte Onychomycosis of the Toenails: A US Analysis
    by Aditya K. Gupta

  • 1998 Cost-Benefit Analysis of Risperidone and Clozapine in the Treatment of Schizophrenia in Israel
    by Gary Ginsberg & Segev Shani & Boaz Lev

  • 1998 The Effects of Acquisition Cost and Budget-Based Compensation on the Attitudes of Pharmacy Directors Toward the Adoption of a Cost-Effective New Drug
    by Mick Kolassa & Mickey C. Smith & Benjamin F. Banahan III & Dewey D. Garner & William F. Shughart

  • 1998 Chlamydia trachomatis in Adolescents and Adults: Clinical and Economic Implications
    by Carlo A. Marra & David M. Patrick & Robert Reynolds & Fawziah Marra

  • 1998 A Prospective View on European Pharmaceutical Research and Development: Policy Options to Reduce Fragmentation and Increase Competitiveness
    by Panos Kanavos

  • 1998 Pharmacoeconomics in the New Millennium: A Pharmaceutical Industry Perspective
    by Rob Thwaites & Raymond J. Townsend

  • 1998 Measurement of Short Term Health Effects in Economic Evaluations
    by Ann M. Holmes

  • 1998 Clinical and Economic Comparison of Sertraline and Fluoxetine in the Treatment of Depression: A 6-Month Double-Blind Study in a Primary-Care Setting in France
    by P. Boyer & J.M. Danion & J.C. Bisserbe & J.M. Hotton & S. Troy

  • 1998 Economic Evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany
    by Peter K. Schadlich & Britta Paschen & Josef Georg Brecht

  • 1998 Medico-Economic Analysis of Diacerein With or Without Standard Therapy in the Treatment of Osteoarthritis
    by Francis Fagnani & Gilles Bouvenot & Jean-Pierre Valat & Thomas Bardin & Laurent Berdah & Antoine Lafuma & Isabelle Bono & Evelyne Eschwege & Renee- Liliane Dreiser

  • 1998 The Effect of Changes in Treatment Patterns on Drug Expenditure
    by Ulf-G. Gerdtham & Magnus Johannesson & Bo Gunnarsson & Margareta Marcusson & Freddie Henriksson

  • 1998 Using Pharmacoeconomic Analysis to Make Drug Insurance Coverage Decisions
    by Aslam H. Anis & Tuhin Rahman & Martin T. Schechter

  • 1998 Economic Evaluation of Desirudin vs Heparin in Deep Vein Thrombosis Prevention after Hip Replacement Surgery
    by Larse-ke Levin & Manfred Horst & David Bergqvist

  • 1998 Cefotaxime: A Pharmacoeconomic Review of its Use in the Treatment of Infections
    by Greg L. Plosker & Rachel H. Foster & Paul Benfield

  • 1998 Single European Currency and Monetary Union: Macroeconomic Implications for Pharmaceutical Spending
    by Panos Kanavos

  • 1998 Cost Effectiveness of a Low-Molecular-Weight Heparin in Prolonged Prophylaxis Against Deep Vein Thrombosis After Total Hip Replacement
    by Bruno Detournay & Andre Planes & Nicole Vochelle & Francis Fagnani

  • 1998 Price Indices of Drugs and the Switching to New Drugs: Two Empirical Examples
    by Ulf-G Gerdtham & Magnus Johannesson & Bo Gunnarsson & Margareta Marcusson & Freddie Henriksson

  • 1998 Cost Implications of Initial Antidepressant Selection in Primary Care
    by Gregory E. Simon & Paul Fishman

  • 1998 Peripheral Arterial Obliterative Disease: Cost of Illness in France
    by Armelle Montron & Eric Guignard & Alain Pelc & Sylvie Comte

  • 1998 Economic Aspects of Antibacterial Adverse Effects
    by Paul M. Beringer & Annie Wong-Berringer & Jay P. Rho

  • 1998 An Outline For a Cost-Effectiveness Analysis of a Drug For Patients With Alzheimer's Disease
    by Jan J.V. Busschbach & Werner B.F. Brouwer & Adrianus van der Donk & Jan Passchier & Frans F.H. Rutten

  • 1998 How to Calculate Indirect Costs in Economic Evaluations
    by Bengt Liljas

  • 1998 Management of Asthma: The Potential Role of Zafirlukast
    by Blair Jarvis & Julie C. Adkins

  • 1998 Utilisation and Expenditures in the Treatment of Patients with Gastro-Oesophageal Reflux Disease: Prevalence and High Cost Factors
    by Tamra J. Lair & Qinggong Fu & Daniel R. Anderson & Joseph A. Crawley

  • 1998 Rheumatoid Arthritis: Diagnosis and Screening
    by Burkhard F. Leeb & Katharina Weber & Josef S. Smolen

  • 1998 Ensuring Appropriate Care in Epilepsy: An Overview of Epidemiological and Cost of Illness Considerations
    by Dominic C. Heaney & Josemir W.A.S. Sander

  • 1998 Management of HIV Infection: The Potential Role of the Lamivudine/Zidovudine Combination Formulation
    by Caroline M. Perry & Julia A. Barman Balfour

  • 1998 Management of Individuals Who Are Obese: Behaviour Modification and Other Aspects
    by Pertti Mustajoki

  • 1998 Developing Clinical Practice Guidelines: The European Experience
    by Richard Grol & Martin Eccles & Herve Maisonneuve & Steven Woolf

  • 1998 Major Components of an Asthma Disease Management Programme
    by Liza C. O'Dowd & Reynold A. Jr Panettieri

  • 1998 Outpatient Parenteral Antibacterial Therapy of Serious Infections: The Role of Ceftriaxone
    by Julia A. Barman Balfour & Harriet M. Lamb

  • 1998 Guidelines for the Prevention of Coronary Heart Disease: Relating Local Needs to Local Initiatives
    by Ole Faergeman

  • 1998 Management of Tuberculosis: Special Considerations
    by Chester Choi

  • 1998 Cholesterol-Lowering Therapy Interventions: A Pharmacoeconomic Assessment
    by Michael A. Kortt & Edward P. Armstrong

  • 1998 Glaucoma: Screening and Diagnostic Considerations
    by Maurice W. Tuck & Ronald P. Crick

  • 1998 Management of Psychiatric Disorders in Patients with Poor Insight
    by Cedric M. Smith & Cynthia A. Pristach

  • 1998 Cardiac Rehabilitation: Guidelines and Recommendations
    by Catherine Monpere

  • 1998 Depression in the Workplace: Epidemiology, Economics and Effects of Treatment
    by James M. Russell & James Patterson & Andrew M. Baker

  • 1998 Pharmacoeconomic Models in Disease Management: A Guide for the Novice or the Perplexed
    by Richard J. Milne

  • 1998 Clinical Benefits and Cost Reduction Associated with a Comprehensive Asthma Management Programme at a Managed Care Organisation
    by Mark D. Groban & Raeburn M. Evans & Bruce Edgren & Linda T. Butt & Alicia De Stefano & Douglas J. Fernandes & Deborah A. Buchner

  • 1998 Management of HIV-1 Infection in Children: Special Considerations
    by Michael T. Brady

  • 1998 Testicular Cancer: Screening, Diagnostic and Therapeutic Considerations
    by Daan ten Bokkel Huinink & Hendrik Jan Keizer

  • 1998 Management of Primary Open-Angle Glaucoma and Ocular Hypertension: The Potential Role of Latanoprost
    by Julia A. Balfour & Julie C. Adkins

  • 1998 Treatment Expectations in Congestive Heart Failure: Implications for Patients Enrolled in Disease Management Programmes
    by Michael W. Rich

  • 1998 Guidelines for the Implementation of Patient-Controlled Analgesia
    by Lynne Campbell & John Plummer

  • 1998 Selective Digestive Decontamination and its Use in Patients with Liver Disease
    by Janus Ong & Zobair M. Younossi

  • 1998 Interactive Voice Response in Disease Management: Providing Patient Outreach and Improving Outcomes
    by Marnie LaVigne & Kent A. Tapper

  • 1998 Management of Dyslipidaemias: The Potential Role of Atorvastatin
    by Michelle I. Wilde & Caroline M. Spencer

  • 1998 Disease Management Approaches to Asthma: What Does it Mean for the Patient?
    by Maureen George

  • 1998 Current Use of Health Status Instruments in Randomised Controlled Trials on Patients with Rheumatoid Arthritis
    by Jaap Fransen & Gerold Stucki

  • 1998 Disease Management and the Role of Pharmacists
    by David Holdford

  • 1998 Current Guidelines for the Diagnosis and Treatment of Breast Cancer
    by Teresa G. Hayes & Leif E. Peterson & Armin D. Weinberg

  • 1998 Screening, Diagnostic and Outcome Tools for Asthma
    by Anthony M.J. Wever & Jopie Wever-Hess & Mark G. Britton

  • 1998 Hypertension as a Candidate for Disease Management Initiatives: Screening and Diagnosis
    by Lawrence R. Krakoff

  • 1998 Osteoporosis as a Candidate for Disease Management: Epidemiological and Cost-of-Illness Considerations
    by David Torgerson & Cyrus Cooper

  • 1998 Eradication of Helicobacter pylori in the Treatment of Uncomplicated Peptic Ulcer Disease
    by Marie A. Chisholm & Mark W. Jackson & William E. Wade

  • 1998 Interventions and Outcomes Management in Migraine
    by Glen D. Solomon

  • 1998 Dementia Screening and Surveillance: Are There Opportunities for Early Detection?
    by Reinhild Mulligan & Anne-Claude Juillerat & Martial Van del Linden

  • 1998 Screening for Cystic Fibrosis
    by Howard Cuckle & Jenni Murray

  • 1998 Management of Advanced Breast Cancer: Defining the Role of Toremifene
    by Stephen M. Holliday & Diana Faulds

  • 1998 The Use of Guidelines for Managing and Treating Osteoarthritis
    by Geza Balint & Bela Szebenyi & John Kirwan

  • 1998 Economic Considerations and Formulary Management of Oral Antipsychotics
    by Michael W. Jann & Lawrence J. Cohen

  • 1998 Computerised Protocol-Driven Prescribing
    by A. Niklas Holmberg & Rob F. Brenninkmeijer

  • 1998 The Effectiveness of An Interactive Electronic Lung Function Monitoring System in the Total Management of Refractory Asthma
    by Grace Baldwin Doherty & Robert N. Ross & Phyllis E. Ross

  • 1998 Assessing the Cost of Illness of Emphysema
    by Julian F. Guest

  • 1998 Incorporating Diabetes Care Into a Health Maintenance Organisation Setting: A Practical Guide
    by Mayer B. Davidson

  • 1998 Estimating Health-Related Quality of Life in Obese Individuals
    by Kevin R. Fontaine & Susan J. Bartlett

  • 1998 Optimising Outcomes in the Treatment of Obesity: Current Evidence for the Effectiveness of Interventions and Future Prospects
    by Martha L. Elks

  • 1998 Management of Alcohol Dependence after Detoxification: The Potential Role of Acamprosate
    by Michelle I. Wilde & Karen L. Goa

  • 1998 Outsourcing: Disease Management's Magic Bullet
    by Alfred Lewis

  • 1998 Integrated Health Management: The Patient-Centred Future of Demand Management
    by Mark A. Levine & Helen A. Birnbaum

  • 1998 Disease Management: Maximising Treatment Adherence and Self-Management
    by Warren E. Todd & Edward H. Ladon

  • 1998 La justicia y el desarrollo económico colombiano
    by Rubio Mauricio

  • 1997 The Current State of Research on Dynamic Economics, A Review Article of Giancarlo Gandolfo's, Economic Dynamics, third edition
    by William A. Barnett

  • 1996 Optimal Selling Mechanisms for Multiproduct Monopolists: Incentive Compatibility in the Presence of Budget Constraints
    by Paulo Klinger Monteiro & Frank H. Page Jr.

  • 1996 Network Competition with Reciprocal Proportional Access Charge Rules
    by Toker Doganoglu & Yair Tauman

  • 1996 Optimal population without repugnant aspects
    by MICHEL, Philippe & PESTIEAUÂ , Pierre

  • 1995 How to Get Alife
    by Tesfatsion, Leigh

  • 1985 A Comment on Consumer Demand Systems with Binding Non-Negativity Constraints
    by Michael Ransom

  • 1980 Criterion Decomposition for the Myopic Sequential Control of Uncertain Systems
    by Tesfatsion, Leigh S.

  • Household demand and welfare: implications of water pricing in Cyprus
    by Soteroula Hajispyrou & Phoebe Koundouri & Panos Pashardes

  • Условия Функционирования И Эффективность Использования Инвестиционно-Инновационных Возможностей Особых Технико-Внедренческих Зон России
    by Zeldner Aleksej Grigor'evich

  • A way out of pay-as-you-go without a double burden
    by Ulrich van Suntum

  • Investment climate and total factor productivity in manufacturing: Analysis of Indian states
    by C.Veeramani & B.N.Goldar

  • Investment climate and total factor productivity in manufacturing: Analysis of Indian states
    by C.Veeramani & B.N.Goldar

  • Wettbewerbsfreiheit, Per se Verbote und die Rule of Reason – Anmerkungen zum institutionenökonomisch-evolutionären Wettbewerbsleitbild
    Freedom to compete, per se rules and the rule of reason – Remarks on the institutional-evolutionary concept for competition policy

    by Dieter Schmidtchen

  • Anti-Sharing
    by Roland Kirstein & Robert Cooter

  • Household demand and welfare: implications of water pricing in Cyprus
    by Panos Pashardes & Phoebe Koundouri & Soteroula Hajispyrou

  • This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.